lenalidomide has been researched along with Multiple Myeloma in 1863 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 230 (12.35) | 29.6817 |
| 2010's | 1084 (58.19) | 24.3611 |
| 2020's | 549 (29.47) | 2.80 |
| Authors | Studies |
|---|---|
| Baculi, F; Carmel, G; Condroski, K; Correa, M; Crea, T; Hansen, JD; Hickman, M; LeBrun, L; Liu, W; Lu, CC; Lu, G; Mahmoudi, A; Man, HW; Muller, G; Ruchelman, A; Vocanson, F; Zhang, W | 1 |
| Baculi, F; Carmel, G; Carmichael, J; Cathers, BE; Chamberlain, PP; Daniel, TO; Hickman, M; Khambatta, G; LeBrun, L; Lu, CC; Lu, G; Man, HW; Matyskiela, ME; Muller, G; Pagarigan, B; Riley, M; Satoh, Y; Schafer, P; Zhang, W | 1 |
| Alexander, M; Baculi, F; Carmichael, J; Cathers, B; Correa, M; Daniel, T; Ebinger, K; Grant, V; Hamann, LG; Hansen, JD; Harris, R; Havens, CG; Huang, D; Kercher, T; Khambatta, G; LeBrun, LA; Leftheris, K; Leisten, J; Lopez-Girona, A; Mendy, D; Moghaddam, M; Nagy, MA; Narla, RK; Piccotti, J; Plantevin, V; Tang, Y; Vessey, R; Whitefield, B | 1 |
| Hogan, L; Kim, MJ; Lassalle-Claux, G; Luiker, K; Murugesan, A; Reiman, T; Selka, A; Touaibia, M; Vaillancourt, E | 1 |
| Jiang, X; Kan, W; Li, J; Li, Y; Mi, T; Wang, Y; Xu, G; Zhou, Y | 1 |
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Chim, CS; Kumar, S; Kwong, YL; Ngai, C; Wong, VKC | 1 |
| Alizadeh, H; Demeter, J; Hardi, A; Illés, Á; Kosztolányi, S; Masszi, T; Mikala, G; Nagy, Z; Plander, M; Schneider, T; Varga, G; Váróczy, L | 1 |
| Anderson, LD; Beksac, M; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Galli, M; Grote, L; Jenner, M; Jiang, R; Kanate, AS; Larocca, A; Liberati, AM; Lindsay, J; Moreau, P; Oriol, A; Pavic, M; Peluso, T; Richardson, PG; Robak, P; Rodriguez-Otero, P; Salomo, M; Schjesvold, F; Sonneveld, P; Vural, F; Weisel, K; White, D; Yagci, M | 1 |
| Chen, D; Feng, P; Gao, T; Liu, X; Luo, Z; Miao, J; Shen, Q; Xiang, J; Zheng, L | 1 |
| Aquino, S; Beksac, M; Boccadoro, M; Bos, G; Broijl, A; Cafro, A; Cavo, M; Cornelisse, P; Croockewit, A; De Rosa, L; Dimopoulos, MA; Dozza, L; Driessen, C; Gay, F; Gregersen, H; Gulbrandsen, N; Hajek, R; Hveding, C; Levin, MD; Ludwig, H; Minnema, MC; Morelli, A; Offidani, M; Oliva, S; Palumbo, GA; Pantani, L; Pour, L; Sonneveld, P; Spencer, A; Troia, R; van de Donk, NWCJ; van de Velden, V; van der Holt, B; Waage, A; Wester, R; Wu, K; Ypma, PF; Zamagni, E; Zander, T; Zweegman, S | 1 |
| Bhutani, M; Braylan, R; Calvo, KR; Choyke, P; Dew, A; Dulau-Florea, A; Emanuel, M; Figg, WD; Hill, E; Kazandjian, D; Korde, N; Kwok, M; Landgren, O; Lee, MJ; Lee, S; Lindenberg, L; Mailankody, S; Manasanch, E; Maric, I; Mena, E; Morrison, C; Patel, N; Petrosyan, A; Roschewski, M; Roswarski, J; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Trepel, JB; Turkbey, B; Wang, HW; Wang, W; Yuan, C; Zhang, Y | 1 |
| Ludwig, H | 2 |
| Chudej, J; Guman, T; Hlebaskova, M; Kucerikova, M; Sokol, J; Stasko, J; Stecova, N; Valekova, L | 1 |
| Kunacheewa, C; Manasanch, EE | 2 |
| Baudi, F; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, M; Hayman, S; Ho, M; Hobbs, M; Hwa, L; Kapoor, P; Kourelis, T; Kumar, S; Kyle, R; Lacy, M; Leung, N; Muchtar, E; Rajkumar, SV; Warsame, R; Zanwar, S | 1 |
| Bova-Solem, M; Carlisle, D; Efebera, YA; Hassoun, H; Laubach, JP; McCarthy, PL; Mulkey, F; Richardson, PG; Santo, K; Suman, VJ; Tuchman, SA; Voorhees, PM | 1 |
| D'Rozario, J; Estell, J; Ho, PJ; Kalff, A; Kemp, R; Kennedy, N; Khong, T; Mitchell, AJ; Mollee, P; Norton, S; Quach, H; Ramachandran, M; Reynolds, J; Spencer, A; Taylor, K | 1 |
| Huang, X; Niesvizky, R; Pu, Z; Xu, G; Zhou, L | 1 |
| Berg, D; Chou, T; Fukunaga, S; Iida, S; Ikeda, T; Izumi, T; Komeno, T; Sasaki, M; Sugiura, K; Terui, Y | 1 |
| Barbato, S; Cavo, M; Mancuso, K; Pantani, L; Rizzello, I; Rocchi, S; Tacchetti, P; Zamagni, E | 1 |
| Assal, A; Banerjee, R; Bumma, N; D'Souza, A; Estrada-Merly, N; Fraser, R; Gale, RP; Hagen, P; Holmberg, L; Hossain, NM; Kumar, S; Lazarus, HM; Lee, C; Mian, H; Miller, KC; Nagler, A; Nathan, S; Nishihori, T; Parrondo, RD; Pasvolsky, O; Patel, S; Qazilbash, MH; Rozovski, U; Schroeder, MA; Shah, N; Shargian-Alon, L; Usmani, SZ; Wang, T; Wirk, B; Yeshurun, M | 1 |
| Cao, J; Chen, D; Chen, L; Du, X; Li, S; Liu, X; Lu, Y; Pei, R; Sha, K; Tang, S; Wu, X; Xie, Y; Ye, P; Zhang, P; Zhuang, XX | 1 |
| Arora, N; Bachanova, V; Janakiram, M; Miller, JS | 1 |
| Cohen, A; Garfall, A; Stadtmauer, E; Susanibar-Adaniya, S; Vogl, D; Waxman, A | 1 |
| Ahmadi, T; Bahlis, N; Basu, S; Delioukina, M; Facon, T; Frenzel, L; Goldschmidt, H; Hulin, C; Kumar, SK; Leleu, X; Mace, JR; Macro, M; Moreau, P; Nahi, H; O'Dwyer, M; Orlowski, RZ; Perrot, A; Plesner, T; Quach, H; Raje, N; Tiab, M; Tromp, B; Uhlar, CM; Usmani, SZ; Van Rampelbergh, R; Venner, CP; Vermeulen, J; Wang, J; Weisel, K | 1 |
| Fan, Z; Feng, R; Guo, X; Huang, F; Liu, Q; Ning, X; Sun, J; Wei, Q; Wei, X; Wei, Y; Xu, N | 1 |
| Ali, SA; Biavati, L; Borrello, I; Ferguson, A; Gandhi, A; Gittelman, RM; Gocke, CB; Huff, CA; Imus, P; Johnson, S; Noonan, KA; Rudraraju, L; Sanders, C; Sidorski, A; Stevens, MA; Vignali, M; Ye, X; Zucchinetti, C | 1 |
| Alizadeh, H; Czibere, B; Eröss, B; Farkas, N; Gede, N; Hanák, L; Hegyi, P; Imrei, M; Kiss, S; Nagy, B; Soós, A; Szakács, Z | 1 |
| Al-Juhaishi, T; Bashir, Q; Champlin, RE; Gaballa, MR; Kaufman, GP; Kebriaei, P; Lee, HC; Ma, J; Manasanch, EE; Murphy, R; Nieto, Y; Orlowski, RZ; Patel, KK; Qazilbash, MH; Ramdial, JL; Rezvani, K; Saini, NY; Shpall, EJ; Srour, SA; Tang, G; Tanner, MR; Thomas, SK; Ullah, MR; Weber, DM | 1 |
| Aldaoud, A; Behlendorf, T; Dechow, T; Eschenburg, H; Grebhardt, S; Groschek, M; Hansen, R; Knauf, W; Potthoff, K; Siebenbach, HU; Söling, U; Vannier, C | 1 |
| Antonia Martino, E; Ballanti, S; Barone, M; Boccadoro, M; Botta, C; Bringhen, S; Bruzzese, A; Cangialosi, C; Cascavilla, N; Catalano, L; Cavo, M; Conticello, C; De Stefano, V; Derudas, D; Di Raimondo, F; Di Renzo, N; Donatella Vincelli, I; Farina, G; Frigeri, F; Galli, M; Garibaldi, B; Gentile, M; Mangiacavalli, S; Mele, A; Mele, G; Morabito, F; Musso, M; Musto, P; Neri, A; Offidani, M; Palmieri, S; Pantani, L; Pavone, V; Pia Falcone, A; Reddiconto, G; Ria, R; Rizzello, I; Rocchi, S; Rossi, E; Tacchetti, P; Teresa Petrucci, M; Tripepi, G; Vigna, E; Zamagni, E | 1 |
| Asemissen, AM; Benner, A; Besemer, B; Blau, IW; Bokemeyer, C; Goldschmidt, H; Görner, M; Graeven, U; Hänel, M; Jauch, A; Ko, YD; Leypoldt, LB; Lutz, R; Mann, C; Munder, M; Peceny, R; Reinhardt, HC; Salwender, H; Staib, P; Tichy, D; Weisel, KC; Zago, M | 1 |
| Bassermann, F; Bertsch, U; Eichner, R; Emde-Rajaratnam, M; Goldschmidt, H; Heider, M; Hose, D; Keller, U; Rudelius, M; Salwender, H; Scheid, C; Schick, M; Seckinger, A; Slawska, J; Stroh, J; Weisel, K | 1 |
| Hagihara, M; Hanai, H; Inoue, M; Kubo, K; Kushi, R; Mita, M; Ohara, S; Sugi, T; Uchida, T; Yasu, T | 1 |
| Agrawal, V; Aljurf, M; Anderson, LD; Banerjee, R; Bashey, A; Battiwalla, M; Beitinjaneh, A; Chakraborty, R; Chhabra, S; D'Souza, A; Dhakal, B; Dholaria, B; Estrada-Merly, N; Fraser, R; Giralt, S; Hashmi, S; Janakiram, M; Kumar, S; Lee, C; Lekakis, L; Murthy, HS; Parrondo, R; Qazilbash, M; Shah, N; Sidana, S; Usmani, S; Wangjam, T | 1 |
| Bokemeyer, C; Ghandili, S; Leypoldt, LB; Weisel, KC | 1 |
| Heimberg, L; Knop, S | 1 |
| Kitayama, C; Mashiko, S; Mizuno, S; Sanada, S | 1 |
| Bal, S; Callander, NS; Chhabra, S; Cornell, RF; Costa, LJ; D'Souza, A; Dhakal, B; Dholaria, BR; Giri, S; Godby, KN; Hall, A; Hardwick, P; Hari, P; Medvedova, E; Omel, J; Schmidt, TM; Silbermann, R | 1 |
| Aziz, MIA; Chng, WJ; Ng, K; Wong, XY | 1 |
| Adelman, K; Amaka, S; de Leval, L; Donaldson, NL; Donovan, KA; Duffy, J; Fischer, ES; Gaulard, P; Hagner, PR; Heavican-Foral, TB; Iqbal, J; Jain, S; Jones, MK; Koch, R; Liu, H; Nelson, GM; Ng, SY; Nirmal, AJ; Nowak, RP; Powers, F; Stevenson, KE; Thakurta, A; Trevisani, C; Weinstock, DM; Wu, G; Wu, W; Xu, R; Yang, L | 1 |
| Bahlis, NJ; Basu, S; Belhadj-Merzoug, K; Benboubker, L; Caillot, D; Cook, G; Decaux, O; Facon, T; Goldschmidt, H; Hebraud, B; Hulin, C; Kobos, R; Kumar, S; Manier, S; Mohty, M; Nahi, H; Pei, H; Plesner, T; Quach, H; Raje, N; Touzeau, C; Uhlar, CM; Ukropec, J; Usmani, SZ; Van Rampelbergh, R; Venner, CP; Weisel, K; Zweegman, S | 1 |
| Hattori, Y; Kuroda, M; Nakayama, J; Ochiya, T; Yamamoto, T; Yamamoto, Y | 1 |
| Berenson, JR; Bujarski, S; Eades, BR; Emamy-Sadr, M; Green, T; Souther, E; Spektor, TM; Sutanto, C; Swift, RA; To, J | 1 |
| Baljevic, M; Callander, NS; Castillo, JJ; Hillengass, J; Kumar, SK; Lim, MY; Martin, T; Sborov, DW; Streiff, MB | 1 |
| Bashir, Q; Feng, L; Huo, XJ; Lee, HC; Manasanch, EM; Morphey, A; Olsem, J; Orlowski, RZ; Patel, KK; Qazilbash, MH; Shah, JJ; Thomas, SK; Weber, DM | 1 |
| Dimopoulos, MA; Kastritis, E; Terpos, E | 1 |
| Chen, L; Djebbari, F; Ellis, L; Eyre, TA; Gomes, AR; Gray, N; Khera, A; Kothari, J; Lees, C; Lim, WY; Moore, S; Panitsas, F; Prideaux, S; Prodger, C; Ramasamy, K; Rampotas, A; Sangha, G; Tsagkaraki, I | 1 |
| Alekseeva, Y; Bakker, NA; Byrne, C; Coriu, D; Delimpasi, S; Dimopoulos, MA; Doronin, V; Hájek, R; Harmenberg, J; Lazzaro, A; Legiec, W; Liberati, AM; Maisnar, V; Masszi, T; Mateos, MV; Mikala, G; Minarik, J; Moody, V; Pour, L; Richardson, PG; Robak, P; Rosiñol, L; Salogub, G; Schjesvold, FH; Sonneveld, P; Špička, I; Symeonidis, A; Thuresson, M | 1 |
| Asawa, P; Chahine, Z; Lister, J; Sadashiv, S; Samhouri, Y; Vusqa, UT | 1 |
| Holstein, SA; Kesireddy, M | 1 |
| Ding, J; Ding, X; Gu, H; Zhong, C | 1 |
| Darif, M; Demarquette, H; Dimopoulos, MA; Doronin, V; Du, J; Fenk, R; Kumar, S; Labotka, R; Lee, C; Leleu, X; Levin, MD; Mellqvist, UH; Montes, YG; Pompa, A; Quach, H; Ramasamy, K; Sati, H; Schjesvold, F; Vinogradova, O; Vorog, A | 1 |
| Chung, DJ; DeWolf, S; Elhanati, Y; Perica, K; Rangesa, M; Sharma, S; Young, JW | 1 |
| Grant, SJ; Silberstein, J; Tuchman, S | 1 |
| Chang, H; Chen, G; Fu, C; Gong, F; Jin, S; Kang, L; Liu, D; Liu, M; Liu, W; Pan, J; Shang, J; Shi, X; Tang, F; Wu, D; Yan, L; Yan, Z; Yao, F; Yu, L; Zhou, J; Zhu, M; Zhu, X | 1 |
| Bruno, B; Caballero-Velázquez, T; Einsele, H; Fanin, R; Gahrton, G; García-Cadenas, I; Granell, M; Herrera, P; López-Corral, L; Nahi, H; Patriarca, F; Pérez-Simón, JA; Reguera, JL; Reinoso-Segura, M | 1 |
| Bianchi, G; Browne, P; Cahill, MR; Crotty, GM; Cummings, K; DiPietro, H; Dowling, P; Gilligan, O; Guerrero Garcia, T; Hayden, PJ; Hennessy, BJ; Krawczyk, J; Laubach, JP; Masone, K; Murphy, PT; O'Dwyer, ME; O'Gorman, P; O'Keeffe, D; O'Leary, HM; Perera, MR; Quinn, J; Richardson, PG; Rosenblatt, J; Saeed, K; Savell, A; Scott, K; Tierney, C; Yee, AJ | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Lee, K; Matous, J; Mouro, J; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K | 1 |
| Dimopoulos, MA; Lonial, S; Richardson, P | 1 |
| Attal, M; Benboubker, L; Chretien, ML; Dejoie, T; Facon, T; Hulin, C; Jacquet, C; Karlin, L; Leleu, X; Loiseau, HA; Manier, S; Mohty, M; Moreau, P; Perrot, A; Planche, L; Roussel, M; Tiab, M; Touzeau, C | 1 |
| Bourhis, F; Davies, FE; Guyot, P; Saunders, E | 1 |
| Futo, T; Hattori, Y; Hirao, M; Ichikawa, D; Matsushita, M; Uozaki, R; Yamaguchi, T; Yamamoto, T | 1 |
| Bohl, SR; Bullinger, L; Conrad, T; Döhner, H; Dolnik, A; Gütschow, M; Haji, M; Keller, U; Krönke, J; Kull, M; Mertins, P; Müller, S; Ng, YLD; Popp, O; Ramberger, E; Steinebach, C; Walther, W | 1 |
| Blevins, F; Hughes, D; Lerner, A; Li, KY; Mann, M; Milrod, CJ; Patel, P; Sanchorawala, V; Sloan, JM | 1 |
| Ammann, E; Cavo, M; Dimopoulos, MA; Facon, T; He, J; Kumar, S; Lam, A; Mateos, MV; Mendes, J; San-Miguel, J; van Beekhuizen, S; Yuan, Z | 1 |
| DeCosta, L; Dirnberger, F; Goldschmidt, H; Kumar, S; Nooka, AK; Spencer, A; Terpos, E; Weisel, K; Yusuf, A | 1 |
| Afrough, A; Bashir, Q; Champlin, RE; Delgado, R; Hosing, C; Kaufman, GP; Kebriaei, P; Lee, HC; Ma, J; Manasanch, EE; Murphy, R; Orlowski, RZ; Pasvolsky, O; Patel, KK; Popat, UR; Qazilbash, MH; Saini, N; Shpall, EJ; Srour, S; Thomas, SK; Ullah, MR; Weber, DM | 1 |
| Du, L; Liu, W; Pichiorri, F; Rosen, ST | 1 |
| Bachanek-Mitura, O; Chocholska, S; Czabak, O; Hus, M; Mlak, R; Muzyka-Kasietczuk, J; Szczyrek, M; Szudy-Szczyrek, A | 1 |
| Brillac, C; Fau, JB; Gaudel-Dedieu, N; Koiwai, K; Nguyen, L; Rachedi, F; Sebastien, B; Semiond, D; Thai, HT; van de Velde, H; Veyrat-Follet, C | 1 |
| Cairns, DA; Cook, G; Davies, FE; de Tute, RM; Drayson, MT; Gregory, WM; Henderson, R; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Menzies, T; Morgan, GJ; Owen, RG; Pawlyn, C; Rawstron, A | 1 |
| Eom, KS; Kim, HJ; Kim, SY; Lee, JY; Lee, SE; Lim, JY; Min, CK; Park, SS; Yoon, JH | 1 |
| Aslam, M; Gul, E; Jimenez-Zepeda, VH; Kardjadj, M; Kotb, R; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Mian, H; Reece, D; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 2 |
| Benson, D; Cocucci, E; Cottini, F; Guo, L; Hughes, T; Liu, B; Lozanski, G; Rodriguez, J; Sharma, N; Yang, Y | 1 |
| Hidaka, M; Iida, H; Kada, A; Kagoo, T; Komeno, T; Miyata, Y; Nagai, H; Saito, AM; Sawamura, M; Sunami, K; Takezako, N; Yokoyama, A | 1 |
| Anderson, LD; Badros, A; Bartlett, JB; Chari, A; Cortoos, A; Efebera, Y; Holstein, SA; Jakubowiak, A; Kaufman, JL; Lin, TS; Nooka, AK; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Shune, L; Vermeulen, J; Voorhees, P; Wildes, T | 1 |
| Chung, W; Iida, S; Iwasaki, H; Kuroda, J; Kuwayama, S; Lee, K; Matsue, K; Matsumoto, M; Nishio, M; Sugiura, I; Sunami, K | 1 |
| Candelaria, PV; Daniels-Wells, TR; Martínez-Maza, O; Nava, M; Penichet, ML | 1 |
| Ailawadhi, S; Alegria, V; Chanan-Khan, AA; Chapin, D; LaPlant, BR; Moustafa, MA; Parrondo, RD; Paulus, A; Roy, V; Sher, T | 1 |
| Gogia, A; Gupta, R; Kumar, L; Kumar, S; Malik, PS; Pathak, N; Prasad, CP; Sahoo, RK; Sharma, A | 1 |
| Buonomo, M; El Jurdi, N; Giubellino, A; Kabbur, G; Schultz, B | 1 |
| Gupta, A; Gupta, RK; Hillengass, J; Holstein, SA; McCarthy, PL; Suman, VJ; Taneja, A | 1 |
| Badros, AZ; Hardy, N; Kocoglu, M; Rapoport, AP; Rybinski, B | 1 |
| Gonsalves, WI; Lam, S; M Saunders, I; Momper, JD; Salama, E; Tzachanis, D | 1 |
| Bashir, Q; Bassett, R; Champlin, RE; Gaballa, MR; Kaufman, GP; Kebriaei, P; Lee, HC; Lin, P; Ma, J; Manasanch, EE; Murphy, R; Nieto, Y; Orlowski, RZ; Pasvolsky, O; Patel, KK; Qazilbash, MH; Ramdial, J; Rauf, M; Rezvani, K; Saini, N; Shpall, EJ; Srour, SA; Tang, G; Tanner, MR; Thomas, SK; Ullah, MR; Weber, DM | 1 |
| Hata, H; Kawano, Y; Matsuoka, M; Takashio, S; Tsujita, K; Ueda, M | 1 |
| Gordon, A; Hassoun, H; Hollmann, TJ; Kuo, AM; Landau, HJ; Lesokhin, AM; Lezcano, C; Mailankody, S; Markova, A; Shah, U; Tan, CC | 1 |
| Hanamura, I | 1 |
| Anderson, A; Dytfeld, D; Iskander, K; Jakubowiak, AJ; Jasielec, J; Kazandjian, D; Kervin, TA; Landgren, O; McFadden, I; Roussel, M | 1 |
| Touzeau, C | 1 |
| Bahlis, NJ; Beksaç, M; Belch, A; Berdeja, J; Cavo, M; Dimopoulos, MA; Ganetsky, A; Goldschmidt, H; Grosicki, S; Jou, YM; Kaufman, JL; Larocca, A; Laubach, JP; Lazaroiu, M; Legieć, W; Liberati, AM; Lonial, S; Magen, H; Mateos, MV; Petrucci, MT; Popa McKiver, M; Reece, D; Richardson, PG; Špička, I; Weisel, K; White, D | 1 |
| Attal, M; Chalayer, E; Collet, P; Frenzel, L; Guyotat, D; Karlin, L; Leleu, X; Talbot, A; Tardy, B | 1 |
| Rajkumar, SV | 6 |
| Cascavilla, N; Curci, P; Di Renzo, N; Falcone, AP; Germano, C; Guarini, A; Mazza, P; Mele, A; Mele, G; Melillo, L; Musto, P; Palazzo, G; Palumbo, G; Pastore, D; Pavone, V; Reddiconto, G; Rossini, B; Specchia, G; Tarantini, G | 1 |
| Buzoianu, AD; Ciechanover, A; Dima, D; Drula, R; Ghiaur, G; Gulei, D; Iluta, S; Iuga, C; Tomuleasa, C | 1 |
| Antonioli, E; Ballanti, S; Belotti, A; Boccadoro, M; Bonalumi, A; Botta, C; Bringhen, S; Brunori, M; Bruzzese, A; Califano, C; Cascavilla, N; Cavo, M; Cerchione, C; Consoli, U; Conticello, C; Criscuolo, C; Cupelli, L; Curci, P; De Stefano, V; Derudas, D; Di Raimondo, F; Di Renzo, N; Farina, G; Frigeri, F; Gagliardi, A; Galli, M; Gamberi, B; Gangemi, D; Gentile, M; Giuliani, N; Iaccino, E; Lombardo, A; Mangiacavalli, S; Marcacci, G; Martino, EA; Martino, M; Mele, G; Mendicino, F; Mimmi, S; Morabito, F; Musto, P; Neri, A; Offidani, M; Palmieri, S; Palumbo, G; Patriarca, F; Petrucci, MT; Pietrantuono, G; Pompa, A; Ria, R; Rocco, S; Rossi, E; Sgherza, N; Stocchi, R; Tripepi, G; Uccello, G; Vigna, E; Vincelli, D; Zamagni, E; Zambello, R | 1 |
| Patrick, H; Ramasamy, K; Rashid, S | 1 |
| Groot, CAU; Sonneveld, P; van Beurden-Tan, CHY | 1 |
| Barone, M; Botta, C; Bruzzese, A; Cangialosi, C; Catalano, L; Cavo, M; Conticello, C; Di Raimondo, F; Falcone, AP; Farina, G; Gamberi, B; Garibaldi, B; Gentile, M; Iaccino, E; Mancuso, K; Martino, EA; Mele, A; Mele, G; Mendicino, F; Morabito, F; Musso, M; Musto, P; Neri, A; Palmieri, S; Pavone, V; Reddiconto, G; Rizziello, I; Rocchi, S; Tacchetti, P; Tripepi, G; Vigna, E; Vincelli, ID; Zamagni, E | 1 |
| Ayorinde, T; Chung, DJ; Comenzo, RL; Devlin, S; Giralt, S; Hassoun, H; Kewalramani, T; Korde, N; Lahoud, OB; Landau, H; Landgren, O; Lendvai, N; Lesokhin, AM; Mailankody, S; Nguyen, J; Weltz, J | 1 |
| Chambers, W; Dores, GM; Jones, SC; Nadeau Nguyen, M; Nayernama, A | 1 |
| Best, P; Bird, J; Bowcock, S; Boyd, K; Cairns, DA; Cook, G; Coulson, AB; Dawkins, B; de Tute, R; Drayson, M; Gardner, H; Henderson, R; Hockaday, A; Jackson, G; Jenner, M; Jones, J; Kaiser, M; Kishore, B; Meads, D; Olivier, C; Owen, R; Parrish, C; Pawlyn, C; Rabin, N; Royle, KL | 1 |
| Agha, ME; Alsina, M; Anderson, KC; Anderson, LD; Andreescu, AC; Attal, M; Avet-Loiseau, H; Campagnaro, EL; Cohen, AD; Cornell, RF; Foley, A; Fulciniti, M; Gasparetto, C; Gentile, T; Ghobrial, IM; Giralt, SA; Godby, KN; Gowin, K; Hashmi, H; Hassoun, H; Hebert, K; Hurd, DD; Jacobus, SJ; Jagannath, S; Kamble, RT; Kaufman, JL; Khan, AM; Laubach, JP; Libby, EN; Liedtke, M; Lonial, S; Maglio, ME; Masone, K; McCarthy, PL; Medvedova, E; Milner, CP; Moreau, P; Munshi, NC; Nadeem, O; Nathwani, N; Openshaw, TH; Orlowski, RZ; Paba-Prada, C; Pasquini, MC; Perrot, A; Raje, NS; Richardson, PG; Samur, MK; Schlossman, RL; Scott, E; Torka, P; Voorhees, PM; Weller, EA; Yee, AJ; Zeytoonjian, AA; Zonder, JA | 1 |
| Bargay, J; Blade, J; Blanchard, MJ; Burgos, L; Calasanz, MJ; Cedena, MT; Cordon, L; de la Cruz, J; de la Rubia, J; Flores-Montero, J; Garcés, JJ; Hernandez, MT; Lahuerta, JJ; Martin, J; Martinez-Lopez, J; Martínez-Martinez, R; Mateos, MV; Orfao, A; Ortiol, A; Paiva, B; Perez, JJ; Puig, N; Rios, R; Rodriguez-Otero, P; Rosiñol, L; San-Miguel, JF; Sanoja-Flores, L; Sureda, A | 1 |
| Abba, M; Gajkowska-Kulik, J; Sadowska-Klasa, A; Zaucha, JM | 1 |
| Dusetzina, SB; Jazowski, SA; Wilson, L; Zafar, SY; Zullig, LL | 1 |
| Atsuta, Y; Fukuhara, N; Hanamura, I; Iida, H; Iida, S; Inagaki, Y; Ito, M; Kasahara, S; Kitagawa, J; Kurata, M; Kuroda, J; Kuwatsuka, Y; Murakami, S; Nagai, H; Nakamura, N; Okamoto, A; Okura, M; Ri, M; Taji, H; Tsujimura, H; Yoshimitsu, M | 1 |
| Ali, S; Anwer, F; Ashraf, S; Ehsan, H; Khalid, F; Khan, I; Khan, SI; Khouri, J; Mazzoni, S; Neupane, K; Rafae, A; Samaras, C; Valent, J; Wahab, A | 1 |
| Ando, K; Kamiya, Y; Machida, S; Murayama, N; Ogiya, D; Saito, R; Shiraiwa, S; Suzuki, R; Tazume, K; Yamazaki, H | 1 |
| Alwafi, H; Awawdeh, SA; Liew, D; Naser, AY; Ofori-Asenso, R; Qadus, S | 1 |
| Beavis, PA; Bezman, NA; Campbell, K; D'Souza, C; Darcy, PK; Harrison, SJ; Jenkins, MR; Keam, SP; Macdonald, S; Meyran, D; Neeson, PJ; Prince, HM; Quach, H; Richardson, K; Ritchie, DS; Robbins, M; Todd, K; Trapani, JA; Zhu, JJ | 1 |
| Chen, W; Geng, C; Jian, Y; Yang, G; Zhou, H | 1 |
| Costa, BA; Mouhieddine, TH; Richter, J | 1 |
| Bai, H; Fang, BJ; Fu, WJ; Liao, AJ; Lu, J; Niu, T; Wang, YF; Zhao, HG | 1 |
| Davis, JA; Gaffney, KJ; Hashmi, H; Shockley, A; Smith, D; Weeda, E | 1 |
| Gandolfi, S; McCaughan, GJ; Moore, JJ; Richardson, PG | 1 |
| Besse, L; Choudhry, P; Driessen, C; Eyquem, J; Ferguson, ID; Hale, M; Kasap, C; Kishishita, A; Leung, KK; Lin, YT; Lopez-Girona, A; Martin, TG; Miao, W; Mullins, RD; Naik, A; Nieves Vasquez, W; Nix, MA; Patiño-Escobar, B; Posey, AD; Prakash, S; Ramos, E; Shah, N; Talbot, A; Tuomivaara, ST; Vandenberg, S; Wells, JA; Wiita, AP; Wolf, JL; Wong, SW | 1 |
| Doucette, KR; Vesole, DH | 1 |
| Ansari-Pour, N; Chavda, S; Fitzsimons, E; Flynt, E; Gooding, S; Karagoz, K; Kazeroun, M; Ortiz Estevez, M; Pierceall, W; Polonskaia, A; Ramasamy, K; Royston, D; Salazar, M; Sirinukunwattana, K; Thakurta, A; Towfic, F; Vyas, P; Yong, K | 1 |
| Anderson, LD; Derman, BA; Grinblatt, DL; Gurbuxani, S; Jakubowiak, AJ; Jasielec, J; Jiang, K; Kansagra, A; Karrison, T; Kin, A; Major, A; Narula, S; Rayani, S; Stefka, AT; Zonder, J | 1 |
| Kang, Y; Li, Z; Mathews, P; McDonnell, DP; Norris, J; Paul, B; Sha, Y; Wang, E; Wu, J; Zhao, Y | 1 |
| Atta, M; Deplano, S; Innes, A; McVinnie, K; Nadal-Melsio, E | 1 |
| AlZahmi, A; Berger, K; Cenzer, I; Mansmann, U; Ostermann, H; Schleinkofer, T; Theurich, S | 1 |
| Alchahin, G; Boncila, SD; Bouaka, C; Fofana, AS; Fongoro, S; Haussaire, D; Samaké, M; Sy, S; Torrents, J; Valensi, RC; Yattara, H | 1 |
| Derman, B; Jakubowiak, A; Major, A | 1 |
| Afari, J; Berenson, JR; Bessudo, A; Cohen, A; Eades, BM; Eshaghian, S; Gabrail, N; Jhangiani, H; Kim, C; Kim, S; Kubba, S; Neidhart, JD; Spektor, TM; Swift, RA; Turner, C; Vescio, R | 1 |
| Bashir, Q; Champlin, RE; Kebriaei, P; Lee, HC; Masood, A; Milton, DR; Nieto, Y; Orlowski, RZ; Pasvolsky, O; Patel, KK; Qazilbash, MH; Ramdial, J; Rauf, M; Saini, N; Shpall, EJ; Srour, S; Tang, G; Tanner, MR; Thomas, SK; Weber, DM | 1 |
| Berenson, JR; Bujarski, S; Eades, BM; Eshaghian, S; Ghermezi, M; Kim, C; Lim, S; Martinez, D; Moss, RA; Schwartz, G; Spektor, TM; Swift, RA; To, J; Turner, C; Vescio, R | 1 |
| Das, P; Dimopoulos, MA; Dytfeld, D; Grosicki, S; Hori, M; Jou, YM; LeBlanc, R; Leleu, X; Moreau, P; Popa McKiver, M; Raab, MS; Richardson, PG; San-Miguel, J; Suzuki, K; Takezako, N; Yao, D | 1 |
| Hayashi, K; Ishii, A; Ohno, S; Shimizu, R; Tanaka, H | 1 |
| Fu, AZ; Kaila, S; Medhekar, R; Patel, S; Ran, T | 1 |
| Adam, Z; Adamová, Z; Boichuk, I; Dvořáková, K; Koukalová, R; Král, Z; Krejčí, M; Packová, B; Pour, L; Řehák, Z; Sandecká, V; Štork, M | 1 |
| Chen, F; Huo, Z; Liu, P; Luo, Z | 1 |
| Kumar, S; Lonial, S; Mateos, MV; Rajkumar, SV | 1 |
| Arguiñano, JM; Bargay, J; Bladé, J; de Arriba, F; Hernández, MT; Lahuerta, JJ; López, J; López-Corral, L; Mateos, MV; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Rosiñol, L; Rubia, J; Salvador, C; San-Miguel, J | 1 |
| Boppana, SH; Czyzyk, J; Kaushal, A; Klomjit, N | 1 |
| Liu, Y; Su, J; Wen, J; Xu, F; Yue, J; Zhang, Y; Zhou, Q | 1 |
| Anderson, LD; Baljevic, M; Bartlett, JB; Chari, A; Cortoos, A; Costa, LJ; Efebera, YA; Holstein, SA; Kaufman, JL; Laubach, J; Lin, TS; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Silbermann, R; Vermeulen, J; Voorhees, PM | 1 |
| Berdeja, J; Buadi, FK; Chari, A; Deol, A; Fiala, MA; Gao, F; Gregory, TK; Hofmeister, CC; Kaufman, JL; Martin, TG; Nathwani, N; Rettig, MP; Rosko, A; Slade, M; Vij, R | 1 |
| Mai, EK | 1 |
| Bao, S; Chai, G; Chen, X; Liu, C; Mao, J; Zhi, Y; Zhu, J | 1 |
| Chang, H; Cui, J; Hou, L; Li, Y; Niu, T; Pan, L; Tang, W; Wang, F; Xiang, B; Zhang, L; Zheng, Y; Zou, Z | 1 |
| Franz, J; Myrus, E; Richter, J; Sanchez, L | 1 |
| Cao, X; Jiao, B; Wu, G; Zhang, X | 1 |
| Blevins, F; Bradshaw, GA; Choiniere, J; Fraser, CS; Hata, AN; Kalocsay, M; Li, C; Miller, JW; Presser, A; Qin, X; Sanchorawala, V; Sarosiek, KA; Sarosiek, S; Spetz, JKE; Yu, S | 1 |
| Arcaini, L; Barilà, G; Belotti, A; Benvenuti, P; Cafro, A; Cartia, CS; Farina, F; Fazio, F; Ferretti, VV; Galli, M; Klersy, C; Mangiacavalli, S; Marcatti, M; Masoni, V; Mazza, R; Mina, R; Olivares, C; Pagani, G; Palumbo, M; Paris, L; Petrucci, MT; Pezzatti, S; Pompa, A; Soldarini, M; Zambello, R | 1 |
| Ansari-Pour, N; Avet-Loiseau, H; Estevez, MO; Flynt, E; Gooding, S; Mavrommatis, K; Morgan, G; Munshi, N; Samur, M; Stong, N; Thakurta, A; Towfic, F; Walker, B | 1 |
| Dubin, DP; Gulati, N; Han, J; Jagannath, S; Owji, S; Parekh, S; Tan, K; Yassky, D | 1 |
| Abro, B; Barnell, EK; Campbell, KM; Chavez, M; Cotto, KC; Duncavage, EJ; Fiala, MA; Frater, JL; Griffith, M; Griffith, OL; Hassan, A; King, JA; Kohnen, DR; Kreisel, F; Lee, YS; Newcomer, KF; Parikh, BA; Ruzinova, MB; Skidmore, ZL; Spies, NC; Uy, GL; Vij, K; Vij, R; Wang, T; Wartman, LD; Welch, JS | 1 |
| Alizadeh, H; Illés, Á; Lovas, S; Mikala, G; Obajed Al-Ali, N; Plander, M; Rajnics, P; Szemlaky, Z; Szita, V; Varga, G; Váróczy, L | 1 |
| Abousedu, YAI; Doghaim, M; Ghanem, OM; Sayer, F; Sayer, K | 1 |
| Chernikov, MV; Gemdzhian, EG; Ivanova, VL; Ptushkin, VV; Ulyanova, MA; Vinogradova, OY; Vorobyev, VI; Zherebtsova, VA | 1 |
| Jang, HY; Kim, CJ; Kim, IW; Lee, HK; Oh, JM; Yoon, SS | 1 |
| Baumert, B; Borowiecka, E; Kulig, P; Machaliński, B; Milczarek, S; Osękowska, B; Paczkowska, E; Sommerfeld, K; Zdziarska, B; Łanocha, A | 1 |
| Bici, A; Nachar, VR; Pianko, MJ | 1 |
| Guo, H; Liu, X; Liu, Y; Wang, H; Yang, J; Zhou, K | 1 |
| Asemissen, AM; Bertsch, U; Besemer, B; Dürig, J; Fenk, R; Geer, T; Gezer, D; Goldschmidt, H; Hänel, M; Heilmeier, B; Hoffmann, M; Holderried, TAW; Huhn, S; Khandanpour, C; Klaiber-Hakimi, M; Knauf, W; Kriegsmann, K; Luntz, SP; Mai, EK; Mann, C; Müller, M; Munder, M; Nievergall, E; Raab, MS; Riesenberg, H; Salwender, HJ; Scheid, C; Schroers, R; Thomalla, J; Tichy, D; Trautmann-Grill, K; von Metzler, I; Weinhold, N; Weisel, KC | 1 |
| Boyiadzis, M; Franz, J; Jones, JR; Klem, ML; Lontos, K; Saleem, K; Shaikh, N; Yabes, JG | 1 |
| Borsi, E; Bratosin, F; Cerbu, B; Costachescu, D; Negrean, RA; Potre, C; Potre, O; Samfireag, M; Secosan, C | 1 |
| Jo, JC; Kim, HR; Kim, K; Kim, SH; Lee, JH; Lee, JJ; Lee, JY; Min, CK; Moon, JH; Shin, HJ | 1 |
| Bruzzese, A; Filippelli, G; Gentile, M; Iaccino, E; Lucia, E; Martino, EA; Mendicino, F; Morabito, F; Neri, A; Olivito, V; Vigna, E | 1 |
| Lesokhin, AM; Maclachlan, KH | 1 |
| Aguet, F; Anand, S; Aranha, MP; Badros, AZ; Baginska, J; Bhutani, M; Boruchov, A; Bustoros, M; Dutta, AK; Flechon, L; Getz, G; Ghobrial, IM; Hallisey, M; Haradhvala, NJ; Heilpern-Mallory, D; Jakubowiak, A; Laubach, J; Lightbody, ED; Manier, S; Mateos, MV; Matous, J; Mouhieddine, TH; Nadeem, O; Redd, RA; Richardson, P; Rosenblatt, JM; Savell, A; Sklavenitis-Pistofidis, R; Su, NK; Tahri, S; Trippa, L; Ujwary, S; Usmani, SZ; Varmeh, S; Vredenburgh, JJ; Wu, T; Yee, AJ; Zavidij, O; Zonder, J | 1 |
| Ahn, JS; Ahn, SY; Cho, D; Chu, TH; Jung, SH; Kim, HJ; Kim, M; Lee, JJ; Lee, KH; Phan, MT; Song, GY; Thangaraj, JL; Vo, MC; Yang, DH | 1 |
| Bartoszek, RL; Brennan, A; Brogdon, JL; Bu, D; Carreno, BM; Chen, F; Cohen, AD; Cosey, A; Ferthio, R; Four, M; Fraietta, JA; Garfall, AL; Gonzalez, VE; Gupta, M; Hexner, EO; Hwang, WT; June, CH; Koterba, N; Kulikovskaya, I; Lacey, SF; Lancaster, E; Leskowitz, R; Linette, GP; Mansfield, KG; Miao, F; Milone, MC; Nelson, AM; Patchin, M; Plesa, G; Shea, KM; Siegel, DL; Stadtmauer, EA; Susanibar-Adaniya, SP; Tian, L; Vogl, DT; Waxman, AJ; Wilson, WV; Xu, R; Young, RM | 1 |
| Asano, A; Hagiwara, S; Hirade, K; Iida, S; Inagaki, H; Kinoshita, S; Komatsu, H; Kusumoto, S; Maeda, Y; Marumo, Y; Masaki, A; Nakashima, T; Narita, T; Ri, M; Suzuki, T; Tachita, T | 1 |
| Gupta, N; Nafees, S; Sharma, A; Vashist, A | 1 |
| Bagwell, AK; Meyers, G; Nauta, AC; Radu, S; Wilson, J | 1 |
| Abe, S; Furukawa, H; Kameoka, J; Kobayashi, M; Kodera, T; Murakami, K; Nomura, J; Oka, Y; Okitsu, Y; Shirota, Y; Takahashi, S; Takeda, T | 1 |
| Fukushima, H; Honda, A; Imadome, KI; Iwasaki, A; Jona, M; Kishino, Y; Kurokawa, M; Maki, H; Morita, K; Nishikawa, M; Ushiku, T; Yatomi, Y; Yoshida, M | 1 |
| Collinge, AD; Driessens, G; Ensbey, KS; Furlan, SN; Hill, GR; Holmberg, LA; Koyama, M; Legg, SR; Minnie, SA; Nemychenkov, NS; Olver, SD; Schmidt, CR; Sekiguchi, T; Sester, DP; Spencer, A; Takahashi, S; Varelias, A; Waltner, OG; Zhang, P | 1 |
| Hiramatsu, Y; Matsumoto, M; Suzuki, K; Takezako, N; Tamai, Y | 1 |
| Corvatta, L; Morè, S; Offidani, M | 1 |
| Cairns, DA; Cook, G; Davies, FE; Drayson, MT; Gregory, W; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Menzies, T; Morgan, GJ; Olivier, C; Owen, RG; Pawlyn, C | 1 |
| Boyd, K; Cairns, DA; Cook, G; Cray, N; Davies, FE; Drayson, M; Holroyd, A; Houlston, R; Jackson, G; Jenner, M; Kaiser, MF; Morgan, GJ; Nichols, I; Owen, R; Panopoulou, A; Pawlyn, C | 1 |
| Aumann, S; Gatt, ME; Lebel, E; Parnasa, E; Ribak, Y; Rubin, L; Saban, R; Shamriz, O; Tal, Y; Talmon, A; Vainstein, V | 1 |
| Matsue, K; Murata, R; Nakao, S; Takamatsu, H; Ueda, M; Yamashita, T; Yoroidaka, T; Yoshihara, K; Yoshihara, S | 1 |
| Binder, M; Buadi, FK; Charalampous, C; Dingli, D; Dispenzieri, A; Fonder, AL; Gertz, MA; Goel, U; Gonsalves, W; Hayman, SR; Hobbs, MA; Hwa, YL; Kapoor, P; Kourelis, T; Kumar, S; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Rajkumar, SV; Warsame, R | 1 |
| Aktas Samur, A; Anderson, KC; Avet-Loiseau, H; Bazarbachi, AH; Corre, J; Fulciniti, M; Magrangeas, F; Minvielle, S; Moreau, P; Munshi, NC; Parmigiani, G; Perrot, A; Richardson, PG; Roncador, M; Samur, MK; Shammas, MA; Sperling, AS; Szalat, R; Thakurta, A | 1 |
| Bhak, RH; Bocharova, I; Cheng, M; Cherepanov, D; Cranmer, H; Dabora, J; DerSarkissian, M; Duh, MS | 1 |
| Beksac, M; Gurman, G; Ilhan, O; Koyun, D; Seval, GC; Topcuoglu, P; Yuksel, MK | 1 |
| Chng, WJ; Dash, AB; Dimopoulos, MA; Iida, S; Kumar, SK; Labotka, R; Lonial, S; Moreau, P; Morgan, GJ; Rajkumar, SV; Suryanarayan, K; Twumasi-Ankrah, P; Villarreal, M; Vorog, A; Zhang, X | 1 |
| Alfayez, M; Alshehry, NF; Altaf, SY; Marei, MA; Motabi, IH; Tailor, IK; Zaidi, SZ | 1 |
| Engelhardt, M; Wäsch, R | 1 |
| Bashir, Q; Champlin, RE; Gaballa, MR; Kebriaei, P; Lee, HC; Lin, P; Masood, A; Milton, DR; Nieto, Y; Orlowski, RZ; Pasvolsky, O; Patel, KK; Qazilbash, MH; Ramdial, J; Saini, N; Sami, SS; Shpall, EJ; Srour, S; Tang, G; Tanner, MR; Thomas, SK; Weber, DM | 1 |
| Corvatta, L; Manieri, MV; Morè, S; Offidani, M; Olivieri, A | 1 |
| Akiyama, H; Fujimori, C; Hagino, T; Hidai, H; Kurimoto, M; Motomura, S; Murai, Y; Osanai, S; Saga, R; Sano, S | 1 |
| Aoe, S; Ashizawa, M; Fujiwara, SI; Hatano, K; Hyodo, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, SI; Koyama, S; Mashima, K; Minakata, D; Morita, K; Murahashi, R; Nagayama, T; Nakashima, H; Noguchi, A; Ohmine, K; Oyama, T; Sato, K; Toda, Y; Umino, K; Yamamoto, C; Yokoyama, D | 1 |
| Feng, P; Gao, T; Liu, X; Shen, Q; Xiang, J; Zheng, L | 1 |
| Gong, D; Huang, W; Wang, Z; Yin, S; Zhou, K | 1 |
| Du, J; Feng, ZY; Fu, WJ; Guo, P; He, HY; Jiang, H; Li, L; Liu, J; Lu, J; Qiang, WT | 1 |
| Yang, C; Zhuang, JL | 1 |
| Garcia-Horton, V; Guyot, P; Lin, PL; Richter, J; Sievert, M; Singh, E; Taiji, R; Zhou, ZY | 1 |
| Banerjee, R; Banez, MT; Cheplowitz, H; Chung, A; Costello, C; Fine, J; Guglielmo, J; Kumar, A; Lo, M; Patel, N; Rath, C; Rosenberg, AS; Saunders, IM; Wilson, M; Yoo, C; Young, R | 1 |
| Ali, SB; Hissaria, P; Horvath, N; Le, TA; Lee, WI; Smith, W | 1 |
| Dai, Y; Jin, F; Jin, T; Liang, X; Liu, S; Xu, W; Zhao, X; Zhou, H | 1 |
| Kozyk, M; Palii, S; Secor, B; Strubchevska, K | 1 |
| Bergsagel, PL; Meermeier, EW | 1 |
| Anderson, LD; Badros, A; Chari, A; Cortoos, A; Efebera, Y; Holstein, SA; Jakubowiak, A; Kaufman, JL; Lin, TS; Nooka, AK; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Shune, L; Voorhees, P; Wildes, T | 1 |
| Alaibac, M; Gnesotto, L; Mioso, G; Piaserico, S; Russo, I | 1 |
| Bhatnagar, B; Dilip, D; Geyer, MB; Glass, JL; Hassoun, H; Klein, V; Landau, H; Lozanski, G; Mims, AS; Park, JH; Roshal, M; Shaffer, BC; Xiao, W; Zhang, Y | 1 |
| Abid, MB; Afrough, A; Al Hadidi, S; Aljurf, M; Anderson, LD; Badawy, SM; Banerjee, R; Battiwalla, M; D'Souza, A; de Lima, M; Dholaria, B; Estrada-Merly, N; George, G; Gergis, U; Gowda, L; Hashmi, S; Hildebrandt, GC; Holmberg, LA; Kaur, G; Kharfan-Dabaja, MA; Kumar, SK; Lee, CH; Lekakis, LJ; Majhail, NS; Mian, H; Miller, KC; Munshi, PN; Murthy, HS; Nieto, Y; Nishihori, T; Patel, SS; Pawarode, A; Qazilbash, MH; Ragon, BK; Saad, A; Shah, MV; Shah, N; Solh, M; Strouse, C; Usmani, SZ; Vesole, DH; Wirk, B | 1 |
| Lan, T; Li, J; Li, P; Liu, P; Maihemaiti, A; Ren, L; Wang, P; Wang, W; Wang, Y; Xu, J; Xu, T; Yang, Y; Zhou, C | 1 |
| Endo, M; Fujiwara, M; Goto, M; Shimizu, T; Uchida, M | 1 |
| Costa, L; Kapur, R; Mohyuddin, GR | 1 |
| Bernabei, L; Bonner, EE; Cruz, Z; Eriksson, H; Gabrilovich, DI; Garcia-Gerique, L; Lawler, M; Lin, C; Liu, Q; Mastio, J; Muthumani, K; Nefedova, Y; Poncz, M; Rosenwasser, M; Törngren, M; Vogl, DT; Vogl, T | 1 |
| Patel, AP | 1 |
| Iida, S; Mateos, MV; Raje, N; Reece, D | 1 |
| Cho, SH; Hong, J; Jeong, JY; Kang, MK; Kim, J; Lee, YR; Moon, JH; Seo, AN; Yang, HT | 1 |
| Ammann, E; Facon, T; Fonseca, R; Hashim, M; He, J; Kumar, S; Lam, A; Nair, S; Wildgust, M | 1 |
| Anderson, K; Bumma, N; D'Souza, A; Dhakal, B; Estrada-Merly, N; Fraser, R; Freytes, CO; Hildebrandt, GC; Holmberg, L; Krem, MM; Kumar, S; Lazarus, HM; Lee, C; Lekakis, L; Mian, H; Murthy, HS; Nathan, S; Nishihori, T; Parrondo, R; Patel, SS; Qazilbash, MH; Shah, N; Sidana, S; Solh, M; Strouse, C; Vesole, DH | 1 |
| González-Calle, V; Mateos, MV | 1 |
| Handa, H; Iida, S; Ishida, T; Kato, K; Mori, A; Ozaki, S | 1 |
| Štork, M | 1 |
| Anagnostopoulos, A; Arcese, W; Beksac, M; Bolaman, AZ; Bulabois, CE; Bunjes, D; Deconinck, E; Delforge, M; Eikema, DJ; Fenk, R; Gagelmann, N; Hayden, PJ; Itälä-Remes, M; Koster, L; Labussière-Wallet, H; Lund, J; McDonald, A; Nabil, Y; Netelenbos, T; Reményi, P; Schönland, S; Stoppa, AM; Thurner, L; van Gorkom, G; Yakoub-Agha, I | 1 |
| Barril, X; Bertran-Mostazo, A; Duro, J; Juárez-Jiménez, J; Miñarro-Lleonar, M | 1 |
| Boichuk, I; Fidrichova, A; Hajek, R; Jelinek, T; Jungova, A; Knechtova, Z; Maisnar, V; Minarik, J; Pavlicek, P; Pika, T; Pospisilova, L; Pour, L; Radocha, J; Sedlak, F; Sevcikova, S; Spicka, I; Stork, M; Straub, J | 1 |
| Bargay, J; Bladé, J; Carrillo, E; Clavero, E; De Arriba, F; Dourdil, V; Escalante, F; García-Mateo, A; González, E; González, S; González-Calle, V; González-Rodríguez, AP; Hernández, MT; Lahuerta, JJ; López, J; Martínez-Lopez, J; Mateos, MV; Moreno, MJ; Ocio, EM; Oriol, A; Pérez-de-Oteyza, J; Puertas, B; Rey-Bua, B; Ríos-Tamayo, R; Rosiñol, L; San Miguel, JF; Sureda, A | 1 |
| Atrash, S; Bhutani, M; Druhan, LJ; Fesenkova, K; Foureau, DM; Friend, R; Guo, F; Norek, S; Paul, B; Pineda-Roman, M; Rigby, K; Robinson, M; Symanowski, JT; Tucker, MR; Usmani, SZ; Varga, C; Voorhees, PM | 1 |
| Brazauskas, R; D'Souza, A; Dong, J; Dwinell, MB; Giralt, S; Janz, S; Krishnan, A; Landau, H; Mohan, M; Pasquini, MC; Stadtmauer, E; Teng, BQ; Yun, G | 1 |
| Chen, G; Chen, Z; Du, K; Li, Y; Zhang, J | 1 |
| Bessou, A; Colin, X; De Nascimento, J; Gorsh, B; Landi, S; Leleu, X; Paka, P; Wang, PF | 1 |
| Berasategui Fuertes, M; González Fernández, A; Larrea Ramírez, A; Sanhueza Torres, I | 1 |
| Albayrak, M; Altuntas, F; Bakırtaş, M; Başcı, S; Basturk, A; Çakar, MK; Dal, MS; Dogu, MH; Ekinci, O; Eser, B; Giden, AO; Gulturk, E; Hacıbekiroglu, T; Kalpakci, Y; Korkmaz, S; Miskioglu, M; Ozatli, D; Serin, I; Ulas, T; Yiğenoğlu, TN | 1 |
| Bahlis, N; Basu, S; Borgsten, F; Duran, J; Facon, T; Frenzel, L; Goldschmidt, H; Hulin, C; Kumar, SK; Leleu, X; Macro, M; Moreau, P; Nahi, H; Orlowski, RZ; Perrot, A; Plesner, T; Quach, H; Raje, N; Rampelbergh, RV; Uhlar, CM; Usmani, SZ; Vermeulen, J; Wang, J; Weisel, K | 1 |
| Bardin, C; Hulin, C; Madelaine, I; Moreau, P; Rioufol, C; Slimano, F; Tournamille, JF | 1 |
| Cao, J; Ding, J; Du, J; Hu, D; Jiang, S; Liang, X; Sun, G; Wang, G; Wang, Y; Zeng, T | 1 |
| Neri, P; Nijhof, I | 1 |
| Anguille, S; Avivi, I; Cavo, M; Chen, D; Cohen, YC; Connors, K; Costa, LJ; Dhakal, B; Dytfeld, D; Einsele, H; Fernández de Larrea, C; Florendo, E; Gilbert, J; Griffin, J; Harrison, SJ; Ho, PJ; Ishida, T; Jackson, CC; Khan, AM; Kim, SJ; Leleu, X; Lendvai, N; Li, K; Lonardi, C; Martínez-López, J; Mateos, MV; Moreau, P; Nagle, S; Oriol, A; Pacaud, L; Patel, N; Popat, R; Roeloffzen, W; San-Miguel, J; Schecter, JM; Sidana, S; Slaughter, A; Spencer, A; Touzeau, C; van de Donk, NWCJ; Yeh, TM; Yong, K; Zudaire, E | 1 |
| Katayama, S; Ota, M; Yamaga, M | 1 |
| Barrak, J; Benboubker, L; Calmettes, C; Charvet-Rumpler, A; Chouaid, C; Clement-Filliatre, L; Honeyman, F; Hulin, C; Karlin, L; Laribi, K; Leleu, X; Macro, M; Maloisel, F; Richez, V; Stoppa, AM; Vincent, L; Zerazhi, H | 1 |
| Bowles, K; Brown, SR; Cook, G; De Tute, RM; Drayson, MT; Garg, M; Hall, A; Houlston, RS; Ingleson, E; Jackson, G; Jenner, MW; Kaiser, MF; Lokare, A; Messiou, C; Newnham, N; Owen, RG; Pratt, G; Roberts, S; Sherborne, A; Walker, K | 1 |
| Blau, IW; Bories, P; Bringhen, S; Dong, L; Fitzmaurice, T; Gassiot, M; Karlin, L; Le Roux, N; Macé, S; Marcatti, M; Martinez-Lopez, J; Mateos, MV; Moreau, P; Nogai, A; Ocio, EM; Oliva, S; Oprea, C; Perrot, A; Rodriguez-Otero, P; San-Miguel, JF; Wang, SY | 1 |
| Abe, Y; Chou, T; Handa, H; Ito, S; Mori, I; Sasaki, M; Shinozaki, T; Suzuki, K; Takezako, N; Yoshida, T | 1 |
| Chen, H; Xu, W; Xu, Y; Yu, J; Zhou, F; Zhou, Y | 1 |
| Dunn, R; Harrison, SJ; Kalff, A; Quach, H; Reynolds, J; Shortt, J; Spencer, A; Walker, P; Wallington-Gates, C; Wellard, C | 1 |
| Cordner, T; Fiala, MA; Loh, KP; Mian, H; Silberstein, AE; Wildes, TM | 1 |
| Costa, B; Delforge, M; Dimopoulos, M; Facon, T; Hulin, C; Leleu, X; Manier, S; Mouro, J; Sturniolo, M; Weisel, K | 1 |
| Ginn, M; Strouse, C; Struble, E | 1 |
| Jeon, YW; Lee, JY; Min, CK; Park, SS; Shin, SH; Yahng, SA | 1 |
| Cao, Y; Dhodapkar, M; Hall, KH; Harvey, RD; Hofmeister, CC; Joseph, NS; Kaufman, JL; Liu, Y; Lonial, S; Maples, KT; Nooka, AK; Sun, LF | 1 |
| Bashir, Q; Champlin, RE; Kebriaei, P; Lee, HC; Lin, P; Masood, A; Milton, DR; Nieto, Y; Orlowski, RZ; Pasvolsky, O; Patel, KK; Qazilbash, MH; Ramdial, J; Saeed, A; Saini, N; Sami, SS; Shpall, EJ; Srour, S; Tanner, MR; Thomas, SK; Weber, DM | 1 |
| Anderson, K; Avigan, D; Bisharat, L; Callander, N; Cheloni, G; Chodon, T; Chung, DJ; Devine, S; Dhakal, B; Efebera, Y; Geller, N; Ghiasuddin, H; Hematti, P; Holmberg, L; Howard, A; Johnson, B; Karagkouni, D; Lazarus, HM; Logan, B; Malek, E; McCarthy, P; McKenna, D; Mendizabal, A; Munshi, N; Nooka, A; O'Donnell, L; Pasquini, MC; Rapoport, AP; Reese, J; Rosenblatt, J; Shah, N; Soiffer, R; Somaiya Dutt, P; Stroopinsky, D; Uhl, L; Vlachos, IS; Waller, EK; Wu, J; Young, JW | 1 |
| Azaman, I; Chng, WJ; Chong, PSY; Chooi, JY; Chung, TH; Koh, MY; Leow, ACY; Lim, JSL; Tan, TZ; Teoh, PJ; Toh, SHM | 1 |
| Alonso, R; Ayala, R; Calbacho, M; Cedena, MT; Cruz, J; Cuellar, C; de la Cruz, J; Hernández-Ibarburu, G; Iñiguez, R; Jiménez-Ubieto, A; Lopez-Muñoz, N; Martinez-Lopez, J; Meloni, L; Pedrera, M; Pérez-Rey, D; Sanchez-Pina, JM; Serrano, P | 1 |
| Chung, DJ; Ciardiello, A; Derkach, A; Diamond, B; Giralt, SA; Hassoun, H; Hultcrantz, M; Korde, N; Lahoud, OB; Landau, HJ; Landgren, O; Lesokhin, A; Maclachlan, K; Mailankody, S; Nemirovsky, D; Patel, D; Scordo, M; Shah, GL; Shah, U; Tan, CR; Usmani, SZ | 1 |
| Bargay, J; Bladé, J; Blanchard, MJ; Cabañas, V; Cabezudo, E; Carrillo-Cruz, E; Casado, LF; Cedena, MT; de Arriba, F; de la Cruz, J; Encinas, C; González, ME; González-Montes, Y; Hernández, MT; Jarque, I; Krsnik, I; Lahuerta, JJ; Martí, JM; Martínez-López, J; Mateos, MV; Oriol, A; Paiva, B; Palomera, L; Puig, N; Ríos, R; Rosiñol, L; Sampol, A; San Miguel, J; Sureda, A | 1 |
| Fiala, MA; Kavanaugh, M; Loncharich, AJ; Sanfilippo, KM; Schroeder, MA; Slade, MJ; Stockerl-Goldstein, K; Vickroy, A; Vij, R; Wilson, C | 1 |
| Arroyo, CH; Beksac, M; Besemer, B; Bourhis, JH; Eikema, DJ; Engelhardt, M; Haenel, M; Hayden, PJ; Jost, E; Kröger, N; Kuball, J; Manier, S; Mateos, MV; Mclornan, D; Michieli, M; Moraleda, JM; Rabin, N; Schaap, N; Schönland, S; Schub, N; Schuermans, C; Tilmont, R; Wilson, KMO; Yakoub-Agha, I; Za, T; Zinger, N | 1 |
| Bekri, S; Cho, HJ; Costa, LJ; Hamidi, H; Neparidze, N; Nielsen, TG; Raval, A; Sareen, R; Vij, R; Wassner-Fritsch, E; Wong, S | 1 |
| Furukawa, Y; Iha, H; Ikeda, S; Kikuchi, J; Osada, N; Takahashi, N; Yasui, H | 1 |
| Abel, GA; Bihn, J; Brophy, M; Corrigan, J; Dharne, M; Do, NV; Driver, JA; DuMontier, C; Fillmore, NR; Gaziano, JM; Hassan, H; Kim, DH; La, J; Munshi, NC; Yellapragada, S; Yildirim, C | 1 |
| Furihata, H; Imai, Y; Kosako, H; Miyakawa, T; Nagaoka, K; Nagasaka, T; Nishino, K; Sawasaki, T; Shibata, N; Shoya, Y; Tanokura, M; Taya, A; Usui, M; Yamanaka, S; Yanagihara, Y; Yoshida, S | 1 |
| Filanovsky, K; Shvidel, L; Stanevsky, A; Temper, N | 1 |
| Anderson, KC; Bladé, J; Dispenzieri, A; Durie, BG; Facon, T; Kumar, S; Laubach, JP; Lonial, S; Mateos, MV; Moreau, P; Munshi, N; O'Donnell, E; O'Gorman, P; Perrot, A; Raje, N; Richardson, PG; Rosiñol, L; Voorhees, P | 1 |
| Amatangelo, M; Arnao, M; Bahlis, NJ; Berdeja, JG; Casas-Avilés, I; Gong, J; Karanes, C; Katz, J; Kim, K; Lamba, M; Li, S; Lonial, S; Maciag, P; Martinez-Lopez, J; Mateos, MV; Oriol, A; Orlowski, RZ; Pawlyn, C; Peluso, T; Pierce, DW; Poon, J; Popat, R; Pourdehnad, M; Quach, H; Ramasamy, K; Richardson, PG; Rodríguez Otero, P; Spirli, A; Trudel, S; Vangsted, AJ; Wong, L | 1 |
| Cho, HJ; Ciardiello, A; Coffey, DG; Dawson, T; Diamond, B; Diaz-Mejia, JJ; Gnjatic, S; Gonzalez-Kozlova, E; Green, DJ; Kazandjian, D; Kim-Schulze, S; Landgren, O; Lee, B; Lesokhin, A; Luo, P; Maura, F; Pugh, TJ; Rahman, A; Smith, E; Warren, EH; Xie, H; Xu, Y; Zhang, Y | 1 |
| Aslam, M; Bergstrom, D; Chu, MP; Côté, J; Gul, E; Jimenez-Zepeda, VH; Kaedbey, R; Kotb, R; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Mian, H; Reece, D; Reiman, A; Sebag, M; Song, K; Stakiw, J; Su, J; Venner, CP; White, D | 1 |
| Bashir, Q; Champlin, RE; Ghanem, S; Kebriaei, P; Lee, HC; Lin, P; Masood, A; Milton, DR; Nieto, Y; Orlowski, RZ; Pasvolsky, O; Patel, KK; Qazilbash, MH; Ramdial, J; Saini, N; Shpall, EJ; Srour, S; Tanner, MR; Thomas, SK; Weber, DM | 1 |
| Hayashi, S; Kondo, E; Kondo, T; Nishimura, H; Shimizu, R; Uchida, K; Wada, H; Yokoi, M | 1 |
| Davies, FE; Dhanasiri, S; Le Nouveau, P; Leleu, X; Vogel, P; Weisel, K | 1 |
| Czabak, O; Czyż, J; Derman, BA; Druzd-Sitek, A; Dytfeld, D; Giannopoulos, K; Gil, L; Jakubowiak, AJ; Jamroziak, K; Kubicki, T; Lahoud, OB; Majcherek, M; Matuszak, M; Mikulski, D; Puła, B; Robak, P; Rybka, J; Stefka, A; Szczepaniak, T; Szukalski, Ł; Tyczyńska, A; Usnarska-Zubkiewicz, L; Wróbel, T; Zaucha, JM; Łojko-Dankowska, A | 1 |
| Anderson, LD; Bumma, N; Chari, A; Cortoos, A; Costa, LJ; Costello, C; Cowan, AJ; Dinner, S; Efebera, YA; Holstein, SA; Jakubowiak, A; Kaufman, JL; Laubach, J; Lin, TS; Nathwani, N; Orlowski, RZ; Patel, S; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Shain, KH; Silbermann, R; Usmani, SZ; Voorhees, PM; Wildes, TM | 1 |
| Cooper, JD; DeStefano, CB; Pham, K; Shou, K; Sunderland, K; Thornton, JA | 1 |
| Avet-Loiseau, H; Bargay, J; Besozzi, D; Blade, J; Blanco, L; Botta, C; Cedena, MT; Correale, P; de Arriba, F; Gentile, M; Gironella, M; Goicoechea, I; Goldschmidt, H; González-Garcia, ME; Hernandez, MT; Lahuerta, JJ; Larrayoz, M; Lopez, A; Martinez Climent, JA; Martinez-Lopez, J; Mateos, MV; Moraleda, JM; Nobile, MS; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Papetti, DM; Perez, C; Pérez-Montaña, A; Puig, N; Rios Tamayo, R; Roccaro, A; Rodriguez, S; Rosiñol, L; San-Miguel, JF; Sarvide, S; Siragusa, S; Sureda, A; Termini, R; Zabaleta, A | 1 |
| Kwak, LW; Qazilbash, MH | 1 |
| Fukuta, H; Hagiwara, H; Hashimoto, H; Iida, S; Ikuta, K; Kamiya, T; Kusumoto, S; Nakayama, T | 1 |
| Bal, S; Callander, NS; Chhabra, S; Cornell, RF; Costa, LJ; D'Souza, A; Dhakal, B; Dholaria, BR; Giri, S; Godby, KN; Hall, AC; Hardwick, P; Hari, P; Medvedova, E; Omel, J; Schmidt, TM; Silbermann, R | 1 |
| Baldini, L; Beksac, M; Bila, J; Boccadoro, M; Carson, R; Delimpasi, S; Dimopoulos, MA; Einsele, H; Kampfenkel, T; Katodritou, E; Kosh, M; Liu, W; Mateos, MV; Moreau, P; Orfanidis, I; Oriol, A; Sonneveld, P; Symeonidis, A; Terpos, E; Tran, N; Wang, J | 1 |
| Bye, AP; Gibbins, JM; Grech, H; Khan, D; Kriek, N; Laffan, M; Mitchell, JL; Ramasamy, K; Rana, RH; Sage, T; Shapiro, S; Thakurta, A; Unsworth, AJ | 1 |
| Tsukada, N | 1 |
| Kuroda, Y | 1 |
| van de Donk, NWJC; Zweegman, S | 1 |
| Abramson, HN | 1 |
| Akdeniz, A; Aslan, C; Aslaner Ak, M; Bağcı, M; Çeneli, Ö; Dağlı, M; Dal, MS; Demircioğlu, S; Doğan, A; Erol, HA; Ertop, Ş; Gedük, A; Gürsoy, V; Keklik Karadağ, F; Merter, M; Oruç Uysal, A; Özkalemkaş, F; Saydam, G; Seçilmiş, S; Tekinalp, A; Terzi Demirsoy, E; Ural, C | 1 |
| Cheng, Q; Hu, Y; Li, J; Li, Q; Sun, C; Xu, A; Yan, H; Zhang, B; Zhao, F | 1 |
| Gupta, N; Kapoor, S; Sharma, A | 1 |
| Kobayashi, Z | 1 |
| Sato, S | 1 |
| Adamkovich, N; Alizadeh, H; Bereczki, Á; Borbényi, Z; Csacsovszki, O; Csukly, Z; Egyed, M; Farkas, P; Illés, Á; Lovas, S; Masszi, T; Mikala, G; Nagy, Z; Plander, M; Rajnics, P; Rejtő, L; Schneider, T; Szaleczky, E; Szendrei, T; Szomor, Á; Varga, G; Váróczy, L; Wohner, N; Wolf, K | 1 |
| Baturevych, A; Carlson, P; Clouser, CR; Curtis, W; Hause, RJ; Hauskins, C; Jessup, HK; Jiang, Y; Johnstone, TG; Jones, JC; Kugler, D; Ports, MO; Salmon, RA; Sather, B; Sierra, C; Soni, N; Wimberly, L; Works, M | 1 |
| Chen, Y; He, Y; Hu, Y; Li, Y; Xie, X; Zhang, H | 1 |
| Berenson, JR; Bujarski, S; Cao, J; Chen, H; Hekmati, T; Li, M; Ng, N; Nosrati, JD; Sanchez, E; Soof, CM; Spektor, TM; Tang, G; Wang, CS; Wen, M; Xu, N; Zahab, B | 1 |
| Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E | 1 |
| Nohgawa, M; Oka, S; Ono, K | 4 |
| Chantry, AD; Down, JM; Evans, HR; Green, AC; Hudson, K; Lath, D; Lawson, MA; Owen, R; Paton-Hough, J; Reilly, GC; Walkley, B | 1 |
| Besse, L; Driessen, C; Hess, D; Hitz, F; Kraus, M; Mey, U; Novak, U; Pabst, T; Rondeau, S; Samaras, P; Seipel, K; Silzle, T; Stüdeli, S; Vilei, SB | 1 |
| Arguiñano, JM; Bargay, J; Bladé, J; Blanchard, MJ; Casado, LF; de Arriba, F; Gironella, M; González, AP; González, ME; González-Montes, Y; Hernández, MT; Jarque, I; Krsnik, I; Lahuerta, JJ; López-Anglada, L; Martí, JM; Martínez-Martínez, R; Mateos, MV; Moraleda, JM; Oriol, A; Paiva, B; Palomera, L; Rios, R; Rosiñol, L; San Miguel, JF; Sureda, A | 1 |
| Alexanian, R; Feng, L; Johnson, RJ; Lee, HC; Morphey, A; Orlowski, RZ; Shah, JJ; Thomas, SK; Wang, ML; Weber, DM; Wesson, ET | 1 |
| Abildgaard, N; Bos, G; Brouwer, R; Coenen, J; Deenik, W; Durian, M; Gimsing, P; Hansson, M; Haukås, E; Hinge, M; Klein, S; Levin, MD; Leys, R; Lissenberg-Witte, B; Mellqvist, UH; Nielsen, LK; Salomo, M; Sinnige, H; Sonneveld, P; Stege, C; Szatkowski, D; Tanis, B; van de Donk, N; van der Hem, K; van der Holt, B; van der Velden, A; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S | 1 |
| Benson, DM; Bumma, N; Chaudhry, M; Chen, DT; Devarakonda, S; Efebera, YA; Hofmeister, CC; Khan, A; Rosko, A; Sborov, D; Sharma, N; Williams, NY; Zhao, Q | 1 |
| Hashmi, H; Maghavani, DP; Reynolds, SB | 1 |
| Berenson, JR; Ghermezi, M; Spektor, TM | 1 |
| An, Z; Guo, X; Li, F; Li, H; Mei, J; Shao, J; Song, P; Wang, X; Zhai, Y; Zhao, Q; Zhou, X | 1 |
| Falcetta, FS; Manica, D; Morais, VD; Pithan, CDF; Ribeiro, MR; Ribeiro, RA; Salazar, AP; Sekine, L; Sosnoski, M; Ziegelmann, PK | 1 |
| Dahmash, F; Elmaagacli, AH; Huber, M; Jehn, C; Niggemann, C; Salwender, H; Shikova, Y; Singh, A; Vierbuchen, M | 1 |
| Mo, CC; Richardson, PG | 1 |
| Barth, PM; Olszewski, AJ; Reagan, JL | 1 |
| Paumgartten, FJR | 1 |
| Aquino, S; Baldini, L; Ballanti, S; Boccadoro, M; Bringhen, S; Cellini, C; D'Agostino, M; De Rosa, L; Falco, P; Gazzera, G; Gentile, M; Grasso, M; Hájek, R; Larocca, A; Marasca, R; Palumbo, A; Paris, L; Pavone, V; Pescosta, N; Petrucci, MT; Pezzatti, S; Poggiu, M; Rota-Scalabrini, D; Santoro, A; Spada, S; Tosi, P | 1 |
| Agajanian, R; Agarwal, A; Bahlis, NJ; Chung, W; Kaya, H; Malek, E; Mouro, J; Pierceall, WE; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, KW; Srinivasan, S; Stockerl-Goldstein, K; Talamo, G; Zafar, F | 1 |
| Beedie, SL; Chau, CH; Figg, WD; Gere, S; Huang, PA; Kazandjian, D; Korde, N; Landgren, O; Mailankody, S; Venzon, DJ | 1 |
| Abouzaid, S; Agarwal, A; Hari, P; Parikh, K; Ung, B | 1 |
| Mathews, KB; Mauro, J; Sredzinski, ES | 1 |
| Chou, T; Iida, S; Ishida, T; Izumi, T; Ozaki, S; Ri, M; Shumiya, Y; Sugiura, I; Sunami, K; Suzuki, K; Takezako, N | 1 |
| Anderson, KC; Baz, R; Becker, PS; Chuma, S; Ghobrial, IM; Henrick, P; Hornburg, K; Laubach, J; Liu, CJ; Perez, RP; Redd, RA; Reyes, K; Richardson, PG; Robbins, MD; Sabbatini, P; Savell, A; Sklavenitis-Pistofidis, R; Zavidij, O | 1 |
| Anttila, P; Bazia, P; Heiskanen, J; Huotari, V; Ilveskero, S; Jantunen, E; Kakko, S; Kananen, K; Launonen, K; Lievonen, J; Lundan, T; Luoma, S; Mäntymaa, P; Ollikainen, H; Partanen, A; Pelliniemi, TT; Putkonen, M; Räsänen, A; Säily, M; Sankelo, M; Selander, T; Siitonen, T; Sikiö, A; Silvennoinen, R; Suominen, M; Terävä, V; Tienhaara, A | 1 |
| Agirrezabal, I; Campioni, M; Gonzalez-McQuire, S; Hajek, R; Jandova, P; Maisnar, V; Minarik, J; Pour, L; Spicka, I | 1 |
| Cavo, M; Dimopoulos, MA; Facon, T; Gebregergish, SB; Heeg, B; Lam, A; Mateos, MV; Nair, S; Pisini, M; Slavcev, M; van Beekhuizen, S | 1 |
| Fuchida, SI; Hatsuse, M; Matsui-Maegawa, S; Murakami, S; Okano, A; Shimazaki, C; Shimura, K; Taminishi-Katsuragawa, Y | 1 |
| Hagiwara, S; Handa, H; Hatake, K; Hori, M; Ito, S; Kinoshita, G; Kubo, K; Matsumoto, M; Miyoshi, M; Nakaseko, C; Ohashi, K; Ohta, K; Shelat, SG; Suzuki, K; Takezako, N | 1 |
| Arsène-Henry, A; Bouscary, D; Kirova, Y; Mignot, F; Schernberg, A; Vignon, M | 1 |
| Buchanan, V; D'Souza, VK; Dhanasiri, S; Ramasamy, K; Robinson, S; Thom, H; Weisel, K | 1 |
| Jakubowiak, AJ; Johnson, D; Nakamura, Y; Park, JH; Rosebeck, S; Stefka, AT | 1 |
| Amatangelo, M; Bjorklund, CC; Chiu, H; Couto, S; Flynt, JE; Kang, J; Katz, M; Ortiz, M; Pierceall, W; Polonskaia, A; Ren, Y; Thakurta, A; Towfic, F; Wang, M | 1 |
| Abe, Y; Ishida, T; Miyazaki, K; Nashimoto, J; Ogura, M; Okazuka, K; Sato, K; Suzuki, K; Tsukada, N; Uto, Y; Yoshiki, Y | 1 |
| Kimball, A; Klippel, Z; Tekle, C | 1 |
| Dhanasiri, S | 1 |
| Adams, A; Estcourt, LJ; Jakob, T; Kuhr, K; Langer, P; Monsef, I; Ocheni, S; Piechotta, V; Scheckel, B; Scheid, C; Skoetz, N; Theurich, S | 1 |
| Barwick, BG; Bernal, L; Boise, LH; Chen, Z; Dhodapkar, MV; Goyal, S; Gupta, VA; Heffner, LT; Hofmeister, CC; Jaye, DL; Joseph, N; Kaufman, JL; Lonial, S; Nooka, AK; Schmidt, TM; Wu, J | 1 |
| Bargay, J; Blade, J; Blanchard, MJ; Burgos, L; Calasanz, MJ; Cedena, MT; Cordón, L; de la Cruz, J; de la Rubia, J; Flores-Montero, J; Garcia-Sanz, R; Gutierrez, NC; Hernandez, MT; Krsnik, I; Lahuerta, JJ; Lopez-Anglada, L; Maldonado, R; Martin, J; Martin-Ramos, ML; Martinez-Lopez, J; Martinez-Martinez, R; Mateos, MV; Moraleda, JM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rios, R; Rosiñol, L; San-Miguel, JF; Sanoja-Flores, L; Sureda, A; Van Dongen, JJM; Vidriales, MB | 1 |
| Djebbari, F; Fourali, S; Kothari, J; Lynes, JA; McLain-Smith, S; Ramasamy, K; Sharpley, FA | 1 |
| Garcia, DA; Li, A; Li, S; Libby, EN; Lyman, GH; Warnick, G; Wu, Q | 1 |
| Aboulafia, DM; Hwang, DG; Peterson, JF; Sinit, RB; Vishnu, P | 1 |
| Brioli, A; Fabisch, C; Hänel, M; Hochhaus, A; Illmer, T; Knop, S; Krammer-Steiner, B; Manz, K; Mügge, LO; Pfirrmann, M; Prange-Krex, G; Schwarzer, AC; von Lilienfeld-Toal, M | 1 |
| Delimpasi, S; Dialoupi, I; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Giannouli, S; Kanellias, N; Kastritis, E; Migkou, M; Mparmparousi, D; Ntanasis-Stathopoulos, I; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E; Tsirigotis, P; Xirokosta, A; Ziogas, DC | 1 |
| Cahn, JY; Courby, S; Deteix, C; Larabi, A; Meunier, M; Schacherer, M | 1 |
| Eom, HS; Jung, KS; Kim, HJ; Kim, JS; Kim, K; Kim, SH; Lee, JJ; Lee, JO; Min, CK; Shin, HJ | 1 |
| Fiala, M; Mian, H; Wildes, TM | 1 |
| Abril, L; Ibarra, G; Oriol, A; Senin, A | 1 |
| Kada, A; Komeno, T; Saito, AM; Sawamura, M; Sunami, K; Takezako, N; Yokoyama, A | 1 |
| Bang, SM; Cho, SH; Do, YR; Eom, HS; Jo, JC; Kim, HJ; Kim, J; Kim, JS; Kim, K; Kim, MK; Kim, SH; Lee, HS; Lee, JH; Lee, JJ; Lee, MH; Lee, WS; Lee, Y; Lim, SN; Min, CK; Mun, YC; Park, SK; Park, Y; Shin, HJ; Yi, JH; Yoon, DH; Yoon, SS | 1 |
| Ardoino, I; Baldini, L; Cafro, AM; Carniti, C; Corradini, P; Corso, A; Crippa, C; Galli, M; Gherlinzoni, F; Marcatti, M; Montefusco, V; Nozza, A; Patriarca, F; Pezzatti, S; Sammassimo, S; Zambello, R | 1 |
| Anwer, F; Bin Riaz, I; Chakraborty, R; Khan, SU; Khorana, AA; Kumar, S; Majhail, NS; Malik, SU; Marneni, N; Mejia Garcia, A; Murad, MH; Rajkumar, SV; Wang, Z | 1 |
| Horisawa, Y; Kazuma, Y; Matsui, H; Matsumoto, T; Sarca, AD; Shindo, K; Shirakawa, K; Shirakawa, R; Stanford, E; Takaori-Kondo, A; Yamazaki, H | 1 |
| Balasundaram, N; David, S; Devasia, AJ; Ganesan, S; George, B; Mathews, V; Palani, HK | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
| Berenson, JR; Eades, BM; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Moss, RA; Sanchez, A; Schwartz, G; Spektor, TM; Stampleman, L; Swift, RA; To, J; Turner, C; Vescio, R | 1 |
| Gunji, T; Katori, M; Masuoka, H; Nishiwaki, K; Suzuki, K; Yano, S | 1 |
| Bayer, R; Becker, M; Chung, D; Devlin, S; Gentile, T; Giralt, S; Hassoun, H; Landau, H; Lesser, M; O'Dweyer, K | 1 |
| Alegre Del Rey, EJ; Gimeno Ballester, V; Matas Hoces, A; Olry de Labry Lima, A; Ríos Sánchez, E | 1 |
| Akashi, K; Choi, I; Iwasaki, H; Kamimura, T; Miyamoto, T; Mori, Y; Muta, T; Ogawa, R; Tanimoto, K; Yamasaki, S; Yoshimoto, G | 1 |
| de Vassoigne, F; Gaugler, B; Malard, F; Marjanovic, Z; Mohty, M; Ricard, L; Stocker, N | 1 |
| Byrne, M; Chinratanalab, W; Cornell, RF; Culos, KA; Engelhardt, BG; Goodman, S; Gopalakrishnan, R; Jagasia, M; Kassim, AA; McArthur, E; Mosse, CA; Patel, DA; Savani, BN; Sengsayadeth, S | 1 |
| Bahlis, NJ; Benboubker, L; Chiu, C; Cook, G; Dimopoulos, MA; Ho, PJ; Kaufman, JL; Kim, K; Krevvata, M; Leiba, M; Moreau, P; Okonkwo, L; Qi, M; Qin, X; San-Miguel, J; Takezako, N; Trivedi, S; Ukropec, J; White, DJ | 1 |
| Iida, S; Shibayama, H; Shibayama, K; Suzuki, K; Takamatsu, H; Yamazaki, H | 1 |
| Altuntaş, F; Batgi, H; Dal, MS; Kızıl Çakar, M; Merdin, A; Yiğenoğlu, TN | 1 |
| Bernhard, H; Bertsch, U; Blau, IW; Brossart, P; Dürig, J; Elmaagacli, A; Fuhrmann, S; Giesen, N; Goerner, M; Goldschmidt, H; Hänel, M; Hielscher, T; Hillengass, J; Hoffmann, M; Hose, D; Hügle-Dörr, B; Huhn, S; Jauch, A; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Merz, M; Munder, M; Raab, MS; Rabold, B; Salwender, HJ; Scheid, C; Seckinger, A; Tichy, D; Weisel, KC | 1 |
| Mulay, S; Singh, M; Thomas, VM | 1 |
| Afifi, S; Busam, KJ; Giralt, S; Hassoun, H; Lacouture, ME; Nguyen, J; Singh, N | 1 |
| Aoki, S; Asano, A; Fukuda, S; Iida, S; Ito, A; Kanamori, T; Kinoshita, S; Komatsu, H; Kubo, K; Kusumoto, S; Ri, M; Tachita, T; Tohkin, M; Totani, H; Yamagata, K; Yoshida, T | 1 |
| Bladé, J; Clemens, PL; Deraedt, W; Jakubowiak, A; Krishnan, A; Lonial, S; Luo, M; Moreau, P; Nnane, I; Oriol, A; Qi, M; Sun, YN; Ukropec, J; Usmani, SZ; Xu, XS; Zhou, H | 1 |
| Djebbari, F; Eyre, TA; Kothari, J; McLain-Smith, S; Moore, S; Ramasamy, K; Sharpley, FA; Vallance, G | 1 |
| Arnulf, B; Attal, M; Belhadj, K; Caillot, D; Dhanasiri, S; Escoffre, M; Facon, T; Garderet, L; Guo, S; Hebraud, B; Hulin, C; Karlin, L; Leleu, X; Macro, M; Moreau, P; Perrot, A; Roussel, M; Stoppa, AM; Weng, J | 1 |
| Borsi, E; Caratozzolo, I; Cavo, M; De Cicco, G; Dozza, L; Fusco, A; Mancuso, K; Martello, M; Marzocchi, G; Pantani, L; Rizzello, I; Rocchi, S; Tacchetti, P; Terragna, C; Testoni, N; Zamagni, E | 1 |
| Antonioli, E; Attingenti, E; Ballanti, S; Belotti, A; Boccadoro, M; Bonalumi, A; Botta, C; Bringhen, S; Brunori, M; Califano, C; Capalbo, S; Cascavilla, N; Cavo, M; Cerchione, C; Consoli, U; Conticello, C; Criscuolo, C; Curci, P; De Stefano, V; Derudas, D; Di Raimondo, F; Di Renzo, N; Fraticelli, V; Frigeri, F; Gagliardi, A; Galli, M; Gamberi, B; Gangemi, D; Gentile, M; Giuliani, N; Lombardo, A; Mangiacavalli, S; Marcacci, G; Martino, M; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Patriarca, F; Petrucci, MT; Pitino, A; Pompa, A; Recchia, AG; Ria, R; Rocco, S; Rossi, E; Siniscalchi, A; Specchia, G; Stocchi, R; Tripepi, G; Uccello, G; Vigna, E; Vincelli, D; Zamagni, E; Zambello, R | 1 |
| Dialoupi, I; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Kanellias, N; Kastritis, E; Kokkali, NA; Malandrakis, P; Migkou, M; Ntanasis-Stathopoulos, I; Papatheodorou, A; Roussou, M; Terpos, E | 1 |
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Lesokhin, AM; Wills, B; Wudhikarn, K | 1 |
| Diamond, B; Hillengass, J; Kazandjian, D; Landgren, CO; Maclachlan, K; Maura, F; Turesson, I | 1 |
| Dew, A; Hill, E; Kazandjian, D | 1 |
| Lu, SX | 1 |
| Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P | 1 |
| Avet-Loiseau, H; Badola, S; Bahlis, NJ; Berg, D; Cavo, M; Di Bacco, A; Esseltine, DL; Ganly, P; Keats, JJ; Kumar, SK; Langer, C; Li, B; Lin, J; Luptakova, K; Masszi, T; Moreau, P; Munshi, NC; Pour, L; Rajkumar, SV; Richardson, PG; Shen, L; van de Velde, H; Viterbo, L; Zhang, J | 1 |
| Aryal, M; Chhabra, S; D'Souza, A; Dhakal, B; Ghose, S; Giri, S; Hamadani, M; Hari, PN; Janz, S; Narra, RK; Pathak, LK; Smunt, TL; Szabo, A | 1 |
| Biran, N; Donato, ML; Goldberg, S; Ip, A; Kaur, G; Siegel, DS; Vesole, DH | 1 |
| Corvatta, L; Costantini, B; Maracci, L; Morè, S; Offidani, M; Olivieri, A | 1 |
| Fernández, GI; Ribera, JM; Sabater, LA | 1 |
| Agis, H; Blank, A; Blau, IW; Chatterjee, M; Einsele, H; Engelhardt, M; Ferstl, B; Goldschmidt, H; Griese, J; Härtle, S; Jarutat, T; Peschel, C; Raab, MS; Röllig, C; Schub, N; Weirather, J; Weisel, K; Winderlich, M | 1 |
| Daguenet, E; Fouillet, L; Guyotat, D; Laurent, B; Le Jeune, C; Sapet, M | 1 |
| Fujieda, A; Ino, K; Kashima, E; Katayama, N; Masuya, M; Nato, Y; Tawara, I | 1 |
| Aitchison, R; Dimopoulos, MA; Gavriatopoulou, M; Hajek, R; Jelinek, T; Jenner, MW; Kastritis, E; Katodritou, E; Kothari, J; Kotsopoulou, M; Maouche, N; Minarik, J; Ntanasis-Stathopoulos, I; Pika, T; Plonkova, H; Ramasamy, K; Terpos, E; Vallance, GD; Zomas, A | 1 |
| Abe, Y; Fujita, H; Handa, H; Hayashi, T; Ishida, T; Kiguchi, T; Kimura, H; Kondo, S; Kosugi, H; Kubo, K; Mitani, K; Morita, S; Murakami, H; Ohashi, K; Ohta, K; Omoto, E; Ozaki, S; Sakai, R; Shimizu, K; Sunami, K; Takamatsu, H; Takezako, N; Yamamoto, S | 1 |
| Alavi, A; Ayash, L; Chi, J; Deol, A; Kim, S; Kin, A; Modi, D; Ratanatharathorn, V; Uberti, JP | 1 |
| Dechow, T; Hackanson, B; Knop, S; Merz, M; Scheytt, M; Schmidt, C | 1 |
| Almaula, DK; Boise, LH; Dhodapkar, MV; Gupta, VA; Heffner, LT; Hofmeister, CC; Joseph, NS; Kaufman, JL; Lonial, S; Nooka, AK | 1 |
| Cornell, RF; Engelhardt, BG; Goldhaber, SZ; Hall, R; Harrell, S; Jagasia, M; Moslehi, J; Piazza, G; Rubinstein, SM; Wyatt, H | 1 |
| Camilleri, M; Checkley, A; Pomplun, S; Rabin, N; Richards, H; Wilson, A | 1 |
| Anderson, LD; Chari, A; Costa, LJ; Costello, C; Cowan, AJ; de Boer, C; Efebera, YA; Hoehn, D; Holstein, SA; Jakubowiak, A; Kaufman, JL; Laubach, J; Lin, TS; Lutska, Y; Murphy, S; Nathwani, N; Orlowski, RZ; Pei, H; Reeves, B; Richardson, PG; Rodriguez, C; Sborov, DW; Shah, N; Shain, KH; Silbermann, R; Ukropec, J; Vermeulen, J; Voorhees, PM; Wildes, TM | 1 |
| Ikeda, N; Kakimoto, T; Kusunoki, Y; Namba-Hamano, T; Takeji, M; Teramoto, K; Wakabayashi, K; Yamamoto, S | 1 |
| Avet-Loiseau, H; Bahlis, NJ; Berg, D; Dash, AB; Di Bacco, A; Li, B; Lin, J; Moreau, P; Richardson, PG; Shen, L; Zhang, J | 1 |
| Ghobrial, IM; Nadeem, O | 1 |
| Acosta-Rivera, M; Agarwal, A; Anz, B; Bahlis, NJ; Bar, M; Berdeja, J; Chung, W; Fonseca, G; Ganguly, S; Matous, J; Pierceall, WE; Quick, D; Reece, D; Samaras, C; Schiller, GJ; Sebag, M; Seet, CS; Siegel, DS; Song, K; Talamo, G; Zafar, F | 1 |
| Kocoglu, M; Li, A; Nageshwar, M; Sanchez-Petitto, G; Singh, Z; Tkaczuk, KHR | 1 |
| Abidi, MH; Barlogie, B; Dispenzieri, A; Durie, BGM; Epstein, J; Hoering, A; Kahanic, SP; Orlowski, RZ; Rajkumar, SV; Reu, FJ; Reynolds, CM; Sexton, R; Thakuri, MC | 1 |
| Hagiwara, S; Hirai, R; Miwa, A; Nakamura, M; Sekine, R; Takeshita, M; Tanimura, A; Togano, T | 1 |
| Hamaguchi, T; Kamiya, KI; Komatsu, J; Nakamichi, K; Nakano, H; Saijo, M; Takano, S; Usui, Y; Yamada, M | 1 |
| Alonso, R; Bahri, N; Cedena, MT; Collado-Yurrita, L; García, C; Lahuerta, JJ; López-Jiménez, J; Martin, T; Martínez-López, J; Moraleda, JM; Ríos-Tamayo, R; Sánchez, R; Shah, N; Valeri, A; Wolf, J; Wong, S | 1 |
| Bradbury, CA; Cairns, DA; Child, JA; Cook, G; Craig, Z; Davies, FE; Drayson, MT; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Morgan, GJ; Owen, RG; Paterson, A; Pawlyn, C | 1 |
| Schoenbeck, KL; Wildes, TM | 1 |
| Cheong, MA; Kanagasabapathy, K; Lim, CC; Loh, A; Lwin, KZL; Nagarajan, C | 1 |
| Abraham, Y; Adams, HC; Avet-Loiseau, H; Axel, A; Bahlis, NJ; Bald, J; Casneuf, T; Ceulemans, H; Chiu, C; Foulk, B; Lysaght, A; Mutis, T; Nielsen, KC; Nijhof, I; Plesner, T; Rusbuldt, J; Schecter, JM; Smets, T; Stevenaert, F; Usmani, SZ; van de Donk, NWCJ; Van der Borght, K; Vanhoof, G | 1 |
| Cao, Y; Chen, CI; Chen, E; Chen, H; Kakar, S; Kukreti, V; Lau, A; Le, LW; Levina, O; Paul, H; Prica, A; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Bakalov, V; Khattab, A; Sadashiv, S; Shaikh, H; Shaikh, S | 1 |
| Allotey, D; Cairns, DA; Clinical Studies Group, UNHO; Collett, C; Cook, G; Davies, FE; Drayson, MT; Garg, M; Gregory, WM; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Russell, NH; Shafeek, S; Striha, A; Waterhouse, A; Williams, CD | 1 |
| Jeon, YH; Kim, GW; Kwon, SH; Lee, DH; Lee, SW; Won, HR; Yeon, SK; Yoo, J | 1 |
| Aryal, MR; Dhakal, B; Giri, S; Grimshaw, A; Huntington, SP; Pathak, R; Yu, H | 1 |
| Chen, Y; Cutter, D; Loh, Y; Master, Z; Mikhaeel, G; Nagarajan, C; Thitsar, SM; Tin, KM; Yeoh, KW | 1 |
| Campbell, DC; Chantry, AD; Chauhan, D; Crawford, LJ; Down, JM; Hamilton, C; Irvine, AE; Krishnan, A; Lawson, MA; McAvera, RM; Morgan, JJ; Morris, TC; Rajalingam, K | 1 |
| Goldschmidt, H; John, L; Scheid, C | 1 |
| Chinen, Y; Fujibayashi, Y; Gütschow, M; Horiike, S; Isa, R; Kobayashi, T; Kuroda, J; Kuwahara-Ota, S; Matsumura-Kimoto, Y; Mizuno, Y; Nishiyama, D; Shimura, Y; Steinebach, C; Takimoto-Shimomura, T; Taniwaki, M; Tsukamoto, T; Yamaguchi, J | 1 |
| Araki, T; Fujitani, Y; Fukada, E; Fukuyama, T; Hisanabe, A; Kaieda, A; Miura, A; Nakamura, K; Takakuwa, T; Yamamura, R | 1 |
| Amico, V; Arcamone, M; Barone, M; Catalano, L; Cerchione, C; Esposito, D; Farina, G; Ferrara, F; Fontana, R; Gagliardi, A; Gentile, M; Palmieri, S; Pane, F; Rocco, S; Scopelliti, A; Sementa, A; Sica, A; Svanera, G; Vincelli, ID; Vitagliano, O | 1 |
| Abdulkarim, H; Siaj, M; Zourob, M | 1 |
| Andreasson, B; Bacon, P; Berthou, C; Blau, IW; Caers, J; Crotty, G; Di Micco, A; Dimopoulos, M; Gamberi, B; Hájek, R; Hernandez, M; Kueenburg, E; Minnema, MC; Parreira, J; Peters, S; Remes, K; Rosettani, B; Semenzato, G; Tholouli, E | 1 |
| Chan, KWH; Chourasia, AH; Erdman, P; Fung, L; Hecht, D; Jones, RJ; Kuiatse, I; Lam, I; Lee, HC; Manasanch, EE; McElwee, B; Mercurio, F; Orlowski, RZ; Richard, N; Shirazi, F; Stirling, DI; Sullivan, R; Torres, E; Wang, H; Zou, J | 1 |
| Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Garg, M; Gregory, WM; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Russell, NH; Striha, A; Taylor, C; Waterhouse, A; Williams, CD; Wilson, J | 1 |
| Afify, R; Carapinha, JL; Elmoty, MA; Elsisi, GH; Khalaf, M | 1 |
| Skarzynski, J | 1 |
| Bittrich, M; Danhof, S; Einsele, H; Gisslinger, B; Gisslinger, H; Hefner, J; Hose, D; Knop, S; Krauth, MT; Schoder, R; Schreder, M; Strifler, S | 1 |
| Barth, P; Costa, LJ; Giri, S; Olszewski, AJ | 1 |
| Benner, A; Bernhard, H; Bertsch, U; Blau, IW; Brossart, P; Dürig, J; Elmaagacli, A; Fuhrmann, S; Goerner, M; Goldschmidt, H; Hänel, M; Hoffmann, M; Hose, D; Jauch, A; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Merz, M; Miah, K; Munder, M; Raab, MS; Salwender, HJ; Sauer, S; Scheid, C; Seckinger, A; Weisel, KC | 1 |
| Aktas Samur, A; Anderson, KC; Avet-Loiseau, H; Corre, J; Fulciniti, M; Han, T; Magrangeas, F; Minvielle, S; Moreau, P; Munshi, NC; Parmigiani, G; Richardson, P; Samur, MK; Shammas, M; Szalat, R; Thakurta, A | 1 |
| Alameda, D; Alignani, D; Bargay, J; Blade, J; Burgos, L; Calasanz, MJ; Cedena, MT; Celay, J; Cordón, L; de la Rubia, J; Flores-Montero, J; Fresquet, V; Garcés, JJ; Garcia-Sanz, R; Goicoechea, I; Gutierrez, NC; Hernandez, MT; Krsnik, I; Lahuerta, JJ; Lara-Astiaso, D; Martin-Sanchez, J; Martinez-Climent, JA; Martinez-Lopez, J; Martinez-Martinez, R; Mateos, MV; Moraleda, JM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Ramos, MM; Rios, R; Rodriguez, I; Rodriguez, S; Rosiñol, L; San Miguel, J; Sarra, J; Sarvide, S; Vidriales, MB; Vilas-Zornoza, A | 1 |
| Gonzalez-McQuire, S; Lebioda, A; Poenisch, W; Rieth, A; Schoehl, M; Singh, M; Steinmetz, HT | 1 |
| Boersma, J; Dhanasiri, S; Lee, D; Ramsden, R; Uyl-de Groot, CA; Zweegman, S | 1 |
| Bing, X; Peifang, L | 1 |
| Berdeja, J; Derman, BA; Dytfeld, D; Griffith, KA; Gurbuxani, S; Hycner, T; Jakubowiak, AJ; Jasielec, JK; Kubicki, T; Major, S; Raje, N; Reece, D; Richardson, P; Rojek, AE; Rosenbaum, CA; Stefka, AT; Stephens, L; Tinari, KM; Vij, R; Wolfe, B; Zimmerman, TM | 1 |
| Shibusawa, M; Tanimoto, T | 1 |
| Mateos, MV; Usmani, SZ | 1 |
| Ashihara, E; Fuchida, SI; Hatsuse, M; Kado, Y; Minegaki, T; Murakami, S; Muraki, Y; Nishiguchi, K; Okano, A; Shimazaki, C; Sugii, H; Toda, Y; Tsujimoto, M; Ueda, K | 1 |
| Alici, E; Gran, C; Ljunggren, HG; Nahi, H; Susek, KH | 1 |
| Rosenbaum, CA | 1 |
| Furukawa, Y; Kikuchi, J | 1 |
| Allinovi, M; Antonioli, E; Attucci, I; Bosi, A; Buzzichelli, A; Cappelli, F; Messeri, M; Nozzoli, C; Perfetto, F; Pilerci, S; Staderini, M | 1 |
| Ammann, EM; Durie, BGM; Facon, T; Kobos, R; Kumar, SK; Lam, A; Maiese, EM; Nonyane, BAS; Usmani, SZ | 1 |
| Aul, C; Baier, J; Boquoi, A; Dienst, A; Fenk, R; Gerrlich, C; Giagounidis, A; Goldschmidt, H; Haas, R; Hauck, K; Heinsch, M; Kobbe, G; Kondakci, M; Kroger, N; Liesenjohann, S; Lopez, D; Mai, EK; Rummel, M; Savickaite, I; Strapatsas, J | 1 |
| Harousseau, JL; Mohty, M | 1 |
| Gleason, C; Harvey, RD; Heffner, LT; Kaufman, JL; Laubach, JP; Lewis, C; Lonial, S; Mina, R; Nooka, AK; Orlowski, RZ; Richardson, P; Shah, JJ; Sharp, C | 1 |
| Abboud, CN; Bartlett, NL; Cashen, AF; Dipersio, JF; Fehniger, TA; Hurd, DD; Jacoby, MA; Jaglowski, SM; Shea, L; Wagner-Johnston, ND; Wan, F; Watkins, MP | 1 |
| Ara, T; Fukuhara, O; Harigae, H; Ito, T; Katsuoka, Y; Kimura, T; Kobayashi, N; Minauchi, K; Nakajima, S; Noji, H; Onishi, Y; Ota, S; Sasaki, O; Yamamoto, J; Yokoyama, H | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Hou, HA; Liu, Y; Qiu, H; Tang, CH | 1 |
| Tang, W; Xiang, B; Xu, Y | 1 |
| Anderson, LD; Chen, W; Fuda, FS; Gagan, J; Germans, SK; Jaso, JM; Koduru, P; Kulak, O; Oliver, D; Patel, P | 1 |
| Anderson, KC; Beksac, M; Belch, A; Dimopoulos, MA; Einsele, H; Ganetsky, A; Grosicki, S; Jou, YM; Lonial, S; Magen, H; Mateos, MV; Matsumoto, M; Moreau, P; Oakervee, H; Orlowski, RZ; Reece, D; Richardson, PG; Röllig, C; San-Miguel, J; Shpilberg, O; Singhal, AK; Spencer, A; Špička, I; Taniwaki, M; Walter-Croneck, A; Weisel, K; White, D; Wu, KL | 1 |
| Bang, SM; Do, YR; Eom, HS; Jo, JC; Kim, HJ; Kim, JS; Kim, K; Kim, MK; Kim, SH; Lee, HS; Lee, JH; Lee, JJ; Lee, MH; Lee, WS; Lee, Y; Lim, SN; Min, CK; Mun, YC; Park, SK; Park, Y; Shin, HJ; Yi, JH; Yoon, DH; Yoon, SS | 1 |
| Bao, L; Chen, B; Ding, K; Fu, C; Hua, L; Huang, Y; Li, B; Li, J; Liu, P; Luo, J; Wang, L; Wang, S; Wang, W; Wu, G; Xia, Z; Xu, T; Yang, W; Yang, Y; Zhang, W; Zhou, X | 1 |
| Anderson, LD; Biyukov, T; Casal, E; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Jenner, M; Moreau, P; Nguyen, TV; Pavic, M; Peluso, T; Richardson, P; Salomo, M; San-Miguel, J; Sonneveld, P; Srinivasan, S; Weisel, K; White, D; Yu, X | 1 |
| Anderson, KC; Arvedson, T; Cho, SF; Friedrich, M; Hsieh, PA; Li, Y; Lin, L; Matthes, K; Munshi, N; Tai, YT; Wahl, J; Wen, K; Xing, L; Yu, T | 1 |
| Barth, P; Giri, S; Olszewski, AJ; Reagan, JL | 1 |
| Agarwal, A; Amatangelo, MD; Bahlis, NJ; Chung, W; Neri, P; Parekh, S; Pierceall, WE; Rahman, A; Serbina, N; Siegel, DS; Thakurta, A; Van Oekelen, O; Young, M | 1 |
| Ando, K; Farooqui, M; Ghori, R; Iida, S; Ishikawa, T; Iwasaki, H; Izutsu, K; Kizaki, M; Koh, Y; Kondo, Y; Kosugi, H; Liao, J; Marinello, P; Maruyama, D; Matsuda, K; Matsumoto, M; Matsumura, I; Miki, H; Onishi, Y; Shimamoto, T; Sunami, K; Suzuki, K; Takezako, N; Teshima, T; Tobinai, K | 1 |
| Cerchione, C; Conticello, C; DI Raimondo, F; Martinelli, G; Romano, A; Santoro, M; Siragusa, S | 1 |
| Asatsuma-Okumura, T; Handa, H; Ito, T; Kishi, T; Kizaki, M; Mizutome, H; Momose, S; Murase, Y; Shimizu, N; Suwa, T; Tateno, S; Yamaguchi, Y; Yamamoto, J | 1 |
| Karsan, A; Martinez-Høyer, S | 1 |
| Auner, HW; Bailey, L; Brown, S; Brudenell Straw, F; Cook, G; Cook, M; Dawkins, B; Flanagan, L; Hinsley, S; Kaiser, MF; McKee, S; Meads, D; Reed, S; Sherratt, D; Walker, K | 1 |
| Anderson, K; Bahlis, N; Belch, A; Brown, D; Chen, C; Cheung, M; Dispenzieri, A; Facon, T; Robinson, S; Shustik, C; Song, K; Srinivasan, S; Tosikyan, A; White, D | 1 |
| Aslam, M; Atenafu, E; Cherniawsky, HM; Gul, E; Jimenez-Zepeda, VH; Kotb, R; Kukreti, V; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Reece, D; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 2 |
| Cook, G; DeCosta, L; Delforge, M; Desgraz, R; Gay, F; Mateos, MV; Moreau, P; Szabo, Z; Weisel, K | 1 |
| Ahmed, Z; Anwer, F; Ashraf, A; Ehsan, H; Faisal, MS; Khakwani, M; Khan, A; Mushtaq, K; Rafae, A; Rehan, T; Shah, Z; Wahab, A | 1 |
| Antonioli, E; Barilà, G; Bonalumi, A; Buda, G; Cavo, M; Cea, M; di Giovanni Bezzi, C; Dozza, L; Furlan, A; Mancuso, K; Martello, M; Marzocchi, G; Pantani, L; Petrini, M; Quaresima, M; Rizzello, I; Rocchi, S; Scalese, M; Staderini, M; Tacchetti, P; Zamagni, E | 1 |
| Beksaç, M; Mikhael, J; Richardson, PG; Špička, I | 1 |
| Abonour, R; Agarwal, A; Ailawadhi, S; Durie, BGM; Gasparetto, C; Hardin, JW; Jagannath, S; Kitali, A; Lee, HC; Narang, M; Omel, JL; Rifkin, RM; Srinivasan, S; Terebelo, HR; Toomey, K; Wagner, L | 1 |
| Andres, M; Angelillo-Scherrer, A; Dickenmann, M; Jalowiec, KA; Kremer Hovinga, JA; Musa, A; Rovó, A; Taleghani, BM | 1 |
| Chen, M; Chen, W; Jiang, Q; Li, T; Liu, Y; Peng, J; Shi, X; Wu, J; Xi, X; Yu, X; Zhang, S; Zhu, Y | 1 |
| Avet-Loiseau, H; Bahlis, NJ; Benboubker, L; Casneuf, T; Chari, A; Cochrane, T; Cook, G; Dimopoulos, MA; Iida, S; Joy Ho, P; Kaufman, JL; Kim, JS; Kim, K; Kobos, R; Krevvata, M; Leiba, M; Magen, H; Miles Prince, H; Moreau, P; Morton, J; O'Rourke, L; Oriol, A; San-Miguel, J; Sutherland, HJ; Takezako, N; Trivedi, S; Ukropec, J; Usmani, SZ; White, D | 1 |
| Bailly, C; Barbato, S; Boccadoro, M; Bodet-Milin, C; Caillot, D; Carlier, T; Cavo, M; Chauvie, S; Dozza, L; Fanti, S; Gallamini, A; Gamberi, B; Garderet, L; Gay, F; Karlin, L; Kraeber-Bodéré, F; Macro, M; Moreau, P; Nanni, C; Patriarca, F; Perrot, A; Sonneveld, P; Tacchetti, P; Versari, A; Zamagni, E | 1 |
| Aho, S; Boulin, M; Boutet, M; Caillot, D; Chretien, ML; Cosme, E; Cransac, A; Favennec, C; Giroud, M; Gueneau, P; Schreder, L | 1 |
| Capalbo, S; Cascavilla, N; Citiso, S; Curci, P; De Francesco, R; De Risi, C; Di Renzo, N; Falcone, AP; Germano, C; Giannotta, A; Greco, A; Greco, G; Guarini, A; Mazza, P; Mele, A; Mele, G; Miccolis, R; Morciano, MR; Offidani, M; Palazzo, G; Palumbo, G; Pastore, D; Pavone, V; Prete, E; Reddiconto, G; Rizzi, R; Sabatelli, S; Sanpaolo, G; Sibilla, S; Specchia, G; Tarantini, G; Tonialini, L; Vergine, C | 1 |
| Ailawadhi, S; Alegria, V; Chanan-Khan, AA; Parrondo, RD; Roy, V; Sher, T | 1 |
| Cote, S; Fonseca, R; He, J; Lam, A; Maiese, EM; Mehra, M; Nair, S; Potluri, R; Slavcev, M; Ukropec, J; Usmani, SZ; Voorhees, PM | 1 |
| Beilhack, A; Brandl, A; Köpff, S; Krönke, J; Lindner, S; Ng, YLD; Röhner, L; Scheffold, A | 1 |
| Carson, R; Chari, A; Delioukina, M; Hulin, C; Hungria, V; Iida, S; Karlin, L; Kosh, M; Magen, H; Maisnar, V; Masterson, T; McCarthy, H; Parasrampuria, DA; Perrot, A; Pour, L; Qi, M; Rodriguez-Otero, P; Sureda Balari, A; Suzuki, K; Touzeau, C; Yang, S | 1 |
| Goodman, AM; Kim, MS; Prasad, V | 1 |
| Berenson, JR; Eades, B; Emamy-Sadr, M; Regidor, B; Spektor, TM; Swift, R; Tarhini, F | 1 |
| Atanesyan, L; Cairns, DA; Chown, S; Cook, G; Croft, J; Davies, FE; Drayson, MT; Ellis, S; Gregory, WM; Houlston, RS; Hunter, H; Jackson, G; Jenner, MW; Kaiser, MF; Karunanithi, K; Lindsay, J; Morgan, GJ; Owen, RG; Price, A; Savola, S; Sharp, K; Sherborne, AL | 1 |
| Khoury, JD; Tashakori, M | 1 |
| Jacobus, SJ; Kumar, SK; Rajkumar, SV | 1 |
| Costa, L; Jakubowiak, A; Kazandjian, D; Landgren, O; Siegel, D | 1 |
| van de Donk, NWCJ | 2 |
| Korst, CLBM; van de Donk, NWCJ | 1 |
| Bladé, J; Corchete, LA; de Ramón, C; García-Sanz, R; Gutiérrez, NC; Isidro, I; Krzeminski, P; Lahuerta, JJ; Martínez-López, J; Mateos, MV; Misiewicz-Krzeminska, I; Oriol, A; Rojas, EA; Rosiñol, L; San Miguel, J | 1 |
| Antier, C; Moreau, P; Touzeau, C | 1 |
| Hagihara, M; Hua, J; Ide, S; Inoue, M; Ohara, S; Uchida, T | 1 |
| Buadi, F; Cook, J; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, R; Gonsalves, W; Hayman, S; Higgins, A; Hobbs, M; Hwa, YL; Johnson, I; Kapoor, P; Kourelis, T; Kumar, S; Kyle, R; Lacy, M; Leung, N; Rajkumar, VS; Sidana, S; Warsame, R | 1 |
| Arnulf, B; Bahlis, NJ; Chari, A; Delforge, M; Facon, T; Fastenau, J; Gries, KS; He, J; Ho, KF; Hulin, C; Jaccard, A; Karlin, L; Kobos, R; Kumar, S; Mollee, P; Nahi, H; Orlowski, RZ; Perrot, A; Plesner, T; Ramasamy, K; Roussel, M; Uhlar, CM; Usmani, SZ; Van Rampelbergh, R; Wang, J; Weisel, K | 1 |
| Baker, B; Chan, H; Chien, N; Goodman, H; Romeril, K | 1 |
| Bolaman, AZ; Eroğlu Küçükerdiler, H; Ertop, Ş; Sahip, B; Sargın, G; Selim, C; Turgutkaya, A; Yavaşoğlu, İ | 1 |
| Costantini, A; Lasala, R; Morelli, AM; Pulini, S; Ranucci, E; Rocchi, M; Santoleri, F; Spadano, A | 1 |
| Beverloo, HB; Broijl, A; Dumee, B; Hansson, M; Koenders, J; Kuiper, R; Levin, MD; Sonneveld, P; Stevens-Kroef, M; van Beers, EH; van der Holt, B; van der Velden, AWG; van Duin, M; van Vliet, MH; Vermeulen, M; Visser-Wisselaar, H; Waage, A; Zweegman, S | 1 |
| Aitchison, R; Bhatti, Z; Bird, SA; Boyd, K; Bygrave, C; Chander, G; Collings, F; Dungarwalla, M; Jenner, MW; Kishore, B; Kothari, J; Maouche, N; Offer, M; Peniket, A; Ramasamy, K; Robinson, R; Vallance, GD | 1 |
| Pawlyn, C | 1 |
| Bar, N; Giri, S; Huntington, SF; Neparidze, N; Parker, TL; Patel, KK | 1 |
| Baertsch, MA; Bernhard, H; Bertsch, U; Besemer, B; Blau, IW; Brossart, P; Dührsen, U; Dürig, J; Fuhrmann, S; Goerner, M; Goldschmidt, H; Hänel, M; Hielscher, T; Hillengaß, J; Hoffmann, M; Hose, D; Jauch, A; Kunz, C; Lindemann, HW; Lokhorst, H; Luntz, S; Mai, EK; Martin, H; Munder, M; Neben, K; Raab, MS; Salwender, HJ; Scheid, C; Schlenzka, J; Seckinger, A; Sonneveld, P; Weisel, KC | 1 |
| Cairns, DA; Collett, C; Cook, G; Davies, FE; de Tute, RM; Drayson, MT; Garg, M; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Rocci, A; Russell, NH; Snowden, JA; Williams, CD | 1 |
| Americo, AD; Arcuri, LJ | 1 |
| Cheesman, S; De-Silva, D; Kyriakou, C; Lawson, G; Mahmood, S; Papanikolaou, X; Popat, R; Rabin, N; Sachchithananthan, S; Sive, J; Wechalekar, A; Yong, K; Ziff, M | 1 |
| Hou, HA; Liu, Y; Qiu, H; Siggins, S; Tang, CH | 1 |
| Ansari-Pour, N; Bahlis, N; Chamberlain, PP; Dhiman, P; Flynt, E; Gooding, S; Hirst, M; Neri, P; Ortiz Estévez, M; Ramasamy, K; Rozelle, D; Thakurta, A; Towfic, F; Tsai, KT; Vyas, P | 1 |
| Chang, MH; Do, YR; Eom, HS; Jo, JC; Kang, KW; Kim, DS; Kim, JS; Kim, KH; Kim, SH; Koh, Y; Lee, HS; Lee, JH; Lee, JJ; Lee, JY; Lee, WS; Lee, YJ; Min, CK; Park, Y; Shim, H; Shin, DY; Yoon, SS | 1 |
| Bacovsky, J; Brozova, L; Capkova, L; Hajek, R; Heindorfer, A; Jelinek, T; Jindra, P; Jungova, A; Kessler, P; Krhovska, P; Machalkova, K; Maisnar, V; Minarik, J; Mistrik, M; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Skacel, T; Spicka, I; Stejskal, L; Stork, M; Straub, J; Sykora, M; Ullrychova, J | 1 |
| Adachi, Y; Fuchida, SI; Hanamoto, H; Hino, M; Imada, K; Kanakura, Y; Kanda, J; Kaneko, H; Kosugi, S; Kuroda, J; Matsuda, M; Matsumura, I; Nakaya, A; Nomura, S; Ohta, K; Onda, Y; Shibayama, H; Shimazaki, C; Shimazu, Y; Shimura, Y; Takakuwa, T; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Yagi, H; Yamamura, R; Yoshihara, S | 1 |
| Barchnicka, A; Bednarczyk, M; Grosicka, O; Grosicki, S | 1 |
| Abu Zaanona, MI; Patel, P | 1 |
| Cippitelli, M; Fionda, C; Gismondi, A; Kosta, A; Petillo, S; Santoni, A; Stabile, H | 1 |
| Hagihara, M; Hanai, H; Ide, S; Inoue, M; Mita, M; Nishigami, Y; Ohara, S; Saigo, H; Sugi, T; Takabatake, K; Uchida, T | 1 |
| Amin, H; Avet-Loiseau, H; Bahlis, NJ; Casneuf, T; Chiu, C; Iida, S; Kobos, R; Krevvata, M; Lonial, S; Moreau, P; Plesner, T; Qi, M; Qin, X; Ramaswami, P; San-Miguel, J; Spencer, A; Sun, S; Trivedi, S; Ukropec, J; Usmani, SZ; Weisel, K | 1 |
| Chari, A; Delea, TE; Hagiwara, M; Kee, A; Madduri, D; Parikh, K; Pelletier, C | 1 |
| Andriani, A; Annibali, O; Antolino, G; Cantonetti, M; Cimino, G; Coppetelli, U; De Rosa, L; De Stefano, V; di Toritto, TC; La Verde, G; Petrucci, MT; Piciocchi, A; Rizzo, M; Siniscalchi, A; Vozella, F; Za, T | 1 |
| Bellofiore, C; Conticello, C; Del Fabro, V; Di Raimondo, F; Mangiafico, S; Markovic, U; Romano, A; Sapienza, G; Stagno, F; Tamburino, C | 1 |
| Duan, J; Wang, B; Zhou, L | 1 |
| Aizpurua, F; Duarte, PJ; Fantl, D; Foncuberta, C; Garate, G; Giannini, E; Lopresti, S; Milone, J; Ochoa, P; Orlando, S; Riveros, D; Schutz, NP; Shanley, C; Yantorno, S; Zabaljauregui, S | 1 |
| Fujioka, Y; Iida, M; Ishikawa, J; Kosugi, S; Nishikawa, H; Nozaki, K; Shibata, M; Shibayama, H; Sugiyama, D | 1 |
| Atenafu, EG; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Reece, D; Reiman, T; Sebag, M; Song, K; Stakiw, J; Venner, C | 1 |
| Awwad, MHS; Bach, C; Balzer, H; Beier, F; Bitterer, K; Böttcher, M; Bruns, H; Busch, M; Büttner-Herold, M; Eberhardt, M; Gebhard, C; Hundemer, M; Jitschin, S; Krönke, J; Leffler, M; Lischer, C; Mackensen, A; Mougiakakos, D; Rehli, M; Röhner, L; Schütz, C; Stenger, S; Stoll, A; Vera, J; Völkl, S | 1 |
| Colson, K; Grayson, D; Laubach, JP; Masone, K; Mitsiades, CS; Redd, RA; Richardson, PG; Rosenblatt, JM; Tuchman, SA; Warren, D | 1 |
| Derman, BA; Jakubowiak, AJ; Jasielec, JK; Jiang, K; Kubicki, T; McIver, A; Stefka, AT | 1 |
| Cho, J; Kang, D; Kim, JS; Kim, K; Kim, SJ; Min, CK; Mun, YC; Park, Y | 1 |
| Dispenzieri, A; Fonseca, R; Gertz, M; Gonsalves, W; Ketterling, R; Kumar, S; Lacy, M; LaPlant, B; Lasho, T; Mangaonkar, AA; Padrnos, L; Patnaik, MM; Rajkumar, SV; Shi, CX; Stewart, AK; Wudhikarn, K | 1 |
| Bobba, P; Costa, LJ; Hoehn, D; Lin, TS; Lutska, Y; Nathwani, N; Pei, H; Qi, M; Reeves, B; Richardson, PG; Rodriguez, C; Ukropec, J; Voorhees, PM | 1 |
| Amit, I; Avivi, I; Ballan, M; Bornstein, C; Chubar, E; Cohen, YC; Dally, N; David, E; Ganzel, C; Gatt, ME; Gur, C; Jarchowcky-Dolberg, O; Laiba, M; Lavi, N; Li, B; Luttwak, E; Moshe, A; Nemets, A; Pasvolsky, O; Rouvio, O; Shlomi-Loubaton, S; Shpilberg, O; Shvetz, O; Tadmor, T; Vaxman, I; Wang, SY; Weiner, A; Zada, M | 1 |
| Kontoyiannis, DP; Sassine, J | 1 |
| Giles, H; Mistry, J; Murthy, V; Rudzki, Z | 1 |
| Arcila, M; Chung, DJ; Derkach, A; Devlin, SM; Diamond, B; Dogan, A; Giralt, SA; Hassoun, H; Ho, C; Hultcrantz, M; Korde, N; Lahoud, O; Landau, H; Landgren, O; Lendvai, N; Lesokhin, A; Lu, S; Mailankody, S; Mastey, D; Roshal, M; Salcedo, M; Scordo, M; Shah, GL; Shah, U; Smith, EL; Tan, C; Tavitian, E; Werner, K | 1 |
| Bernabei, L; Cohen, AD; Garfall, AL; Gonzalez, VE; June, CH; Lacey, SF; Levine, BL; Melenhorst, JJ; Milone, MC; Plesa, G; Stadtmauer, EA; Tian, L; Vogl, DT; Waxman, A; Young, RM | 1 |
| Antonioli, E; Guglielmelli, P; Loscocco, GG; Mannelli, F; Romano, I; Rotunno, G; Vannucchi, AM; Vergoni, F | 1 |
| Anderson, KC; Badros, A; Beksac, M; Bladé, J; Caers, J; Cavo, M; Dimopoulos, MA; Dispenzieri, A; Einsele, H; Engelhardt, M; Fernández de Larrea, C; Gahrton, G; Gay, F; Hájek, R; Hungria, V; Jurczyszyn, A; Kröger, N; Kyle, RA; Leal da Costa, F; Leleu, X; Lentzsch, S; Mateos, MV; Merlini, G; Mohty, M; Moreau, P; Rasche, L; Reece, D; Richardson, PG; Rosiñol, L; Sezer, O; Sonneveld, P; Usmani, SZ; Van de Donk, NWCJ; Vanderkerken, K; Vesole, DH; Waage, A; Zamagni, E; Zweegman, S | 1 |
| Fuchida, SI; Hino, M; Imada, K; Ishikawa, J; Ito, T; Kanakura, Y; Kanda, J; Kaneko, H; Karasuno, T; Kawata, E; Kosugi, S; Kuroda, J; Matsumura, I; Nakatani, E; Nomura, S; Ohta, K; Shibano, M; Shibayama, H; Shimazaki, C; Shimizu, Y; Shimura, Y; Shindo, M; Takakuwa, T; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Yagi, H | 1 |
| Blevins, F; Hughes, D; Lerner, A; Milrod, CJ; Sanchorawala, V; Sarosiek, S; Sloan, JM | 1 |
| Delforge, M; Kint, N; Vlayen, S | 1 |
| Antonioli, E; Benevolo, G; Bernardini, A; Boccadoro, M; Bonello, F; Bringhen, S; Capra, A; Caravita di Toritto, T; Cascavilla, N; Cellini, C; Corradini, P; D'Agostino, M; Gaidano, G; Galli, M; Giuliani, N; Larocca, A; Marasca, R; Monaco, F; Offidani, M; Patriarca, F; Pompa, A; Rota-Scalabrini, D; Tacchetti, P; Tosi, P | 1 |
| Bashir, Q; Feng, L; Iyer, SP; Kaufman, GP; Kunacheewa, C; Lee, HC; Manasanch, EE; Mehta, R; Orlowski, RZ; Patel, KK; Qazilbash, MH; Saini, N; Srour, S; Thomas, SK; Weber, DM | 1 |
| Bahlis, NJ; Benboubker, L; Facon, T; Karlin, L; Kumar, SK; Lonial, S; Moreau, P; Offner, F; Rajkumar, SV; Richardson, PG; Rifkin, RM; Rigaudeau, S; Rodon, P; Shibayama, H; Suzuki, K; Twumasi-Ankrah, P; Venner, CP; Voog, E; White, DJ; Yoon, SS; Yung, G; Zhang, X | 1 |
| Abdallah, AO; Goodman, AM; Koehn, K; McClune, B; Mohyuddin, GR; Prasad, V; Sborov, D | 1 |
| Gu, XK; Hu, LW; Lan, H; Luo, M | 1 |
| Bahlis, NJ; Ben-Yehuda, D; Carson, R; Cook, G; Dimopoulos, MA; Fastenau, J; Garvin, W; Goldschmidt, H; Gries, KS; Grosicki, S; Oriol, A; Plesner, T; Qin, X; Rabin, N; Renaud, T; San-Miguel, J; Suzuki, K; Yoon, SS | 1 |
| Attal, M; Belhadj, K; Benboubker, L; Caillot, D; Corre, J; Dupuis, J; Escoffre-Barbe, M; Facon, T; Garderet, L; Hébraud, B; Lauwers-Cances, V; Leleu, X; Manier, S; Mariette, C; Moreau, P; Roussel, M; Sonntag, C; Touzeau, C; Wuilleme, S | 1 |
| Arcila, ME; Caple, J; Chansakul, A; Chung, DJ; Ciardello, A; Concepcion, I; Derkach, A; Diamond, B; Dogan, A; Giralt, SA; Harrison, A; Hassoun, H; Ho, C; Hultcrantz, M; Jones, K; Korde, N; Lahoud, OB; Landau, HJ; Landgren, O; Lesokhin, AM; Lu, SX; Maclaughlan, K; Mailankody, S; Maura, F; Murata, K; Piacentini, C; Ramanathan, L; Rispoli, J; Roshal, M; Rustad, EH; Salcedo, M; Sams, A; Schlossman, J; Scordo, M; Shah, G; Shah, UA; Shekarkhand, T; Tan, C; Tavitian, E; Thoren, K; Verducci, D; Werner, K; Yellapantula, V | 1 |
| Elnair, RA; Holstein, SA | 1 |
| Breij, ECW; Chamuleau, MED; Gelderloos, AT; Mutis, T; Nijhof, IS; Overdijk, MB; van der Horst, HJ; Zweegman, S | 1 |
| Abella, E; Alcalá, M; Bustamante, G; Cejalvo, MJ; de la Rubia, J; Duro, R; García, A; García, R; Garzón, S; González, E; González, MS; González, Y; Jarque, I; López, R; Lostaunau, G; Martí, JM; Motlló, C; Pérez-Persona, E; Ramírez-Payer, Á; Sampol, A; Sarrà, J; Sastre, JL; Vázquez-Álvarez, J | 1 |
| Coffey, DG; Cowan, AJ; Gopal, AK; Green, DJ; Holmberg, LA; Kwok, M; Lee, S; Libby, EN; Stevenson, PA; Tuazon, S | 1 |
| Lu, J | 1 |
| Bauhuf, I; Blätte, TJ; Bohl, SR; Bullinger, L; Damm, F; Döhner, H; Dolnik, A; Heckl, D; Knödler, S; Krönke, J; Kull, M; Langer, C; Letai, A; Meyer, T; Miller, D; Röhner, L; Schmalbrock, LK; Szyska, M | 1 |
| Hagihara, M; Inoue, M; Mita, M; Ohara, S; Sugi, T; Uchida, T; Yasu, T | 1 |
| Abdallah, AO; Aziz, M; Hampton, J; Khuder, S; Malik, S; McClune, B; Mohyuddin, GR | 1 |
| Fujimori, Y; Ifuku, H; Imado, T; Kawamoto, H; Misawa, M; Ohe, Y; Okada, M; Shimizu, Y; Takatsuka, H; Yoshihara, K; Yoshihara, S | 1 |
| Cheng, Z; Feng, L; He, F; Wei, R; Wu, Y; Xiao, M; Zhao, G | 1 |
| Karlin, L; Try, M | 1 |
| Alegre, A; Arguiñano, JM; Arnao, M; Bladé, J; Calasanz, MJ; Casanova, M; Cedena, MT; Coleman, M; Cortés-Rodríguez, M; Couto, MDC; de Arriba, F; de la Rubia, J; Encinas, C; Escalante, F; García-Sánchez, R; Garzón, S; Gironella, M; González, E; González, MS; González-Calle, V; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín, J; Martín, ML; Martín-Sánchez, G; Mateos, MV; Niesvizky, R; Ocio, EM; Oriol, A; Paiva, B; Pérez-Persona, E; Puig, N; Ríos, R; Rosiñol, L; San-Miguel, JF; Teruel, AI; Vale, AM | 1 |
| Cheng, CN; Huang, ST; Huang, SY; Lien, PW; Lin, FJ | 1 |
| Bal, S; Costa, LJ | 1 |
| Arcila, ME; Chung, DJ; Derkach, A; Devlin, S; Diamond, B; Dogan, A; Giralt, SA; Hassoun, H; Ho, C; Hultcrantz, M; Korde, N; Lahoud, O; Landau, HJ; Landgren, O; Lesokhin, AM; Lu, SX; Maclachlan, K; Mailankody, S; Maura, F; Murata, K; Peterson, T; Ramanathan, L; Roshal, M; Rustad, EH; Scordo, M; Shah, GL; Shah, U; Smith, EL; Tan, C; Thoren, K | 1 |
| Boccadoro, M; Brandt-Hagens, C; Bruinink, DHO; Capra, A; Cavo, M; D'Agostino, M; Galli, M; Gay, F; Gilestro, M; Hajek, R; Jugooa, R; Offidani, M; Oliva, S; Omedé, P; Pantani, L; Petrucci, MT; Ribolla, R; Rihova, L; Sonneveld, P; Troia, R; van der Holt, B; van der Velden, VHJ; Villanova, T; Vsianska, P | 1 |
| Dhanasiri, S; Ghale, A; Moore, A; Roussel, M; Zamagni, E | 1 |
| Chinen, Y; Fuchida, SI; Hirakawa, K; Horiike, S; Kaneko, H; Kawaji-Kanayama, Y; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumura-Kimoto, Y; Mizutani, S; Muramatsu, A; Nakao, M; Sasaki, N; Shimazaki, C; Shimura, K; Shimura, Y; Takahashi, R; Taniwaki, M; Tsukamoto, T; Uchiyama, H; Uoshima, N; Wada, K | 1 |
| Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Blacklock, H; Boyle, S; Harrison, SJ; Ho, PJ; Hocking, J; McQuilten, ZK; Mollee, P; Moore, EM; Quach, H; Spearing, R; Spencer, A; Wellard, C; Wood, EM | 1 |
| Araki, T; Fujitani, Y; Horiuchi, M; Miura, A; Okayama, Y; Otomaru, I; Takakuwa, T; Yamamura, R | 1 |
| Jackson, GH; Jones, JR; Pawlyn, C | 1 |
| Atenafu, EG; Gorospe, K; Liu, Q; Liyasova, M; Ma, B; McDonald, Z; Piza, G; Reece, D; Taylor, P; Trudel, S; Xu, X; Yang, L; Yao, C | 1 |
| Gajewska, M; Lorent, M; Rzepecki, P; Sawicki, W; Terlikowska-Brzósko, A; Wróbel, K | 1 |
| Duek, A; Kaplan, B; Leiba, M; Segman, Y | 1 |
| Alizadeh, H; Altai, E; Borbényi, Z; Csukly, Z; Dávid Tóth, A; Deák, B; Gaál-Weisinger, J; Hardi, A; Illés, Á; Kohl, Z; Kórád, K; Kosztolányi, S; Lengyel, Z; Lovas, S; Masszi, T; Mikala, G; Modok, S; Nagy, Z; Plander, M; Radványi, G; Rajnics, P; Réka Szita, V; Rencsik, A; Rottek, J; Schneider, T; Szaleczky, E; Szendrei, T; Varga, G; Váróczy, L | 1 |
| Campbell, P; Filshie, R; Guo, M; Kalff, A; Kennedy, N; Khong, T; Norton, S; Oppermann, U; Parekh, S; Pierceall, W; Ramachandran, M; Ren, Y; Reynolds, J; Roberts, AW; Schwarer, A; Spencer, A; Thakurta, A; Walker, P; Wang, M; Young, M | 1 |
| Er, J; Harrison, SJ | 1 |
| Chari, A; Comenzo, RL; de Boer, C; Deraedt, W; Jakubowiak, A; Krishnan, A; Lonial, S; Schecter, JM; Usmani, SZ; Wang, J; Weiss, BM | 1 |
| Adam, Z; Knechtova, Z; Kral, Z; Krejci, M; Pour, L; Sandecka, V; Sevcikova, S; Stork, M | 1 |
| Hagiwara, S; Hanamura, I; Handa, H; Iida, S; Ikeda, T; Imaizumi, Y; Itagaki, M; Kawamura, K; Kondo, T; Kuroda, J; Murakami, J; Nagai, H; Nakamura, Y; Nakao, S; Nakazawa, H; Okura, M; Ozaki, S; Sunami, K; Takahashi, T; Takamatsu, H; Takeuchi, M; Watakabe-Inamoto, K; Yamashita, T | 1 |
| Bargay, J; Blade, J; Blanchard, MJ; Cabañas, V; Cedena, MT; de la Rubia, J; Hernández, MT; Jiménez-Ubieto, A; Krnisk, I; Lahuerta, JJ; Martin, J; Martínez, R; Martínez-López, J; Mateos, MV; Oriol, A; Paiva, B; Palomera, L; Puig, N; Ríos, R; Rosiñol, L; San Miguel, J; Sánchez-Pina, JM; Sureda, A | 1 |
| Liu, M; Zhang, X; Zhong, J | 1 |
| Derkach, A; Hassoun, H; Hultcrantz, M; Korde, N; Lesokhin, A; Lu, S; Mailankody, S; Orozco, J; Patel, D; Peterson, T; Piedra, K; Shah, U; Tan, C; Wilkins, CR | 1 |
| Allan, JN; Boussi, L; Boyer, A; Coleman, M; Ely, S; Flicker, K; Forsberg, PA; Jayabalan, D; Lakritz, S; Liotta, B; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, KA; Ribadeneyra, D; Rossi, AC | 1 |
| Ahn, J; Anand, P; Bansal, M; Biran, N; Donato, M; Feinman, R; Gourna Paleoudis, E; Ivanovski, K; Korngold, R; McBride, L; Pecora, AL; Richter, J; Rowley, S; Siegel, DS; Vesole, DH; Wang, S; Zenreich, J | 1 |
| Baz, R; Kang, HJ; Kim, JA; Kim, JS; Kim, K; Kim, SH; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, WS; Min, CK; Suh, C; Yoo, KH; Yoon, DH; Yoon, SS | 1 |
| Banerjee, D; Bhattacharyya, M; Kalantri, SA; Nath, UK | 1 |
| Garderet, L; Malard, F; Mohty, M; Savani, BN; Sengsayadeth, S | 1 |
| Becker, PS; Bensinger, W; Holmberg, LA | 1 |
| Carrasco, V; Cases, E; Gómez Gonzalez, C; Lázaro Sierra, J | 1 |
| Bahlis, NJ; Basu, S; Chen, G; Corso, A; de Revel, T; Decaux, O; Demuynck, H; Desjardins, P; Ervin-Haynes, A; Facon, T; Granell, M; Guthrie, TH; Huang, SY; Marek, J; Marit, G; Mugge, LO; Nahi, H; Shen, ZX; Stoppa, AM | 1 |
| Anderson, KC; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Caillot, D; Escoffre, M; Facon, T; Fermand, JP; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Macro, M; Maglio, ME; Mathiot, C; Meuleman, N; Moreau, P; Munshi, N; Payen, C; Richardson, PG; Rollet, S; Roussel, M; Weller, EA; Zeytoonjian, AA | 1 |
| Goldschmidt, H; Kellermann, L; Knauf, W; Kohnke, J; Merz, M; Poenisch, W; Tischler, HJ | 1 |
| Sun, H; Ying, L; YinHui, T; Yunliang, Z | 1 |
| Aguiar, PM; Colleoni, GWB; de Mendonça Lima, T; Storpirtis, S | 1 |
| Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajnics, P; Ro, S; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A | 1 |
| Moreau, P; Touzeau, C | 3 |
| Bargou, RC; Bassermann, F; Biersack, H; Einsele, H; Engelhardt, M; Günther, A; Held, S; Hertenstein, B; Junghanss, C; Knop, S; Kunitz, A; Langer, C; Liebert, A; Mügge, LO; Ostermann, H; Reichle, A; Ringhoffer, M; Röllig, C; Rösler, W; Schäfer-Eckart, K; Schreder, M | 1 |
| Faber, LM; Kootte, RS | 1 |
| Chung, DJ; Devlin, SM; Dogan, A; Gao, Q; Giralt, SA; Hassoun, H; Korde, N; Landau, H; Landgren, CO; Lendvai, N; Lesokhin, AM; Mailankody, S; Nguyen, J; Roshal, M; Sabari, J | 1 |
| Baz, R; Benson, DM; Campana, F; Charpentier, E; Lendvai, N; Lesokhin, AM; Martin, T; Munster, P; Vij, R; Wack, C; Wolf, J | 1 |
| Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A | 1 |
| Figg, WD; Kazandjian, D; Korde, N; Landgren, O; Mailankody, S; Peer, CJ; Sissung, TM; Venzon, DJ | 1 |
| Chang, S; Maharaj, S; Seegobin, K; Serrano-Santiago, I; Zuberi, L | 1 |
| An, J; Donovan, KA; Fischer, ES; Ponthier, CM; Sack, R; Seebacher, J; Stadler, MB | 1 |
| Davidoff, AJ; Dusetzina, SB; Eaton, CB; Olszewski, AJ; Trivedi, AN | 1 |
| de Wit, E; Moreau, P | 1 |
| Hollingworth, SA; McKavanagh, D; Mollee, P; Sharkey, MM; Walpole, E | 1 |
| Cao, Z; Tian, C; Yang, H; Zhang, Q; Zhang, Y; Zhu, L | 1 |
| Bouscary, D; Chavarot, N; Karras, A; Lebbe, C; Thervet, E | 1 |
| Morgan, GJ; Rasche, L | 1 |
| Delforge, M; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Song, K; Vogl, DT | 1 |
| Anderson, K; Avigan, D; Gali, R; Hideshima, T; Kufe, D; Tagde, A; Tai, YT; Yin, L | 1 |
| Braga, WMT; Colleoni, GWB; Davies, FE; de Carvalho, MF; de Oliveira, MB; Eugenio, AIP; Fernando, RC; Fook-Alves, VL; Sanson, LFG | 1 |
| Anderson, K; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, MA; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Moreau, P; Palumbo, A; Poulart, V; Reece, D; Richardson, P; San-Miguel, J; Sheng, J; Shpilberg, O; Singhal, A; Spicka, I; Sy, O; Walter-Croneck, A; White, D | 1 |
| Jantunen, E; Mäntymaa, P; Partanen, A; Pelkonen, J; Putkonen, M; Ropponen, A; Sankelo, M; Siitonen, T; Silvennoinen, R; Valtola, J; Varmavuo, V | 1 |
| Chen, X; Du, X; Gupta, N; Hanley, MJ; Hou, J; Hua, Z; Jin, J; Ke, X; Li, H; Li, J; Liu, J; Lu, J; Moreau, P; Richardson, PG; van de Velde, H; Wang, B; Wang, H; Wu, D; Xu, Y; Zhang, X; Zhou, D | 1 |
| Chen, WM; Fu, ZZ; Hu, Y; Huang, XJ; Huang, ZX; Jin, FY; Li, XL; Liao, AJ; Liu, H; Lu, J; Meng, FY; Wang, GM; Wang, XM; Yang, GZ; Zhang, X; Zhong, YP; Zhou, JF | 1 |
| Falcon, CP; Matsui, T; Minagawa, K | 1 |
| Chen, N; Connarn, JN; Gao, Y; Hwang, R; Palmisano, M | 1 |
| Azuma, Y; Fujita, S; Hotta, M; Ishii, K; Ito, T; Nakanishi, T; Nakaya, A; Nomura, S; Satake, A; Tsubokura, Y; Yoshimura, H | 1 |
| Anderson, KC; Attal, M; Bringhen, S; Caillot, D; Gay, F; Holstein, SA; Hulin, C; Jung, SH; Knight, RD; Marit, G; McCarthy, PL; Moreau, P; Musto, P; Palumbo, A; Petrucci, MT; Richardson, PG; Tosi, P; Winograd, B; Yu, Z | 1 |
| Bladé, J; Calderón, M; de Larrea, CF; Díaz, T; Lozano, E; Martínez, A; Mena, MP; Pérez-Galán, P; Rodríguez, V; Rosiñol, L; Roué, G; Tovar, N | 1 |
| Chung, YJ; Jung, SH; Kim, SH; Kim, TW; Lee, M; Lee, SE; Min, CK; Yim, SH | 1 |
| Chan, W; Chen, Y; Du, XL; Lairson, DR | 1 |
| Bello, A; Dodge, R; Gupta, M; Mora, J; Passey, C; Robbins, M; Roy, A; Sheng, J; Tendolkar, A | 1 |
| Syed, YY | 1 |
| Bwire, R; Castaneda, C; Chan-Liston, M; Freeman, J; Hirsch, D; McWilliams, R; Mezo, M; Minton, N; Phillips, L; Sheehan, P | 1 |
| Anderson, KC; Bashey, A; Boyd, M; Callander, NS; Devine, SM; Gentile, TG; Giralt, S; Hari, P; Hars, V; Hassoun, H; Hofmeister, CC; Holstein, SA; Horowitz, MM; Hurd, DD; Isola, L; Jiang, C; Jung, SH; Landau, H; Linker, C; Martin, T; Maziarz, RT; McCarthy, PL; McClune, B; Moreb, JS; Owzar, K; Pasquini, MC; Qazilbash, MH; Richardson, PG; Rodriguez, C; Schlossman, RL; Schultz, C; Shea, TC; Smith, SE; Stadtmauer, EA; van Besien, K; Vij, R; Weisdorf, DJ; Wilson, M | 1 |
| Cairns, D; Cook, G; Davies, FE; Drayson, M; Gregory, WM; Houlston, RS; Jackson, G; Johnson, DC; Jones, JR; Kaiser, MF; Lenive, O; Mitchell, J; Morgan, GJ; Owen, R; Pawlyn, C; Walker, BA; Wardell, C | 1 |
| Andrea, M; Beck, J; Becker, C; Bill, M; Edelmann, T; Gläser, D; Heyn, S; Hoffmann, FA; Jentzsch, M; Kragl, B; Kreibich, U; Lange, T; Mohren, M; Mügge, LO; Niederwieser, D; Pönisch, W; Schliwa, T; Schwarzer, A; Schwind, S; Uhlig, J; Winkelmann, C; Zehrfeld, T | 1 |
| Cho, H; Do, YR; Eom, HS; Jo, JC; Kang, HJ; Kim, JS; Kim, K; Kim, SY; Lee, HS; Lee, JB; Lee, JH; Lee, JJ; Lee, WS; Min, CK; Moon, JH; Mun, YC; Park, Y; Shin, HJ; Suh, C; Yoon, DH | 1 |
| Mikhael, JR | 1 |
| Buadi, FK; Chakraborty, R; Dingli, D; Dispenzieri, A; Gertz, MA; Gonsalves, W; Hayman, SR; Hogan, WJ; Kapoor, P; Kourelis, T; Kumar, SK; Lacy, MQ; Leung, N; Muchtar, E; Warsame, R | 1 |
| Abe, T; Ameda, S; Fujii, S; Kato, J; Kobune, M; Kuroda, H; Maeda, M; Miura, S; Sakano, H; Sato, K; Shibata, T; Uemura, N; Yamada, M | 1 |
| Bhatnagar, V; Farrell, AT; Goldberg, KB; Gormley, NJ; Luo, L; Ma, L; McKee, AE; Pazdur, R; Shen, G; Shen, YL; Shord, S; Sridhara, R; Subramaniam, S | 1 |
| Bergh, J; Camarero Jiménez, J; Demolis, P; Garcia, I; Gisselbrecht, C; Laane, E; Ludwig, H; Martin, M; Moreau, A; Pignatti, F; Salmonson, T; Sancho-López, A; Tzogani, K | 1 |
| Chang, JE | 1 |
| Canoz, O; Eser, B; Kaynar, L; Tiren, N; Yildizhan, E | 1 |
| Thakral, B; Wang, SA | 1 |
| Bloem, AC; Broekmans, MEC; Chiu, C; Frerichs, KA; Groen, RWJ; Krejcik, J; Lokhorst, HM; Musters, RJP; Mutis, T; Nijhof, IS; Plesner, T; Poddighe, PJ; Sasser, AK; van de Donk, NWCJ; van Kessel, B; van Meerloo, J; van Velzen, JF; Zweegman, S | 1 |
| Cheng, B; Guo, Y; Li, X; Ma, D; Tang, S; Wang, J; Wu, W; Xu, J; Zhe, N | 1 |
| Avet-Loiseau, H; Bahlis, NJ; Ben-Yehuda, D; Berg, D; Cavo, M; Chng, WJ; di Bacco, A; Esseltine, DL; Ganly, P; Kumar, S; Langer, C; Lin, J; Masszi, T; Moreau, P; Nagler, A; Palumbo, A; Pluta, A; Pour, L; Rajkumar, SV; Richardson, PG; San-Miguel, J; van de Velde, H; Viterbo, L | 1 |
| Brown, CE; Chang, WC; Forman, SJ; Htut, M; Huynh, C; Krishnan, AY; Lim, L; Pichiorri, F; Sanchez, JF; Thomas, SH; Urak, R; Walter, M; Wang, X; Weng, L; Wong, CW; Yang, L | 1 |
| Al, MJ; Albuquerque de Almeida, F; Armstrong, N; Büyükkaramikli, NC; de Groot, S; Fayter, D; Kleijnen, J; Stirk, L; Wolff, R; Worthy, G | 1 |
| Advani, P; Ailawadhi, S; Chanan-Khan, AA; Colibaseanu, DT; Colon-Otero, G; Frank, RD; Hashmi, SK; Hodge, DO; Kakar, TS; Khera, N; Meghji, Z; Menghani, R; Paulus, A; Paulus, S; Roy, V; Sharma, M; Swaika, A; Temkit, M; Vizzini, MR | 1 |
| Blair, HA | 1 |
| Asmar, F; Christensen, J; Dimopoulos, K; Fibiger Munch-Petersen, H; Gimsing, P; Grønbaek, K; Hermansen, NEU; Liang, G; O'Connel, C; Sjö, L; Sommer Kristensen, L; Søgaard Helbo, A | 1 |
| Birhiray, R; Przybylski, DJ; Reeves, DJ | 1 |
| Guo, H; Sun, X; Wang, B; Xu, W | 1 |
| Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kanellias, N; Kastritis, E; Migkou, M; Ntanasis-Stathopoulos, I; Roussou, M; Terpos, E; Ziogas, DC | 1 |
| Anderson, KC; Attal, M; Holstein, SA; McCarthy, PL; Richardson, PG; Schlossman, RL | 1 |
| Das, M | 1 |
| Ahlberg, L; Alici, E; Blimark, C; Carlsson, C; Forsberg, K; Gréen, H; Gruber, A; Hardling, M; Jakobsen Falk, I; Lauri, B; Lotfi, K; Lund, J; Mellqvist, UH; Nahi, H; Swedin, A | 1 |
| Danhof, S; Einsele, H; Gogishvili, T; Hudecek, M; Knop, S; Löffler, C; Rasche, L; Schreder, M; Strifler, S | 1 |
| Belch, A; Diels, J; Ito, T; Oriol, A; Van Sanden, S; Vogel, M | 1 |
| Boccadoro, M; Giudice, D; Larocca, A; Pautasso, C; Salvini, M; Troia, R | 1 |
| Campioni, M; DeCosta, L; Fink, L; Flinois, A; Gazzola, C; Gonzalez-McQuire, S; Leleu, H; Mennini, FS; Schoen, P; Yong, K | 1 |
| Chung, DJ; Copelan, O; Devlin, SM; Giralt, SA; Hassoun, H; Kenny, S; Koehne, G; Korde, NS; Landau, H; Landgren, CO; Lendvai, N; Lesokhin, AM; Mailankody, S; Maloy, M; Palazzo, M; Perales, MA; Seier, K; Shah, GL | 1 |
| Asimakopoulos, F; Chhabra, S; D'Souza, A; Dhakal, B; Gyawali, B; Hamadani, M; Hari, PN; Jackson, JL; Sieracki, R; Szabo, A; Usmani, SZ | 1 |
| Blaedel, J; Dimopoulos, MA; Facon, T; Goldschmidt, H; Jakubowiak, A; Ludwig, H; Obreja, M; San-Miguel, J; Siegel, DS; Stewart, AK | 1 |
| Bacher, U; Betticher, D; Egger, T; Gössi, U; Jeker, B; Mansouri Taleghani, B; Novak, U; Pabst, T; Zander, T | 1 |
| Mima, A; Nagahara, D; Tansho, K | 1 |
| Catalano, L; Cerchione, C; Martinelli, V; Nappi, D; Pane, F; Pareto, AE; Picardi, M; Romano, A | 1 |
| El-Annan, J; Kellogg, C; Sultan, H | 1 |
| Baden, LR; Hammond, SP; Issa, NC; Laubach, JP; Leblebjian, H; Marty, FM; Pandit, A; Richardson, PG | 1 |
| Abumiya, M; Kanno, S; Kobayashi, T; Miura, M; Niioka, T; Takahashi, N | 1 |
| Dmytrijuk, A; Farrell, AT; Goldberg, KB; McKee, AE; Nie, L; Pazdur, R; Pulte, ED | 1 |
| Blaedel, J; DeCosta, L; Goldschmidt, H; Leleu, X; Mateos, MV; Mikhael, J; Obreja, M; San-Miguel, J; Szabo, Z; Zhou, L | 1 |
| Hoshino, K; Imai, G; Kojima, M; Ooi, A; Takemori, N | 1 |
| Anderson, SM; Beck, B; Lockhorst, R; Ngorsuraches, S; Sterud, S | 1 |
| Abumiya, M; Ikeda, S; Ito, F; Kameoka, Y; Kobayashi, I; Kobayashi, T; Miura, M; Niioka, T; Takahashi, N; Yoshioka, T | 1 |
| Ahdesmäki, O; Ainsworth, C; Bell, J; Hawe, E; Le Moine, JG; Maiese, EM | 1 |
| Chen, M; Mao, B; Wang, X; Xu, C; Zhang, X; Zhao, Y | 1 |
| Admojo, L; Darcy, PK; Davenport, AJ; Fairlie, DP; Gherardin, NA; Godfrey, DI; Harrison, SJ; Jenkins, MR; Kedzierska, K; Loh, L; McCluskey, J; Neeson, PJ; Prince, HM; Quach, H; Richardson, K; Ritchie, DS; Rogers, A; Uldrich, AP | 1 |
| Beeker, A; Bloem, AC; Bos, GMJ; Broijl, A; Couto, S; Faber, LM; Franssen, LE; Klein, SK; Koene, HR; Leguit, RJ; Levin, MD; Lokhorst, H; Mutis, T; Nijhof, IS; Qian, X; Raymakers, R; Ren, Y; Sonneveld, P; Thakurta, A; van de Donk, NWCJ; van der Spek, E; Wang, M; Zweegman, S | 1 |
| Bourquard, P; Chevallier, T; Cousin, C; Dubois, F; Favier, M; Favier-Archinard, C; Le Gall, T; Leguelinel-Blache, G; Passemard, N; Rey, A; Rossi, M; Tora, S | 1 |
| Aldaoud, A; Harde, J; Knauf, W; Losem, C; Mittermueller, J; Neise, M; Niemeier, B; Potthoff, K; Trarbach, T | 1 |
| Armoiry, X; Clarke, A; Connock, M; Cummins, E; Melendez-Torres, GJ; Royle, P; Tsertsvadze, A | 1 |
| Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E | 1 |
| Bensinger, W; Blaedel, J; Dimopoulos, M; Maisnar, V; Mateos, MV; Minarik, J; Moreau, P; Obreja, M; Wang, M | 1 |
| Bajaj, K; Ibrahim, M; Kapila, A; Moore, CA | 1 |
| Abraham, I; Anwer, F; Iftikhar, A; Kapoor, V; Latif, A; McBride, A; Mushtaq, A; Riaz, IB; Zahid, U | 1 |
| Bach, C; Balzer, H; Beier, F; Bisht, S; Bittenbring, JT; Böttcher, M; Boxhammer, R; Bruns, H; Busch, L; Büttner-Herold, M; Dudziak, D; Fabri, M; Gelse, K; Gezer, D; Hennig, FF; Hoffmann, MH; Jitschin, S; Mackensen, A; Mougiakakos, D; Müller, MJ; Neumann, F; Nolting, J; Pallasch, CP; Spriewald, B; Volmer, DA | 1 |
| Adey, DB; Jen, KY; Laszik, ZG; Walavalkar, V | 1 |
| Bai, H; Fan, WJ; Fan, ZQ; Wu, T | 1 |
| Ahlberg, L; Alici, E; Blimark, C; Carlsson, C; Duru, AD; Forsberg, K; Frølund, U; Gahrton, G; Gimsing, P; Gruber, A; Hansson, M; Hardling, M; Holmberg, E; Lauri, B; Lund, J; Mellqvist, UH; Nahi, H; Swedin, A; Vangsted, AJ; Waage, A | 1 |
| Barrio, S; Braggio, E; Collado, L; Folgueira, MD; Hernandez-Lain, A; Linares, M; Martinez-Lopez, J; Ramos, A; Rapado, I; Ruiz, J; Ruiz-Heredia, Y; Sanchez-Vega, B; Stewart, K; Toldos, O | 1 |
| Guo, HM; Liu, XJ; Luo, JM; Nie, ZY; Sun, L; Yang, L | 1 |
| Byrne, M; Chinratanalab, W; Cornell, RF; Engelhardt, BG; Goodman, SA; Harrell, SL; Huang, J; Jagasia, M; Kassim, A; Phillips, S; Rawling, KT; Savani, BN; Sengsayadeth, S | 1 |
| Allatif, O; Attal, M; Belmont, L; Besson, L; Charrier, E; Karlin, L; Lombard, C; Marçais, A; Rouzaire, P; Salles, G; Viel, S; Walzer, T | 1 |
| Camiolo, G; Conticello, C; Di Raimondo, F; Giallongo, C; La Cava, P; Martino, E; Palumbo, GA; Parisi, M; Parrinello, NL; Pirosa, MC; Puglisi, F; Romano, A; Tibullo, D | 1 |
| Dimopoulos, MA; Huang, SY; Iida, S; Kosugi, H; Matsumoto, M; Okamoto, S; Qi, M; Qin, X; Shinagawa, A; Suzuki, K; Takezako, N; Yoon, SS | 1 |
| Fulciniti, M; Lee, SH; Leslie, CS; Mayr, C; Munshi, NC; Samur, MK; Singh, I; Sperling, AS; Tai, YT | 1 |
| Dimopoulos, K; Dissing Sjö, L; Fibiger Munch-Petersen, H; Gimsing, P; Grønbaek, K; Ralfkiaer, E; Winther Eskelund, C | 1 |
| Bhutani, M; Kazandjian, D; Korde, N; Kwok, M; Landgren, O; Leitman, SF; Mailankody, S; Manasanch, E; Panch, S; Sportes, C; Stetler-Stevenson, M; Tageja, N; Yuan, C | 1 |
| Anderson, KC; Basile, FG; Burke, JN; Chen, T; Ghobrial, IM; Harrington, CC; Huff, CA; Laubach, JP; Lively, KJ; Lyons, HF; Munshi, NC; O'Donnell, EK; Paba-Prada, CE; Raje, NS; Richardson, PG; Schlossman, RL; Trippa, L; Wade, PM; Yee, AJ | 1 |
| Berg, D; Hari, P; Lin, HM; Moreau, P; Richardson, PG; Zhu, Y | 1 |
| Adamopoulos, I; Aktypi, A; Anagnostopoulos, A; Briasoulis, E; Delimpasi, S; Douka, V; Fotiou, D; Giannakoulas, N; Giannopoulou, E; Gogos, D; Hatzimichael, E; Katodritou, E; Kioumi, A; Kokoviadou, K; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Megalakaki, A; Nikolaou, E; Papadaki, E; Pappa, V; Repousis, P; Spanoudakis, E; Symeonidis, A; Terpos, E; Timotheatou, D; Vasilopoulos, G; Zikos, P | 1 |
| Johnson, PRE; Mathur, A; Roddie, PH; Storrar, NPF | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Migkou, M; Terpos, E | 1 |
| Bouwmeester, W; Campioni, M; DeCosta, L; Fraňková, H; Gonzalez-McQuire, S; Gregora, E; Hájek, R; Jarkovsky, J; Kessler, P; Maisnar, V; Minařík, J; Pour, L; Špička, I; Sýkora, M; Treur, M | 1 |
| Allen, C; Barac, A; Basaleem, H; Bensenor, I; Cowan, AJ; Curado, MP; Fitzmaurice, C; Foreman, K; Gupta, R; Harvey, J; Hosgood, HD; Jakovljevic, M; Khader, Y; Lad, D; Libby, EN; Linn, S; Mantovani, L; Mokdad, A; Naghavi, M; Nguyen, CT; Nong, VM; Postma, M; Roshandel, G; Shackelford, K; Sisay, M; Tran, TT; Ukwaja, KN; Vollset, SE; Weiderpass, E; Xuan, BT | 1 |
| Berube, C; Coutré, SE; Dinner, S; Dunn, TJ; Gotlib, J; Kaufman, GP; Liedtke, M; Medeiros, BC; Price, E | 1 |
| Burslem, GM; Crews, CM; Cromm, PM; Jaime-Figueroa, S; Morgan, A; Ottis, P; Toure, M | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Calafiore, V; Cerrato, C; Corradini, P; De Paoli, L; Falcone, AP; Gamberi, B; Guglielmelli, T; Hájek, R; Malfitano, A; Mannina, D; Mina, R; Musto, P; Nagler, A; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Ria, R; Spada, S; Spencer, A; Zambello, R | 1 |
| Christos, PJ; Demetres, M; Hammad, H; Leonard, JP; Ruan, J; Yamshon, S | 1 |
| Vandross, A | 1 |
| Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, TW; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, JY; Min, CK; Park, SS; Ryu, DB; Yoon, JH | 1 |
| Bacco, AD; Baz, R; Berdeja, JG; Berg, D; Byrne, C; Chari, A; Estevam, J; Gupta, N; Hofmeister, CC; Htut, M; Lebovic, D; Liao, E; Liedtke, M; Raje, N; Richardson, PG; Rosenbaum, CA; Smith, SD; Vesole, DH | 1 |
| Bowden, J; Buchanan, V; Cook, G; Haller, E; Homer, N; Khan, A; Kuhn, I; Leahy, J; Maguire, Á; Morris, J; O'Dwyer, M; Ruggeri, K; Schmitz, S; Walsh, C | 1 |
| Aceituno, S; Appierto, M; Gozalbo, I; Lizán, L | 1 |
| Jiang, J; Wan, N; Wang, S; Zhang, L; Zhang, TT; Zhang, Z | 1 |
| Abonour, R; Abouzaid, S; Durie, BGM; Gasparetto, CJ; Hardin, JW; Jagannath, S; Kitali, A; Narang, M; Parikh, K; Rifkin, RM; Srinivasan, S; Terebelo, HR; Toomey, K; Wagner, L; Zafar, F | 1 |
| Abadi, U; Bekadja, MA; Beksac, M; Berthou, C; Boccadoro, M; Borbényi, Z; Cavo, M; Černelč, P; Corso, A; Couturier, C; De Stefano, V; Dimopoulos, M; Durán, MS; Feys, C; Kochkareva, Y; Laane, E; Legiec, W; Lejniece, S; Louw, V; Masliak, Z; Mateos, MV; Mohty, M; Nemet, D; Pečeliūnas, V; Pedersen, RS; Potamianou, A; Salwender, H; Silva, J; Stankovic, S; Terpos, E; Thoret-Bauchet, F; Willenbacher, W | 1 |
| Bohn, JP; Oberacher, H; Peschel, I; Steurer, M; Willenbacher, W | 1 |
| Cowley, GS; Ebert, BL; Fischer, ES; Gasser, JA; Sievers, QL | 1 |
| Chen, X; Feng, J; Gao, G; Shen, H; Tang, H; Xu, L; Zhang, N; Zheng, Y | 1 |
| Broijl, A; de Ridder, J; Sonneveld, P; Ubels, J; van Beers, EH; van Vliet, MH | 1 |
| Abonour, R; Durie, BGM; Gasparetto, CJ; Gibson, CJ; Hardin, JW; Jagannath, S; Kitali, A; Narang, M; Rifkin, RM; Srinivasan, S; Swern, AS; Terebelo, HR; Toomey, K; Wagner, L | 1 |
| Björklöf, K; Coriu, D; Dytfeld, D; Fink, L; Markuljak, I; Mihaylov, G; Niepel, D; Ostojic-Kolonic, S; Spicka, I; Toka, KS | 1 |
| Attal, M; Bladé, J; Boccadoro, M; Bringhen, S; Cairns, DA; Davies, F; Di Raimondo, F; Evangelista, A; Gay, F; Hájek, R; Holstein, SA; Hulin, C; Jackson, G; Lahuerta, JJ; Leleu, X; Liberati, AM; Ludwig, H; Macro, M; Mateos, MV; McCarthy, PL; Moreau, P; Morgan, GJ; Offidani, M; Panzani, U; Pawlyn, C; Rosiñol, L; San-Miguel, J; Sonneveld, P; Spada, S; Spencer, A; Terpos, E | 1 |
| Tomlinson, R | 1 |
| Duran, M; Durusoy, R; Patır, P; Şahin, F; Saydam, G; Soyer, N; Töbü, M; Tombuloğlu, M; Ünal, HD; Uysal, A; Vural, F | 1 |
| Engelhardt, M; Grünewald, J; Ihorst, G; Kleber, M; Reinhardt, H; Schmidts, A; Terpos, E; Walz, G; Wäsch, R; Zschiedrich, S | 1 |
| Cella, D; Davis, C; Kudlac, A; McKendrick, J; Oukessou, A; Palumbo, A; Vij, R; Zyczynski, T | 1 |
| Abbasian, M; Adedayo, T; Ambrose, J; Braganza, N; Cavenagh, JD; Chapman, MA; Clifton-Hadley, L; Cook, G; Cook, M; Counsell, N; Crawley, CR; Crowe, J; Herrero, J; Keats, JJ; Koh, M; Lach, A; Oakervee, H; Owen, RG; Popat, R; Pratt, G; Quinn, MF; Roddie, C; Schey, S; Sive, J; Smith, P; Sonneveld, P; Streetly, MJ; Virchis, AE; Willis, F; Yong, K | 1 |
| Guzman, S; Kitahara, S | 1 |
| Dueck, AC; Hayman, S; Kanate, AS; Lonial, S; Manola, J; Mikhael, J; Oettel, K; Rajkumar, SV | 1 |
| Argente-Escrig, H; Balaguer, A; Bataller, L; Gómez, E; Martinez, JC; Sevilla, T | 1 |
| Aitini, E; Andriani, A; Angelucci, E; Annibali, O; Baraldi, A; Bernardini, A; Boccadoro, M; Bringhen, S; Centurioni, R; De Stefano, V; Di Renzo, N; Evangelista, A; Ferrando, P; Grammatico, S; Larocca, A; Marcatti, M; Meneghini, V; Musto, P; Offidani, M; Palmas, A; Palmieri, S; Palumbo, A; Pisani, F; Rizzi, R; Rocco, S; Siniscalchi, A; Spada, S; Storti, S; Vallone, R | 1 |
| Betts, KA; Brun, A; Chen, C; Dimopoulos, MA; Lonial, S; Makenbaeva, D; Mekan, S; Richardson, PG; Signorovitch, JE; Sy, O; Weisel, K; Zichlin, ML | 1 |
| Lamb, YN | 1 |
| Neri, P | 1 |
| Anderson, KC; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Benboubker, L; Brechignac, S; Carlton, V; Chretien, ML; Corre, J; Decaux, O; Dejoie, T; Dib, M; Doyen, C; Eveillard, JR; Facon, T; Faham, M; Fohrer, C; Garderet, L; Harousseau, JL; Hulin, C; Jaccard, A; Karlin, L; Kolb, B; Lauwers-Cances, V; Leleu, X; Macro, M; Maheo, S; Meuleman, N; Mohty, M; Moorhead, M; Moreau, P; Munshi, N; Pegourie, B; Perrot, A; Richardson, PG; Robillard, N; Royer, B; Stoppa, AM; Willis, T | 1 |
| Akashi, K; Aoki, T; Eto, T; Henzan, H; Iwasaki, H; Kamimura, T; Kohno, K; Miyamoto, T; Muta, T; Nagafuji, K; Ogawa, R; Ohno, Y; Sugio, Y; Tanimoto, K; Yamasaki, S; Yoshimoto, G | 1 |
| Gamez, R; Jawahar, A; Nagamine, A | 1 |
| Baron, M; Bihan, K; Biour, M; Cez, A; Roos-Weil, D; Simon, L; Wesner, N | 1 |
| Akashi, K; Fuchida, SI; Fujishima, N; Harada, M; Hiramatsu, Y; Izumi, T; Kuroda, Y; Matsumoto, M; Miyamoto, T; Murayama, T; Okumura, H; Otsuka, E; Shimazaki, C; Sunami, K; Tamaki, S | 1 |
| Boireau, S; Cartron, G; Cavalli, G; Goldschmidt, H; Herviou, L; Hose, D; Kassambara, A; Moreaux, J; Müller-Tidow, C; Requirand, G; Robert, N; Seckinger, A; Vincent, L | 1 |
| Bang, SM; Jo, JC; Kim, JS; Kim, K; Lee, HS; Lee, JJ; Lee, JO; Lee, YJ; Min, CK; Shin, J; Suh, C; Yoon, SS | 1 |
| Ahmed, S; Alousi, AM; Bashir, Q; Champlin, RE; Delgado, R; Hosing, CM; Kebriaei, P; Lee, HC; Manasanch, EE; Nieto, Y; Orlowski, RZ; Patel, KK; Patel, R; Popat, UR; Qazilbash, MH; Rondon, G; Saini, NY; Thomas, SK; Varma, A; Weber, DM | 1 |
| Chehab, S; Chen, Z; Harvey, RD; Kaufman, JL; Lonial, S; Nooka, A; Panjic, EH; Zhang, C | 1 |
| Gupta, N; Kumar, R; Sharma, A | 1 |
| Chao, N; Ebens, A; Foreman, O; Gasparetto, C; Hu, J; Kang, Y; Kozlowski, C; Lazarchick, J; Roof, L; Sha, Y; Venkta, JK; Zheng, J | 1 |
| Hillengass, J; Iqbal, SM; Krabak, M; McCarthy, P; Sarow, J; Stecklein, K | 1 |
| Avet-Loiseau, H; Azais, I; Barrier, J; Bauwens, D; Bobin, A; Bonnin, A; Bouyier, S; Bridoux, F; Brigaud, A; Daras, C; Dieval, C; Diolez, J; Durand, G; Fleck, E; Fouquet, G; Franques, P; Fuzibet, JG; Gardeney, H; Gil, A; Gruchet, C; Guidez, S; Javaugue, V; Legros, L; Leleu, X; Levy, A; Machet, A; Moya, N; Plasse, F; Primault, S; Princet, I; Richez, V; Sabirou, F | 1 |
| Belch, A; Capra, M; Clemens, PL; Dimopoulos, MA; Gomez, D; Ho, PJ; Iida, S; Jansson, R; Leiba, M; Medvedova, E; Min, CK; Schecter, J; Sonneveld, P; Sun, YN; Xu, XS; Zhang, L | 1 |
| Aljama, MA; Bin Riaz, I; Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Gonsalves, WI; Hogan, WJ; Kapoor, P; Kourelis, TV; Kumar, SK; Lacy, MQ; Leung, N; Muchtar, E; Rajkumar, SV; Sidiqi, MH; Warsame, R | 1 |
| Craft, M; Crispin, P; Koo, RM; Lalloo, S | 1 |
| Ferrari, RH; Kumar, SK; Laubach, JP; Lonial, S; O'Donnell, EK; Raje, N; Richardson, PG; Skacel, T; Voorhees, P; Zweegman, S | 1 |
| Bailly, S; Croizier, C | 1 |
| Kambe, E; Sato, S; Tamai, Y | 1 |
| Campbell, KS; Cohen, AD; Pazina, T | 1 |
| Figg, WD; Hill, E; Kazandjian, D; Korde, N; Landgren, O; Mailankody, S; Roschewski, M | 1 |
| Bates, JS; Jones, AR; Reeves, BN; Schepers, AJ; Tuchman, SA | 1 |
| Amini, B; Berkova, Z; Feng, L; Hildebrandt, M; Lee, HC; Manasanch, EE; Orlowski, RZ; Shah, JJ; Thomas, SK; Weber, DM | 1 |
| Guo, H; Jiang, Y; Ran, X; Su, B; Wang, L; Zhao, N; Zheng, X; Zhu, X | 1 |
| Binder, M; Buadi, FK; Dispenzieri, A; Fonder, A; Gertz, MA; Go, RS; Gonsalves, WI; Hayman, SR; Hobbs, M; Hwa, YL; Kapoor, P; Kourelis, T; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lust, JA; Rajkumar, SV; Russell, SJ; Warsame, R; Zeldenrust, SR | 1 |
| Alsina, M; Baz, R; Brayer, J; Fridley, BL; Hillgruber, N; Lee, JH; Naqvi, SMH; Shain, KH; Sullivan, DM | 1 |
| Breitkreutz, I; Goldschmidt, H; Raab, M | 1 |
| Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Garg, M; Gregory, WM; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Karunanithi, K; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Russell, NH; Striha, A; Williams, CD | 1 |
| de la Calle, VG; Mateos, MV | 1 |
| Bernardini, A; Boccadoro, M; Cavo, M; Conticello, C; Gambella, M; Gamberi, B; Gilestro, M; Grammatico, S; Larocca, A; Liberati, AM; Muccio, VE; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Rocci, A; Saraci, E; Sonneveld, P; Spada, S; Troia, R | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Kanellias, N; Kastritis, E; Migkou, M; Ntanasis-Stathopoulos, I; Papatheodorou, A; Roussou, M; Terpos, E; Trougakos, IP; Ziogas, DC | 1 |
| Blommestein, HM; Franken, MG; Sonneveld, P; Uyl-de Groot, CA; van Beurden-Tan, CHY; Zweegman, S | 1 |
| Amsler, IG; Bacher, U; Betticher, D; Egger, T; Jeker, B; Luethi, JM; Mansouri Taleghani, B; Novak, U; Pabst, T; Zander, T | 1 |
| Holstein, SA; McCarthy, PL; Suman, VJ | 1 |
| Berenson, JR; Chen, H; Hekmati, T; Li, M; Nosrati, JD; Patil, S; Sanchez, E; Schlossberg, RE; Soof, CM; Tanenbaum, EJ; Tang, G; Vidisheva, A; Wang, C; Zahab, B | 1 |
| Li, S; Maman, STD; Meng, XY; Xiao, YN | 1 |
| Christopoulou, G; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gerofotis, A; Kastritis, E; Katodritou, E; Konstantinidou, P; Kourakli, A; Ntanasis-Stathopoulos, I; Symeonidis, A; Terpos, E; Zagouri, F | 1 |
| Bashey, A; Blackwell, B; Brunstein, C; Devine, S; Efebera, Y; Ganguly, S; Gasparetto, C; Geller, N; Giralt, S; Hari, P; Horowitz, MM; Knust, K; Koreth, J; Krishnan, A; Landau, H; McCarthy, P; Nelson, C; Pasquini, MC; Qazilbash, MH; Shah, N; Somlo, G; Stadtmauer, EA; Vesole, DH; Vij, R; Vogl, DT | 1 |
| Blum, KA; Blum, W; Byrd, JC; Foster, DJR; Gao, Y; Grever, MR; Hofmeister, CC; Hughes, JH; Marcucci, G; Phelps, MA; Reuter, SE; Upton, RN | 1 |
| Ando, K; Aoyama, Y; Kawada, H; Kitamura, Y; Nakamura, Y; Ogawa, Y; Suzuki, R; Warita, T | 1 |
| Barosi, G; Gale, RP | 2 |
| Gertz, M; Vaxman, I | 1 |
| Berdeja, JG; Berg, D; Hamadani, M; Hari, P; Kaufman, JL; Kumar, SK; Laubach, JP; Liao, E; Lonial, S; Niesvizky, R; Rajkumar, SV; Richardson, PG; Roy, V; Stewart, AK; Vescio, R | 1 |
| Anderson, S; Ho, PJ; Kiernan, M | 1 |
| Alizadeh, H; Bátai, Á; Deák, B; Demeter, J; Illés, Á; Kosztolányi, S; Mikala, G; Nagy, Z; Pető, M; Plander, M; Schneider, T; Szendrei, T; Szomor, Á; Varga, G; Váróczy, L | 1 |
| Evert, M; Grube, M; Herr, W; Reichle, A; Schelker, RC; Vogelhuber, M; Wagner, B | 1 |
| Ban, S; Hidaka, Y; Kaneko, Y; Kawamoto, S; Misawa, H; Nagahori, K; Okamura, T; Takeda, T; Ueda, Y; Yoshino, A | 1 |
| Alahmadi, M; Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Ashby, C; Begum, DB; Cairns, DA; Cook, G; Davies, FE; Drayson, MT; Ellis, S; Greaves, M; Gregory, WM; Jackson, GH; Johnson, D; Jones, JR; Kaiser, MF; Melchor, L; Morgan, GJ; Owen, RG; Pawlyn, C; Rasche, L; Sherborne, AL; Walker, BA; Wardell, C; Weinhold, N | 1 |
| Ahmann, JM; Bergsagel, PL; Braggio, E; Bruins, LA; de Campos, CB; Porter, B; Riggs, DL; Shi, CX; Stewart, AK; Wang, X; Zhu, YX | 1 |
| Bernabei, L; Bushweller, JH; Busino, L; Chang, R; Florens, L; Garfall, AL; Gutierrez-Uzquiza, A; Illendula, A; Saraf, A; Vogl, DT; Washburn, MP; Zheng, XY; Zhou, N | 1 |
| Brozova, L; Flochova, E; Gregora, E; Hajek, R; Jelinek, T; Jungova, A; Kralikova, E; Maisnar, V; Minarik, J; Pour, L; Radocha, J; Spicka, I; Stecova, N; Stefanikova, Z | 1 |
| Attal, M; Avet-Loiseau, H; Caillon, H; Decaux, O; Dejoie, T; Moreau, P | 1 |
| Abeykoon, JP; Kapoor, P; Zanwar, S | 1 |
| Fujiwara, T; Fukuhara, N; Furukawa, E; Harigae, H; Ichikawa, S; Kawajiri, A; Nakagawa, R; Onishi, Y; Onodera, K; Saito, K; Sano, S | 1 |
| Antunes, L; Bento, MJ; Chacim, S; Lefèvre, C; Pereira, M; Pereira, S; Rocha-Gonçalves, F; Zagorska, A | 1 |
| Ali, N; Beck, R; Covut, F; de Lima, M; Dosani, T; Downes, K; Fox, R; Kim, BG; Maitta, R; Malek, E; Pinto, R; Reese, J | 1 |
| Caballero García, A; Córdova Martínez, A; Fernández-Lázaro, CI; Fernández-Lázaro, D | 1 |
| Kapoor, P; Rajkumar, SV | 1 |
| Auger-Quittet, S; Bareau, B; Belhadj-Merzoug, K; Benboubker, L; Bosson, JL; Boyle, E; Cliquennois, M; Decaux, O; Fuzibet, JG; Karlin, L; Leleu, X; Leyronnas, C; Orsini-Piocelle, F; Pegourie, B; Pernod, G; Rey, P; Rodon, P; Royer, B; Slama, B; Tiab, M; Voog, E; Zarnitsky, C | 1 |
| Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S | 1 |
| Mateos, MV; Moreau, P; Zamagni, E | 1 |
| Gkastari, V; Hadjiaggelidou, C; Katodritou, E; Konstantinidou, P; Mandala, E; Markala, D; Papanikolaou, A; Papatheodorou, A; Terpos, E; Triantafyllou, T; Verrou, E; Yiannaki, E | 1 |
| Ahmadi, T; Arkenau, HT; Boccadoro, M; Cavenagh, J; Chen, D; Chiu, C; de Boer, C; Gay, F; Krejcik, J; Laubach, JP; Minnema, MC; Moreau, P; Perrot, A; Plesner, T; Richardson, PG; Schecter, JM | 1 |
| Adachi, Y; Akashi, K; Choi, I; Fuchida, SI; Fujishima, N; Harada, M; Kiguchi, T; Kuroda, Y; Maeda, A; Matsumoto, M; Miyamoto, T; Nagafuji, K; Nakazato, T; Omoto, E; Sunami, K; Suzumiya, J; Takamatsu, H; Takamatsu, Y; Yamamura, R; Yujiri, T | 1 |
| Buettner, R; Caserta, E; Christofferson, A; Gunes, EG; Keats, JJ; Khalife, J; Krishnan, A; Li, H; Marcucci, G; Morales, C; Palmer, J; Pichiorri, F; Pozhitkov, A; Rosen, ST; Rosenzweig, MA; Sanchez, JF; Synold, TW; Troadec, E; Vaidehi, N; Viola, D; Wu, X | 1 |
| Anderson, KC; Chauhan, D; Du, T; Filippakopoulos, P; Li, D; Park, PMC; Picaud, S; Qi, J; Ray, A; Song, Y; Wimalasena, VK; Wu, L | 1 |
| Abe, Y; Kitadate, A; Kobayashi, H; Matsue, K; Miura, D; Narita, K; Takeuchi, M; Terao, T; Tsushima, T | 1 |
| Auclair, D; Bahlis, NJ; Barwick, BG; Boise, LH; Dhodapkar, MV; Gupta, VA; Hofmeister, CC; Jaye, DL; Kaufman, JL; Keats, JJ; Lonial, S; Neri, P; Nooka, AK; Vertino, PM | 1 |
| Dote, S; Hira, D; Itakura, S; Ito, K; Kobayashi, Y; Noda, S; Terada, T; Yamada, S; Yasu, T | 1 |
| Bolwell, BJ; Corrigan, D; Dean, R; Gerds, A; Hamilton, BK; Hill, BT; Jagadeesh, D; Kalaycio, M; Khouri, J; Liu, HD; Majhail, NS; Pohlman, B; Reu, F; Sobecks, R | 1 |
| Avigan, DE; Farooqui, MZH; Ghori, R; Marinello, P; Mateos, MV; Moreau, P; Munshi, N; Ocio, EM; Orlowski, RZ; Reece, D; Rodríguez-Otero, P; San-Miguel, J; Siegel, DS | 1 |
| Boise, LH; Gleason, C; Gupta, VA; Heffner, LT; Joseph, NS; Kaufman, JL; Lonial, S; Nooka, AK | 1 |
| Gay, F; Mina, R | 1 |
| Fujinami, H; Iida, S; Ishida, T; Ito, A; Kinoshita, S; Komatsu, H; Kusumoto, S; Marumo, Y; Masaki, A; Narita, T; Oshima, Y; Ri, M; Sasaki, H; Tachita, T; Totani, H; Yoshida, T | 1 |
| Cao, Y; Jiang, J; Liang, Z; Lin, T; Wan, N; Wang, S; Xie, J; Zhang, T | 1 |
| Andrulis, M; Benner, A; Bertsch, U; Blau, IW; Duerig, J; Fenk, R; Fronhoffs, S; Goldschmidt, H; Graeven, U; Haenel, M; Hansen, T; Hensel, M; Hillengass, J; Hose, D; Huhn, S; Hundemer, M; Jauch, A; Kunz, C; Lindemann, HW; Martens, U; Munder, M; Raab, MS; Salwender, H; Scheid, C; Seidel-Glaetzer, A; Wattad, M; Weisel, K | 1 |
| Ahmadi, T; Attal, M; Bahlis, N; Basu, S; Chiu, C; Facon, T; Frenzel, L; Goldschmidt, H; Hulin, C; Kobos, R; Kumar, S; Leleu, X; Mace, JR; Macro, M; Moreau, P; Nahi, H; O'Dwyer, M; Orlowski, RZ; Perrot, A; Plesner, T; Qi, M; Quach, H; Raje, N; Tiab, M; Uhlar, CM; Usmani, SZ; Van Rampelbergh, R; Venner, CP; Wang, J; Weisel, K | 1 |
| Laubach, J | 1 |
| Alegre-Del Rey, EJ; Epstein, D; García Mochón, L; Gimeno-Ballester, V; Matas Hoces, A; Olry de Labry Lima, A; Ríos Sánchez, E; Ríos Tamayo, R | 1 |
| Bergin, K; Bowen, KM; Couto, S; Guzman, R; Kalff, A; Khong, T; Mithraprabhu, S; Ren, Y; Reynolds, J; Spencer, A; Thakurta, A; Wang, M | 1 |
| Bahlis, NJ; Bailey, K; Duggan, P; Jimenez-Zepeda, VH; McCulloch, S; Neri, P; Tay, J; Yau, P | 1 |
| Ballanti, S; Ben-Yehuda, D; Boccadoro, M; Cascavilla, N; Cavo, M; Corradini, P; De Paoli, L; Di Raimondo, F; Galieni, P; Gay, F; Hajek, R; Liberati, AM; Montefusco, V; Musolino, C; Musto, P; Nagler, A; Nozzoli, C; Offidani, M; Patriarca, F; Ribolla, R; Sonneveld, P; Spada, S | 1 |
| Alici, E; Borg Bruchfeld, J; Gahrton, G; Gran, C; Lund, J; Månsson, R; Nahi, H; Uttervall, K; Wålinder, G | 1 |
| Chen, W; Lu, J | 1 |
| Alfaro, V; Banh, RH; Cannell, P; Carella, AM; D'Rozario, JM; Dimopoulos, MA; Extremera, S; Greil, R; Hájek, R; Huang, SY; Kahatt, C; Ludwig, H; Martínez, S; Mateos, MV; Meuleman, N; Min, CK; Oakervee, HE; Ocio, EM; Sonneveld, P; Spicka, I; Symeonidis, A | 1 |
| Amico, V; Benevolo, G; Bernardini, A; Boccadoro, M; Bringhen, S; Cangiolosi, C; De Paoli, L; Evangelista, A; Falcone, AP; Fraticelli, V; Giuliani, N; Hájek, R; Innao, V; Larocca, A; Ledda, A; Liberati, AM; Mina, R; Montefusco, V; Musto, P; Oddolo, D; Offidani, M; Palumbo, A; Paris, L; Patriarca, F; Romano, A; Spada, S; Zambello, R | 1 |
| Abril, L; Clapés, V; Gassiot, S; González, Y; Ibarra, G; Maluquer, C; Morgades, M; Motlló, C; Oriol, A; Ribera, JM | 1 |
| Miething, CC | 1 |
| Kim, GW; Kwon, SH; Lee, DH; Ryu, HW; Won, HR; Yeon, SK | 1 |
| Araki, T; Fujitani, Y; Miura, A; Ohta, K; Takakuwa, T; Takeoka, Y; Yamamura, R | 1 |
| Bruyer, A; Cartron, G; de Boussac, H; De Bruyne, E; Gourzones, C; Hose, D; Jourdan, M; Kassambara, A; Maes, A; Moreaux, J; Pasero, P; Robert, N; Seckinger, A; Vincent, L | 1 |
| Cavo, M | 2 |
| Arcani, R; Azouza, W; Brunet, C; Colle, J; Costello, R; Fanciullino, R; Farnault, L; Ivanov, V; Lafage, M; Mercier, C; Pourroy, B; Roche, P; Suchon, P; Venton, G | 1 |
| Costello, C | 1 |
| Avivi, I; Cavo, M; Facon, T; Farooqui, MZH; Ghori, RU; Grigoriadis, G; Jagannath, S; Karlin, L; Kosugi, H; LeBlanc, R; Lim, ABM; Lonial, S; Marinello, P; McCroskey, RD; Oriol, A; Rifkin, RM; San-Miguel, J; Schjesvold, F; Suzuki, K; Takezako, N; Usmani, SZ; Yimer, HA | 1 |
| Liang, SH; Yeh, SP | 1 |
| Furukawa, Y; Hagiwara, S; Hori, M; Iha, H; Izumi, T; Kikuchi, J; Koyama, D; Kuroda, Y; Suzuki, A; Toyama-Sorimachi, N; Yasui, H | 1 |
| Ataca Atilla, P; Atilla, E; Beksaç, M; İdilman, R; Yalçıner, M | 1 |
| Leahy, J; Walsh, C | 1 |
| Ackerly Wallweber, H; Acosta-Alvear, D; Amiot, M; Ashkenazi, A; Beresini, MH; Braun, MG; Chen, YA; Clark, K; De Bruyn, T; Gogineni, A; Gomez-Bougie, P; Haley, B; Harnoss, JM; Heidersbach, A; Kan, D; Kaufman, S; Laing, ST; Lawrence, DA; Le Thomas, A; Lee, D; Lorenzo, M; Lu, M; Ly, J; Marsters, SA; Merchant, M; Qing, J; Reichelt, M; Rudolph, J; Sandoval, W; Segal, E; Shemorry, A; Sherbenou, DW; Totpal, K; VanWyngarden, MJ; Walter, P; Wang, W; Weimer, RM; Wu, J | 1 |
| Abouzaid, S; Chari, A; Ni, Q; Parikh, K | 1 |
| Cirstea, D; Eda, H; Fulciniti, M; Mahindra, A; Nemani, N; Patel, K; Raje, N; Santo, L; Scullen, T; Vallet, S; Yee, A | 1 |
| Alsina, M; Bensinger, WI; Kunkel, LA; Lee, S; Martin, TG; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M; Wong, AF | 1 |
| Iida, S; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Mori, F; Niimi, A; Ri, M; Suzuki, T; Yoshida, T | 1 |
| Amraoui, K; Belhadj, K; Dupuis, J; Jannière-Nartey, C; Maître, B | 1 |
| Kizaki, M; Tokuhira, M; Watanabe, R | 1 |
| García-Muñoz, R; Muñoz-Rodríguez, A; Rabasa, P; Robles-de-Castro, D | 1 |
| Lacy, MQ | 2 |
| Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A | 1 |
| Chen, C; Chu, CM; Jiang, H; Jimenez-Zepeda, V; Kukreti, V; Masih-Khan, E; Reece, DE; Trudel, S; Young, T | 1 |
| Arrivé, L; Carbonell, N; Cervera, P; Dangouloff-Ros, V | 1 |
| Lu, H; Sheng, Z; Yu, J; Zou, Y | 1 |
| Abe, M; Fujii, S | 1 |
| Berno, T; Briani, C; Campagnolo, M; Candiotto, L; Cavaletti, G; Ermani, M; Lucchetta, M; Padua, L; Torre, CD; Zambello, R | 1 |
| Álvarez-Fernández, S; Burrows, FJ; Esparís-Ogando, A; Ocio, EM; Ortiz-Ruiz, MJ; Pandiella, A; Parrott, T; San Miguel, J; Zaknoen, S | 1 |
| Minvielle, S; Moreau, P | 1 |
| Anderson, KC; Carter, SL; Giralt, S; Horowitz, MM; Laport, GG; McCarthy, PL; Pasquini, MC; Rajkumar, SV; Richardson, PG; Stadtmauer, EA | 1 |
| Aoki, T; Danbara, M; Higashihara, M; Katayama, T; Miyazaki, K; Tadera, N; Togano, T | 1 |
| Bolomsky, A; Caltagirone, S; Gisslinger, H; Heintel, D; Jäger, U; Ludwig, H; Palumbo, A; Pfeifer, S; Rocci, A; Schreder, M; Zojer, N | 1 |
| Einsele, H; Jungkunz-Stier, I; Seggewiss-Bernhardt, R; Stühmer, T; Zekl, M | 1 |
| Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L | 1 |
| Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Bhutani, D; Deol, A; Lum, L; Ratanatharathorn, V; Tageja, N; Uberti, J; Valent, J; Zonder, J | 1 |
| Anwer, S; Collings, F; Sternberg, A; Sun, Y; Trace, K | 1 |
| Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
| Arcila, ME; Babu, D; Chimento, D; Chung, DJ; Devlin, SM; Giralt, S; Hassoun, H; Landau, H; Lendvai, N; Lesokhin, A; Weltz, J; Zamarin, D | 1 |
| Abe, M; Fujii, S; Harada, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Takeuchi, K | 1 |
| Fujiwara, T; Fukuhara, N; Harigae, H; Ishizawa, K; Kato, H; Katsuoka, Y; Okitsu, Y; Onishi, Y; Takagawa, M | 1 |
| Amiot, M; Bonnaud, S; Gomez-Bougie, P; Gratas, C; Le Gouill, S; Maïga, S; Moreau, P; Pellat-Deceunynck, C | 1 |
| Cavallo, F; Palumbo, A | 1 |
| Mahindra, A; Saini, N | 2 |
| Brandi, G; Dika, E; Maibach, H; Patrizi, A; Tacchetti, P; Venturi, M | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Kapoor, P; Kumar, S; Kyle, R; Lacy, MQ; McCurdy, A; Rajkumar, SV; Rana, V; Russell, S; Srivastava, G; Zeldenrust, S | 1 |
| Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM | 1 |
| Arakaki, H; Uchihara, JN | 1 |
| Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S | 1 |
| Alonso-Llamazares, J; Chimento, SM; Herschthal, J; Spock, C; Vivas, AC | 1 |
| Cerrato, C; Palumbo, A | 2 |
| Chi, XH; Lu, XC; Yang, B; Yu, RL | 1 |
| Alma, E; Cox, MC; Di Napoli, A; Naso, V; Pelliccia, S; Rebecchini, C | 1 |
| Al-Ali, HK; Beck, J; Edelmann, T; Hebenstreit, K; Heyn, S; Hoffmann, FA; Jäkel, N; Lange, T; Mohren, M; Niederwieser, D; Pönisch, W; Röhrborn, R; Schmalfeld, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Chen, L; Gonzalez, MM; Kidd, L; Nguyen, N; Quesada, J | 1 |
| Arai, R; Fujimoto, K; Isozumi, Y; Koyama, T | 1 |
| Allietta, N; Angermund, R; Beksac, M; Benboubker, L; Broer, E; Couturier, C; Dimopoulos, MA; Facon, T; Mazier, MA; Roddie, H | 1 |
| Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
| Ihara, K; Inomata, H; Kato, J; Kikuchi, S; Koyama, R; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Ono, K; Tanaka, S; Yamada, H; Yamauchi, N; Yano, T | 1 |
| Hirata, T; Inagaki, T; Iwai, M; Katayama, Y; Kawano, H; Kimura, S; Kishi, M; Koide, T; Matsui, T; Minagawa, K; Suzuki, T; Takechi, M | 1 |
| Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kanelias, N; Kastritis, E; Kostouros, E; Politou, M; Roussou, M; Terpos, E | 1 |
| Baladandayuthapani, V; Bjorklund, CC; Jones, RJ; Kuiatse, I; Lin, HY; Orlowski, RZ; Shah, JJ; Thomas, SK; Wang, H; Wang, M; Weber, DM; Yang, J | 1 |
| Mistrík, M; Roziaková, L | 1 |
| Awan, F; Chaudhary, L; Craig, M; Cumpston, A; Hamadani, M; Leadmon, S; Tse, W; Watkins, K | 1 |
| Garden, BC; Lacouture, ME; Nardone, B; Reich, LM; West, DP; Wu, S | 1 |
| Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R | 1 |
| Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G | 1 |
| Ai, H; Cai, Z; Chen, F; Chen, N; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wortman-Vayn, H; Wu, D; Yu, L; Zhang, J; Zhou, DB | 1 |
| Alsina, M; Baz, R; Dalton, WS; Djulbegovic, B; Ho, VQ; Miladinovic, B; Nishihori, T; Ochoa-Bayona, JL; Patel, A; Shain, KH; Sullivan, DM | 1 |
| Chng, WJ; Durie, BG; Eom, HS; Goh, YT; Kim, JS; Kim, K; Lee, JH; Ong, KH; Tan, D; Teoh, G | 1 |
| Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N | 1 |
| He, L; Huang, Z; Liu, SQ; Ma, Z; Zhang, RB | 1 |
| Giannotta, A; Guaragna, G; Mele, G; Melpignano, A; Quarta, G; Spina, A | 1 |
| Forsberg, PA; Mark, TM | 1 |
| Bao, L; Huang, X; Jiang, Q; Lai, Y; Liu, Y; Lu, J; Lu, X; Qin, Y; Zhao, X | 1 |
| Gironella, M; López-Andreoni, L; Mallo, M; Martínez-Morgado, N; Ortega, M; Sánchez-Morata, C; Solé, F; Valcárcel, D; Vallespí, T | 1 |
| Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P | 1 |
| Bargay, J; Bladé, J; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López Corral, L; López, J; Mateos, MV; Olavarría, E; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L; San Miguel, JF | 1 |
| Cırak, MY; Emmez, H; Oner, AY; Pamukçuoğlu, M; Senol, E; Sucak, GT; Tunçcan, OG | 1 |
| Klánová, M; Špička, I | 1 |
| Kasahara, KH; Miyagishima, T; Oda, H; Sawada, K; Sogabe, S; Tateno, T | 1 |
| Avet Loiseau, H; Bonnet, S; Debarri, H; Demarquette, H; Facon, T; Fouquet, G; Gay, J; Guidez, S; Herbaux, C; Hulin, C; Leleu, X; Michel, J; Miljkovic, D; Perrot, A; Serrier, C; Tardy, S | 1 |
| Adam, Z; Hajek, R; Pelcova, J; Plasil, M; Raja, KR; Rihova, L | 1 |
| Delbeuck, X; Facon, T; Le Rhun, E; Leleu, X; Lenfant, P; Mackowiak, MA; Noel, MP; Pasquier, F; Pollet, M; Rollin-Sillaire, A | 1 |
| Ishida, T | 2 |
| Morgan, GJ | 1 |
| Mark, TM; Meadows, JP | 1 |
| Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Koulieris, E; Kyrtsonis, MC; Michalis, E; Papanikolaou, X; Papatheodorou, A; Pouli, A; Terpos, E; Zervas, K | 1 |
| Greenberg, AJ; Jelinek, DF; Kumar, SK; Rajkumar, SV; Walters, DK | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Wang, L; Xu, YL; Zhang, XQ | 1 |
| Alsina, M; Bensinger, W; Huang, M; Kavalerchik, E; Martin, T; Niesvizky, R; Orlowski, RZ; Siegel, DS; Wang, M | 1 |
| Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS | 1 |
| Alsina, M; Baz, RC; Dalton, WS; Hussein, MA; Lee, JH; Nardelli, LA; Nishihori, T; Nodzon, LA; Ochoa-Bayona, JL; Oliver, EF; Shain, KH; Sullivan, DM; Zhao, X | 1 |
| Berzins, SP; Chan, AC; Godfrey, DI; Harrison, SJ; Leeansyah, E; Neeson, P; Prince, HM; Quach, H; Ritchie, D; Tainton, K | 1 |
| Inoue, Y; Isobe, Y; Kato, M; Miura, I; Nishio, Y; Saito, T; Sakai, H; Sato, K; Suzuki, Y; Takahashi, M; Tsuruoka, Y | 1 |
| Lin, M; Niu, S; Sheng, Z; Zou, Y | 1 |
| Ballester, G; Ballester, O; Yaqub, S | 1 |
| Burnette, BL; Dispenzieri, A; Harris, AM; Kumar, S; Kyle, RA; Rajkumar, SV; Sloan, JA; Tilburt, JC | 1 |
| Liu, H; McCarthy, P | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Tacchetti, P; Zamagni, E; Zannetti, BA | 1 |
| Goto, N; Hara, T; Kanemura, N; Kitagawa, J; Mabuchi, R; Matsumoto, T; Moriwaki, H; Nakamura, H; Nakamura, N; Shibata, Y; Tsurumi, H | 1 |
| Delforge, M; Dimopoulos, MA; Hajek, R; Kropff, M; Lewis, P; Mei, J; Millar, S; Palumbo, A; Petrucci, MT; Zhang, J | 1 |
| Brandt, J; Goldschmidt, H; Herth, I; Heußel, CP; Hundemer, M; Merz, M; Neben, K | 1 |
| Buadi, FK; Dispenzieri, A; Gertz, MA; Kourelis, TV; Kumar, SK; Kyle, RA; Lacy, MQ; Srivastava, G | 1 |
| Lentzsch, S; Schecter, J | 1 |
| Adam, P; Fend, F; Goldschmidt, H; Kanz, L; Weisel, K; Zago, M | 1 |
| Bergsagel, LP; Buadi, FK; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Kumar, SK; Lacy, MQ; Laplant, B; Laumann, K; Mahlman, M; Miceli, T; Mikhael, J; Reeder, C; Stewart, AK; Winters, JL | 1 |
| Boise, LH; Casbourne, D; Gleason, C; Heffner, LT; Kaufman, JL; Langston, A; Lonial, S; Muppidi, S; Nooka, AK; Saxe, D | 1 |
| Akhtar, S; Ansell, SM; Carr, J; Chanan-Khan, A; Chitta, K; Dispenzieri, A; Foran, J; Kumar, S; Mikhael, JR; Miller, KC; Paulus, A; Personett, D; Reeder, CB; Rivera, CE; Roy, V; Thompson, KJ | 1 |
| Bompoint, C; Busson, M; Carmagnat, M; Clave, E; Coman, T; Douay, C; Garderet, L; Glauzy, S; Gorin, NC; Moins-Teisserenc, H; Toubert, A | 1 |
| Caba-Molina, M; Claver-Ferré, C; García-Marcos, SA; Gómez-Morales, M; Martín-Gómez, MA; Palacios-Gómez, ME | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, R; Hayman, SR; Kapoor, P; Kourelis, TV; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Lust, JA; Rajkumar, SV; Russell, SJ; Srivastava, G; Zeldenrust, SR | 1 |
| Andresen, S; Ann Karam, M; Baz, R; Bruening, K; Dean, R; Faiman, B; Habecker, B; Hamilton, K; Hussein, MA; Kalaycio, M; Knight, R; Lazaryan, A; Reed, J; Reu, FJ; Sobecks, R; Srkalovic, G; Sweetenham, JW; Waksman, J; Zeldis, JB | 1 |
| Cavallo, F; Cerrato, C; Mina, R; Palumbo, A | 1 |
| Bradner, JE; Kaelin, WG; Lu, G; Middleton, RE; Mitsiades, CS; Naniong, M; Ott, CJ; Sun, H; Wong, KK | 1 |
| Carr, SA; Ciarlo, C; Comer, E; Ebert, BL; Grauman, P; Hartman, E; Heckl, D; Hurst, SN; Krönke, J; Li, X; McConkey, M; Munshi, N; Narla, A; Schenone, M; Schreiber, SL; Svinkina, T; Udeshi, ND | 1 |
| Abuhejail, RM; Alzoman, NZ; Darwish, IA | 1 |
| Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A | 1 |
| Buadi, FK; Gertz, MA | 1 |
| Leleu, X; Mateos, MV; Palumbo, A; San Miguel, JF | 1 |
| Aldrin, A; Alici, E; Aschan, J; Blimark, C; Carlson, K; Enestig, J; Flogegård, M; Forsberg, K; Gahrton, G; Gruber, A; Haglöf Kviele, H; Johansson, P; Lauri, B; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Näsman, P; Svensson, M; Swedin, A; Uttervall, K | 1 |
| Engelhardt, M; Kleber, M; Knop, S; König, C; Reinhardt, H; Wäsch, R | 1 |
| Hahn, T; McCarthy, PL | 1 |
| Munemoto, S; Murata, R; Nakajima, K; Nakao, S; Takamatsu, H; Terasaki, Y | 1 |
| Guo, S; Hayes, TG; Lin, D; Munker, R; Shi, R | 1 |
| Abe, M; Fujii, S; Harada, T; Ikegame, A; Itoh, K; Iwasa, M; Kagawa, K; Kawai, S; Kuroda, Y; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Tsuji, D; Udaka, K; Yamada-Okabe, H | 1 |
| Ishikawa, O; Motegi, S; Uchiyama, A; Uehara, A; Yamada, K | 1 |
| Perry, C; Polliack, A | 1 |
| Landgren, O; Mailankody, S | 1 |
| Becker, PS; Bensinger, WI; Burwick, N; Green, DJ | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| Alsina, M; Anderson, KC; Colson, K; Esseltine, DL; Feather, J; Francis, D; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, A; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Maglio, ME; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, D; Weller, E; Xie, W | 1 |
| Kyle, RA; Rajkumar, SV | 2 |
| Stewart, AK | 1 |
| Blanco Cid, N; Dacal Quintas, R; Santalla Martínez, M | 1 |
| Engelhardt, M; Kleber, M; Landgren, O; Wäsch, R | 1 |
| Attal, M; Einsele, H; Giralt, S; McCarthy, PL | 1 |
| He, J; Hong, B; Lan, Y; Li, H; Lu, Y; Qian, J; Yang, J; Yi, Q; Zhang, M; Zheng, Y | 1 |
| Collins, DJ; Davies, FE; deSouza, NM; Giles, SL; Messiou, C; Morgan, GJ; Morgan, VA; Simpkin, CJ; West, S | 1 |
| Anderson, KC; Chauhan, D; Coffman, RL; Das, DS; Ray, A; Richardson, P; Tian, Z | 1 |
| Al Ustwani, O; Bhat, SA; Bogner, P; Ghani, S; Grassi, M; Khalid, B; Powell, J | 1 |
| Pratt, G | 1 |
| Anderson, K; Barlogie, B; Boccadoro, M; Bringhen, S; Cavo, M; Ciccone, G; Dimopoulos, MA; Evangelista, A; Hajek, R; Kumar, SK; Larocca, A; Lonial, S; Lupparelli, G; McCarthy, PL; Musto, P; Nooka, AK; Offidani, M; Palumbo, A; Petrucci, MT; Richardson, P; Sonneveld, P; Spencer, A; Usmani, S; van der Holt, B; Waage, A; Zweegman, S | 1 |
| Abumiya, M; Fujishima, N; Hagihara, M; Hirokawa, M; Kameoka, Y; Kobayashi, T; Matsumoto, M; Miura, M; Niioka, T; Sawada, K; Shida, S; Tagawa, H; Takahashi, N | 1 |
| Acharya, C; Anderson, KC; Cagnetta, A; Cea, M; Christie, AL; Craigen, J; Fieles, W; Gliddon, L; Hoang, B; Kung, AL; Mayes, PA; Munshi, NC; Richardson, P; Tai, YT; Tunstead, J; Yates, J; Zhong, MY | 1 |
| Bowman, IA; Chen-Kiang, S; Coleman, M; Ely, S; Jayabalan, D; Mark, TM; Niesvizky, R; Pearse, RN; Pekle, K; Quinn, R; Rodriguez, M; Rossi, AC; Shah, M; Zafar, F | 1 |
| Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
| Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N | 1 |
| Brioli, A; Cavo, M; Davies, FE; Melchor, L; Morgan, GJ; Morilla, R; Pawlyn, C; Stephens, C; Titley, I; Vijayaraghavan, G; Zeisig, A | 1 |
| Asaoku, H; Chou, T; Harada, T; Hayashi, K; Itagaki, M; Kuroda, Y; Mina, R; Murakami, H; Ozaki, S; Palumbo, A; Saitoh, T; Shimazaki, C; Shimizu, K; Suzuki, K; Yoshiki, Y | 1 |
| Bird, J; Bowcock, S; Cook, G; Davies, F; Lai, M; Low, E; Morgan, G; Owen, R; Pratt, G; Rabin, N; Snowden, J; Wechalaker, A; Yong, K | 1 |
| Chen, CY; Chen, YC; Chou, SJ; Chou, WC; Hou, HA; Huang, SY; Lin, CW; Lin, HH; Lu, HY; Tang, JL; Tien, HF; Tsay, W; Wu, SJ; Yao, M | 1 |
| Brossart, P; Busch, A; Fingerhut, L; Hahn-Ast, C; Janzen, V; Maurer, O; Mügge, LO; von Lilienfeld-Toal, M; Wolf, D; Zeh, D | 1 |
| Borrello, I; Ghosh, N; Huff, CA; Tucker, N; Wozney, J; Zahurak, M | 1 |
| Delforge, M; Devos, T; Dierickx, D; Janssens, A; Raddoux, J; Verhoef, G; Zelis, N | 1 |
| Bonini, C; Caprioli, C; Cocito, F; Corradini, P; Dalto, S; De Philippis, C; Dodero, A; Farina, L; Galli, M; Maura, F; Montefusco, V; Mussetti, A; Pennisi, M; Perrone, G; Rezzonico, F; Roncari, L; Soldarini, M; Spina, F; Stefanoni, P | 1 |
| Atenafu, EG; Chen, C; Kukreti, V; Masih-Khan, E; Reece, DE; Sun, HL; Trudel, S; Winter, A; Yeboah, E | 1 |
| Bringhen, S; Donato, F; Gay, F; Palumbo, A; Troia, R | 1 |
| Kanz, L; Weisel, K | 1 |
| Anderson, KC; Burke, JN; Cirstea, DD; Ghobrial, IM; Hari, P; Hideshima, T; Laubach, JP; Mahindra, AK; Marcheselli, R; Munshi, NC; Raje, NS; Richardson, PG; Rodig, SJ; Schlossman, RL; Scullen, TA; Weller, EA; Yee, AJ | 1 |
| Adams, A; Alsina, M; Becker, PS; Bensinger, W; Giralt, SA; Hari, P; Logan, B; McClune, B; Pasquini, MC; Popplewell, LL; Qazilbash, M; Riches, M; Rowley, S; Stadtmauer, EA; Vesole, DH; Weisdorf, D; Zhong, X | 1 |
| Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT | 1 |
| Castells, M; Fanning, L; Laubach, J; Lee, MJ; Richardson, P; Schlossman, R; Wickner, P | 1 |
| Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Borrello, I; Bui, M; Ghosh, N; Noonan, KA; Rudraraju, L | 1 |
| Anderson, KC; Bianchi, G; Richardson, PG | 1 |
| Paumgartten, FJ | 1 |
| Bergsagel, PL; Braggio, E; Bruins, LA; Champion, MD; Chang, XB; Fonseca, R; Jedlowski, P; Kortuem, KM; Lacy, M; Langlais, P; LaPlant, B; Laumann, K; Luo, M; Mikhael, J; Schmidt, JE; Shi, CX; Stewart, AK; Zhu, YX | 1 |
| Aerts, JL; Corthals, J; De Keersmaecker, B; Fostier, K; Heirman, C; Schots, R; Thielemans, K; Wilgenhof, S | 1 |
| Richardson, P | 3 |
| Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I | 1 |
| Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jasielec, J; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Stockerl-Goldstein, K; Vesole, DH; Vij, R | 1 |
| Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M | 1 |
| Alexandrescu, DT; Bockorny, B; Dasanu, CA | 1 |
| Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ | 1 |
| Ichinohe, T; Oshima, K | 1 |
| Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chretien, ML; Corre, J; Facon, T; Fruchart, C; Gentil, C; Hebraud, B; Hulin, C; Huynh, A; Lauwers-Cances, V; Leleu, X; Marit, G; Moreau, P; Pegourie, B; Robillard, N; Roussel, M; Stoppa, AM; Wuilleme, S | 1 |
| Gao, L; Gao, M; Shi, J; Tao, Y; Tompkins, VS; Wu, X; Xu, H; Yang, G; Zhan, F | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Coelho, I; Costa, C; Esteves, S; João, C; Lucio, P | 1 |
| Ailawadhi, S; Alamgir, A; Asano, H; Chanan-Khan, A; Kim, MY; Sposto, R; Swaika, A | 1 |
| Akashi, K; Aoki, T; Ito, Y; Kamimura, T; Miyamoto, T; Yokota, N | 1 |
| Bjorklund, CC; Corchete, LA; Couto, S; Delgado, M; Díaz-Rodríguez, E; Fernández-Lázaro, D; Garayoa, M; García-Gómez, A; Gutiérrez, NC; López-Corral, L; Mateos, MV; Montero, JC; Ocio, EM; Paíno, T; Pandiella, A; San-Miguel, JF; San-Segundo, L; Wang, M | 1 |
| Cheesman, S; D'Sa, S; Dickson, J; Khan, I; Popat, R; Rabin, N; Smith, D; Yong, K | 1 |
| Anglin, P; Atenafu, EG; Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Mikhael, JR; Reece, DE; Trudel, S | 1 |
| Ben Yehuda, D; Boccadoro, M; Cafro, A; Caravita, T; Carella, AM; Catalano, L; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Evangelista, A; Gay, F; Genuardi, M; Marcatti, M; Musto, P; Nagler, A; Offidani, M; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Ribakovsky, E; Zamagni, E | 1 |
| Avigan, D; Rosenblatt, J | 1 |
| Anderson, K; Attal, M; Avet-Loiseau, H; Bahlis, N; Banos, A; Belch, AR; Benboubker, L; Binder, D; Catalano, J; Cavenagh, J; Cavo, M; Chen, C; Chen, G; de la Rubia, J; Delforge, M; Dimopoulos, MA; Dispenzieri, A; Ervin-Haynes, A; Facon, T; Fermand, JP; Geraldes, C; Hulin, C; Jacques, C; Knight, R; Lee, JJ; Ludwig, H; Moreau, P; Oriol, A; Pinto, A; Qiu, L; Tiab, M; Van Oostendorp, J; Weisel, K; White, DJ | 1 |
| Ando, K; Hata, T; Imaizumi, Y; Imanishi, D; Makiyama, J; Miyazaki, Y; Sawayama, Y; Taguchi, J; Taniguchi, H; Tsushima, H | 1 |
| Mateos, MV; Miguel, JF | 1 |
| Kumar, S; Singla, A | 1 |
| Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C | 1 |
| Facon, T; Hulin, C; Moreau, P | 2 |
| McCarthy, PL; Palumbo, A | 1 |
| Vincent Rajkumar, S | 1 |
| Koeppen, S | 1 |
| Abe, T; Fujii, S; Jomen, W; Kanari, Y; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Sakurai, T; Sato, M; Usami, M; Yamada, M; Yoshida, M | 1 |
| Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L | 1 |
| Hobeika, L; Self, SE; Velez, JC | 1 |
| Bargetzi, M; Mischo, A; Nair, G; Petrausch, U; Pfrommer, S; Renner, C; Samaras, P; Schanz, U; Schmidt, A; Seifert, B; Stenner-Liewen, F; Stupp, R; Taverna, C | 1 |
| Dimopoulos, MA; Dispenzieri, A; Gertz, MA; Kastritis, E; Kumar, S; Orlowski, R; Shah, J; Shah, RA; Terpos, E | 1 |
| Shibayama, H | 1 |
| Nakaseko, C | 1 |
| Tsurumi, H | 1 |
| Andreyev, HJ; Davies, FE; Kaiser, MF; Khan, MS; Morgan, GJ; Muls, A; Pawlyn, C; Sriskandarajah, P | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Tomita, S; Wakabayashi, M | 1 |
| Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K | 1 |
| Baz, R; Dimopoulos, MA; Hussein, M; Li, JS; Nagarwala, Y; Swern, AS; Weiss, L | 1 |
| Adachi, Y; Fuchida, S; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kobayashi, T; Kosugi, S; Kuroda, J; Matsuda, M; Matsumura, I; Nakatani, E; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uchiyama, H; Uoshima, N; Yagi, H | 1 |
| Aziz, M; Braggio, E; Bruins, LA; Champion, M; Jedlowski, P; Keith Stewart, A; Kortuem, KM; Schmidt, JE; Sereduk, C; Shi, CX; Yin, H; Zhu, YX | 1 |
| Bakker, J; de Jong-Korlaar, R; Groen, RW; Lokhorst, HM; Martens, AC; Mutis, T; Nijhof, IS; Noort, WA; Parren, PW; van Bueren, JJ; van de Donk, NW; van Kessel, B | 1 |
| Adam, Z; Autzinger, EM; Greil, R; Heintel, D; Kasparu, H; Kuehr, T; Ludwig, H; Müldür, E; Poenisch, W; Rauch, E; Weißmann, A; Zojer, N | 1 |
| Anabuki, K; Arakawa, Y; Ikezoe, T; Kubota, T; Sakai, M; Takaoka, M; Togitani, K; Tsukuda, T; Yokoyama, A | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Berdeja, JG; Berg, D; Di Bacco, A; Estevam, J; Gupta, N; Hamadani, M; Hari, P; Hui, AM; Kaufman, JL; Kumar, SK; Laubach, JP; Liao, E; Lonial, S; Niesvizky, R; Rajkumar, V; Richardson, PG; Roy, V; Stewart, AK; Vescio, R | 1 |
| Ben-Yehuda, D; Bensinger, WI; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, AJ; Kukreti, V; Ludwig, H; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, GG; Minarik, J; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajkumar, SV; Rajnics, P; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Suvorov, A; Tonda, ME; Wang, M; Xing, B; Yang, X; Zojwalla, N | 1 |
| Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ | 2 |
| Costa, LJ; Dermer, SJ; Kumar, S; Stowell, SA | 1 |
| Andre, P; Lammerts van Bueren, JJ; Lokhorst, HM; Morel, Y; Mutis, T; Nijhof, IS; Parren, PW; van de Donk, NW; van Kessel, B | 1 |
| Anderson, KC; Ghobrial, IM; Glavey, S; Görgün, GT; Kawano, Y; Manier, S; Moschetta, M; Roccaro, AM | 1 |
| Fagiolari, G; Migliorato, A; Moggio, M; Montagnese, F; Musumeci, O; Portaro, S; Rodolico, C | 1 |
| Bacchiarri, F; Bosi, A; Donnini, I; Guarrera, A; Longo, G; Nozzoli, C; Staderini, M; Veltroni, A | 1 |
| Gooding, S; King, AJ; Ramasamy, K | 1 |
| Guglielmelli, T; Palumbo, A | 1 |
| Du, W; Hasegawa, Y; Hattori, Y; Hozumi, M; Ichikawa, D; Matsuo, K; Matsushita, M; Oikawa, T; Ozaki, Y; Shiheido, H; Tabata, N; Terada, F; Yamada, T; Yanagawa, H | 1 |
| Nakaseko, C; Sakaida, E; Takeda, Y | 1 |
| Buquicchio, C; Capalbo, S; Cascavilla, N; Curci, P; Di Renzo, N; Ditonno, P; Falcone, A; Guarini, A; Iannitto, E; Mazza, P; Mele, G; Melpignano, A; Minoia, C; Palazzo, G; Palumbo, G; Pavone, V; Polimeno, G; Quarta, G; Reddiconto, G; Ria, R; Rizzi, R; Rossini, B; Specchia, G; Tarantini, G; Vacca, A | 1 |
| Liu, G; Sheng, Z | 1 |
| Colson, K | 1 |
| Holstein, SA; Laubach, JP; McCarthy, PL; Richardson, PG | 1 |
| Asvadi, P; Cuddihy, A; Dunn, RD; Jiang, V; Jones, DR; Khong, T; Spencer, A; Wong, MX | 1 |
| Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
| Shen, Q; Zhuang, Y | 1 |
| Bashir, Q; Champlin, RE; Cornelison, A; Fox, PS; Hosing, CM; Kebriaei, P; Lin, P; Nieto, Y; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Shpall, EJ; Thall, PF | 1 |
| Collet, P; Kong, S; Marotte, H; Thomas, T | 1 |
| Ikeda, T; Kimura, F; Okamura, I; Sato, K | 1 |
| Blin, N; Brissot, E; Clavert, A; Dubruille, V; Gastinne, T; Gaugler, B; Guillaume, T; Le Gouill, S; Mahe, B; Mohty, M; Moreau, P; Roland, V | 1 |
| Ai, H; Cai, Z; Chen, F; Chen, N; DeMarco, D; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wang, J; Wu, D; Yu, L; Zhang, J; Zhou, DB | 1 |
| Caffrey, MK | 1 |
| Arnulf, B; Bahlis, NJ; Canepa, L; Delforge, M; Eisenmann, JC; Ervin-Haynes, A; Escoffre-Barbe, M; Ezaydi, Y; Facon, T; Fragasso, A; Giraldo-Castellano, P; Guo, S; Houck, V; Langer, C; Lemieux, B; Leyvraz, S; Minuk, L; Monzini, MS; Song, K; Vogl, DT; Yoon, SS; Zarnitsky, C | 1 |
| Heaney, ML | 1 |
| Arikian, SR; Binder, G; Corvino, FA; Gibson, CJ; Hu, XH; Hussein, M; Milentijevic, D; Nagarwala, Y; Surinach, A; Usmani, SZ | 1 |
| Allred, J; Bergsagel, PL; Buadi, FK; Dispenzieri, A; Fonseca, R; Gertz, MA; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Rajkumar, SV; Reeder, CB; Rivera, CE; Roy, V; Stewart, AK | 1 |
| Hoskote, SS; Onigkeit, JA; Reddy, DR | 1 |
| Gandhi, V; He, J; Orlowski, RZ; Shentu, S; Stellrecht, CM; Yang, J; Zaman, S | 1 |
| Adler, AI; Burke, MJ; George, E | 1 |
| Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Mayampurath, A; Mellacheruvu, D; Nesvizhskii, AI; Ngoka, L; Richardson, PG; Rosebeck, S; Sreekumar, A; Volchenboum, S | 1 |
| Kim, Y; Schmidt-Wolf, IG | 1 |
| Cejalvo, MJ; de la Rubia, J | 1 |
| Bay, JO | 1 |
| Laubach, JP; Richardson, PG | 1 |
| Boccadoro, M; Bringhen, S; Cavo, M; Conticello, C; Cuomo, C; D'Arena, G; Gay, F; Grossi, A; Guariglia, R; Larocca, A; Milone, G; Morabito, F; Musto, C; Musto, P; Offidani, M; Palumbo, A; Petrucci, MT; Pietrantuono, G; Simeon, V; Tacchetti, P; Villani, O; Zamagni, E | 1 |
| Blommestein, HM; de Groot, S; Huijgens, PC; Sonneveld, P; Uyl-de Groot, CA; Verelst, SG | 1 |
| McCormack, PL | 1 |
| Printz, C | 1 |
| Areethamsirikul, N; Reece, DE | 1 |
| Kobayashi, T; Kuroda, J; Taniwaki, M | 1 |
| Guo, XN; Qiao, SK; Ren, HY; Ren, JH | 1 |
| Braggio, E; Bruins, L; Jedlowski, P; Kortüm, KM; Shi, CX; Stewart, AK; Zhu, YX | 1 |
| Anderson, KC; Cottini, F; Gorgun, G; Hideshima, T; Jakubikova, J; Mimura, N; Munshi, NC; Ohguchi, H; Richardson, PG; Tai, YT | 1 |
| Anderson, JE; Anderson, KC; Avet-Loiseau, H; Bianchi, G; Cowens, KB; Dorfman, DM; Görgün, G; Harada, T; Hideshima, T; Kikuchi, S; Laubach, JP; Magrangeas, F; Minvielle, S; Munshi, NC; Ohguchi, H; Paula, S; Raje, N; Richardson, PG; Samur, MK; Singh, A; Suzuki, R; Tai, YT; White, RE | 1 |
| Akasaka, H; Ito, K; Kodaka, T; Sakane, E; Takahashi, T; Tsunemine, H; Yoshioka, S | 1 |
| Andre, P; Benson, DM; Caligiuri, MA; Cohen, AD; Efebera, YA; Hofmeister, CC; Jagannath, S; Munshi, NC; Spitzer, G; Zerbib, R | 1 |
| Aleman, A; Anand, P; Batra, V; Bednarz, U; Bilotti, E; Guerrero, L; Ivanovski, K; Mato, A; McBride, L; McNeill, A; Raucci, L; Richter, JR; Siegel, DS; Sims, T; Smith, J; Vesole, DH | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, J; Maglio, ME; Mitsiades, CS; Munshi, NC; O'Donnell, EK; Paba-Prada, C; Raje, N; Richardson, PG; Schlossman, R; Varga, C; Warren, D; Weinstock, M; Weller, E; Xie, W | 1 |
| Anderson, KC; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, M; Einsele, H; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Matsumoto, M; Moreau, P; Oakervee, H; Orlowski, RZ; Palumbo, A; Poulart, V; Reece, D; Richardson, P; Röllig, C; San-Miguel, J; Singhal, A; Spencer, A; Spicka, I; Taniwaki, M; Walter-Croneck, A; White, D; Wu, KL | 1 |
| Cheah, CY; Manasanch, EE; Oo, TH; Orlowski, RZ | 1 |
| Carter, C; Cook, G; Parrish, C; Scott, GB; Wood, PM | 1 |
| Benson, DM; Bowers, MA; Devine, S; Efebera, Y; Hofmeister, CC; Huang, Y; Humphries, K; Sborov, DW; Williams, N | 1 |
| Ikebe, T; Itani, K; Miyazaki, Y; Nagamatsu, K; Ogata, M; Ohtsuka, E; Saburi, M; Saburi, Y | 1 |
| An, N; Chen, S; Hu, Y; Huang, Z; Li, X; Shen, M; Sun, W; Zhan, X; Zhang, J; Zhong, Y | 1 |
| Bladé, J; García-Sanz, R; Lahuerta, JJ; Martínez-López, J; Mateos, MV; Ocio, EM; Paiva, B; Rosiñol, L; San Miguel, JF | 1 |
| Battistutta, C; Berno, T; Bonaldi, L; Branca, A; Briani, C; Cavraro, M; De March, E; Gurrieri, C; Lico, A; Martines, A; Minotto, C; Piazza, F; Sechettin, E; Semenzato, G; Temporin, F; Trentin, L; Zambello, R | 1 |
| Amatya, R; Belch, A; Dimopoulos, M; Gibson, CJ; Jacques, C; Moreau, P; Palumbo, A; San Miguel, J; Schey, S; Song, KW; Sonneveld, P; Sternas, L; Weisel, K; Yu, X; Zaki, M | 1 |
| Callander, NS; Chanan-Khan, AA; Fonseca, R; Jacobus, S; Rajkumar, SV; Stewart, AK; Weiss, M | 1 |
| Dimopoulos, MA; Kastritis, E; Terpos, E; Zagouri, F | 1 |
| Arnulf, B; Bridoux, F; Caulier, A; Chevret, S; Cohen, C; El Karoui, K; Fermand, JP; Jaccard, A; Javaugue, V; Knebelmann, B; Royer, B; Szalat, R; Touchard, G | 1 |
| Isoda, A; Koumoto, M; Matsumoto, M; Matsumoto, Y; Miyazawa, Y; Ookawa, M; Sato, N; Sawamura, M | 1 |
| Kadowaki, M; Kohno, K; Okamura, S; Takase, K; Yamasaki, S | 1 |
| Arthur, DC; Bhutani, M; Braylan, R; Burton, D; Calvo, KR; Carpenter, A; Carter, G; Choyke, P; Costello, R; Cunningham, SC; Faham, M; Figg, W; Gounden, V; Kazandjian, D; Kong, KA; Korde, N; Kurdziel, K; Kwok, M; Lamping, L; Landgren, O; Lindenberg, L; Mailankody, S; Manasanch, EE; Maric, I; Morrison, C; Mulquin, M; Peer, C; Roschewski, M; Sissung, TM; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wall, Y; Weng, L; Wu, P; Yuan, C; Zhang, Y; Zingone, A; Zuchlinski, D | 1 |
| Sofronescu, AG; Wedel, W | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, L; Kapoor, P; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Majithia, N; Russell, SJ; Vincent Rajkumar, S | 1 |
| Borrello, I; Consoli, ML; Conticello, C; Corso, A; Di Raimondo, F; Forte, S; Marchionni, L; Milone, G; Parrinello, NL; Pompa, A; Romano, A | 1 |
| Fong, R; Lo, M; Tan, M; Young, R | 1 |
| Chen-Kiang, S; He, X; Huang, X; Jaffrey, SR; Jiang, X; Liu, Y; Xu, G; Zhou, Y | 1 |
| Ailawadhi, S; Bartlett, B; Durie, B; Fredette, S; Hoering, A; Lipe, B; Orlowski, RZ; Rosenzweig, M; Sexton, R; Shah, JJ; Usmani, SZ; Valent, J; Zonder, JA | 1 |
| Abe, Y; Ikeda, M; Meshitsuka, S; Miyazaki, K; Shingaki, S; Suzuki, K; Tsukada, N; Yoshiki, Y | 1 |
| Abruzzese, MP; Cecere, F; Cippitelli, M; Fionda, C; Molfetta, R; Paolini, R; Peruzzi, G; Petrucci, MT; Ricciardi, MR; Santoni, A; Soriani, A; Vulpis, E; Zingoni, A | 1 |
| Buadi, FK; Cheng, WY; Dea, K; Dispenzieri, A; Duh, MS; Engebretson, AE; Kumar, SK; Lacy, MQ; Lafeuille, MH; Lefebvre, P; Ma, E; Niculescu, L; Patt, D; Quick, M; Rajkumar, SV; Rembert, D | 1 |
| Boise, LH; Kaufman, J; Lonial, S | 1 |
| Benevolo, G; Boccadifuoco, L; Boccadoro, M; Caravita, T; Cavallo, F; Cavo, M; Cerrato, C; Ciccone, G; Corradini, P; Delforge, M; Di Raimondo, F; Dimopoulos, MA; Donato, F; Gay, F; Guglielmelli, T; Hajek, R; Hardan, I; Jacques, C; Larocca, A; Musto, P; Nagler, A; Nozzoli, C; Palumbo, A; Patriarca, F; Petrucci, MT; Pezzatti, S; Vincelli, D; Yu, Z | 1 |
| Kurtin, SE; Ridgeway, JA; Tinsley, SM | 1 |
| Fujii, S; Fujita, M; Kanari, Y; Kato, J; Kuroda, H; Maeda, M; Sakamoto, H; Sato, T; Shimoyama, S; Usami, M; Yamada, M; Yoshida, M | 1 |
| Choi, NR; Hoang, MD; Jung, SH; Kim, HJ; Lee, HJ; Lee, JJ; Lee, YK; Nguyen-Pham, TN; Thanh-Tran, HT; Vo, MC | 1 |
| Birgin, A; Buadi, FK; Duarte, L; Fiala, M; Gertz, MA; Krishnan, A; Kumar, SK; LaPlant, B; Laumann, K; Levy, J; Maharaj, M; Roy, V; Stockerl Goldstein, K; Vij, R; Zimmerman, T | 1 |
| Chim, CS; Chng, WJ; Esseltine, DL; Goh, YT; Gupta, N; Hanley, MJ; Hui, AM; Kim, K; Lee, JH; Min, CK; Venkatakrishnan, K; Wong, RS; Yang, H | 1 |
| Kawaguchi, M; Konuma, S; Nehashi, Y; Okuda, Y; Uchimura, N | 1 |
| Bucalossi, A; Cioffi Squitieri, N; Guerrini, S; Mazzei, FG; Mazzei, MA; Volterrani, L | 1 |
| Bacci, F; Di Bartolomeo, P; Morelli, AM; Pulini, S; Torti, L | 1 |
| Bullement, A; Dickens, E; Elvidge, J; Gooding, S; Lau, IJ; Lee, D; Ramasamy, K; Roberts, P; Sheikh, M; Wong, J | 1 |
| Hazlehurst, L; Lynch, CC; Shay, G | 1 |
| Byrd, JC; Canella, A; Cascione, L; Caserta, E; Consiglio, J; Cordero Nieves, H; Efebera, YA; Hofmeister, CC; Kaur, B; Mo, X; Pichiorri, F; Radomska, HS; Rizzotto, L; Sborov, DW; Smith, E; Stefano, V; Stiff, A; Zanesi, N | 1 |
| Amatangelo, M; Bjorklund, CC; Breider, M; Chopra, R; Couto, S; Daniel, TO; Gandhi, AK; Hagner, PR; Havens, CG; Kang, J; Klippel, A; Lu, L; Ning, Y; Ren, Y; Thakurta, AG; Wang, M | 1 |
| Anttila, P; Bazia, P; Heiskanen, J; Jantunen, E; Kakko, S; Kananen, K; Kuittinen, T; Kutila, A; Launonen, K; Lundan, T; Ollikainen, H; Putkonen, M; Räsänen, A; Remes, K; Säily, M; Selander, T; Siitonen, TM; Sikiö, A; Silvennoinen, R; Suominen, M; Terävä, V | 1 |
| Ebert, BL; Fink, EC | 1 |
| Bi, E; Hong, S; Qian, J; Wang, M; Yi, Q; Zhang, L; Zheng, C | 1 |
| Ichikawa, K; Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Sugimoto, K; Tomita, S; Wakabayashi, M | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Go, RS; Hayman, SR; Hwa, YL; Kapoor, P; Kaufman, GP; Kumar, SK; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, S | 1 |
| Cong, Z; Song, X; Wilson, K | 1 |
| Buadi, F; Dispenzieri, A; Gertz, MA; Gonsalves, W; Kumar, S; Lacy, MQ; Rajkumar, SV; Vu, T | 1 |
| Bargay, J; Bengoechea, E; Bladé, J; Cabrera, C; Cedena, MT; Encinas, C; Gironella, M; González, Y; Gutiérrez, NC; Hernández, MT; Lahuerta, JJ; Martín Ramos, ML; Martín, J; Martínez, R; Martínez-López, J; Mateos, MV; Ocio, EM; Oriol, A; Paiva, B; Pérez de Oteyza, J; Puig, N; Rosiñol, L; San-Miguel, J; Teruel, AI | 1 |
| Ebert, BL; Guirguis, AA | 1 |
| Basu, S; Belch, AR; Berger, A; Binder, G; Cavenagh, JD; Ervin-Haynes, A; Facon, T; Gibson, CJ; Guo, S; Hulin, C; Nagarwala, Y; Nooka, A; Pelligra, CG; Usmani, SZ; White, D; Yiu, W | 1 |
| Bogunia-Kubik, K; Butrym, A; Frontkiewicz, D; Gębura, K; Mazur, G; Rybka, J; Łacina, P | 1 |
| Cai, XY; Guo, XF; Guo, XL; Guo, XN; Ren, JH; Yang, DY; Zhang, JN | 1 |
| Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kalapanida, D; Kastritis, E; Liacos, CI; Matsouka, C; Migkou, M; Mparmparousi, D; Tasidou, A; Terpos, E | 1 |
| Berardi, M; Biagioli, T; Bosi, A; Brogi, M; Caldini, A; Nozzoli, C; Staderini, M; Terreni, A | 1 |
| Andersson, BS; Berenson, JR; Champlin, RE; Chang, VT; Guan, X; Qazilbash, MH; Shen, Y; Wang, J; Wang, ML; Wang, Y; Yang, F; Zhang, W | 1 |
| Holstein, SA; McCarthy, PL | 2 |
| Boccadoro, M; Campbell, P; Carella, A; Catalano, L; Conticello, C; Corradini, P; Evangelista, A; Gay, F; Hajek, R; Liberati, AM; Magarotto, V; Malfitano, A; Offidani, M; Oliva, S; Omedè, P; Palumbo, A; Patriarca, F; Pescosta, N; Petrò, D; Petrucci, MT; Pour, L; Pulini, S; Ria, R; Siniscalchi, A; Spada, S; Spencer, A | 1 |
| Becht, R; Bołkun, Ł; Butrym, A; Błońska, D; Charliński, G; Dębski, J; Dmoszyńska, A; Druzd-Sitek, A; Dytfeld, D; Hałka, J; Hołojda, J; Hus, M; Januszczyk, J; Jurczyszyn, A; Knopińska-Posłuszny, W; Kuliczkowski, K; Kłoczko, J; Lech-Marańda, E; Legieć, W; Malenda, A; Nowicki, A; Pogrzeba, J; Rymko, M; Rzepecki, P; Stella-Hołowiecka, B; Subocz, E; Torosian, T; Urbanowicz, A; Urbańska-Ryś, H; Usnarska-Zubkiewicz, L; Zaucha, JM; Zdziarska, B; Zubkiewicz-Kucharska, A | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Martello, M; Pantani, L; Rizzello, I; Rocchi, S; Tacchetti, P; Terragna, C; Zamagni, E; Zannetti, BA | 1 |
| Facon, T | 1 |
| Binder, G; Grigorian, M; Lee, C; Nolan, R; Rice, G | 1 |
| Alemayehu, WG; Bos, GM; Broijl, A; Cornelisse, PB; de Weerdt, O; Kersten, MJ; Levin, MD; Lokhorst, H; Meijer, E; Sonneveld, P; Stevens-Kroef, M; Tanis, BC; Vellenga, E; Wijermans, PW; Wittebol, S | 1 |
| Belhadj, K; Bensinger, W; Chen, G; Cheung, MC; Derigs, HG; Dib, M; Dimopoulos, MA; Eom, H; Ervin-Haynes, A; Facon, T; Gamberi, B; Hall, R; Jaccard, A; Jardel, H; Karlin, L; Kolb, B; Lenain, P; Leupin, N; Liu, T; Marek, J; Rigaudeau, S; Roussel, M; Schots, R; Tosikyan, A; Van der Jagt, R | 1 |
| Airoldi, I; Amiot, M; Aversa, F; Bolzoni, M; Campanini, N; Donofrio, G; Ferri, V; Fiorini, E; Giuliani, N; Guasco, D; Maiga, S; Mancini, C; Marchica, V; Martella, E; Storti, P; Toscani, D | 1 |
| Bargay, J; Bladé, J; Corchete, LA; de Arriba, F; de la Rubia, J; Esteves, G; Giraldo, P; Hernández, J; Hernandez, MT; Lahuerta, JJ; López-Corral, L; Mateos, MV; Oriol, A; Paiva, B; Perez-Simon, JA; Prosper, F; Puig, N; Rosiñol, L; San Miguel, JF; Sanchez-Abarca, LI; Teruel, AI; Vidriales, MB | 1 |
| Chaturvedi, S; Mohty, M; Nagler, A; Neff, A; Savani, BN; Savani, U | 1 |
| Cao, L; Fang, Q; Lu, T; Ma, D; Wang, J; Wang, P; Wu, W; Zhao, J | 1 |
| Hagiwara, S; Iida, S; Ishida, T; Ito, A; Kanamori, T; Kato, C; Kinoshita, S; Komatsu, H; Kusumoto, S; Masuda, A; Murakami, S; Nakashima, T; Narita, T; Ri, M; Suzuki, N; Totani, H; Yoshida, T | 1 |
| Benevolo, G; Bernardini, A; Boccadoro, M; Bringhen, S; Ciccone, G; Conticello, C; De Paoli, L; Falcone, AP; Gentili, S; Giuliani, N; Guglielmelli, T; Hajek, R; Ledda, A; Liberati, AM; Magarotto, V; Maisnar, V; Mina, R; Montefusco, V; Musolino, C; Offidani, M; Palumbo, A; Patriarca, F; Pietrantuono, G; Pulini, S; Ruggeri, M; Zambello, R | 1 |
| Bouchnita, A; Eymard, N; Koury, MJ; Moyo, TK; Volpert, V | 1 |
| Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB | 1 |
| Arai, N; Fujiwara, S; Homma, M; Kabasawa, N; Kawaguchi, Y; Kobayashi, K; Nakamaki, T; Okino, K; Shiozawa, E; Takimoto, M; Tate, G; Tazawa, S; Yamochi, T | 1 |
| Abonour, R; Durie, BG; Gasparetto, C; Hardin, JW; Kenvin, L; Knight, R; Lu, JJ; Mehta, J; Nagarwala, Y; Narang, M; Rifkin, RM; Shah, JJ; Srinivasan, S; Terebelo, H; Toomey, K | 1 |
| Badros, A; Berdeja, J; Bleickardt, E; Gupta, M; Jagannath, S; Kaufman, JL; Lynch, M; Manges, R; Paliwal, P; Tendolkar, A; Vij, R; Zonder, J | 1 |
| Bos, GM; Brouwer, RE; Coenen, JL; Deenik, W; Durian, MF; Gruber, A; Hansson, M; Haukås, E; Klein, SK; Levin, MD; Leys, MR; Mattijssen, EV; Mellqvist, UH; Plesner, T; Salomo, M; Sinnige, HA; Sonneveld, P; Stevens-Kroef, MJ; Szatkowski, DL; Tanis, BC; van de Donk, NW; van der Hem, KG; van der Holt, B; van der Velden, AW; Visser-Wisselaar, H; Waage, A; Westerman, M; Zweegman, S | 1 |
| Goto, C; Goto, H; Ichihashi, A; Kasahara, S; Nagaya, K; Osawa, T; Tachi, T; Takahashi, T; Teramachi, H; Umeda, M; Yasuda, M | 1 |
| Kobayashi, H; Komori, H; Nakamura, Y; Namba, K; Oi, N; Sato, H; Taniguchi, Y; Yahata, H | 1 |
| Cai, Z; Chen, F; DeMarco, D; Du, X; Hou, J; Jin, J; Ke, X; Li, X; Mei, J; Meng, F; Wu, D; Yu, L; Zhang, J; Zhou, DB | 1 |
| Chen, CY; Chen, HY; Chen, MJ; Hsu, PH; Huang, SY; Hung, KH; Lin, FR; Lin, KI; Su, ST; Tsai, MD; Wu, PC; Wu, WJ | 1 |
| Qian, W; Wang, B; Xu, G; Yang, M | 1 |
| Berkova, Z; Champlin, RE; Cleeland, C; Feng, L; Mendoza, TR; Orlowski, RZ; Qazilbash, MH; Shah, JJ; Thomas, SK; Wang, M; Weber, DM | 1 |
| Chou, T; Ervin-Haynes, A; Hirata, H; Houck, V; Iida, S; Ikeda, T; Ishizawa, K; Matsue, K; Matsumoto, M; Matsumura, I; Midorikawa, S; Ogaki, Y; Ogawa, Y; Otsuka, M; Shimizu, T; Shinagawa, A; Suzuki, K; Takezako, N; Taniwaki, M; Terui, Y; Uchida, T | 1 |
| Bjorklund, CC; Cathers, BE; Chopra, R; Daniel, TO; Gandhi, AK; Leisten, J; Lopez-Girona, A; Lu, L; Mendy, D; Miller, K; Narla, RK; Ning, Y; Orlowski, RZ; Raymon, HK; Rychak, E; Shi, T; Thakurta, A | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kalapanida, D; Kanellias, N; Kastritis, E; Migkou, M; Roussou, M; Terpos, E; Zagouri, F | 1 |
| Beguin, Y; Caers, J; Decaux, O; Dimopoulos, M; Engelhardt, M; Fernández de Larrea, C; Heusschen, R; Jurczyszyn, A; Kastritis, E; Leleu, X; Ludwig, H; Mateos, MV; Minnema, M; Palumbo, A; Wäsch, R; Zojer, N | 1 |
| Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W | 1 |
| Agarwal, S; Barley, K; Chari, A; He, W; Jagannath, S | 1 |
| Li, Y; Wang, X; Yan, X | 1 |
| Berno, T; Cortelazzo, S; DE March, E; Marabese, A; Meneghini, V; Mian, M; Mondello, P; Patriarca, F; Pescosta, N; Pizzolo, G; Semenzato, G; Tinelli, M; Turri, G; Zambello, R | 1 |
| Al-Ani, F; Bermejo, JM; Louzada, M; Mateos, MV | 1 |
| Brophy, TM; Browne, PV; Hayden, PJ; Lavin, M; O'Connell, N; O'Donnell, JS; O'Sullivan, JM; Rawley, O; Ryan, K | 1 |
| Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Childs, R; Costello, R; Korde, N; Kwok, M; Landgren, O; Loeliger, K; Maric, I; Mo, C; Noel, P; Poon, A; Silver, S; Simakova, O; Sloand, E; Young, N; Zhang, Y; Zingone, A | 1 |
| Anderson, KC; Attal, M; Avet-Loiseau, H; Bladé, J; Caers, J; Chng, WJ; Durie, BG; Einsele, H; Goldschmidt, H; Hillengass, J; Kyle, RA; Lonial, S; Mateos, MV; Moreau, P; Orlowski, R; Palumbo, A; San Miguel, J; Siegel, D; Sonneveld, P; Usmani, S; van de Donk, NW | 1 |
| Jurczyszyn, A; Olszewska-Szopa, M; Skotnicki, AB | 1 |
| Cartron, G; Ceballos, P; Chopra, R; Cren, M; Duperray, C; Jourdan, M; Klein, B; Moreaux, J; Robert, N; Rossi, JF; Schafer, P; Vincent, L | 1 |
| Leebeek, FW | 1 |
| Coelho, I; Esteves, GV; Esteves, S; Freitas, J; Geraldes, C; Gomes, F; João, C; Lúcio, P; Neves, M | 1 |
| Gertz, M; Muchtar, E | 1 |
| Afifi, S; Lesokhin, A; Michael, A | 1 |
| Baertsch, MA; Fenk, R; Goerner, M; Goldschmidt, H; Graeven, U; Haenel, M; Hielscher, T; Hillengaß, J; Ho, AD; Hose, D; Jauch, A; Klein, S; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Martin, H; Merz, M; Nogai, A; Noppeney, R; Raab, MS; Reimer, P; Salwender, H; Scheid, C; Schlenzka, J; Schmidt-Hieber, M; Schmidt-Wolf, IG; Weisel, K; Wuchter, P | 1 |
| Arana, P; Bargay, J; Bladé, J; Cabrera, C; Cedena, MT; Cordon, L; Echeveste, MA; Encinas, C; Flores-Montero, J; Gironella, M; Gonzalez, Y; Gutierrez, NC; Hernandez, MT; Lahuerta, JJ; Martin, J; Martín-Ramos, ML; Martinez, R; Martinez-Lopez, J; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Puig, N; Rosiñol, L; San Miguel, JF; Teruel, AI; Van Dongen, JJ; Vidriales, MB | 1 |
| Bahlis, NJ; Baker, BW; Berg, DT; Buadi, FK; Cavo, M; Di Bacco, A; Ganly, P; Garderet, L; Gimsing, P; Grzasko, N; Hansson, M; Hui, AM; Jackson, SR; Kumar, S; Laubach, JP; Lin, J; Masszi, T; Moreau, P; Palumbo, A; Pour, L; Richardson, PG; Sandhu, I; Simpson, DR; Stoppa, AM; Touzeau, C; van de Velde, H | 1 |
| Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U | 1 |
| Chen, M; Dong, B; Dong, T; Guan, P; Li, J; Liu, T; Ma, H; Niu, T; Pan, L; Shuai, X; Valencia, CA; Wang, F; Wu, Y; Xiang, B; Xie, L; Zhang, L; Zhu, H; Zou, X | 1 |
| Chang, XB; Erickson, P; Hou, YX; Langlais, P; Luo, M; Mandarino, LJ; Shi, CX; Stewart, K; Xu, Q; Xu, Y; Zhu, J; Zhu, Y | 1 |
| Chinen, Y; Fushiki, S; Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Maegawa, S; Mizutani, S; Nagoshi, H; Sasaki, N; Shimura, Y; Tando, S; Taniwaki, M; Tatekawa, S; Tsukamoto, T | 1 |
| An, N; Huang, ZX; Jiang, XX; Li, X; Shen, M; Zhang, JJ | 1 |
| Chen, LM; Liu, HB | 1 |
| Cooney, J; Gray, D; Greil, R; Leleu, X; Minarik, J; O'Gorman, P; Sanz, RG; Szabo, Z; Terpos, E; Williams, C | 1 |
| Chalayer, E; Chapelle, C; Elalamy, I; Laporte, S; Leleu, X; Tardy, B | 1 |
| Aggarwal, SK; Barber, BL; Benedict, Á; Campioni, M; Giannopoulou, A; Houisse, I; Jakubowiak, AJ; Panjabi, S; Tichy, E | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Iakovaki, M; Kanellias, N; Kastritis, E; Migkou, M; Panagiotidis, I; Terpos, E; Ziogas, DC | 1 |
| Hagihara, M; Hua, J; Inoue, M; Uchida, T | 1 |
| Montefusco, V; Musto, P | 1 |
| Gino-Moor, S; Khateeb, A; Kreiniz, N; Polliack, A; Tadmor, T | 1 |
| Abraham, J; Arnulf, B; Bridoux, F; Chen, N; Desport, E; Fermand, JP; Jaccard, A; Moreau, S; Moumas, E | 1 |
| Bassermann, F; Eichner, R; Einsele, H; Fernández-Sáiz, V; Garz, AK; Germing, U; Götze, KS; Haass, C; Heider, M; Jacobs, L; Keller, U; Knop, S; Knorn, AM; Kuster, B; Langer, C; Lemeer, S; Peschel, C; Platzbecker, U; Rudelius, M; Schmid, B; Slawska, J; Targosz, BS; van Bebber, F | 1 |
| Baladandayuthapani, V; Dawson, CW; Iempridee, T; Jones, RJ; Kenney, SC; Lee, HC; Lin, HC; Mertz, JE; Orlowski, RZ; Shah, JJ; Wang, X; Weber, DM | 1 |
| Azais, I; Belch, A; Chen, G; Dakhil, S; Dimopoulos, MA; Doyen, C; Dührsen, U; Eek, R; Ervin-Haynes, A; Facon, T; Garderet, L; Gisslinger, H; Goncalves, C; Houck, V; Hulin, C; Hunter, H; LeBlanc, R; Leleu, X; Leupin, N; Lu, J; Macro, M; Offner, F; Pégourié, B; Petrucci, MT; Rodon, P; Romeril, K; Royer, B; Shustik, C; Song, K | 1 |
| Chen, W; Gao, S; Huang, L; Shu, C; Xia, T; Zeng, T; Zhang, F | 1 |
| Hollmann, S; LeBlanc, R; Tay, J | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, M; Kim, TW; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Lim, JY; Min, CK; Min, WS; Ryu, DB; Yoon, JH | 1 |
| Boquoi, A; Bruns, I; Cadeddu, RP; Deenen, R; Dienst, A; Fenk, R; Haas, R; Heinzler, N; Kobbe, G; Köhrer, K; Majidi, F; Schroeder, T; Strapatsas, T; Wilk, CM | 1 |
| Arguiñano, JM; Bargay, J; Bladé, J; Corral, LL; de Arriba, F; de la Rubia, J; García, JL; Giraldo, P; Hernández, MT; Lahuerta, JJ; López, J; Mateos, MV; Miguel, JS; Oriol, A; Paiva, B; Palomera, L; Prosper, F; Quintana, N; Rosiñol, L | 1 |
| Moreau, P; Rajkumar, SV | 1 |
| Alsina, M; Baz, R; Dalton, W; Fisher, K; Fulp, W; Hampras, S; Kenvin, L; Knight, R; Komrokji, R; Lee, JH; Nishihori, T; Olesnyckyj, M; Rollison, DE; Shain, KH; Sullivan, D; Xu, Q | 1 |
| Avet-Loiseau, H; Ben-Yehuda, D; Bensinger, W; Dimopoulos, MA; Fonseca, R; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Kukreti, V; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, G; Minarik, J; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rosiñol, L; Siegel, D; Špička, I; Stewart, AK; Wang, M | 1 |
| Badiali, S; Bari, A; Cocito, F; Corso, A; Gentile, M; Guarini, A; Marcheselli, L; Marcheselli, R; Mazzone, C; Mele, G; Minoia, C; Morabito, F; Musto, P; Palumbo, A; Pozzi, S; Ria, R; Rivolti, E; Sacchi, S; Vincelli, I | 1 |
| Kimura, M; Kokuryou, T; Matsuoka, T; Mitani, Y; Nakao, T; Okada, K; Usami, E; Yamakawa, M; Yoshimura, T | 1 |
| Kovarikova, A; Kusenda, J | 1 |
| Callander, NS; Dreosti, LM; Fonseca, R; Jacobus, SJ; Lacy, MQ; Rajkumar, SV; Stadtmauer, EA; Stewart, AK; Weiss, M | 1 |
| Alapat, D; Avery, D; Bailey, C; Barlogie, B; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Jethava, Y; Khan, R; Mitchell, A; Morgan, G; Petty, N; Sawyer, J; Schinke, C; Smith, R; Stein, C; Steward, D; Thanendrarajan, S; Tian, E; van Rhee, F; Waheed, S; Yaccoby, S; Zangari, M | 1 |
| Krönke, J; Lindner, S | 1 |
| Iqbal, N; Majid, H; Shaikh, MU; Tariq, MU | 1 |
| Lonial, S; Nooka, AK | 1 |
| Goto, T; Iida, K; Kasamatsu, Y; Shimizu, S; Shirano, M | 1 |
| Ahmadi, T; Arkenau, HT; Basse, L; Clemens, PL; de Boer, C; Gimsing, P; Guckert, ME; Khokhar, NZ; Krejcik, J; Lassen, U; Laubach, JP; Lemech, C; Lisby, S; Lokhorst, HM; Minnema, MC; Palumbo, A; Plesner, T; Richardson, PG; Sasser, AK; Wang, J; Yeh, H | 1 |
| Kaufman, J; Laubach, J; Lonial, S; Mateos, MV; Reece, D; Richardson, P | 1 |
| Barilà, G; Berno, T; Briani, C; Cacciavillani, M; Campagnolo, M; Dalla Torre, C; De March, E; Ermani, M; Lico, A; Lucchetta, M; Salvalaggio, A; Zambello, R | 1 |
| Buadi, FK; Chakraborty, R; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Hogan, WJ; Kapoor, P; Kumar, S; Lacy, MQ; Leung, N; Muchtar, E | 1 |
| Gray, E; Krishna, A; Majer, I; Polanyi, Z; Roy, A; van de Wetering, G | 1 |
| Abonour, R; Biran, N; Callander, NS; Fonseca, R; Greipp, PR; Jacobus, S; Katz, MS; Rajkumar, SV; Siegel, DS; Vesole, DH; Williams, ME | 1 |
| Kobayashi, T; Miura, M; Niioka, T; Takahashi, N | 1 |
| Buchanan, J; Cocks, K; Dimopoulos, MA; Hájek, R; Jakubowiak, AJ; Ludwig, H; Masszi, T; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Tonda, M; Xing, B; Yang, X; Zojwalla, N | 1 |
| Lee, HS; Min, CK | 1 |
| Cornell, RF; Gailani, D; Garcia, D; Laubach, J; Li, W; Maglio, ME; Moslehi, J; Richardson, PG | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Terpos, E | 2 |
| Bensinger, WI; Berdeja, JG; Birrer, NE; Burke, JN; Jones, SS; Libby, EN; Markelewicz, RJ; Raje, NS; Richardson, PG; Supko, JG; Tamang, DL; Voorhees, PM; Wallace, EE; Wheeler, CA; Yang, M; Yee, AJ | 1 |
| Beeker, A; Bloem, AC; Bos, GMJ; Broijl, A; Faber, LM; Franssen, LE; Klein, SK; Koene, HR; Levin, MD; Lokhorst, HM; Mutis, T; Nijhof, IS; Oostvogels, R; Raymakers, R; Sonneveld, P; van de Donk, NWCJ; van der Spek, E; van Kessel, B; van Spronsen, DJ; van Velzen, J; Westerweel, PE; Ypma, PF; Zweegman, S | 1 |
| Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R | 1 |
| Aghemo, E; Corvatta, L; Gay, F; Gentili, S; Maracci, L; Offidani, M; Palumbo, A | 1 |
| Chen, Y; Chen, Z; He, Z; Shi, Y; Wang, C; Yu, L; Zhang, L | 1 |
| Usmani, SZ | 2 |
| Bashir, Q; Champlin, RE; Kebriaei, P; Manasanch, EE; Mian, I; Milton, DR; Nieto, Y; Oran, B; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Shpall, EJ | 1 |
| Bargou, RC; Bauer, S; Beilhack, A; Brandl, A; Brünnert, D; Chatterjee, M; Kreßmann, S; Mottok, A; Müller, E; Rosenwald, A; Scholz, CJ; Schraud, H; Steinbrunn, T; Stühmer, T | 1 |
| Bhutani, M; Burton, D; Calvo, KR; Carter, G; Costello, R; de Larrea, CF; Figg, WD; Gil, LA; Kazandjian, D; Korde, N; Kwok, M; Lamping, L; Landgren, O; Manasanch, EE; Maric, I; Mulquin, M; Roschewski, M; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wu, P; Yuan, C; Zingone, A; Zuchlinski, D | 1 |
| Abe, M; Aihara, K; Amachi, R; Bat-Erdene, A; Cui, Q; Endo, I; Fujii, S; Harada, T; Iwasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Sogabe, K; Teramachi, J; Yoshida, S | 1 |
| Ahmadi, T; Bahlis, NJ; Ben Yehuda, D; Chiu, C; Dimopoulos, MA; Goldschmidt, H; Guckert, M; Khokhar, NZ; Komarnicki, M; Lisby, S; Moreau, P; Nahi, H; O'Rourke, L; Oriol, A; Orlowski, RZ; Plesner, T; Qin, X; Rabin, N; Reece, D; Richardson, PG; San-Miguel, J; Suzuki, K; Usmani, SZ; Yoon, SS | 1 |
| Fujimi, A; Hashimoto, A; Hirayama, Y; Horiguchi, H; Ibata, S; Iyama, S; Kamihara, Y; Kato, J; Kobune, M; Konuma, Y; Kuroda, H; Miyanishi, K; Murase, K; Nagamachi, Y; Ono, K; Sato, T; Takada, K; Tatekoshi, A; Yoshida, M | 1 |
| Cartia, CS; Cazzola, M; Cocito, F; Corso, A; Ferretti, V; Klersy, C; Mangiacavalli, S; Pompa, A; Varettoni, M | 1 |
| Lipe, B; Mikhael, J; Vukas, R | 1 |
| Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH | 1 |
| Bernardini, A; Boccadoro, M; Caravita, T; Conticello, C; Drandi, D; Ferrero, S; Gambella, M; Gay, F; Genuardi, M; Gilestro, M; Liberati, AM; Muccio, VE; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Passera, R; Patriarca, F; Pautasso, C; Pescosta, N; Petrucci, MT; Rocci, A; Saraci, E | 1 |
| Laubach, JP; Longo, DL; Paba Prada, CE; Richardson, PG | 1 |
| Asante, D; Buadi, FK; Herrmann, J; Lerman, A; Reneau, JC; Sangaralingham, LR; van Houten, H | 1 |
| Bier, G; Fritz, J; Horger, M; Ioanoviciu, SD; Kum, S; Schabel, C; Weisel, K | 1 |
| Bleickardt, E; Chou, T; Iida, S; Kinoshita, G; Miyoshi, M; Nagai, H; Pandya, D; Robbins, M | 1 |
| Chao, NJ; Gasparetto, C; Green, MM; Horwitz, ME; Kang, Y; Li, Z; Long, GD; Lopez, RD; Rizzieri, DA; Sarantopoulos, S; Sivaraj, D; Sullivan, KM; Sung, AD | 1 |
| Anand, P; Bilotti, E; Biran, N; Ivanovski, K; McBride, L; Richter, JR; Sanchez, L; Siegel, DS; Vesole, DH | 1 |
| Atenafu, EG; Chen, C; Chu, CM; Kotchetkov, R; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Avorn, J; Gagne, JJ; Kesselheim, AS; Landon, J; Luo, J | 1 |
| Akashi, K; Aoki, T; Ito, Y; Iwasaki, H; Kamezaki, K; Kamimura, T; Kato, K; Kikushige, Y; Miyamoto, T; Mori, Y; Shima, T; Takenaka, K; Tochigi, T; Yamauchi, T; Yoshimoto, G | 1 |
| Atenafu, EG; Bahmanyar, M; Chang, H; Hou, J; Pourabdollah, M; Reece, D | 1 |
| Anh-NguyenThi, T; Jaya Lakshmi, T; Jung, SH; Kim, HJ; Lee, HJ; Lee, JJ; Nguyen-Pham, TN; Vo, MC | 1 |
| Boccadoro, M; Bringhen, S; Corvatta, L; Gay, F; Gentili, S; Larocca, A; Leoni, P; Maracci, L; Offidani, M; Troia, R | 1 |
| Cavo, M; Mancuso, K; Pantani, L; Pezzi, A; Rizzello, I; Rocchi, S; Tacchetti, P; Zamagni, E; Zannetti, BA | 1 |
| Lonial, S; Ribeiro, M; Scott, S; Xia, C | 1 |
| Berenson, A; Berenson, JR; David, M; Eades, B; Eshaghian, S; Gottlieb, J; Halleluyan, R; Harutyunyan, NM; Nassir, Y; Spektor, TM; Swift, R; Udd, KA; Vardanyan, S; Wang, J | 2 |
| Boyd, KD; Cairns, DA; Collett, C; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Henderson, R; Jackson, GH; Jenner, M; Jones, JR; Kaiser, MF; Kishore, B; Lindsay, J; Morgan, GJ; Owen, RG; Pawlyn, C; Pratt, G; Russell, NH; Sigsworth, R; Striha, A; Williams, C | 1 |
| Cabrera César, E; Fernández Aguirre, MC; González Fernández, A | 1 |
| Cherai, M; Garderet, L; Nguyen-Quoc, S; Norol, F; Rosenzwajg, M; Tanguy, ML; Trébéden-Negre, H; Vieillard, V | 1 |
| Agarwal, A; Bhutani, M; Chow, E; Friend, R; Usmani, SZ; Voorhees, PM | 1 |
| Buclin, T; Burnier, M; Dao, K; Figg, WD; Kissling, S; Lu, Y; Peer, CJ; Stadelmann, R | 1 |
| Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T | 1 |
| Bringhen, S; Di Raimondo, F; Gay, F; Gentile, M; Grazia Recchia, A; Greco, R; Larocca, A; Magarotto, V; Morabito, F; Musto, P; Offidani, M; Palumbo, A; Petrungaro, A; Ria, R; Teresa Petrucci, M; Tripepi, G; Uccello, G; Vigna, E | 1 |
| Boccadoro, M; Cafro, AM; Campbell, P; Caravita, T; Carella, AM; Catalano, L; Conticello, C; Evangelista, A; Falcone, AP; Gay, F; Hajek, R; Liberati, AM; Malfitano, A; Montefusco, V; Musto, P; Nagler, A; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Salvini, M; Spada, S; Spencer, A; Troia, R | 1 |
| Chen, CC; Chen, TY; DeMarco, D; Dunn, P; Hua, Y; Huang, SY; Jacques, C; Kao, WY; Lin, HY; Lin, SF; Lin, TH; Puccio-Pick, M; Wang, MC; Yeh, SP; Yu, YB | 1 |
| Bargou, R; Bassermann, F; Bullinger, L; Bunjes, D; Döhner, H; Einsele, H; Engelhardt, M; Greiner, A; Knop, S; Kolmus, S; Köpff, S; Krönke, J; Kuchenbauer, F; Kull, M; Langer, C; Mügge, LO; Schreder, M; Straka, C; Teleanu, V | 1 |
| Ahmann, GJ; Bergsagel, PL; Braggio, E; Chesi, M; Fonseca, R; Panchabhai, SC; Sebastian, S; Shi, CX; Stewart, AK; Van Wier, SA; Zhu, YX | 1 |
| Climente-Martí, M; Guchelaar, HJ; Guglieri-López, B; Merino-Sanjuán, M; Moes, DJ; Pérez-Pitarch, A; Porta-Oltra, B | 1 |
| Bolomsky, A; Fritz, V; Heintel, D; Hübl, W; Ludwig, H; Müldür, E; Palumbo, A; Rocci, A; Schlangen, K; Spada, S; Weißmann, A; Willheim, M; Zojer, N | 1 |
| Rajan, AM; Rajkumar, SV | 1 |
| Landgren, O | 1 |
| Manasanch, EE | 1 |
| Bello, A; Dodge, R; Gibiansky, L; Gupta, M; Mora, J; Passey, C; Roy, A; Sheng, J | 1 |
| Deng, M; Lin, Q; Mei, Z; Song, Y; Yang, J; Yin, Q; Zhu, X; Zuo, W | 1 |
| Bernöster, K; Häder, T; Pinkas, J; Schönfeld, K; Uherek, C; Zuber, C | 1 |
| Cai, Z; Cang, Y; Gao, S; Geng, C; Lin, X; Liu, J; Song, T | 1 |
| Fuchida, SI; Hatsuse, M; Murakami, S; Odaira, E; Okano, A; Shimazaki, C | 1 |
| Barilà, G; Bonaldi, L; Cabrelle, A; Carrino, M; Costacurta, M; Gianesin, K; Macaccaro, P; Manni, S; Manzoni, M; Martines, A; Neri, A; Nunes, SC; Piazza, F; Semenzato, G; Taiana, E; Trentin, L; Tubi, LQ; Zambello, R | 1 |
| Chen, G; Chen, WM; Eom, HS; Ervin-Haynes, A; Facon, T; Huang, SY; Hulin, C; Kim, HJ; Kim, K; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Liu, T; Lu, J; Min, CK; Qiu, L; Shen, ZX; Yiu, W; Yoon, SS | 1 |
| Boudreault, JS; Moreau, P; Touzeau, C | 1 |
| Álvarez Rivas, MÁ; Chic Acevedo, C; García Torres, E | 1 |
| Bunnapradist, S; Danovitch, G; Huang, E; Lum, EL; Pham, T | 1 |
| Hamahata, K; Nohgawa, M; Oka, S; Shiragami, H; Takeuchi, S | 1 |
| Baker, B; Blacklock, H; Browett, P; Cannell, P; Corbett, G; Cowan, L; Dimopoulos, MA; Fernyhough, L; Forsyth, C; Harrison, S; Henderson, R; Link, E; Miles Prince, H; Neylon, A; Quach, H; Swern, A; Trotman, J; Underhill, C | 1 |
| Berchem, G; Giuliani, M; Janji, B | 1 |
| Lentzsch, S; Raza, S; Safyan, RA | 1 |
| Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rajnics, P; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A | 1 |
| Badarinath, S; Berenson, J; Cartmell, A; Harb, W; Lyons, R; Manges, R; McIntyre, K; Mohamed, H; Nourbakhsh, A; Rifkin, R | 1 |
| Deisseroth, A; Farrell, AT; Goldberg, KB; Gormley, NJ; Kaminskas, E; Ko, CW; Kormanik, N; Nie, L; Pazdur, R | 1 |
| Brigo, F; Masi, E; Nardone, R; Pagani, E; Tezzon, F | 1 |
| Coleman, M; Ely, S; Forsberg, P; Gergis, U; Greenberg, J; Guarneri, D; Jayabalan, D; Mark, TM; Mayer, S; Niesvizky, R; Pearse, R; Pekle, K; Perry, A; Rossi, A; Sherbenou, D; Shore, T; Tegnestam, L; Van Besien, K | 1 |
| Li, B; Li, G; Liu, Y; Sheng, Z; Wang, L | 1 |
| Arnould, B; Bacon, P; Gilet, H; Kyriakou, C; Leleu, X; Lewis, P; Murphy, P; Petrucci, MT; Vande Broek, I | 1 |
| Dimopoulos, MA; Kastritis, E; Rajkumar, SV | 1 |
| Garderet, L; Gorin, NC; Isnard, F | 1 |
| Harousseau, JL | 7 |
| Gieseler, F | 1 |
| Musch, A | 1 |
| Bladé, J; Dimopoulos, MA; Kastritis, E; Ludwig, H; Rosinol, L | 1 |
| Boccadoro, M; Cavallo, F; Falco, P; Larocca, A; Liberati, AM; Musto, P; Palumbo, A | 1 |
| Christos, PJ; Coleman, M; Furst, JR; Harpel, J; Jayabalan, D; LaRow, A; Leonard, JP; Mark, T; Niesvizky, R; Pearse, RN; Schuster, MW; Shore, T; Stern, J; Zafar, F | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Ballester, O | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kubo, T; Kuroda, Y; Munemasa, S; Okikawa, Y; Sakai, A; Shimose, S | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S | 1 |
| Atkins, H; Belch, AR; Canning, LA; Kovacs, MJ; LeBlanc, R; Leitch, HA; Reece, DE; Voralia, M; White, D | 1 |
| Bloem, AC; Bogers-Boer, L; Lokhorst, HM; van de Donk, NW; van der Spek, E; van Kessel, B | 1 |
| Akin, C; Ferenc, V; Kluin-Nelemans, HC; Peters, WG; Valent, P; van Doormaal, JJ; van Iperen, C | 1 |
| Goldschmidt, H; Hegenbart, U; Hillengass, J; Ho, AD; Hundemer, M; Klein, U; Kosely, F; Moehler, T; Neben, K; Schmitt, S | 1 |
| Schiffer, CA; Srinivasan, S | 1 |
| Barlogie, B; Burington, B; Crowley, J; Shaughnessy, JD; Zhan, F | 1 |
| Berenson, JR; Yellin, O | 1 |
| Blum, KA; Byrd, JC; Dalton, JT; Farley, KL; Grever, MR; Hofmeister, CC; Johnson, AJ; Liu, Q; Muthusamy, N; Phelps, MA; Schaaf, LJ | 1 |
| Paydas, S | 1 |
| Martínez-Baños, DM; Niesvizky, R | 1 |
| Attal, M; Dimopoulos, M; Harousseau, JL; Hussein, M; Knop, S; Ludwig, H; Palumbo, A; San Miguel, J; Sonneveld, P; von Lilienfeld-Toal, M | 1 |
| Aarts, T; Emmelot, M; Lokhorst, HM; Minnema, MC; Mutis, T; van der Veer, MS | 1 |
| Dimopoulos, MA; Kastritis, E | 1 |
| Dyer, C | 2 |
| Attal, M; Chen, C; Cibeira, MT; Dimopoulos, MA; Knight, RD; Olesnyckyj, M; Rajkumar, SV; Spencer, A; Wang, M; Weber, DM; Yu, Z; Zeldis, JB | 1 |
| Bladé, J; Rosiñol, L | 1 |
| Fonseca, R; Rajkumar, SV | 1 |
| Booth, B; Dagher, R; Farrell, A; Hazarika, M; Justice, R; Pazdur, R; Rock, E; Sridhara, R; Williams, G | 1 |
| Agrawal, YP; Cesarman, E; Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Furman, RR; Jayabalan, D; Lee, JW; Lent, R; Leonard, JP; Mark, T; Matthew, S; Mazumdar, M; Niesvizky, R; Pearse, RN; Wang, YL | 1 |
| Lonial, S | 3 |
| Anderson, KC; Attal, M; Cavo, M; Gertz, MA; Giralt, S; Ludwig, H; Morgan, GJ | 1 |
| Anderson, KC; Balk, SP; Catley, L; Exley, MA; Munshi, NC; Podar, K; Prabhala, R; Shammas, MA; Song, W; Tai, YT; van der Vliet, HJ; Wang, R | 1 |
| Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT | 1 |
| Palumbo, A; Rajkumar, SV | 1 |
| Wiernik, PH | 1 |
| Behrens, J; Bird, J; Cavenagh, J; Cook, G; Davies, F; Morgan, G; Morris, C; Schey, S; Tighe, J; Williams, C | 1 |
| Alexandrescu, DT; Dasanu, CA | 1 |
| Coleman, M; Mark, T; Niesvizky, R | 1 |
| Ambrus, JL; Islam, A | 1 |
| Tuscano, JM | 1 |
| Bianchi, L; Böckeler, M; Kanz, L; Mayer, F; Terracciano, LM; Weisel, KC | 1 |
| Dmoszyńska, A | 1 |
| Borrello, I | 1 |
| Bargou, RC; Einsele, H; Falk, K; Gerecke, C; Glasmacher, A; Knop, S; Liebisch, P; Maeder, U; Platzbecker, U; Sezer, O; Topp, MS; Vollmuth, C | 1 |
| Higa, GM; Saad, AA; Sharma, M | 1 |
| Anagnostopoulos, N; Christoulas, D; Delimbassi, S; Dimopoulos, MA; Economopoulos, T; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Michali, E; Pouli, A; Roussou, M; Symeonidis, A; Terpos, E; Zervas, K; Zomas, A | 1 |
| Jonásová, A; Neuwirtová, R; Novotová, E; Spicka, I; Straub, J | 1 |
| Baker, RD; Finkbiner, KL; Henry, DW; Kettle, JK; Klenke, SE; Williams, CB | 1 |
| Belch, A; Dimopoulos, MA; Facon, T; Knight, RD; Niesvizky, R; Olesnyckyj, M; Prince, MH; San Miguel, JF; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB | 1 |
| Bergsagel, PL; Buadi, F; Dalton, RJ; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR | 1 |
| Bahlis, NJ; Bruyere, H; Chang, H; Chen, C; Fu, T; Horsman, DE; Mansoor, A; Masih-Khan, E; Reece, D; Roland, B; Song, KW; Stewart, DA; Trieu, Y | 1 |
| Cavenagh, J; Lonial, S | 1 |
| Meijer, E; Sonneveld, P | 1 |
| Benevolo, G; Boccadoro, M; Canepa, L; Falco, P; Falcone, A; Gay, F; Gozzetti, A; Knight, RD; Larocca, A; Luraschi, A; Magarotto, V; Morabito, F; Nozza, A; Palumbo, A; Petrucci, MT; Zeldis, JB | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D | 1 |
| Anderson, KC; Badros, AZ; Bensinger, W; Berenson, J; Hussein, M; Irwin, D; Jagannath, S; Kenvin, L; Knight, R; Olesnyckyj, M; Richardson, P; Singhal, S; Vescio, R; Williams, SF; Yu, Z; Zeldis, J | 1 |
| Giralt, S; Krishnan, A; Mccarthy, P; Pasquini, MC; Somlo, G; Stadtmauer, E; Vesole, DH | 1 |
| Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG | 1 |
| Abonour, R; Alsina, M; Bahlis, NJ; Boccia, RV; Chen, C; Coutre, SE; Knight, RD; Kumar, S; Matous, J; Niesvizky, R; Pietronigro, D; Rajkumar, V; Reece, DE; Richardson, P; Siegel, D; Stadtmauer, EA; Vescio, R; Zeldis, JB | 1 |
| Anderson, KC; Bensinger, W; Bergsagel, L; Blade, J; Cavo, M; Comenzo, RL; Durie, BG; Einsele, H; Giralt, S; Harousseau, JL; Kumar, S; Lentzsch, S; Lonial, S; Ludwig, H; Munshi, N; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Stadtmauer, EA; Tosi, P; Vesole, D | 1 |
| Kist, JM; Rosenbach, M; Thieu, KP; Xu, X | 1 |
| Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Blaise, D; El-Cheikh, J; Fehse, B; Hildebrandt, Y; Hoffmann, F; Kröger, N; Lioznov, M; Mohty, M; Schilling, G; Wolschke, C; Zander, AR | 1 |
| Barnett, DB; Boysen, M; Chung, H; Gajraj, E; Longson, C | 1 |
| Attal, M; Chen, C; Dimopoulos, MA; Knight, RD; Niesvizky, R; Olesnyckyj, M; Petrucci, MT; Spencer, A; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB | 1 |
| Brunetti, AE; Cafforio, P; Dammacco, F; De Matteo, M; Maiorano, E; Silvestris, F | 1 |
| Machálková, K; Maisnar, V | 1 |
| Chanan-Khan, A; Lee, K; Miller, KC; Sher, T | 1 |
| Brady, HA; Chan, KW; Escoubet-Lozach, L; Gandhi, AK; Jensen-Pergakes, K; Lin, IL; Muller, GW; Schafer, PH; Verhelle, D; Worland, PJ | 1 |
| Layzer, R; Wolf, J | 1 |
| Anderson, KC; Carreau, N; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL | 1 |
| San Miguel, JF | 1 |
| Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E | 1 |
| Abonour, R; Callander, NS; Fonseca, R; Greipp, PR; Jacobus, S; Katz, M; Rajkumar, SV; Siegel, DS; Vesole, DH; Williams, ME | 1 |
| Gay, F; Palumbo, A | 3 |
| Anderson, KC; Carreau, NA; Chauhan, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Raje, N; Richardson, PG; Schlossman, RL | 1 |
| Powles, R; Sirohi, B | 1 |
| Dimopoulos, MA; Fink, L; Finlayson, A; Fu, T; Knight, R; Niesvizky, R; Polavaram, L; Tricot, G; Weber, D; Zangari, M; Zhan, F | 1 |
| Dereure, O; Guillot, B; Michot, C | 1 |
| Bonkowski, J; Kolesar, JM; Vermeulen, LC | 1 |
| Rowan, K | 1 |
| Hussein, M; Srkalovic, G | 1 |
| Ozaki, S | 1 |
| Atadja, P; Crusoe, E; de Alava, E; Fernández-Lázaro, D; Garayoa, M; Hernández-Iglesias, T; Maiso, P; Ocio, EM; Pandiella, A; San-Miguel, JF; San-Segundo, L; Shao, W; Vilanova, D; Yao, YM | 1 |
| Hassett, AC; Lentzsch, S; List, A; Mapara, MY; Monaghan, SA; Moscinski, L; Pal, R; Ragni, MV; Roodman, GD; Schafer, P | 1 |
| Anderson, KC; Chauhan, D; Ciccarelli, B; Palladino, MA; Richardson, PG; Singh, AV | 1 |
| Mateos, MV; San-Miguel, JF | 1 |
| Ghobrial, IM; Stewart, AK | 1 |
| Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gay, F; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR | 1 |
| Azaïs, I; Brault, R; Debiais, F | 1 |
| Bakan, CE; Benson, DM; Devine, SM; Elder, P; Hamadani, M; Hofmeister, CC; Krugh, D; O'Donnell, L; Panzner, K; Smith, MK | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F | 1 |
| Attal, M; Avet-Loiseau, H; Belhadj, K; Dorvaux, V; Fermand, JP; Garderet, L; Hulin, C; Minvielle, S; Moreau, P; Soulier, J; Yakoub-Agha, I | 1 |
| Bauer, F; Dasanu, CA; Reale, MA | 1 |
| Lokhorst, HM; Minnema, MC; van de Donk, NW; Wittebol, S | 1 |
| Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S | 1 |
| Bartlett, JB; Capone, L; Fang, W; Gandhi, AK; Hampton, G; Kang, J; Lopez-Girona, A; Mendy, D; Parton, A; Sapinoso, L; Schafer, P; Tran, T; Wu, L; Xu, S; Zhang, LH | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Hogan, WJ; Kumar, S; Lacy, MQ | 1 |
| Lokhorst, HM; Minnema, MC; van de Donk, NW; van der Spek, E | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S | 1 |
| Curran, JJ; Lin, RJ; Niewold, TB; Song, J; Sweiss, NJ; Zimmerman, TM | 1 |
| Kulharya, A; Shah, R; Ustun, C; Yuan, J | 1 |
| Chen, Y; Kiatsimkul, P; Nugent, K; Raj, R | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Bizzari, JP; Jacques, C; Knight, RD; Tozer, A; Zeldis, JB | 1 |
| Ludwig, H; Zojer, N | 1 |
| Baz, R; Chanan-Khan, AA; Finley-Oliver, E; Hussein, MA; Lebovic, D; Lee, K; Miller, KC; Patel, M; Sher, T; Wood, M | 1 |
| Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
| Boccadoro, M; Canepa, L; Crugnola, M; Falco, P; Falcone, AP; Federico, V; Genuardi, M; Larocca, A; Magarotto, V; Palumbo, A; Petrucci, MT; Sanpaolo, G | 1 |
| Iida, S | 1 |
| Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W | 1 |
| Goldschmidt, H; Ho, AD; Schmitt, S | 1 |
| Cook, R; Cunningham, K; Gardler, M; Hummel, K; Luger, SM; Mangan, PA; Nazha, A; O'Doherty, U; Porter, DL; Schuster, S; Siegel, D; Stadtmauer, EA; Vogl, DT | 1 |
| Ales, M; Caravita, T; Cupelli, L; de Fabritiis, P; Niscola, P; Perrotti, A; Siniscalchi, A; Tendas, A | 1 |
| Alexanian, R; Delasalle, K; Giralt, S; Wang, M | 1 |
| Kumar, S | 3 |
| Gleason, C; Kaufman, J; Lonial, S | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Di Raimondo, F; Falco, P; Larocca, A; Magarotto, V; Palumbo, A | 1 |
| Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C; Taverna, C | 1 |
| Baiocchi, RA; Bakan, CE; Becknell, B; Benson, DM; Byrd, JC; Caligiuri, MA; Devine, SM; Efebera, Y; Greenfield, CN; Hofmeister, CC; Lozanski, G; Mishra, A; Porcu, P; Rotem-Yehudar, R; Smith, MK; Yu, J; Zhang, J | 1 |
| Attal, M; Chen, C; Corso, A; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Spencer, A; Wang, M; Weber, DM; Yu, Z; Zeldis, JB | 1 |
| Hájek, R; Holánek, M | 1 |
| Mateos, MV | 2 |
| Dimopoulos, MA; Jagannath, S; Lonial, S | 1 |
| Boccadoro, M; Dispenzieri, A; Falco, P; Gay, F; Gertz, MA; Keith Stewart, A; Kumar, S; Palumbo, A; Petrucci, MT; Vincent Rajkumar, S | 1 |
| Calandra, G; Gandhi, PJ; Ho, AD; Klein, LM; Marulkar, S; McSweeney, PA; Micallef, IN | 1 |
| Einsele, H; Kortuem, M | 1 |
| Feilchenfeldt, J; Györik, S; Lerch, E; Mazzucchelli, L; Quadri, F | 1 |
| Bhandari, M; Callander, N; Flinn, I; Gasparetto, C; Glass, J; Grosman, D; Hari, P; Krishnan, A; Kumar, SK; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Sahovic, EA; Shi, H; Webb, IJ; Wolf, JL | 1 |
| Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gika, D; Grapsa, I; Kastritis, E; Migkou, M; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Destian, S; Hwang, BJ; Jagannath, S; Mazumder, A; Méndez, CE; Vesole, DH | 1 |
| Bergsagel, PL; Buadi, F; Dingli, DD; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Kapoor, P; Ketterling, RP; Kumar, S; Kyle, RA; Lacy, MQ; Rajkumar, SV; Sinha, S; Stewart, AK; Witzig, TE | 1 |
| Higginson, I; Schey, S | 1 |
| Boyd, K; Corderoy, S; Davies, FE; Hazel, B; Jenner, M; Ladon, D; Morgan, GJ; Phekoo, K; Ramasamy, K; Schey, SA | 1 |
| Chou, T; Hatake, K; Hotta, T; Iida, S; Lau, H; Murakami, H; Nagai, H; Okamoto, S; Shimizu, K; Takagi, T; Takatoku, M; Takeshita, K | 1 |
| Alegre, A; de Castro, CM; Dimopoulos, M; Goldschmidt, H; Masliak, Z; Olesnyckyj, M; Reece, D; Stadtmauer, EA; Weber, DM; Yu, Z; Zonder, JA | 1 |
| Brodoefel, H; Claussen, CD; Fenchel, M; Horger, M; Konaktchieva, M; Kraus, S; Weisel, K | 1 |
| Fielding, K; Neeson, P; Quach, H; Ritchie, DS | 1 |
| Chen-Kiang, S; Coleman, M; Dispenzieri, A; Fonseca, R; Gay, F; Gertz, MA; Greipp, PR; Jayabalan, DS; Kumar, S; Kyle, RA; Lacy, MQ; Leonard, J; Lust, JA; Mark, T; Niesvizky, R; Pearse, R; Rajkumar, SV; Roy, V; Stewart, AK; Witzig, TE | 1 |
| Anderson, KC; Bandi, M; Calabrese, E; Cirstea, D; Fabre, C; Görgün, G; Hideshima, T; Hu, Y; Mimura, N; Munshi, N; Nahar, S; Perrone, G; Raje, N; Richardson, P; Santo, L; Soydan, E; Tai, YT | 1 |
| Aguilar, C; de la Rubia, J; del Campo, R; García, I; González, N; Ibáñez, A; Martínez, R; Palomera, L; Picón, I; Rodríguez, JN; Roig, M; Sanz, MA; Vera, JA | 1 |
| Chanan-Khan, A; Deeb, G; Lee, K; Miller, KC; Sher, T | 1 |
| Fine, DM; Holanda, DG; Huff, CA; Lipson, EJ; McDevitt, MA | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E | 1 |
| Berno, T; Briani, C; Campagnolo, M; Zambello, R | 1 |
| Bocchia, M; Crupi, R; Defina, M; Gozzetti, A | 1 |
| Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J | 1 |
| Goldschmidt, H; Heiss, C; Hielscher, T; Ho, AD; Klein, U; Neben, K | 1 |
| Grivas, PD; Saloura, V | 1 |
| Gajra, A; Singh, A | 1 |
| Abidi, MH; Barlogie, B; Bolejack, V; Crowley, J; Durie, BG; Hussein, MA; Moore, DF; Whittenberger, BF; Zonder, JA | 1 |
| Mey, UJ | 1 |
| Theodorescu, D; Wilson, SS | 1 |
| Chang, H; Chen, C; Jiang, A; Qi, C; Reece, D; Trieu, Y | 1 |
| Harrison, SJ; Hsu, AK; Neeson, P; Prince, HM; Quach, H; Ritchie, DS; Smyth, MJ; Tai, T; Trapani, JA | 1 |
| Ballanti, S; Corvatta, L; Gentili, S; Gozzetti, A; Leoni, P; Liberati, AM; Nozzoli, C; Offidani, M; Palumbo, A; Polloni, C; Pulini, S | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Liedtke, M; Medeiros, BC | 1 |
| Guglielmelli, T; Palumbo, A; Petrucci, MT; Saglio, G | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| Bakker, JM; de Weers, M; Lokhorst, HM; Mutis, T; Parren, PW; van der Veer, MS; van Kessel, B; Wittebol, S | 1 |
| Alpmann, P; Blaum-Feder, S; Carson, D; Endo, T; Kim, Y; Krämer, S; Lu, D; Schmidt-Wolf, IG | 1 |
| San-Miguel, JF | 1 |
| Baz, R; Davies, F | 1 |
| Dimopoulos, MA; Terpos, E | 1 |
| Morgan, G | 1 |
| Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Hamata, L; Hogge, DE; Mourad, YA; Nantel, SH; Narayanan, S; Nevill, TJ; Nitta, J; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Venner, CP | 1 |
| Richardson, PG | 1 |
| Alici, E; Gahrton, G; Jansson, M; Nahi, H; Sutlu, T | 1 |
| Buda, G; Galimberti, S; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Bjorklund, CC; Davis, RE; Kornblau, SM; Kuhn, DJ; Ma, W; Orlowski, RZ; Shah, JJ; Wang, M; Wang, ZQ | 1 |
| Armoiry, X; Aulagner, G; Benboubker, L; Facon, T; Fagnani, F; Fermand, JP; Hulin, C; Moreau, P | 1 |
| Kristinsson, SY | 1 |
| Carrier, M; Le Gal, G; Lee, AY; Tay, J; Wu, C | 1 |
| Bravo, ML; Dimopoulos, MA; Harousseau, JL; Knight, RD; Olesnyckyj, M; Rajkumar, SV; San-Miguel, JF; Siegel, D; Stadtmauer, EA; Weber, DM; Zeldis, JB | 1 |
| Abe, M; Fujii, S; Harada, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Ozaki, S; Takeuchi, K | 1 |
| Attal, M; Beksaç, M; da Costa, FL; Davies, FE; Delforge, M; Dimopoulos, MA; Einsele, H; Hajek, R; Harousseau, JL; Ludwig, H; Mellqvist, UH; Morgan, GJ; Palumbo, A; San-Miguel, JF; Sonneveld, P; Zweegman, S | 1 |
| Basile, A; Berardi, S; Caivano, A; Capalbo, S; Cascavilla, N; Coluccia, AM; Dammacco, F; de Luca, E; De Luisi, A; Di Pietro, G; Ditonno, P; Ferrucci, A; Guarini, A; Maffia, M; Moschetta, M; Pieroni, L; Quarta, G; Ranieri, G; Ria, R; Ribatti, D; Urbani, A; Vacca, A | 1 |
| Haan, J; Molendijk, WJ; Tannemaat, MR; Vries, EP | 1 |
| Adamia, S; Anderson, KC; Blotta, S; Cervi, D; Cholujova, D; Daley, JF; Delmore, J; Jakubikova, J; Klippel, S; Kong, SY; Kost-Alimova, M; Laubach, J; Leiba, M; Mitsiades, CS; Ooi, M; Richardson, PG; Sedlak, J | 1 |
| Anderson, KC; Laubach, JP; Mitsiades, CS; Richardson, PG; Schlossman, RL | 1 |
| Benevolo, G; Berruti, A; Boccadoro, M; Bringhen, S; Caravita, T; Cavallo, F; Corradini, P; Gay, F; Guglielmelli, T; Montefusco, V; Offidani, M; Palumbo, A; Petrucci, MT; Piro, E; Rrodhe, S; Saglio, G | 1 |
| Lacy, MQ; Tefferi, A | 1 |
| Mateos, MV; San-Miguel, J | 1 |
| Schots, R | 1 |
| Abraham, J; Awan, FT; Craig, M; Gibson, L; Hamadani, M; Jillella, A; Kochuparambil, ST; Osman, S; Remick, SC | 1 |
| Aguado, B; Alegre, A; Calvo, JM; Cánovas, A; Castillo, I; de la Serna, J; García, FL; Giraldo, P; Hernández, MT; Ibáñez, Á; Lahuerta, JJ; Martínez-Chamorro, C; Oriol, A; Palomera, L; Ríos, E; Rodríguez, JN | 1 |
| Galson, DL; Lentzsch, S; Li, S; Mapara, M; Monaghan, SA; Ouyang, H; Pal, R; Schafer, P | 1 |
| Bosi, A; Maratea, D; Messori, A; Nozzoli, C | 1 |
| Lonial, S; Mitsiades, CS; Richardson, PG | 1 |
| Tageja, N | 1 |
| Anderson, KC; Bandi, M; Chauhan, D; Cirstea, D; Gorgun, G; Hideshima, T; Hu, Y; Mahindra, A; Munshi, NC; Nelson, EA; Patel, K; Pozzi, S; Raje, N; Rodig, S; Santo, L; Squires, M; Unitt, C; Vallet, S | 1 |
| González Rodríguez, AP | 1 |
| García Sánchez, PJ; González Rodríguez, AP; Mesa, MG; Pérez Persona, E | 1 |
| Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR | 1 |
| Beksac, M; Bladé, J; Cavenagh, J; Cavo, M; Delforge, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Kropff, M; Leal da Costa, F; Louw, V; Ludwig, H; Magen-Nativ, H; Mendeleeva, L; Nahi, H; Palumbo, A; Plesner, T; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M | 1 |
| Lyseng-Williamson, KA; Scott, LJ | 2 |
| Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B | 1 |
| Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Kapoor, P; Kumar, S; Kyle, RA; Lacy, MQ; Laumann, KM; Mandrekar, SJ; Rajkumar, SV; Witzig, TE | 1 |
| Engelhardt, M; Finke, J; Jakob, T; Technau, K; Wäsch, R | 1 |
| Bringhen, S; Mateos, MV; Palumbo, A; San Miguel, JF | 1 |
| Endo, I; Miura, A; Murata, Y; Ohashi, K | 1 |
| Kim, JH; Scialli, AR | 1 |
| Kyle, RA; Steensma, DP | 1 |
| Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M | 1 |
| Goldschmidt, H; Moehler, T | 1 |
| Gahrton, G | 1 |
| Abraham, J; Bridoux, F; Debiais, C; Delbès, S; Desport, E; Fermand, JP; Hanf, W; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G | 1 |
| Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A | 1 |
| Kyle, RA | 2 |
| Citro, A; Corradini, P; Crippa, C; De Muro, M; Falcone, AP; Galli, M; Gentili, S; Grasso, M; Guglielmelli, T; Montefusco, V; Olivero, B; Patriarca, F; Rossi, D; Sammassimo, S; Spina, F | 1 |
| Brown, K; Clayton, W; Figaro, MK; Jagasia, S; Kassim, A; Lakhani, VT; Usoh, C | 1 |
| Alegre, A; Calle, C; Calvo-Villas, JM; García-Sánchez, R; Hernández, MT; Ramírez, G | 1 |
| Ikezoe, T; Kubota, T; Kuwayama, Y; Sakai, M; Yokoyama, A | 1 |
| Anderson, KC; Anderson, T; Barrickman, JC; Campagnaro, EL; Esseltine, DL; Griffith, KA; Harvey, CK; Hofmeister, CC; Jakubowiak, AJ; Kaminski, MS; Kelley, SL; Laubach, JP; Lonial, S; Mietzel, MA; Raje, NS; Reece, DE; Richardson, PG; Schlossman, RL; Tendler, CL; Wear, SM; Zimmerman, TM | 1 |
| Allred, J; Bergsagel, PL; Buadi, FK; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, SK; Lacy, MQ; Laumann, K; Lust, JA; Mikhael, JR; Rajkumar, SV; Reeder, CB; Russell, SJ; Stewart, K; Witzig, TE; Zeldenrust, SR | 1 |
| Aisa, Y; Ito, C; Mihara, A; Nakazato, T; Sanada, Y | 1 |
| Buadi, F; Detweiler-Short, K; Dingli, D; Dispenzieri, A; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Lust, J; Madan, S; Rajkumar, SV; Zeldenrust, S | 1 |
| Goldschmidt, H; Hegenbart, U; Herth, I; Ho, AD; Hose, D; Hundemer, M; Klein, B; Neuber, B; Schoenland, S; Tolliver, C; Witzens-Harig, M | 1 |
| Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Reeder, C; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S | 1 |
| Ishak, J; Rodrigues, F | 1 |
| Allegra, A; Alonci, A; Catena, S; D'Angelo, A; Gerace, D; Greve, B; Musolino, C; Penna, G; Russo, S | 1 |
| Bartlett, JB; Bolomsky, A; Brady, H; Chopra, R; Daniel, T; Gaidarova, S; Gisslinger, H; Heintel, D; Hilgarth, B; Jäger, U; Lopez-Girona, A; Ludwig, H; Mendy, D; Schafer, PH; Schreder, M; Zhang, LH; Zojer, N | 1 |
| Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B | 1 |
| Barker, A; Coates, S; Spurgeon, S | 1 |
| Dimopoulos, MA; Hussein, M; Swern, AS; Weber, D | 1 |
| Liu, L; Ran, X; Sheng, Z; Wang, B; Wang, L | 1 |
| Fukushima, T; Iwao, H; Nakamura, T; Umehara, H | 1 |
| Chang, H; Jiang, A; Reece, D | 1 |
| Benson, DM; Byrd, JC; Chan, KK; Chen, CS; Chen, P; Farag, SS; Garr, CL; Grever, MR; Hade, EM; Hicks, WJ; Hofmeister, CC; Ji, J; Johnson, AJ; Kraut, EH; Lee, S; Liu, Z; Phelps, MA; Pichiorri, F; Rozewski, DM; Schaaf, LJ; Yang, X | 1 |
| Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I | 1 |
| Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB | 1 |
| Adam, Z; Feit, J; Hájek, R; Klincová, M; Krejčí, M; Mayer, J; Pour, L; Szturz, P; Vašků, V; Zahradová, L | 1 |
| Ahmann, GJ; Callander, NS; Fonseca, R; Greipp, PR; Haug, JL; Henderson, KJ; Jacobus, SJ; Kumar, SK; Rajkumar, SV; Siegel, DS; Uno, H; Van Wier, SA | 1 |
| Bergsagel, PL; Bjorklund, CC; Braggio, E; Bruins, LA; Chang, XB; Fonseca, R; Orlowski, RZ; Schmidt, JE; Shi, CX; Stewart, AK; Van Wier, S; Zhu, YX | 1 |
| Möller, J; Murthy, A; Nicklasson, L | 1 |
| Tokuhira, M | 1 |
| Ahmann, GJ; Callander, NS; Fonseca, R; Greipp, PR; Henderson, KJ; Jacobus, SJ; Kumar, S; Rajkumar, SV; Siegel, DS; Uno, H; Van Wier, SA; Williams, ME | 1 |
| Dimeski, G; Wood, P | 1 |
| Bolesta, S; Boruah, PK; Shetty, SM | 1 |
| Knop, S | 1 |
| Glasmacher, A; Gorschlüter, M; Schmidt-Wolf, IG; Schwamborn, K | 1 |
| Hata, H | 1 |
| Alsina, M; Nishihori, T | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Benson, DM; Crawford, BS; Efebera, Y; Elder, P; Hofmeister, CC; Mori, S; Phillips, G; Roddy, JV | 1 |
| Andre, P; Bakan, CE; Benson, DM; Bléry, M; Bonnafous, C; Caligiuri, MA; Clever, D; Collins, SM; Efebera, Y; Farag, SS; Hofmeister, CC; Liang, J; Romagne, F; Srivastava, S; Zhang, J; Zhang, S | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Hogan, WJ; Kumar, SK; Lacy, MQ; Micallef, IN; Rajkumar, SV; Sinha, S | 1 |
| Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R | 1 |
| Fenaux, P; Freeman, J; Palumbo, A; Weiss, L | 1 |
| Cives, M; Dammacco, F; Milano, A; Silvestris, F | 1 |
| Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, P; Hayman, S; Keith Stewart, A; Khan, ML; Kumar, SK; Lacy, MQ; Laumann, KM; Leif Bergsagel, P; Lust, J; Mikhael, JR; Reece, DE; Reeder, CB; Russell, S; Vincent Rajkumar, S; Zeldenhurst, S | 1 |
| Ashida, T; Emoto, M; Hirase, C; Matsumura, I; Morita, Y; Ojima, M; Rai, S; Serizawa, K; Shimada, T; Taniguchi, Y; Tatsumi, Y; Yamaguchi, T | 1 |
| Jena, RK; Kansurkar, SS; Swain, M; Swain, TR | 1 |
| Dimopoulos, MA; Eleftherakis-Papapiakovou, E; Gkotzamanidou, M; Grapsa, I; Kastritis, E; Nikitas, N; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Carney, DA; Gangatharan, SA; Harrison, SJ; Januszewicz, EH; Prince, HM; Ritchie, DS; Wolf, MM | 1 |
| Landgren, O; Mailankody, S; Thomas, A | 1 |
| Allegra, A; Alonci, A; Cannavò, A; D'Angelo, A; Musolino, C; Penna, G; Petrungaro, A; Romeo, G; Russo, S | 1 |
| Reece, D; Scott, E | 1 |
| Appel, A | 1 |
| Constans, T; Cottier, JP; Dardaine, V; Eudo, C; Hommet, C; Mondon, K; Petit, A; Rippault, H | 1 |
| Iino, M | 1 |
| Hajek, R; Kovarova, L; Muthu Raja, KR | 1 |
| Blin, N; Clavert, A; Dubruille, V; Le Gouill, S; Loirat, M; Mahe, B; Malard, F; Mohty, M; Moreau, P; Pennetier, M; Peterlin, P; Planche, L; Roland, V; Tessoulin, B; Touzeau, C | 1 |
| Abumiya, M; Kameoka, Y; Miura, M; Sawada, K; Takahashi, N | 1 |
| Moehler, T | 1 |
| Gil, L; Komarnicki, M; Rupa-Matysek, J | 1 |
| Borrello, I; Emerling, A; Ferguson, A; Huff, CA; Noonan, K; Pasetti, MF; Rudraraju, L | 1 |
| Greig, N; Sandoval, F; Shannon, E; Stagg, P | 1 |
| Figueiredo, A; João, C; Martins, HF | 1 |
| Esteves, GV; Mariz, JM | 1 |
| Anderson, KC; Bernett, MJ; Cemerski, S; Chen, H; Chu, SY; Desjarlais, JR; Horton, HM; Karki, S; Kong, SY; Lazar, GA; Muchhal, US; Munshi, NC; Nguyen, DH; Pong, E; Tai, YT | 1 |
| Awan, F; Bunner, P; Craig, M; Cumpston, A; Deremer, D; Hamadani, M; Jillella, A; Kochuparambil, ST; Kota, V; Leadmon, S; Morrison, D; Osman, S; Speir, E; Watkins, K | 1 |
| Chang, H; Chen, MH; Qi, CX; Saha, MN | 1 |
| Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A | 1 |
| Anderson, KC; Colson, K; Doss, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Lunde, L; McKenney, M; Mitsiades, C; Munshi, NC; Noonan, K; Redman, KC; Richardson, PG; Schlossman, RL; Warren, D | 1 |
| Attal, M; Avet-Loiseau, H; Bourin, P; Cordelier, P; Corre, J; Espagnolle, N; Facon, T; Fournié, JJ; Gadelorge, M; Hébraud, B; Huynh, A; Klein, B; Labat, E; Moreau, P; Roussel, M | 1 |
| Brandenburg, N; Dimopoulos, MA; Morgan, GJ; Niesvizky, R; Richardson, PG; Weber, DM; Yu, Z | 1 |
| Chanan-Khan, AA; Dimopoulos, MA; Jagannath, S; Ludwig, H; San Miguel, JF | 1 |
| Hahn-Ast, C; Kuhn, S; Langer, C; Oehrlein, K; Pönisch, W; Sturm, I; Weisel, KC | 1 |
| Anderson, K; Laubach, J; Mahindra, A; Munshi, N; Raje, N; Richardson, PG | 1 |
| Berenson, JR; Bravin, E; Cartmell, A; Chen, CS; Flam, M; Hilger, JD; Kazamel, T; Nassir, Y; Swift, RA; Vescio, R; Woliver, T; Yellin, O | 1 |
| Anand, P; Bello, E; Bendarz, U; Bilotti, E; McBride, L; McNeill, A; Olivo, K; Siegel, DS; Tufail, M; Vesole, DH | 1 |
| Carson, D; Endo, T; Gast, SM; Kim, Y; Lu, D; Schmidt-Wolf, IG | 1 |
| Adami, F; Briani, C; Citton, V; Lessi, F; Manara, R; Zambello, R | 1 |
| Jin, X; Zhang, YZ | 1 |
| Chanan-Khan, AA; Kasyapa, CS; Sher, T | 1 |
| Mizutani, M; Ohya, E; Sekine, T | 1 |
| Callander, N; Estevam, J; Flinn, I; Hari, P; Kumar, S; Mulligan, G; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Shi, H; Stewart, AK; Turturro, F; Webb, IJ; Wolf, J | 1 |
| Alexandrescu, DT; Dasanu, CA; Mitsis, D | 1 |
| Blaise, D; Calmels, B; Castagna, L; Chabannon, C; Crocchiolo, R; Duran, S; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Ladaique, P; Lemarie, C; Oudin, C; Schiano De Colella, JM; Stoppa, AM | 1 |
| Abbas, M; Agha, M; Boyiadzis, M; Burt, S; Dai, L; Kennedy, RC; Lentzsch, S; Mapara, MY; Normolle, D; O'Sullivan, A; Pregja, SL; Roodman, GD; Shuai, Y; Waas, J; Zonder, JA | 1 |
| Tsuda, H; Tsuji, T; Yamasaki, H; Yokoo, E | 1 |
| Barosi, G; Billio, A; Boccadoro, M; Cavo, M; Corradini, P; Marchetti, M; Massaia, M; Merlini, G; Palumbo, A; Tosi, P; Tura, S | 1 |
| Abbas, J; Butcher, CD; Costa, LJ; Hogan, KR; Kang, Y; Kramer, C; Littleton, A; McDonald, K; Shoptaw, K; Stuart, RK | 1 |
| Balducci, M; Chiusolo, P; De Stefano, V; Giannotta, C; Laurenti, L; Leone, G; Luigetti, M; Sabatelli, M; Sica, S; Sorà, F; Vannata, B | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gkotzamanidou, M; Kanellias, N; Kastritis, E; Papatheodorou, A; Terpos, E | 1 |
| Garcia-Sanz, R; Mateos, MV; Ocio, E; San Miguel, JF | 1 |
| Fonseca, R | 1 |
| Giralt, S | 1 |
| Braggio, E; Cesarman-Maus, G; Fonseca, R | 1 |
| Diez-Campelo, M; Giraldo, P; Hernández, MT; López-Corral, L; Matarraz, S; Mateos, MV; Orfao, A; Paiva, B; Pérez, E; San Miguel, JF | 1 |
| Facon, T; Harousseau, JL; Jagannath, S; Kaufman, JL; Leleu, X; Lonial, S; Mazumder, A; Moreau, P; Singhal, AK; Tsao, LC; Vij, R; Westland, C | 1 |
| Beksac, M; Ben Yehuda, D; Bladé, J; Cascavilla, N; Catalano, J; Cavo, M; Corso, A; Delforge, M; Dimopoulos, MA; Gisslinger, H; Hajek, R; Herbein, L; Iosava, G; Jacques, C; Kloczko, J; Kropff, M; Langer, C; Mei, J; Palumbo, A; Petrucci, MT; Plesner, T; Radke, J; Spicka, I; Weisel, K; Wiktor-Jędrzejczak, W; Yu, Z; Zodelava, M | 1 |
| Anderson, KC; Barry, S; Bashey, A; Bennett, E; Bressler, L; Callander, NS; Devine, SM; Gabriel, DA; Gentile, T; Giralt, S; Hari, P; Hars, V; Hassoun, H; Hofmeister, CC; Horowitz, MM; Hurd, DD; Isola, L; Jiang, C; Kelly, M; Landau, H; Levitan, D; Linker, C; Martin, T; Maziarz, RT; McCarthy, PL; McClune, B; Moreb, JS; Owzar, K; Pasquini, MC; Postiglione, J; Qazilbash, MH; Richardson, PG; Rosenbaum, C; Schlossman, R; Seiler, M; Shea, TC; Stadtmauer, EA; Van Besien, K; Vij, R; Weisdorf, DJ | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Decaux, O; Dumontet, C; Facon, T; Garderet, L; Harousseau, JL; Hulin, C; Lauwers-Cances, V; Leleu, X; Leyvraz, S; Marit, G; Mathiot, C; Michallet, M; Moreau, P; Payen, C; Pegourie, B; Roussel, M; Stoppa, AM; Vekemans, MC; Voillat, L | 1 |
| Badros, AZ | 1 |
| Brown, RE; Dhanasiri, S; Schey, S; Stern, S | 1 |
| Avet-Loiseau, H; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Davies, F; de la Rubia, J; Delimpasi, S; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Hess, U; Ludwig, H; Mellqvist, UH; Moreau, P; Palumbo, A; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M | 1 |
| Alegre, A; Dimopoulos, MA; Goldschmidt, H; Mark, T; Niesvizky, R; Terpos, E | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Rushworth, SA | 1 |
| Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T | 1 |
| Kalff, A; Quach, H; Spencer, A | 1 |
| Ahmed, A; Al-Zoubi, A; Anderson, T; Couriel, D; Detweiler-Short, K; Durecki, DE; Dytfeld, D; Griffith, KA; Jagannath, S; Jakubowiak, AJ; Jobkar, T; Kaminski, M; Lebovic, D; McDonnell, K; Mietzel, M; Nordgren, B; Stockerl-Goldstein, K; Vesole, DH; Vij, R | 1 |
| Caraffa, P; Caravita, T; de Fabritiis, P; Gentili, S; Leoni, P; Offidani, M; Perrotti, A; Siniscalchi, A | 1 |
| Ahmad, N; Al Sayed, Y; Atrash, S; Barlogie, B; Chauhan, N; Crowley, J; Heuck, CJ; Hoering, A; Nair, B; Petty, N; Sexton, R; Usmani, SZ; van Rhee, F; Waheed, S | 1 |
| Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS | 1 |
| Anderson, KC; Arnason, J; Avigan, D; Glotzbecker, B; Joyce, RM; Kufe, D; Kufe, T; Levine, JD; Luptakova, K; Mills, H; Rosenblatt, J; Stroopinsky, D; Tzachanis, D; Vasir, B; Zwicker, JI | 1 |
| Borrello, I; Chanan-Khan, AA; Dimopoulos, M; Foà, R; Hellmann, A; Knight, R; Lonial, S; Swern, AS; Weber, D | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E | 1 |
| Fujiwara, S; Hata, H; Iyama, K; Izaki, M; Kawano, Y; Mitsuya, H; Okuno, Y; Sakai, A; Wada, N; Yamasaki, H; Yuki, H | 1 |
| Cai, X; Ding, K; Duan, Q; Han, Y; Liu, X; Sun, Z; Wang, A; Wu, J; Zhu, W | 1 |
| Takamatsu, Y | 1 |
| Lentzsch, S; Pan, B | 1 |
| Brunetti, O; Cives, M; Longo, V; Silvestris, F; Simone, V | 1 |
| Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC | 1 |
| Brower, V | 1 |
| Ay, C; Pabinger, I; Thaler, J | 1 |
| Boccadoro, M; Bringhen, S; Cerrato, C; Gay, F; Palumbo, A; Pautasso, C | 1 |
| Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Burchert, A; Hansen, T; Hildebrandt, Y; Klyuchnikov, E; Kröger, N; Kropff, M; Pflüger, KH; Schilling, G; Stübig, T; Wolschke, C; Zabelina, T; Zander, AR | 1 |
| Berenson, JR; Eshaghian, S | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Berenson, JR; Chen, H; Hunter, K; Jones-Bolin, S; Li, J; Li, M; Ruggeri, B; Sanchez, E; Wang, C | 1 |
| Cockwell, P; Cook, M; Stringer, S | 1 |
| Bladé, J; Dimopoulos, MA; Kastritis, E | 1 |
| Bashir, Q; Bayraktar, UD; Champlin, RE; Ciurea, SO; Qazilbash, M | 1 |
| Kortuem, KM; Stewart, AK; Zhu, YX | 1 |
| Suzuki, K | 2 |
| Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
| Arima, N; Kawada, H | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Carella, AM; Cavallo, F; De Paoli, L; Falco, P; Freilone, R; Gaidano, G; Gay, F; Grasso, M; Guglielmelli, T; Larocca, A; Mina, R; Molica, S; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Rocci, A; Rossi, D; Siez, ML | 1 |
| Alexander, M; Kirsa, S; Lingaratnam, S; Mellor, JD; Teoh, KC | 1 |
| Atanackovic, D; Ayuk, F; Dreger, P; Hegenbart, U; Heinzelmann, M; Hildebrandt, Y; Kröger, N; Schönland, S; Stübig, T; Wolschke, C; Zander, A | 1 |
| Dhodapkar, KM; Dhodapkar, MV; Miesowicz, F; Monesmith, T; Nair, S; Neparidze, N; Richter, J; Sundaram, R; Zhang, L | 1 |
| Aisa, Y; Ito, C; Mihara, A; Nakazato, T | 1 |
| Banglawala, S; Lentz, EM; Reece, DE; Seki, JT | 1 |
| Allegra, A; Alonci, A; Catena, S; Musolino, C; Rizzotti, P; Rotondo, F; Russo, S | 1 |
| Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA | 1 |
| Boccadoro, M; Cavallo, F; Larocca, A; Mina, R; Palumbo, A | 1 |
| Bahlis, NJ; Belch, A; Chapman, JA; Chen, C; Couban, S; Harnett, E; Kovacs, MJ; Macdonald, DA; Marcellus, DC; Meyer, RM; Reece, DE; Reiman, T; Stewart, AK; White, DJ | 1 |
| Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I | 1 |
| Bergsagel, PL; Gutierrez, NC; Mateos, MV; Rajkumar, SV; San Miguel, JF | 1 |
| Ludwig, H; Sonneveld, P | 1 |
| Agnelli, L; Bolzoni, M; Bonomini, S; Giuliani, N; Guasco, D; Neri, A; Rizzoli, V; Storti, P; Todoerti, K; Toscani, D | 1 |
| Chim, CS; Choi, PT; Lee, WK | 1 |
| Hildebrandt, GC; Panu, LD; Shahan, JL | 1 |
| Benson, DM; Byrd, JC; Devine, SM; Dunavin, NC; Efebera, YA; Elder, P; Greenfield, C; Heerema, N; Hofmeister, CC; Ketcham, J; Merritt, L; Penza, S; Phillips, GS; Rieser, G; Rose, KS; Wei, L | 1 |
| Chihara, D; Iwama, K; Matsue, K; Nishida, Y; Sugihara, H; Takeuchi, M; Tsuda, K; Ugai, T; Yamakura, M | 1 |
| Dai, L; Gollin, SM; Lentzsch, S; Mapara, MY; Monaghan, SA; Normolle, DP | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Anderson, KC; Bradwin, G; Connell, B; Doyle, M; Ghobrial, I; Hong, F; Lockridge, L; Mitsiades, C; Munshi, N; Richardson, P; Rosovsky, R; Schlossman, R; Soiffer, RJ; Tocco, D; Warren, D; Weller, E | 1 |
| Delforge, M; Dimopoulos, MA; Hájek, R; Kropff, M; Lewis, P; Mei, J; Nixon, A; Palumbo, A; Petrucci, MT; Zhang, J | 1 |
| Alsina, M; Anand, P; Anderson, KC; Baz, R; Bilotti, E; Chen, M; Doss, D; Ghobrial, IM; Jacques, C; Kelley, SL; Larkins, G; Laubach, J; Loughney, N; McBride, L; Munshi, NC; Nardelli, L; Richardson, PG; Schlossman, R; Siegel, D; Sullivan, D; Wear, S; Zaki, MH | 1 |
| Fuchida, S; Haruyama, H; Hatsuse, M; Murakami, S; Okano, A; Shimazaki, C | 1 |
| Alexanian, R; Delasalle, K; Wang, M | 1 |
| Binder, G; Borrello, I; Durie, B; Hussein, M; Khan, Z; Pashos, C | 1 |
| Chen-Kiang, S; Christos, P; Coleman, M; Jayabalan, D; Mark, T; Niesvizky, R; Pearse, R; Pekle, K; Rossi, A; Zafar, F | 1 |
| Ba-Mancini, A; Henk, HJ; Huang, H; Teitelbaum, A | 1 |
| Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST | 1 |
| Siegel, D | 1 |
| Ganesh, N; Senthilkumar, CS | 1 |
| McCarthy, PL | 1 |
| Lonial, S; Miguel, JF | 1 |
| Mina, R; Palumbo, A | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Berry, L; Boe, M; Chesi, M; Del Rosario, G; Du, C; Ebens, A; Friedman, LS; Leif Bergsagel, P; Mariathasan, S; Munugalavadla, V; Slaga, D; Sun, L; Yan, Y | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Bréchignac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Garderet, L; Hennache, B; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Meuleman, N; Michallet, M; Moreau, P; Pegourie, B; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Traulle, C | 1 |
| Anderson, JL; Anderson, KC; Görgün, GT; Hideshima, T; Laubach, J; Maguire, C; Munshi, NC; Raje, N; Richardson, PG; Whitehill, G | 1 |
| Benson, DM | 1 |
| Adel, N; Chen, X; Chimento, D; Chung, DJ; Comenzo, R; Giralt, S; Hassoun, H; Landau, H; Lendvai, N; Lesokhin, A; Pozotrigo, M; Reich, L; Riedel, E | 1 |
| Niu, S; Sheng, Z; Wang, H; Xu, J; Yu, J; Zou, Y | 1 |
| Anderson, KC; Balinski, K; Catley, LP; Chauhan, D; Davies, F; Deocampo, R; Doss, D; Freeman, A; Hideshima, T; Kelly, K; LeBlanc, R; McKenney, M; Mechlowicz, J; Mitsiades, C; Rich, R; Richardson, PG; Ryoo, JJ; Schlossman, RL; Weller, E; Zeldis, J | 1 |
| Barlogie, B; Shaughnessy, J; Tricot, G; Zangari, M | 1 |
| Anderson, KC | 7 |
| Mehta, J; Singhal, S | 2 |
| Hattori, Y | 1 |
| Barlogie, B | 1 |
| Bartlett, JB; Dalgleish, AG; Dredge, K | 1 |
| Gibson, AD; Klem, J; Price, N; Reddy, GK | 1 |
| Anderson, K; Richardson, P | 1 |
| Anderson, KC; Antin, JH; Chauhan, D; Hideshima, T; Ishitsuka, K; Kumar, S; Le Gouill, S; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, P; Stirling, DI | 1 |
| Akman, HO; Batuman, OA; Berenson, JR; Braunstein, M; Chen, L; Dai, K; Hussain, MM; Klueppelberg, U; Maroney, J; Norin, AJ; Ozçelik, T; Smith, EL; Vakil, V; Zhang, H | 1 |
| Jung, W; Schroers, R; Zettl, F | 1 |
| Bauters, F; Berthon, C; Facon, T; Guieze, R; Kuhnovsky, F; Leleu, X; Micol, JB; Moreau, AS; Terriou, L; Yakoub-Agha, I | 1 |
| Knight, R | 1 |
| Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Kabat, B; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, SJ; Witzig, TE; Zeldenrust, SR | 1 |
| Teo, SK | 1 |
| Bartlett, JB; Stirling, D; Tozer, A; Zeldis, JB | 1 |
| Harousseau, JL; Moreau, P | 1 |
| Elice, F; Tricot, G; Zangari, M | 1 |
| Crane, E; List, A | 1 |
| Anderson, KC; Prince, HM | 1 |
| Greipp, P | 1 |
| Hussein, MA | 1 |
| Anderson, KC; Bae, J; Breitkreutz, I; Catley, L; Chauhan, D; Coffey, R; Grewal, IS; Hideshima, T; Li, XF; Munshi, NC; Podar, K; Richardson, P; Schlossman, R; Song, W; Tai, YT; Treon, SP | 1 |
| Hammond, JM; Maier, SK | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG | 1 |
| Murakami, H | 1 |
| Badros, A; Deng, A; Gaspari, A; Harvey, V; Junkins-Hopkins, JM; Oghilikhan, M; Samuels, A; Sina, B; Strobel, D | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Kaufman, JL; Lonial, S; Sinha, R | 1 |
| Hussein, MA; Srkalovic, JG; Suppiah, R | 1 |
| Coiteux, V; Facon, T; Leleu, X | 1 |
| Chang, DH; Dhodapkar, MV; Hassoun, H; Jagannath, S; Klimek, V; Liu, N; Mazumder, A; Nimer, SD | 1 |
| Kyle, RA; Vincent Rajkumar, S | 1 |
| DeLap, RJ; Knight, R; Zeldis, JB | 1 |
| Hess, U | 1 |
| Blood, E; Rajkumar, SV | 1 |
| Kumar, S; Rajkumar, SV | 1 |
| Barlogie, B; Crowley, J; Durie, BG; Hussein, MA; McCoy, J; Zonder, JA | 1 |
| Hussein, MA; Kalmadi, SR | 1 |
| Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J | 1 |
| Boccadoro, M; Palumbo, A; Rodeghiero, F; Rus, C; Zeldis, JB | 1 |
| Davies, MJ | 1 |
| Barrick, M | 1 |
| Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG | 2 |
| Doss, DS | 1 |
| Moreau, P | 1 |
| Andresen, S; Baz, R; Brand, C; Bruening, K; Choueiri, TK; Ellis, Y; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Knight, R; Reed, J; Srkalovic, G; Walker, E; Zeldis, J | 1 |
| Jagannath, S; Mazumder, A | 1 |
| Anderson, KC; Hideshima, T; Raje, N | 1 |
| Okamoto, S | 1 |
| Davis, MD; Dispenzieri, A; Rajkumar, SV; Sviggum, HP | 1 |
| Kenealy, M; Prince, HM | 1 |
| Zangari, M | 1 |
| Angelotta, C; Bennett, CL; Evens, AM; Raisch, DW; Richardson, P; Yarnold, PR; Zonder, JA | 1 |
| Ribatti, D; Vacca, A | 1 |
| Hirsh, J | 1 |
| Barlogie, B; Colla, S; Epstein, J; Shaughnessy, JD; Stephens, O; Wu, X; Xiong, W; Xu, H; Yaccoby, S; Zhan, F | 1 |
| Baz, R; Kalmadi, S; Mahindra, A | 1 |
| Anderson, KC; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Richardson, P; Schlossman, R | 1 |
| Davies, FE; Jenner, M; Morgan, GJ; Phekoo, KJ; Schey, SA; Srikanth, M; Wu, P | 1 |
| Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL | 1 |
| Anderson, KC; Burger, P; Chauhan, D; Fulciniti, M; Ghobrial, IM; Hideshima, T; Leiba, M; Li, XF; Morrison, A; Munshi, NC; Podar, K; Richardson, P; Rumizen, M; Song, W; Tai, YT; Tassone, P | 1 |
| Hulin, C | 1 |
| Chanan-Khan, AA; Lee, K | 1 |
| Buadi, FK; Dispenzieri, A; Fonseca, R; Gastineau, DA; Gertz, MA; Hayman, SR; Kumar, S; Lacy, MQ; Litzow, MR; Rajkumar, SV; Roy, V | 1 |
| Anderson, K; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
| Davis-Lorton, M; Hindenburg, A; Kujawa, J; Phillips, J | 1 |
| Fassas, AB; Tricot, G | 1 |
| Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Jalbrzikowski, J; Jayabalan, D; Lent, R; Leonard, JP; Mark, T; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Zafar, F | 1 |
| Bensinger, W | 1 |
| Anderson, KC; Ghobrial, IM; Ghobrial, J; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Moreau, AS; Richardson, P; Roccaro, A; Schlossman, R | 1 |
| Shah, SR; Tran, TM | 1 |
| Tariman, JD | 1 |
| Rao, KV | 1 |
| Anderson, KC; Breitkreutz, I; Raab, MS | 1 |
| Ambrosini, MT; Boccadoro, M; Bringhen, S; Ciccone, G; Corradini, P; Crippa, C; Di Raimondo, F; Falco, P; Falcone, A; Foà, R; Gay, F; Giuliani, N; Knight, R; Musto, P; Omedè, P; Palumbo, A; Petrucci, MT; Zeldis, JB | 1 |
| Snively, A | 1 |
| Amen, K | 1 |
| McGee, L | 1 |
| Oestreicher, P | 1 |
| Alatakis, S; Bishton, MJ; Januszewicz, H; Liew, MS; Prince, HM | 1 |
| Anderson, KC; Hayden, PJ; Mitsiades, CS; Richardson, PG | 1 |
| Bergsagel, PL; Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Hayman, SR; Kabat, B; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Russell, SJ; Stewart, AK; Witzig, TE; Zeldenrust, SR | 1 |
| Ganser, A; Peest, D | 1 |
| Dammacco, F; Merchionne, F; Perosa, F | 1 |
| Bagchi, S | 1 |
| Browne, R; Chen, J; Hussain, S; Parekh, S | 1 |
| Chen-Kiang, S; Cho, HJ; Christos, PJ; Coleman, M; Ely, S; Furst, JR; Harpel, J; Jalbrzikowski, J; Jayabalan, DS; Larow, A; Lent, R; Leonard, JP; Mark, T; Mathew, S; Mazumdar, M; Naib, T; Niesvizky, R; Pearse, RN; Pekle, K; Schuster, MW; Shore, T; Tepler, J; Zafar, F | 1 |
| Dimopoulos, MA; Kastritis, E; Mitsiades, CS; Richardson, PG | 1 |
| Abonour, R; Alsina, M; Badros, A; Comenzo, R; Durie, B; Giralt, S; Hussein, M; Jakubowiak, A; Lonial, S; Mehta, J; Munshi, NC; Niesvizky, R; Orlowski, R; Siegel, D; Singhal, S; Stadtmauer, EA; Vescio, R; Vesole, DH; Wang, M; Zangari, M | 1 |
| Anderson, K; Chauhan, D; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, P; Schlossman, R | 1 |
| Attal, M; Corso, A; Dimopoulos, M; Dmoszynska, A; Facon, T; Foà, R; Harousseau, JL; Hellmann, A; Knight, RD; Masliak, Z; Olesnyckyj, M; Patin, J; Prince, HM; San Miguel, J; Spencer, A; Yu, Z; Zeldis, JB | 1 |
| Belch, A; Borrello, I; Chanan-Khan, AA; Chen, C; Knight, RD; Lonial, S; Niesvizky, R; Olesnyckyj, M; Patin, J; Rajkumar, SV; Siegel, D; Stadtmauer, EA; Wang, M; Weber, DM; Yu, Z; Zeldis, JB | 1 |
| List, AF | 1 |
| Jagannath, S; Kaufman, J; Lonial, S; Mazumder, A; Niesvizky, R; Vesole, D | 1 |
| Faiman, B | 1 |
| Wiley, KE | 1 |
| Dimopoulos, M; Kastritis, E | 1 |
| Christos, P; Coleman, M; De Sancho, M; Furst, J; Jalbrzikowski, J; Jayabalan, D; Leonard, J; Mark, T; Martínez-Baños, D; Mazumdar, M; Niesvizky, R; Pearse, R; Pekle, K; Zafar, F | 1 |
| Colado, E; García-Sanz, R; Mateos, MV; Olazábal, J; San-Miguel, J | 1 |
| Handa, H; Murakami, H; Saitoh, T | 1 |
| Chou, T | 1 |
| Shimazaki, C | 1 |
| Takatoku, M | 1 |
| Richards, TA; Thomas, SK; Weber, DM | 1 |
| Decaudin, D; Kirova, YM; Marchand, V; Servois, V | 1 |
| Miwa, A | 1 |
| Anderson, KC; Attal, M; Barlogie, B; Belch, A; Bladé, J; Boccadoro, M; Bringhen, S; Cavo, M; Dimopoulos, MA; Durie, BG; Harousseau, J; Hussein, MA; Joshua, D; Knop, S; Kyle, R; Lonial, S; Ludwig, H; Morgan, GJ; Niesvizky, R; Orlowski, RZ; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Shimizu, K; Sonneveld, P; Vesole, D; von Lilienfeld-Toal, M; Waage, A; Weber, D; Westin, J; Zangari, M; Zonder, JA | 1 |
| Davies, FE; Morgan, GJ; Srikanth, M | 1 |
| Ambinder, RF; Barber, JP; Borrello, I; Brennan, S; Huff, CA; Jones, RJ; Lin, L; Matsui, W; McNiece, I; Peacock, C; Smith, BD; Wang, Q; Watkins, DN | 1 |
| Bladé, J; Cibeira, MT; Cid, MC; Filella, X; Lozano, E; Rosiñol, L; Rozman, M; Segarra, M | 1 |
| Bergsagel, PL; Boesiger, J; Cabou, S; Dueck, A; Ehlenbeck, C; Fonseca, R; Leis, JF; Paripati, H; Pirooz, N; Reeder, C; Slack, J; Stewart, AK; Torloni, AS; Zepeda, VJ | 1 |
| Drach, J; Einsele, H; Miguel, JS; Moreau, P; Morgan, G; Palumbo, A; Sonneveld, P | 1 |
| Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV | 1 |
| Chanan-Khan, AA; Cheson, BD | 1 |
| Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Gertz, MA; Hayman, SR; Kumar, SK; Lacy, MQ; Litzow, MR; Rajkumar, SV | 1 |
| Gertz, MA | 1 |
| Anderson, KC; Boccadoro, M; Palumbo, A; Raje, N; Vallet, S | 1 |
| Batts, ED; Hegerfeldt, Y; Lazarus, HM; Sanchorawala, V | 1 |
| Armoiry, X; Aulagner, G; Facon, T | 1 |
431 review(s) available for lenalidomide and Multiple Myeloma
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.
Topics: Disease Progression; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Quality of Life; Smoldering Multiple Myeloma | 2021 |
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Treatment Outcome | 2021 |
Novel Cell and Immune Engagers in Optimizing Tumor- Specific Immunity Post-Autologous Transplantation in Multiple Myeloma.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Transplantation, Autologous; Tumor Microenvironment | 2022 |
Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Treatment Outcome | 2021 |
Current Treatment Approaches to Newly Diagnosed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous | 2021 |
Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local | 2021 |
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
Topics: Anticoagulants; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Venous Thromboembolism | 2022 |
The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Transplantation, Autologous | 2022 |
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Proteasome Inhibitors | 2022 |
Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2022 |
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Treatment Outcome | 2022 |
Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma - case series and literature review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local | 2022 |
A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Transplantation, Autologous | 2022 |
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Topics: Chromosome Aberrations; Cytogenetic Analysis; Cytogenetics; Humans; Lenalidomide; Multiple Myeloma; Prognosis | 2022 |
Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oligopeptides | 2022 |
Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML.
Topics: Bortezomib; Deubiquitinating Enzymes; Drug Discovery; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Proteasome Endopeptidase Complex; Thalidomide; Ubiquitin | 2022 |
Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis | 2022 |
Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous | 2022 |
Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis.
Topics: Humans; Lenalidomide; Medication Adherence; Melphalan; Multiple Myeloma; Panobinostat; Pharmaceutical Preparations; Thalidomide | 2022 |
Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2022 |
What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Salvage Therapy; Thalidomide | 2022 |
Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; United States | 2022 |
Smoldering multiple myeloma current treatment algorithms.
Topics: Algorithms; Biological Products; Disease Progression; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Paraproteinemias; Smoldering Multiple Myeloma | 2022 |
Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Glycine; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide | 2022 |
No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Quality of Life | 2023 |
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Propensity Score | 2023 |
Brain Abscesses Caused by Nocardia farcinica in a 44-Year Old Woman with Multiple Myeloma: A Rare Case and Review of the Literature.
Topics: Adult; Amikacin; Antineoplastic Agents; Bortezomib; Brain Abscess; Female; Humans; Immunoglobulin G; Lenalidomide; Meropenem; Multiple Myeloma; Nocardia; Nocardia Infections; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.
Topics: Humans; Immunologic Factors; Immunomodulating Agents; Lenalidomide; Lymphoma, B-Cell; Multiple Myeloma; Tumor Microenvironment | 2022 |
Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis.
Topics: Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Transplantation, Autologous | 2022 |
Iatrogenic systemic lymphedema following multiple myeloma treatment.
Topics: Bortezomib; Humans; Iatrogenic Disease; Lenalidomide; Lymphedema; Male; Multiple Myeloma | 2022 |
Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Observational Studies as Topic; Randomized Controlled Trials as Topic; Systematic Reviews as Topic | 2023 |
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Chromosome Aberrations; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Progression-Free Survival | 2023 |
Coexistence of primary mediastinal MALT lymphoma and multiple myeloma like POEMS syndrome: A case report and literature review.
Topics: Bortezomib; Humans; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; POEMS Syndrome; Rituximab; Thymus Neoplasms | 2023 |
Lenalidomide Desensitization for Delayed Cutaneous Reaction: A Case Series and Review of the Literature.
Topics: Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Skin; Transplantation, Autologous | 2023 |
CHEMOTHERAPY-DRIVEN GUT DYSBIOSIS IN PATIENTS WITH MULTIPLE MYELOMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dysbiosis; Humans; Lenalidomide; Multiple Myeloma | 2022 |
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Black People; Bortezomib; Dexamethasone; Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation | 2023 |
Plasma cell myeloma initially diagnosed as light-chain deposition disease on liver biopsy: A case report and literature review.
Topics: Biopsy; Bortezomib; COVID-19; Dexamethasone; Hepatomegaly; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Liver Diseases; Male; Middle Aged; Multiple Myeloma | 2023 |
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunomodulation; Lenalidomide; Multiple Myeloma | 2023 |
Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis | 2023 |
A Meta-Analysis of the Efficacy of Pomalidomide-Based Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma After Lenalidomide Exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
[Updated treatment strategy for transplant-eligible multiple myeloma: current status and future perspectives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Transplantation, Autologous | 2023 |
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.
Topics: Antibodies, Bispecific; Bortezomib; Humans; Immunotherapy; Immunotherapy, Adoptive; Lenalidomide; Multiple Myeloma; Quality of Life | 2023 |
The role of JAK inhibitors in multiple myeloma.
Topics: Dexamethasone; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Methylprednisolone; Multiple Myeloma; Neoplasm Proteins; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2019 |
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Network Meta-Analysis; Thalidomide; Treatment Outcome | 2020 |
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Randomized Controlled Trials as Topic; Thalidomide | 2019 |
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Marrow; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Neoplasms, Second Primary; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Thalidomide | 2019 |
Limited treatment options in refractory multiple myeloma: promising therapeutic developments.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Immunologic Factors; Immunotherapy; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors | 2020 |
Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Anticoagulants; Dexamethasone; Humans; Incidence; Lenalidomide; Multiple Myeloma; Venous Thromboembolism | 2020 |
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Recurrence; Survival Analysis; Thalidomide | 2020 |
Second malignancies in multiple myeloma; emerging patterns and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Neoplasms, Second Primary; Risk Factors; Thalidomide; Transplantation, Autologous | 2020 |
The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Risk Factors; Survival Analysis; Thalidomide; Transplantation, Autologous | 2020 |
Modern treatments and future directions for newly diagnosed multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Survival Analysis; Thalidomide; Transplantation, Autologous | 2020 |
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Disease Progression; Drug Administration Schedule; Early Detection of Cancer; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Randomized Controlled Trials as Topic; Smoldering Multiple Myeloma; Survival Analysis | 2020 |
Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Costs; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2020 |
Developments in consolidation and maintenance strategies in post-remission multiple myeloma.
Topics: Consolidation Chemotherapy; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Survival Rate; Transplantation, Autologous | 2020 |
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.
Topics: Autografts; Humans; Lenalidomide; Multiple Myeloma; Patient Selection; Practice Guidelines as Topic; Stem Cell Transplantation; Time Factors | 2020 |
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.
Topics: Aged; Antibodies, Monoclonal; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma | 2020 |
Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Humans; Lenalidomide; Multiple Myeloma; Treatment Outcome | 2020 |
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment.
Topics: Combined Modality Therapy; Cost-Benefit Analysis; Health Care Costs; Health Resources; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Netherlands; Patient Acceptance of Health Care; Postoperative Care; Public Health Surveillance; Quality of Life; Randomized Controlled Trials as Topic; Transplantation, Autologous; Treatment Outcome | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Cytogenetic Analysis; Fatal Outcome; High-Throughput Nucleotide Sequencing; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Stem Cell Transplantation | 2020 |
Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Progression-Free Survival; Proteasome Inhibitors; Risk Assessment; Risk Factors; Stem Cell Transplantation; Time Factors | 2021 |
Mechanisms of lenalidomide sensitivity and resistance.
Topics: Adaptor Proteins, Signal Transducing; Anemia, Macrocytic; Angiogenesis Inhibitors; Antineoplastic Agents; Autophagy; Cell Differentiation; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytokines; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Megakaryocytes; Multiple Myeloma; Neoplasm Proteins; Neovascularization, Pathologic; Phosphoprotein Phosphatases; Ubiquitin-Protein Ligases | 2020 |
Isatuximab for the treatment of relapsed/refractory multiple myeloma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Treatment Outcome | 2020 |
Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature.
Topics: Aged; Factor VIII; Hemophilia A; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Thalidomide | 2020 |
Sequencing multiple myeloma therapies with and after antibody therapies.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2020 |
Should all newly diagnosed MM patients receive CD38 antibody-based treatment?
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Melphalan; Membrane Glycoproteins; Multiple Myeloma; Neoplasm Proteins; Thalidomide | 2020 |
Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Proteasome Inhibitors; Treatment Outcome | 2021 |
Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bortezomib; Consensus; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; New Zealand; Practice Guidelines as Topic; Thalidomide | 2020 |
Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Network Meta-Analysis; Progression-Free Survival; Recurrence | 2021 |
Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Ikaros Transcription Factor; Immunity; Immunomodulation; Lenalidomide; Lymphocytes; Mice; Multiple Myeloma; Thalidomide | 2021 |
The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Bortezomib; Drug Therapy, Combination; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; NF-kappa B; Ubiquitin-Protein Ligases | 2021 |
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Disease Management; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasmacytoma; Prognosis; Transplantation, Autologous | 2021 |
Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bortezomib; Control Groups; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Progression-Free Survival; Quality Control; Randomized Controlled Trials as Topic; Remission Induction; United States | 2021 |
Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors | 2021 |
A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Progression-Free Survival; Randomized Controlled Trials as Topic | 2021 |
Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.
Topics: B-Cell Maturation Antigen; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin D; Immunologic Factors; Immunotherapy, Adoptive; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Receptors, Chimeric Antigen; Recurrence; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2022 |
Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Neoplasms; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
The efficacy and safety of lenalidomide in the treatment of multiple myeloma patients after allo-hematopoietic stem-cell transplantation: a systematic review and meta-analysis.
Topics: Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Homologous; Treatment Outcome | 2021 |
Posttransplant maintenance therapy in multiple myeloma: the changing landscape.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Molecular Targeted Therapy; Multiple Myeloma; Postoperative Care; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
Two cases of permanent indwelling catheter for long-term administration of intrapleural chemotherapy.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Catheters, Indwelling; Dexamethasone; Drainage; Fatal Outcome; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Pleural Effusion, Malignant; Rituximab; Thalidomide; Thoracentesis | 2017 |
Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Incidence; Infections; Lenalidomide; Mortality; Multiple Myeloma; Publication Bias; Risk; Severity of Illness Index; Thalidomide | 2017 |
Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide | 2017 |
Daratumumab for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Immunotherapy; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Risk; Risk Assessment; Thalidomide; Thromboembolism | 2017 |
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Glycine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Oligopeptides; Panobinostat; Proteasome Inhibitors; Recurrence; Thalidomide | 2017 |
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Factors; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
The Clinical Pharmacology of Elotuzumab.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dexamethasone; Drug Interactions; Humans; Lenalidomide; Multiple Myeloma | 2018 |
Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Topics: Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2017 |
[Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2017 |
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Technology Assessment, Biomedical; Thalidomide | 2018 |
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Recurrence; Thalidomide; Thrombocytopenia | 2017 |
Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prospective Studies; Proteasome Inhibitors; Recurrence; Survival Analysis; Thalidomide | 2018 |
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Transplantation, Autologous; Vorinostat | 2017 |
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Boron Compounds; Dexamethasone; Glycine; Half-Life; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Salvage Therapy; Thalidomide; Tissue Distribution | 2018 |
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drugs, Investigational; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Neoadjuvant Therapy; Network Meta-Analysis; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2018 |
Ixazomib in the management of relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials as Topic; Dexamethasone; Disease Management; Glycine; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Recurrence | 2018 |
Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Randomized Controlled Trials as Topic | 2018 |
Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Topics: Drug Therapy, Combination; Evidence-Based Medicine; Humans; Immunocompromised Host; Immunologic Factors; Immunosuppressive Agents; Incidence; Induction Chemotherapy; Lenalidomide; Middle Aged; Multiple Myeloma; Observational Studies as Topic; Opportunistic Infections; Randomized Controlled Trials as Topic; Risk; Thalidomide | 2018 |
Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cost-Benefit Analysis; Dexamethasone; Disease-Free Survival; Glycine; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Proteasome Inhibitors; Quality-Adjusted Life Years; Technology Assessment, Biomedical | 2018 |
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunotherapy; Lenalidomide; Membrane Glycoproteins; Multiple Myeloma; Neoplasm Proteins; Signaling Lymphocytic Activation Molecule Family | 2018 |
Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Treatment Outcome | 2018 |
[Research and Applications Progress of Lenalidomide in Relapsed / Refractory Blood System Diseases -Review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Thalidomide | 2018 |
Immunomodulatory effects of CD38-targeting antibodies.
Topics: Adenosine; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes, Regulatory; B7-H1 Antigen; Humans; Immunologic Factors; Lenalidomide; Membrane Glycoproteins; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Programmed Cell Death 1 Receptor; T-Lymphocytes, Regulatory; Thalidomide | 2018 |
Optimizing therapy in bortezomib-exposed patients with multiple myeloma.
Topics: Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2018 |
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Multiple Myeloma; Venous Thromboembolism | 2018 |
Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Proteasome Inhibitors; Survival Rate; Treatment Outcome | 2017 |
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trial
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2018 |
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Network Meta-Analysis; Randomized Controlled Trials as Topic | 2018 |
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Programmed Cell Death 1 Receptor; Progression-Free Survival; Quality of Life; Recurrence; Treatment Failure | 2018 |
Ixazomib for the treatment of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors | 2018 |
[Daratumumab for multiple myeloma].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2018 |
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; GPI-Linked Proteins; Humans; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Macrophages; Mice; Multiple Myeloma; Natural Cytotoxicity Triggering Receptor 1; NK Cell Lectin-Like Receptor Subfamily K; Phagocytosis; Plasma Cells; Receptors, IgG; Signaling Lymphocytic Activation Molecule Family; Transcription Factors | 2018 |
A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Progression-Free Survival; Randomized Controlled Trials as Topic; Transplantation, Autologous | 2019 |
[First-line treatment of multiple myeloma].
Topics: Antineoplastic Agents; Bortezomib; Germany; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2019 |
Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Network Meta-Analysis; Prednisone; Thalidomide; Treatment Outcome | 2019 |
Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?
Topics: Autografts; Disease-Free Survival; Humans; Lenalidomide; Meta-Analysis as Topic; Multiple Myeloma; Quality of Life; Randomized Controlled Trials as Topic; Transplantation, Autologous | 2019 |
Risk adapted post-transplant maintenance in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma.
Topics: Cerebrospinal Fluid; Female; Humans; Immunologic Factors; Lenalidomide; Leukoencephalopathy, Progressive Multifocal; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Stem Cell Transplantation | 2019 |
Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Geriatric Assessment; Humans; Lenalidomide; Multiple Myeloma; Outcome Assessment, Health Care; Survival Analysis | 2019 |
[Immunomodulator drugs for the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2018 |
Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2019 |
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.
Topics: Humans; Lenalidomide; Multiple Myeloma; Pharmaceutical Preparations; Progression-Free Survival; Proportional Hazards Models | 2020 |
Cost-effectiveness of lenalidomide plus low-dose dexamethasone for newly diagnosed multiple myeloma patients ineligible for stem cell transplantation in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; China; Combined Modality Therapy; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Observational Studies as Topic; Quality-Adjusted Life Years; Stem Cell Transplantation; Thalidomide | 2019 |
Current approaches for the treatment of multiple myeloma.
Topics: Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thalidomide; Transplantation, Autologous | 2013 |
Continuous treatment with new agents for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide | 2013 |
Diagnosis and therapy of multiple myeloma.
Topics: Age Factors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide | 2013 |
Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
Topics: Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstitial; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
[Lenalidomide maintenance therapy in patients with multiple myeloma].
Topics: Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide | 2013 |
Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.
Topics: Angiogenesis Inhibitors; Exanthema; Humans; Incidence; Lenalidomide; Multiple Myeloma; Thalidomide | 2013 |
[Multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Prognosis; Pyrazines; Thalidomide | 2013 |
Management of double-refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Retreatment; Thalidomide | 2013 |
Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Doxorubicin; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2014 |
Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Odds Ratio; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2014 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Initial treatment of transplant candidates with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Medicine; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
New developments in post-transplant maintenance treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Postoperative Period; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Role of consolidation therapy in transplant eligible multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide | 2013 |
Role of consolidation/maintenance therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Initial treatment of transplant-ineligible patients in multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chromosome Aberrations; Glucocorticoids; Humans; Immunophenotyping; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Quality of Life; Remission Induction; Thalidomide | 2014 |
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Autografts; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Remission Induction; Thalidomide; Time Factors; Transplantation Conditioning | 2013 |
Update on second primary malignancies in multiple myeloma: a focused review.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Risk; Thalidomide | 2014 |
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
Topics: Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2014 |
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide | 2014 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Microenvironment | 2014 |
Lenalidomide.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Thalidomide | 2014 |
Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Double-Blind Method; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2014 |
Current challenges in the management of patients with relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2011 |
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; TOR Serine-Threonine Kinases | 2011 |
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Maintenance therapy for multiple myeloma.
Topics: Angiogenesis Inhibitors; Combined Modality Therapy; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous | 2014 |
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Risk Assessment; Thalidomide; Translocation, Genetic | 2014 |
Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide | 2014 |
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Humans; Hypercalcemia; Kidney Diseases; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2014 |
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning | 2014 |
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Targeting the bone marrow microenvironment in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Microenvironment | 2015 |
Managing multiple myeloma in the over 70s: a review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Density Conservation Agents; Bortezomib; Comorbidity; Cyclophosphamide; Dexamethasone; Diphosphonates; Fractures, Compression; Geriatric Assessment; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Palliative Care; Stem Cell Transplantation; Thalidomide; Vertebroplasty | 2015 |
Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2016 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide | 2015 |
Management of relapsed multiple myeloma after autologous stem cell transplant.
Topics: Autografts; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Stem Cell Transplantation; Thalidomide | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
Lenalidomide in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation; Survival Rate; Thalidomide | 2015 |
Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Thalidomide | 2015 |
Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2015 |
The risk of secondary primary malignancies after therapy for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Incidence; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Recurrence; Retreatment; Risk; Risk Assessment; Risk Factors; Thalidomide; Treatment Outcome | 2015 |
Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
Topics: Biomarkers; Cytogenetic Analysis; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide; Tumor Microenvironment | 2015 |
Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2015 |
[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisolone; Recurrence; Thalidomide | 2015 |
Treatment for patients with newly diagnosed multiple myeloma in 2015.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Precision Medicine; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2015 |
An update on the use of lenalidomide for the treatment of multiple myeloma.
Topics: Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2015 |
Practical Management of Lenalidomide-Related Rash.
Topics: Exanthema; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Thalidomide | 2015 |
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Topics: Bone and Bones; Bone Marrow; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Tumor Microenvironment | 2016 |
The novel mechanism of lenalidomide activity.
Topics: Animals; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Proteasome Endopeptidase Complex; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2015 |
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literat
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Osteogenesis; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Thalidomide | 2015 |
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond.
Topics: Angiogenesis Inhibitors; Animals; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Substrate Specificity; Thalidomide; Transcription, Genetic; Ubiquitination | 2015 |
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Topics: Disease-Free Survival; Humans; Immunosuppressive Agents; Infections; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Survival Analysis; Survival Rate; Thalidomide; Thromboembolism | 2016 |
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; Salvage Therapy; Thalidomide | 2016 |
Maintenance therapy for multiple myeloma in the era of novel agents.
Topics: Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Flow Cytometry; Hematology; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2015 |
Venous thromboembolism in hematopoietic stem cell transplant recipients.
Topics: Allografts; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Postoperative Complications; Thalidomide; Venous Thromboembolism | 2016 |
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Dexamethasone; Diphosphonates; Disease Progression; Europe; Humans; Immunoglobulin Light Chains; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Risk Factors; Thalidomide; Tumor Burden | 2016 |
Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis.
Topics: Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2016 |
Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Topics: Anti-Inflammatory Agents; Anticoagulants; Aspirin; Dexamethasone; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Risk; Thalidomide; Venous Thromboembolism | 2016 |
Sorafenib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Proliferation; Humans; Lenalidomide; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thalidomide | 2016 |
[Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide | 2015 |
Update of thrombosis in multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis; Warfarin | 2016 |
Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease-Free Survival; Humans; Immunotherapy; Lenalidomide; Multiple Myeloma; Thalidomide | 2016 |
Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Multiple myeloma, immunotherapy and minimal residual disease.
Topics: Antineoplastic Agents; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Humans; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual | 2016 |
The molecular mechanism of thalidomide analogs in hematologic malignancies.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Casein Kinase I; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Interleukin-2; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Peptide Hydrolases; Protein Binding; Proteolysis; Signal Transduction; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2016 |
Is Maintenance Therapy for Everyone?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Disease Management; Humans; Lenalidomide; Maintenance Chemotherapy; Molecular Targeted Therapy; Mortality; Multiple Myeloma; Proportional Hazards Models; Thalidomide; Treatment Outcome | 2016 |
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Treatment Outcome | 2016 |
Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Induction Chemotherapy; Infections; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Randomized Controlled Trials as Topic; Risk; Thalidomide | 2016 |
Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
Topics: Bortezomib; Consolidation Chemotherapy; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2016 |
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Risk Factors; Thalidomide; Thromboembolism; Thrombosis | 2017 |
Current treatments for renal failure due to multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Renal Insufficiency; Thalidomide | 2016 |
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib | 2017 |
Stem Cell Transplantation in Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2017 |
The role of maintenance therapy in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous | 2016 |
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Design; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Complement System Proteins; Cytotoxicity, Immunologic; Humans; Lenalidomide; Multiple Myeloma; Phagocytosis; Thalidomide | 2016 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide | 2017 |
Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Immunotherapy; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2017 |
An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide | 2017 |
Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma.
Topics: Alveolitis, Extrinsic Allergic; Angioedema; Angiogenesis Inhibitors; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Thalidomide; Tomography, X-Ray Computed | 2016 |
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Proteasome Inhibitors; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2017 |
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.
Topics: Animals; B7-H1 Antigen; Disease Progression; Humans; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Programmed Cell Death 1 Receptor; Thalidomide | 2017 |
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Quality of Life; Thalidomide; Venous Thromboembolism | 2017 |
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Topics: Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2017 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia | 2008 |
Maintenance treatment in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2008 |
Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
Topics: Antineoplastic Agents; Blood Coagulation; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myeloma; Platelet Activation; Risk Assessment; Thalidomide; Thrombin; Thrombophilia; Thrombosis; Treatment Outcome; von Willebrand Factor | 2008 |
[Lenalidomide. Treatment of multiple myeloma].
Topics: Antineoplastic Agents; Drug Interactions; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
Pathogenesis and treatment of renal failure in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Lenalidomide and its role in the management of multiple myeloma.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
Frontline treatment of multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome | 2008 |
New drugs in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2008 |
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2009 |
The role of novel drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2008 |
Advances in therapy of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2008 |
Practical considerations for multiple myeloma: an overview of recent data and current options.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide | 2008 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism | 2009 |
Treatment of newly diagnosed myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Clinical Trials as Topic; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Risk; Thalidomide; Translocation, Genetic; Transplantation Conditioning | 2009 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; United Kingdom | 2009 |
Multiple myeloma: epidemiology and therapeutic options.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Medical Oncology; Multiple Myeloma; Patient Care Management; Prognosis; Thalidomide | 2008 |
Diagnosis and the current trends in multiple myeloma therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2008 |
Treatment of multiple myeloma in the targeted therapy era.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning | 2009 |
Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous | 2009 |
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide | 2009 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Genetic Predisposition to Disease; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome | 2009 |
Novel therapies in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2009 |
Lenalidomide in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2009 |
The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Costs; Drug Interactions; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2010 |
Immunomodulatory compounds (IMiDs) in the treatment of multiple myeloma.
Topics: Clinical Trials, Phase III as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2009 |
[New treatment strategies for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Discovery; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide; Vincristine | 2009 |
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Disease Management; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning; Venous Thrombosis | 2009 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning | 2009 |
ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Interferon-alpha; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
New treatments for myeloma.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide | 2010 |
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Decision Making; Decision Trees; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2010 |
New developments in the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide | 2010 |
Lenalidomide in multiple myeloma: current role and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Rate; Thalidomide | 2010 |
[Molecular-targeted therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Drug Delivery Systems; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2010 |
Role of autologous stem cell transplantation in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Patient Selection; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2009 |
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Plasma Cells; Pyrazines; Retreatment; Switzerland; Thalidomide | 2010 |
[The use of lenalidomide in the treatment of multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2010 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism | 2010 |
Multiple myeloma - current issues and controversies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2010 |
Optimising patient outcomes in myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Risk Assessment; Thalidomide; Treatment Outcome | 2010 |
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Transcription, Genetic | 2010 |
Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Dura Mater; Fatal Outcome; Humans; Lenalidomide; Male; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
Cost-effectiveness of lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Thalidomide | 2010 |
Drug-mediated and cellular immunotherapy in multiple myeloma.
Topics: Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; Combined Modality Therapy; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunologic Memory; Immunotherapy; Immunotherapy, Active; Immunotherapy, Adoptive; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Pyrazines; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide; Tumor Escape | 2010 |
Plasma cell leukaemia and other aggressive plasma cell malignancies.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2010 |
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Sweden; Thalidomide | 2010 |
Lenalidomide: a synthetic compound with an evolving role in cancer management.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Treatment Outcome | 2010 |
Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Thromboembolism; Warfarin | 2011 |
[Current treatment strategies for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide | 2010 |
Rare bladder tumors: caveat emptor.
Topics: Abnormalities, Drug-Induced; Disease Progression; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Pregnancy; Radiotherapy; Salvage Therapy; Thalidomide; Urinary Bladder; Urinary Bladder Neoplasms | 2010 |
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Plasma cell leukemia: concepts and management.
Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasms, Second Primary; Palliative Care; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Lenalidomide mode of action: linking bench and clinical findings.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Secondary Prevention; Thalidomide | 2010 |
Ten years of improvement in the management of multiple myeloma: 2000-2010.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Clinical impact of chromosomal aberrations in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Thrombosis in multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism | 2010 |
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
Topics: Cohort Studies; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thromboembolism | 2011 |
Management of older patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
New immunomodulatory drugs in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neutropenia; Thalidomide; Treatment Outcome | 2011 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide | 2011 |
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Treatment options for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Medical Oncology; Models, Biological; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2011 |
Lenalidomide - current understanding of mechanistic properties.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Communication; Cell Proliferation; Cytokines; Humans; Immunologic Factors; Lenalidomide; Lymphocyte Activation; Mice; Multiple Myeloma; Rats; Signal Transduction; Stromal Cells; T-Lymphocytes; Thalidomide | 2011 |
Management of the adverse effects of lenalidomide in multiple myeloma.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Dose-Response Relationship, Drug; Gastrointestinal Diseases; Humans; Infections; Lenalidomide; Multiple Myeloma; Neutropenia; Practice Guidelines as Topic; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome; Venous Thromboembolism | 2011 |
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Congresses as Topic; Disease-Free Survival; Europe; Evidence-Based Practice; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide | 2011 |
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
Therapy of relapsed and refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lactones; Lenalidomide; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Secondary Prevention; Thalidomide | 2011 |
[New insights in the treatment of myeloma with renal failure].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Fluid Therapy; Humans; Hypercalcemia; Immunoglobulin Light Chains; Kidney Failure, Chronic; Lenalidomide; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide | 2011 |
Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Multiple Myeloma; Prednisolone; Stevens-Johnson Syndrome; Thalidomide | 2012 |
Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous | 2012 |
Genomic stratification of multiple myeloma treated with novel agents.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Genomics; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2012 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia | 2011 |
[Current treatment strategies with novel agents for multiple myeloma].
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous | 2011 |
Continuous treatment in multiple myeloma - ready for prime time?
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Secondary Prevention; Thalidomide | 2011 |
Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Norway; Scotland; Sweden; Thalidomide | 2011 |
[Treatment of multiple myeloma by immunomodulatory drugs].
Topics: Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Thalidomide | 2011 |
Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2011 |
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Topics: Administration, Oral; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Product Surveillance, Postmarketing; Renal Insufficiency; Thalidomide; Time Factors | 2012 |
Lenalidomide in multiple myeloma: current experimental and clinical data.
Topics: Animals; Antineoplastic Agents; Apoptosis; Clinical Trials as Topic; Humans; Immune System; Lenalidomide; Medical Oncology; Models, Biological; Multiple Myeloma; Osteoclasts; Thalidomide; Treatment Outcome | 2012 |
Clinical experience with thalidomide and lenalidomide in multiple myeloma.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytokines; Down-Regulation; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome | 2012 |
[Thrombotic complications following the treatment of multiple myeloma with new agents].
Topics: Anthracyclines; Anticoagulants; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Thrombosis | 2011 |
Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Thalidomide | 2012 |
Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Thalidomide | 2012 |
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Risk Assessment; Thalidomide | 2012 |
Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide; Treatment Outcome | 2012 |
Latest advances and current challenges in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Thalidomide | 2012 |
[Lenalidomide in hematological malignancies---review].
Topics: Angiogenesis Inhibitors; Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2012 |
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Practice; Hematology; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Grading; Practice Guidelines as Topic; Pyrazines; Societies, Medical; Thalidomide | 2012 |
Thrombosis in multiple myeloma (MM).
Topics: Anthracyclines; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Thalidomide; Thrombosis | 2012 |
European perspective on multiple myeloma treatment strategies: update following recent congresses.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Congresses as Topic; Europe; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prospective Studies; Renal Insufficiency; Retrospective Studies; Thalidomide | 2012 |
Lenalidomide in multiple myeloma: Current status and future potential.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |
(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2012 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Thalidomide | 2012 |
Novel lenalidomide-based combinations for treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2013 |
Lenalidomide maintenance for multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prognosis; Randomized Controlled Trials as Topic; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome; Young Adult | 2012 |
Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Thalidomide; Venous Thromboembolism | 2012 |
Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |
Multiple myeloma: improved outcomes with new therapeutic approaches.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Achieving an early myeloma response in patients with kidney impairment.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Glomerular Filtration Rate; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Thalidomide | 2012 |
Fifty years of melphalan use in hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Gene Expression; Humans; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Teratogens; Thalidomide; Ubiquitin-Protein Ligases | 2013 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide | 2012 |
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors | 2012 |
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comprehension; Drug-Related Side Effects and Adverse Reactions; Humans; Kinetics; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
[Successful treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with systemic amyloidosis].
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2012 |
Novel immunomodulatory compounds in multiple myeloma.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Molecular Structure; Multiple Myeloma; Thalidomide | 2013 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Lenalidomide-based combined therapy induced alterations in serum proteins of multiple myeloma patient: a follow-up case report and overview of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Female; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Zoledronic Acid | 2013 |
Induction therapy for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Part II: role of maintenance therapy in transplant-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine | 2013 |
Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Proportional Hazards Models; Thalidomide; Treatment Outcome | 2013 |
High-dose therapy and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gene Expression Profiling; Humans; Interferons; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide | 2002 |
Novel therapies in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2003 |
[Thalidomide treatment in multiple myeloma].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Dexamethasone; Drug Therapy, Combination; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Thalidomide | 2003 |
The role of immunomodulatory drugs in multiple myeloma.
Topics: Adjuvants, Immunologic; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Drug Screening Assays, Antitumor; Female; Humans; Immunotherapy; Lenalidomide; Male; Mice; Mice, Mutant Strains; Mice, Nude; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome | 2003 |
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Protease Inhibitors; Pyrazines; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome; Universities | 2003 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasms; T-Lymphocytes; Thalidomide; Tumor Necrosis Factor-alpha | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide | 2004 |
[Thalidomide: mechanisms of action and new insights in hematology].
Topics: Amyloidosis; Angiogenesis Inhibitors; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Forecasting; Hematologic Diseases; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrence; Thalidomide; Time Factors; Waldenstrom Macroglobulinemia | 2005 |
Clinical update: novel targets in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2004 |
Novel approaches to the management of myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2005 |
IMiDs: a novel class of immunomodulators.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2005 |
Properties of thalidomide and its analogues: implications for anticancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Adhesion Molecules; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Screening Assays, Antitumor; Endothelium, Vascular; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; T-Lymphocyte Subsets; Thalidomide | 2005 |
Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.
Topics: Clinical Trials as Topic; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2005 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Disease-Free Survival; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2005 |
Immunomodulatory drugs in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cytokines; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neovascularization, Physiologic; Thalidomide | 2005 |
Immunomodulatory drugs.
Topics: Humans; Immunosuppressive Agents; Interleukin-12; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Multiple Myeloma; Myelodysplastic Syndromes; Neovascularization, Pathologic; T-Lymphocytes; Thalidomide | 2005 |
Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2005 |
Lenalidomide: patient management strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2005 |
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Interleukin-6; Lenalidomide; Models, Immunological; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide | 2005 |
Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide | 2005 |
Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Topics: Animals; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; MEDLINE; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2006 |
Current therapeutic uses of lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
[New strategy for the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning | 2005 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
Novel treatment approaches for patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drug Design; Heat-Shock Proteins; Histones; Humans; Lenalidomide; Multiple Myeloma; Oncogene Protein v-akt; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Recurrence; Remission Induction; Signal Transduction; Thalidomide | 2006 |
Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma.
Topics: Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
[Prognostic factors and new treatments of multiple myeloma].
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Treatment of multiple myeloma: an emphasis on new developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors | 2006 |
Thalidomide and lenalidomide in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2006 |
Advancing access to myeloma treatment: administration, side effects, and implications for survival.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Health Services Accessibility; Humans; Immunosuppressive Agents; Information Services; Lenalidomide; Multiple Myeloma; Nurse's Role; Oncology Nursing; Patient Education as Topic; Protease Inhibitors; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Survival Rate; Thalidomide | 2006 |
Advances in the treatment of multiple myeloma: a nursing perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protease Inhibitors; Pyrazines; Quality of Life; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
Lenalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Bone Marrow; Clinical Trials as Topic; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Safety; Stem Cell Transplantation; Thalidomide; Tumor Necrosis Factor-alpha | 2006 |
Advances in oral therapy in the treatment of multiple myeloma.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antineoplastic Agents; Dexamethasone; Drug Monitoring; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Nurse's Role; Oncology Nursing; Patient Care Planning; Patient Education as Topic; Quality of Life; Thalidomide; Treatment Outcome | 2006 |
[New drugs for myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Thalidomide and lenalidomide in multiple myeloma.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Remission Induction; Thalidomide | 2006 |
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
[Recent progress in diagnosis of and therapy for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide | 2006 |
Current status of new drugs for the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms; Thalidomide; Thromboembolism | 2006 |
Risk of thrombosis with lenalidomide and its prevention with aspirin.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thrombosis | 2007 |
The emerging role of novel therapies for the treatment of relapsed myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Thalidomide | 2007 |
Lenalidomide: the emerging role of a novel targeted agent in malignancies.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Thalidomide | 2007 |
Emerging drugs in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
[New treatment of multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2007 |
Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Multiple Myeloma; Polyethylene Glycols; Recurrence; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
New drugs for myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2007 |
Tandem transplants in the treatment of multiple myeloma. Pro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
Lenalidomide in myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide | 2007 |
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation.
Topics: Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2007 |
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide | 2007 |
Lenalidomide in myelodysplastic syndrome and multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2007 |
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; Dyspnea; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Nurse's Role; Nursing Assessment; Oncology Nursing; Thalidomide; Thrombocytopenia; Thromboembolism; Treatment Failure | 2007 |
Lenalidomide in the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Drug Approval; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Patient Education as Topic; Thalidomide; United States | 2007 |
Targeted treatments to improve stem cell outcome: old and new drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2007 |
Novel therapies in myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
[Therapy of multiple myeloma: indications and options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden | 2007 |
New therapies in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Management of relapsed and relapsed refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
The treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
Multiple myeloma and treatment-related thromboembolism: oncology nurses' role in prevention, assessment, and diagnosis.
Topics: Antineoplastic Agents; Drug Monitoring; Early Diagnosis; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Compliance; Primary Prevention; Risk Factors; Thalidomide; Thromboembolism | 2007 |
[Diagnosis and management guideline for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Reference Standards; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2007 |
[Development of thalidomide analogs for the treatment of multiple myeloma (MM)].
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Design; Humans; Immunologic Factors; Lenalidomide; Lymphocyte Activation; Multiple Myeloma; T-Lymphocytes; Thalidomide | 2007 |
[Role of stem cell transplantation in treatment of multiple myeloma].
Topics: Age Factors; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Heterologous | 2007 |
[Molecular targeting therapy for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A | 2007 |
Lenalidomide in multiple myeloma.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Thalidomide | 2007 |
[Advances in therapeutic strategies for multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2007 |
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Topics: Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Premedication; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2008 |
An update on drug combinations for treatment of myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2008 |
Lenalidomide: a new therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Thalidomide | 2008 |
Multiple myeloma: novel approaches for relapsed disease.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
Lenalidomide for the treatment of B-cell malignancies.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Waldenstrom Macroglobulinemia | 2008 |
Current therapy of myeloma induced renal failure.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Humans; Immune System; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
Lenalidomide in the treatment of multiple myeloma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
366 trial(s) available for lenalidomide and Multiple Myeloma
| Article | Year |
|---|---|
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate; Thalidomide | 2021 |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2022 |
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Europe; Humans; Lenalidomide; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasm, Residual; Progression-Free Survival; Time Factors; Young Adult | 2021 |
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Smoldering Multiple Myeloma | 2021 |
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Thalidomide | 2021 |
A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Japan; Lenalidomide; Multiple Myeloma | 2022 |
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Progression-Free Survival; Survival Rate | 2021 |
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Progression-Free Survival | 2022 |
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Oligopeptides | 2022 |
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Frailty; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2022 |
Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Cell Maturation Antigen; Dexamethasone; Humans; Lenalidomide; Methylprednisolone; Multiple Myeloma; Nitriles; Prospective Studies; Pyrazoles; Pyrimidines | 2022 |
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; COVID-19 Drug Treatment; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Phenylalanine; SARS-CoV-2; Thalidomide | 2022 |
Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Multiple Myeloma; Prospective Studies | 2022 |
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Proteasome Inhibitors; Thalidomide | 2022 |
Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.
Topics: Antigens, Neoplasm; Autografts; Cancer Vaccines; Dendritic Cells; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; RNA, Messenger; Transplantation, Autologous | 2022 |
Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lenalidomide; Multiple Myeloma; Prospective Studies; Transplantation, Autologous | 2022 |
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment.
Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation Conditioning; Transplantation, Homologous | 2022 |
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Middle Aged; Multiple Myeloma; Prospective Studies | 2022 |
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Plasma Cell; Quality of Life; Thalidomide | 2022 |
All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2022 |
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome | 2022 |
Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2022 |
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma | 2022 |
Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
Topics: Anticoagulants; Bortezomib; Dexamethasone; gamma-Globulins; Humans; Lenalidomide; Multiple Myeloma; Venous Thromboembolism | 2022 |
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2022 |
Topics: Aged; Clinical Trials, Phase III as Topic; Frailty; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Quality of Life; Randomized Controlled Trials as Topic; United Kingdom | 2022 |
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous | 2022 |
Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Leukopenia; Multiple Myeloma; Prospective Studies; Thalidomide | 2022 |
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Imides; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Proteasome Inhibitors | 2022 |
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.
Topics: Humans; Lenalidomide; Middle Aged; Multiple Myeloma | 2022 |
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Survival Analysis | 2023 |
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Smoldering Multiple Myeloma | 2022 |
Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous; Venous Thromboembolism | 2022 |
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous | 2022 |
A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes, Regulatory; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Positron Emission Tomography Computed Tomography; Prospective Studies | 2023 |
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma | 2022 |
Maintenance therapy in multiple myeloma: Two is not always better than one.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Treatment Outcome; Vorinostat | 2023 |
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Vorinostat | 2023 |
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Progression-Free Survival; Stem Cell Transplantation; Transplantation, Autologous | 2023 |
Pharmacokinetic and bioequivalence of lenalidomide in multiple myeloma patients.
Topics: Administration, Oral; Area Under Curve; Biological Availability; Capsules; Cross-Over Studies; Humans; Lenalidomide; Multiple Myeloma; Tablets; Therapeutic Equivalency | 2023 |
Randomized phase II study of weekly carfilzomib 70 mg/m
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Treatment Outcome | 2023 |
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pandemics; Recurrence | 2023 |
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Topics: Antineoplastic Agents, Immunological; B-Cell Maturation Antigen; Drug Resistance, Neoplasm; Humans; Immunotherapy, Adoptive; Lenalidomide; Multiple Myeloma; Neurotoxicity Syndromes; Progression-Free Survival | 2023 |
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous | 2023 |
A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16).
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Cohort Studies; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Dexamethasone; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous | 2023 |
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
Topics: Humans; Lenalidomide; Multiomics; Multiple Myeloma; Proteomics; Tumor Microenvironment | 2023 |
More intensive therapy has a better effect for frail parents with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Frail Elderly; Frailty; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
Topics: Administration, Oral; Antibodies; Antineoplastic Agents; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Recurrence; Ubiquitin-Protein Ligases | 2023 |
Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous | 2023 |
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thrombocytopenia | 2023 |
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Treatment Outcome | 2023 |
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pneumonia | 2023 |
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Frail Elderly; Frailty; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Dexamethasone; Female; HIV Protease Inhibitors; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nelfinavir | 2019 |
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Transplantation Conditioning; Transplantation, Autologous | 2019 |
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Salvage Therapy; Thalidomide | 2019 |
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Thalidomide | 2020 |
Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Survival Rate; Vorinostat | 2020 |
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Progression-Free Survival; Treatment Outcome | 2020 |
Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2020 |
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Gene Expression; Genotype; Humans; Hyperbilirubinemia; Hypoalbuminemia; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Polymorphism, Single Nucleotide; Prospective Studies; Treatment Outcome; Ubiquitin-Protein Ligases | 2019 |
Effect of a Smart Pill Bottle and Pharmacist Intervention on Medication Adherence in Patients with Multiple Myeloma New to Lenalidomide Therapy.
Topics: Aged; Aged, 80 and over; Cost-Benefit Analysis; Drug Packaging; Electrical Equipment and Supplies; Female; Humans; Lenalidomide; Male; Medication Adherence; Middle Aged; Multiple Myeloma; Patient Satisfaction; Pharmaceutical Services; Pharmacists; Pharmacy Technicians; Pilot Projects; Professional Role; Prospective Studies; Reminder Systems; Text Messaging; United States | 2019 |
Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Japan; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; Neutrophils; Oligopeptides; Platelet Count; Progression-Free Survival; Treatment Outcome | 2020 |
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Patient Safety; Receptors, CXCR4; Survival Rate; Treatment Outcome | 2020 |
RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Finland; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Survival Rate | 2019 |
Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Czech Republic; Dexamethasone; Disease-Free Survival; Drug Costs; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Quality-Adjusted Life Years; Registries | 2020 |
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Japan; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Stem Cell Transplantation; Treatment Outcome | 2020 |
The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies | 2020 |
The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma.
Topics: Aged; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Registries; Retrospective Studies; Thalidomide; Thromboembolism | 2020 |
Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Double-Blind Method; Female; Frail Elderly; Frailty; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisolone; Progression-Free Survival | 2020 |
Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma | 2019 |
The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Republic of Korea; Survival Rate | 2020 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Nitriles; Pyrazoles; Pyrimidines; Survival Rate | 2020 |
A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Dexamethasone; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma | 2020 |
Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Treatment Outcome | 2020 |
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2020 |
Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Treatment Outcome | 2020 |
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Thalidomide; Transplantation, Autologous | 2020 |
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Topics: Administration, Intravenous; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Treatment Outcome | 2020 |
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Phenylalanine; Progression-Free Survival; Randomized Controlled Trials as Topic; Recurrence; Thalidomide | 2020 |
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2020 |
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate | 2020 |
Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Survival Rate | 2020 |
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Myocardial Infarction; Pilot Projects; Proof of Concept Study; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Stroke; Thalidomide; Thrombophilia; Venous Thromboembolism; Venous Thrombosis | 2020 |
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Patient Selection; Transplantation, Autologous | 2020 |
Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boron Compounds; Chromosome Aberrations; Dexamethasone; Gene Expression Regulation, Neoplastic; Glycine; Humans; Lenalidomide; Multiple Myeloma; Mutation; NF-kappa B; Prognosis; Progression-Free Survival; Signal Transduction; Transcriptome; Treatment Outcome | 2020 |
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2020 |
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2020 |
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Progression-Free Survival; Risk Assessment; Thalidomide; Thrombophilia; Thrombosis; Transplantation, Autologous; Venous Thromboembolism; Vincristine | 2020 |
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; Humans; Immunologic Factors; Immunomodulation; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Thalidomide; Treatment Outcome | 2021 |
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Survival Rate | 2021 |
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Resistance, Neoplasm; Female; Flow Cytometry; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Progression-Free Survival; Treatment Outcome | 2021 |
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Progression-Free Survival | 2020 |
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Survival Rate | 2020 |
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Vorinostat | 2020 |
Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Febrile Neutropenia; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Progression-Free Survival; Remission Induction; Treatment Outcome; Young Adult | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Rate | 2020 |
Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2020 |
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Thalidomide | 2021 |
The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a prote
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dexamethasone; Glycine; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Proteasome Inhibitors; Randomized Controlled Trials as Topic; Thalidomide | 2020 |
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Disease Progression; Drug Administration Schedule; Eligibility Determination; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Progression-Free Survival; Thalidomide; Time Factors; United States | 2020 |
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Survival Rate | 2021 |
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human; Cytogenetic Analysis; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Survival Rate; Translocation, Genetic | 2020 |
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Patient Reported Outcome Measures; Quality of Life; Time Factors; Treatment Outcome | 2021 |
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial.
Topics: Aged; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide | 2020 |
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cost-Benefit Analysis; Dexamethasone; Drug Costs; Health Care Costs; Humans; Lenalidomide; Markov Chains; Multiple Myeloma; Outcome Assessment, Health Care; Progression-Free Survival; Quality-Adjusted Life Years | 2021 |
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
Topics: Antineoplastic Agents; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2021 |
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Survival Analysis; United Kingdom | 2021 |
Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Canada; Databases, Factual; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma | 2021 |
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat | 2021 |
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transplantation, Autologous | 2021 |
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Dexamethasone; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Progression-Free Survival; Proof of Concept Study | 2021 |
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B-Cell Maturation Antigen; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy, Adoptive; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Programmed Cell Death 1 Receptor; Receptors, Chimeric Antigen; Survival Rate; Thalidomide | 2021 |
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Databases, Factual; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Risk Factors; Survival Rate | 2021 |
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Survival Rate | 2021 |
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate | 2021 |
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Patient Reported Outcome Measures; Progression-Free Survival; Quality of Life; Recurrence; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome | 2021 |
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Topics: Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Survival Analysis; Treatment Outcome | 2021 |
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pilot Projects | 2021 |
Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma.
Topics: Adult; Aged; Bortezomib; Dexamethasone; Feasibility Studies; Female; Hematopoietic Stem Cell Mobilization; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies | 2021 |
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome | 2021 |
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Topics: Administration, Oral; Aged; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm, Residual; Progression-Free Survival | 2021 |
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Marrow Cells; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Survival Rate | 2021 |
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Transplantation, Autologous | 2021 |
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Oligopeptides | 2021 |
Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Prognosis; Progression-Free Survival; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2021 |
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Treatment Outcome | 2021 |
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features.
Topics: Aged; Humans; Lenalidomide; Multiple Myeloma; Progression-Free Survival | 2022 |
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2017 |
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2017 |
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide; Young Adult | 2017 |
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2017 |
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Eruptions; Follow-Up Studies; Glycine; Hematologic Diseases; Humans; Lenalidomide; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Nausea; Peripheral Nervous System Diseases; Platelet Count; Thalidomide; Vomiting | 2017 |
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Immunoglobulins; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2017 |
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; China; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Placebo Effect; Thalidomide | 2017 |
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.
Topics: Adult; Double-Blind Method; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Placebos; Survival Analysis; Thalidomide; Transplantation, Autologous; Young Adult | 2017 |
Neutral tumor evolution in myeloma is associated with poor prognosis.
Topics: Exome; Female; Gene Frequency; Genetic Drift; Humans; Immunologic Factors; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Male; Multiple Myeloma; Mutation; Prognosis; Thalidomide; Tumor Microenvironment | 2017 |
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Prospective Studies; Thalidomide | 2017 |
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Approval; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; United States | 2017 |
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide | 2017 |
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; B-Lymphocytes; Cell Line, Tumor; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Monocytes; Multiple Myeloma; T-Lymphocytes; Thalidomide | 2017 |
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Proportional Hazards Models; Thalidomide | 2017 |
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Prospective Studies; Skin Diseases; Treatment Outcome | 2018 |
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
Topics: Adult; Aged; Autografts; Bacterial Vaccines; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Vaccination; Viral Vaccines | 2018 |
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Survival Analysis | 2018 |
Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Dexamethasone; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunologic Factors; Japan; Lenalidomide; Male; Multiple Myeloma; Treatment Outcome | 2018 |
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.
Topics: Female; Humans; Immunity, Cellular; Interferon-gamma; Killer Cells, Natural; Lenalidomide; Male; Mucosal-Associated Invariant T Cells; Multiple Myeloma; Neoplasm Proteins; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2018 |
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE st
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Recurrence | 2018 |
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma | 2018 |
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retreatment; Treatment Outcome | 2018 |
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Multiple Myeloma; Patient Reported Outcome Measures; Prospective Studies; Treatment Outcome | 2018 |
Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
Topics: Absenteeism; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease Progression; Double-Blind Method; Female; Glycine; Health Resources; Health Services; Hospitalization; Humans; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Time Factors | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2018 |
Low frequency of CD3
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD4 Antigens; Dexamethasone; Female; Humans; Infections; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; NK Cell Lectin-Like Receptor Subfamily B; Recurrence; Risk Factors | 2018 |
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2018 |
Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Ribosomal Proteins; Treatment Outcome | 2018 |
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Quality of Life; Registries; Thalidomide; United States | 2018 |
Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Quality of Life; Survival Rate; Thalidomide | 2018 |
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Lenalidomide; Machine Learning; Multiple Myeloma; Mutation; Proportional Hazards Models; Sequence Analysis, RNA; Transcriptome; Treatment Outcome; United States | 2018 |
Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Drug Monitoring; Female; Humans; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Renal Insufficiency; Survival Analysis; Treatment Outcome | 2018 |
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Plasma Cells; Survival Rate | 2018 |
A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.
Topics: Bortezomib; Consolidation Chemotherapy; Dexamethasone; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2019 |
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Oligopeptides; Progression-Free Survival; Remission Induction; Treatment Outcome | 2018 |
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Eligibility Determination; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Panobinostat; Transplantation, Autologous | 2018 |
Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Risk Factors; Survival Rate | 2019 |
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Intention to Treat Analysis; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Progression-Free Survival; Transplantation, Autologous; Treatment Outcome | 2019 |
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Diseases; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Stem Cell Transplantation; Survival Rate | 2019 |
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Female; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Peptide Fragments; Procollagen; Ribonuclease, Pancreatic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Progression-Free Survival; Prospective Studies; Remission Induction; Reoperation; Time Factors; Transplantation, Autologous; United States; Young Adult | 2019 |
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Follow-Up Studies; Glycine; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prognosis; Survival Rate | 2019 |
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clonal Evolution; Exome Sequencing; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; Remission Induction; Thalidomide; Treatment Outcome | 2019 |
Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.
Topics: Adolescent; Adult; Biomarkers, Tumor; Bortezomib; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Reagent Kits, Diagnostic; Transplantation, Autologous; Treatment Outcome; Young Adult | 2019 |
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazoles; Pyridones; Thalidomide; Venous Thromboembolism | 2019 |
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival | 2019 |
Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prognosis; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2019 |
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.
Topics: Antibodies, Monoclonal, Humanized; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma | 2019 |
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2019 |
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prospective Studies; Quality of Life; Research Design; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Progression-Free Survival | 2019 |
Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study).
Topics: Adaptor Proteins, Signal Transducing; Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dexamethasone; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Proteomics; Ubiquitin-Protein Ligases | 2019 |
Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Depsipeptides; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peptides, Cyclic; Survival Rate; Thalidomide | 2019 |
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Treatment Outcome | 2020 |
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pneumonia; Progression-Free Survival; Proportional Hazards Models; Survival Rate; Treatment Outcome | 2019 |
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Thalidomide; Treatment Outcome | 2013 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Lenalidomide; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Pain; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisolone; Recurrence; Thalidomide | 2013 |
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Risk; Survival Rate; Thalidomide | 2013 |
Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cohort Studies; Dexamethasone; Female; Flow Cytometry; Humans; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2014 |
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Polyethylene Glycols; Remission Induction; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.
Topics: Cytokines; Female; Humans; Immunologic Factors; Lenalidomide; Lymphocyte Count; Male; Multiple Myeloma; Natural Killer T-Cells; Thalidomide | 2014 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Marrow Transplantation; Combined Modality Therapy; Cost-Benefit Analysis; Data Collection; Disease-Free Survival; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Quality of Life; Thalidomide; Transplantation, Autologous; Young Adult | 2013 |
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Quality of Life; Thalidomide; Treatment Outcome | 2014 |
Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.
Topics: Administration, Intravenous; Adult; Aged; Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infection Control; Kaplan-Meier Estimate; Karyotyping; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proportional Hazards Models; Remission Induction; Salvage Therapy; Thalidomide; Thrombosis; Treatment Outcome; Vincristine | 2014 |
A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Thalidomide; Transplantation Conditioning; Transplantation, Homologous | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Sirolimus; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2014 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2014 |
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Risk Factors; Thalidomide; Treatment Outcome | 2014 |
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; France; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2014 |
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Disease-Free Survival; Economics, Pharmaceutical; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Thalidomide | 2014 |
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Thalidomide; Treatment Outcome | 2015 |
Autologous transplantation and maintenance therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2014 |
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2014 |
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2014 |
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anemia; Dexamethasone; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Dialysis; Survival Analysis; Thalidomide; Thrombocytopenia; Treatment Outcome | 2015 |
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Follow-Up Studies; Glycine; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Proteasome Inhibitors; Safety; Survival Rate; Thalidomide | 2014 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide | 2015 |
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2015 |
Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; China; Dexamethasone; Disease-Free Survival; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Renal Insufficiency; Thalidomide | 2015 |
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Sectional Studies; Dexamethasone; Female; Health Status; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Thalidomide | 2015 |
Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide | 2015 |
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Plasma Cells; Polyethylene Glycols; Precision Medicine; Proteomics; Pyrazines; Thalidomide | 2015 |
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Immune System; Immunoglobulin G; Immunotherapy; Killer Cells, Natural; Lenalidomide; Ligands; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, KIR; Thalidomide; Treatment Outcome | 2015 |
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Survival Rate; Thalidomide; Vorinostat | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Receptors, Immunologic; Recurrence; Signaling Lymphocytic Activation Molecule Family; Thalidomide | 2015 |
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Survival Rate; Thalidomide; Vorinostat | 2015 |
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Quality of Life; Thalidomide | 2015 |
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Prednisone; Quality of Life; Thalidomide | 2015 |
Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Female; Fibrin Fibrinogen Degradation Products; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2015 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maryland; Middle Aged; Multiple Myeloma; National Institutes of Health (U.S.); Neoplasm, Residual; Oligopeptides; Pilot Projects; Proteasome Inhibitors; Risk Factors; Thalidomide; Time Factors; Treatment Outcome; United States | 2015 |
Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents.
Topics: Adult; Aged; Aged, 80 and over; Blood Cell Count; Drugs, Investigational; Female; Humans; Induction Chemotherapy; Lenalidomide; Leukocyte Count; Lymphocytes; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neoplasm Staging; Neutrophils; Retrospective Studies; Risk Assessment; Thalidomide | 2015 |
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide | 2015 |
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2015 |
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2015 |
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.
Topics: Adult; Aged; Autografts; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2016 |
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Cyclophosphamide; Czech Republic; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Risk Factors; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2015 |
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Lenalidomide; Logistic Models; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Proliferation; Demography; Dexamethasone; Female; Humans; Immunophenotyping; Induction Chemotherapy; Killer Cells, Natural; Lenalidomide; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Risk Factors; T-Lymphocytes; Thalidomide | 2016 |
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2016 |
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Demography; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2016 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Immunophenotyping; Integrins; Lenalidomide; Male; Melphalan; Models, Genetic; Multiple Myeloma; Neoplasm, Residual; Phenotype; Plasma Cells; Prednisone; Prognosis; Thalidomide | 2016 |
Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Dexamethasone; Female; Humans; Kidney Diseases; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Retreatment; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome; Withholding Treatment | 2016 |
Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2016 |
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Quality of Life; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.
Topics: Aged; Aged, 80 and over; Dexamethasone; Disease Progression; Female; Humans; Japan; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide | 2016 |
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatio
Topics: Adult; Aged; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Dexamethasone; Drug Monitoring; Female; Humans; Immunity; Lenalidomide; Male; Melphalan; Monitoring, Physiologic; Multiple Myeloma; Neoplasm, Residual; Prednisone; Prognosis; Survival Analysis; Thalidomide; Vincristine | 2016 |
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Disease-Free Survival; Double-Blind Method; Exanthema; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Quality of Life; Thalidomide; Thrombocytopenia | 2016 |
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Creatinine; Dexamethasone; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Kidney Function Tests; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Recurrence; Renal Insufficiency; Thalidomide | 2016 |
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Survival Rate; Thalidomide | 2016 |
Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis.
Topics: Angiogenesis Inhibitors; Bone Marrow; Consolidation Chemotherapy; Erythropoiesis; Fetal Hemoglobin; Hematopoietic Stem Cells; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Myelopoiesis; Thalidomide | 2016 |
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Risk Factors; Survival Rate; Thalidomide | 2016 |
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Risk Factors; Survival Rate; Thalidomide | 2016 |
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Female; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Thalidomide | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2016 |
The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation Conditioning; Vincristine | 2017 |
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Quality of Life; Recurrence; Thalidomide; Young Adult | 2016 |
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrimidines; Thalidomide | 2016 |
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Thalidomide; Treatment Outcome | 2016 |
Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Thalidomide | 2017 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2016 |
A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide; Treatment Outcome | 2016 |
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Leukopenia; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Treatment Outcome | 2017 |
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Vorinostat | 2017 |
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Oligopeptides; Risk Factors; Thalidomide; Vorinostat | 2016 |
Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boron Compounds; Dexamethasone; Drug Administration Schedule; Female; Glycine; Humans; Lenalidomide; Leukopenia; Male; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia | 2017 |
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome; Tumor Burden | 2017 |
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Ikaros Transcription Factor; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide | 2017 |
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Infections; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Remission Induction; Thalidomide; Treatment Outcome | 2017 |
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Prospective Studies; Recurrence; Thalidomide | 2017 |
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide; Treatment Outcome | 2017 |
A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Humans; Lenalidomide; Multiple Myeloma; Patient Safety; Premedication; Thalidomide | 2017 |
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2017 |
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Stem Cells; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2008 |
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Cathepsin K; Cathepsins; Cells, Cultured; Chemokine CCL3; Humans; Integrin alphaVbeta3; Lenalidomide; Multiple Myeloma; Osteoclasts; Osteoprotegerin; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Thalidomide; Trans-Activators; Transcription Factor AP-1; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2008 |
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
Topics: Chromatography, Liquid; Flavonoids; Humans; Lenalidomide; Multiple Myeloma; Piperidines; Recurrence; Spectrometry, Mass, Electrospray Ionization; Thalidomide; Time Factors | 2008 |
Tailored thromboprophylaxis for patients with multiple myeloma treated by IMIDs.
Topics: Aspirin; Chemoprevention; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis | 2008 |
Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Forkhead Transcription Factors; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; T-Lymphocytes, Regulatory; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2009 |
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Interactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Young Adult | 2008 |
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Double-Blind Method; Drug Approval; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Placebos; Thalidomide; United States; United States Food and Drug Administration | 2008 |
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Thalidomide; Time Factors; Treatment Outcome | 2009 |
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Disease-Free Survival; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide; Thrombocytopenia | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Biological; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Risk Assessment; Thalidomide; Time Factors; Treatment Outcome | 2010 |
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2010 |
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Risk Factors; Thalidomide | 2010 |
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Retrospective Studies; Thalidomide; Thrombocytopenia; Treatment Outcome | 2010 |
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Fatigue; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Pain; Pyrazines; Remission Induction; Sensation Disorders; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2011 |
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Thalidomide; Treatment Outcome | 2010 |
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Thalidomide | 2010 |
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Clarithromycin; Dexamethasone; Disease-Free Survival; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide; Thrombocytopenia | 2010 |
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome; Young Adult | 2010 |
Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2011 |
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2012 |
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Compassionate Use Trials; Cross-Sectional Studies; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Registries; Retrospective Studies; Salvage Therapy; Spain; Survival Rate; Thalidomide | 2011 |
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Survival Rate; Thalidomide | 2011 |
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neutropenia; Patient Dropouts; Survival Analysis; Thalidomide | 2011 |
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Drug Eruptions; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphocyte Count; Male; Melphalan; Middle Aged; Multiple Myeloma; Mycophenolic Acid; Prospective Studies; Remission Induction; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 2011 |
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Failure; Treatment Outcome | 2011 |
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Drug Interactions; Humans; Lenalidomide; Maximum Tolerated Dose; Multiple Myeloma; Neoplasm Recurrence, Local; Sirolimus; Survival Rate; Thalidomide; Tissue Distribution; Treatment Outcome | 2011 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Enoxaparin; Female; Humans; Incidence; Israel; Italy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Platelet Aggregation Inhibitors; Pulmonary Embolism; Risk Factors; Thalidomide; Venous Thromboembolism; Venous Thrombosis | 2012 |
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
Topics: Aged; Antineoplastic Agents; Chromosome Aberrations; Dexamethasone; Female; Gene Expression Profiling; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Survival Analysis; Thalidomide | 2011 |
Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2011 |
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Emergence of central nervous system myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2012 |
Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Cohort Studies; Female; Humans; Immunomodulation; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pneumococcal Vaccines; T-Lymphocytes; Thalidomide; Vaccines, Conjugate | 2012 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Quality of Life; Recurrence; Spain; Surveys and Questionnaires; Thalidomide; Thrombocytopenia; Time Factors; Treatment Outcome | 2012 |
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Polyethylene Glycols; Prognosis; Prospective Studies; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2012 |
Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Male; Medication Adherence; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunotherapy, Adoptive; Lenalidomide; Living Donors; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Homologous | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Recurrence; Thalidomide; Treatment Outcome | 2012 |
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Administration Schedule; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2012 |
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Neutropenia; Prednisone; Thalidomide | 2012 |
Lenalidomide after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Stem Cell Transplantation; Thalidomide | 2012 |
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Stem Cell Transplantation; Thalidomide; Young Adult | 2012 |
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Phosphatidylinositol 3-Kinase; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Thalidomide; Treatment Outcome | 2012 |
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Hyperglycemia; Hypophosphatemia; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide | 2012 |
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Dexamethasone; DNA Methylation; Doxorubicin; Drug Administration Schedule; Epigenesis, Genetic; Female; Humans; Immunity, Cellular; Lenalidomide; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Prospective Studies; Pyrazines; T-Cell Antigen Receptor Specificity; Thalidomide; Transplantation, Autologous | 2012 |
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2013 |
Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Survival Rate; Thalidomide | 2013 |
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Topics: Adult; Aged; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Immunologic; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Lymphocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thalidomide; Transplantation Conditioning; Transplantation, Homologous | 2013 |
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Dendritic Cells; Drug Synergism; Female; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Male; Middle Aged; Monocytes; Multiple Myeloma; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2013 |
Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide | 2013 |
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Quality of Life; Surveys and Questionnaires; Thalidomide | 2013 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Lenalidomide; Medical Oncology; Middle Aged; Multiple Myeloma; Pyrazines; Societies, Medical; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Combined Modality Therapy; Constipation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Myeloma Proteins; Nervous System Diseases; Neutropenia; Peripheral Blood Stem Cell Transplantation; Remission Induction; Safety; Salvage Therapy; Thalidomide; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome | 2002 |
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
Topics: Adult; Aged; Dexamethasone; Drug Therapy, Combination; Female; Hematologic Tests; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2005 |
CC-5013 MM 0017: a multicenter, randomized, parallel-group, double-blind, placebo-controlled study of CC-5013 plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Dexamethasone; Double-Blind Method; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Patient Selection; Placebos; Salvage Therapy; Thalidomide | 2003 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Thalidomide; Venous Thrombosis | 2006 |
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recurrence; Thalidomide | 2006 |
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Differentiation; Cell Proliferation; Cell Survival; Cytotoxins; Dexamethasone; Dose-Response Relationship, Drug; Interleukin-6; Lenalidomide; Ligands; Macrophage Colony-Stimulating Factor; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Phosphorylcholine; Pyrazines; RANK Ligand; Stromal Cells; Thalidomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Vincristine | 2007 |
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Creatinine; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neutropenia; Renal Insufficiency; Thalidomide; Thrombocytopenia; Treatment Outcome | 2007 |
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Survival Analysis; Thalidomide | 2007 |
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Thalidomide; Time Factors | 2008 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Double-Blind Method; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide | 2007 |
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
1068 other study(ies) available for lenalidomide and Multiple Myeloma
| Article | Year |
|---|---|
Protein Degradation via CRL4
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Chemistry Techniques, Synthetic; Drug Evaluation, Preclinical; Humans; Ikaros Transcription Factor; Molecular Docking Simulation; Multiple Myeloma; Peptide Hydrolases; Peptide Termination Factors; Phthalimides; Piperidones; Proteolysis; Quantitative Structure-Activity Relationship; Ubiquitin-Protein Ligases | 2018 |
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Crystallography, X-Ray; DNA-Binding Proteins; Fluorescence Resonance Energy Transfer; Heterocyclic Compounds, 4 or More Rings; Humans; Ikaros Transcription Factor; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Phthalimides; Piperidones; Protein Binding; Proteolysis; Ubiquitin-Protein Ligases | 2018 |
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Humans; Inhibitory Concentration 50; Mice; Multiple Myeloma; Recurrence; Stereoisomerism; Treatment Failure; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2020 |
Antimyeloma Potential of Caffeic Acid Phenethyl Ester and Its Analogues through Sp1 Mediated Downregulation of IKZF1-IRF4-MYC Axis.
Topics: Angiogenesis Inhibitors; Apoptosis; Caffeic Acids; Cell Line, Tumor; Down-Regulation; Genes, myc; Humans; Ikaros Transcription Factor; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Phenylethyl Alcohol; Sp1 Transcription Factor; Structure-Activity Relationship | 2020 |
Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity.
Topics: Animals; Cell Proliferation; Drug Design; Female; Humans; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Sulfides; Thalidomide; Xenograft Model Antitumor Assays | 2021 |
Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime
Topics: Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Progression-Free Survival; Retrospective Studies | 2021 |
Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma.
Topics: China; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Therapeutic Equivalency | 2021 |
Myeloma research on the move.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Disease Management; Humans; Immunotherapy, Adoptive; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation | 2021 |
Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cohort Studies; Dexamethasone; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Slovakia | 2022 |
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2021 |
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Caspase 8; Caspase Inhibitors; Drug Therapy, Combination; HEK293 Cells; Humans; K562 Cells; Lenalidomide; Multiple Myeloma | 2021 |
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous | 2022 |
Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies; Survival Rate; Transplantation, Autologous | 2021 |
Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy.
Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Secondary Prevention | 2022 |
[Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment].
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2021 |
An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; CD8-Positive T-Lymphocytes; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local | 2021 |
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2022 |
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Management; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Quality of Life; Recurrence; Retreatment; Treatment Outcome | 2022 |
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Retrospective Studies; Salvage Therapy | 2022 |
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.
Topics: Biomarkers; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Preceding bortezomib administration for a certain period reduces the risk of lenalidomide-induced skin rash.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2022 |
Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Transplantation, Autologous | 2022 |
Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma.
Topics: Acute Kidney Injury; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Kidney; Lenalidomide; Male; Multiple Myeloma; Renal Dialysis | 2022 |
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Topics: Drug Resistance, Neoplasm; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell; Multiple Myeloma; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2022 |
SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma.
Topics: Adaptor Proteins, Vesicular Transport; Cell Adhesion; Extracellular Vesicles; Gene Expression Profiling; Humans; Lenalidomide; Lysosomal-Associated Membrane Protein 2; Multiple Myeloma | 2022 |
Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma | 2022 |
How I treat relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy | 2022 |
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Frailty; Humans; Lenalidomide; Male; Models, Statistical; Multiple Myeloma; Prognosis; Retrospective Studies; Survival Rate; United Kingdom | 2022 |
Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL.
Topics: Aged; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pancytopenia; Thalidomide | 2022 |
What Is Multiple Myeloma?
Topics: Biopsy; Bone Marrow; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; United States | 2022 |
Re: Arcuri and Americo "Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis".
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Network Meta-Analysis | 2022 |
Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells.
Topics: Cell Line, Tumor; Humans; Integrin beta Chains; Lenalidomide; Multiple Myeloma | 2022 |
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma.
Topics: ATPases Associated with Diverse Cellular Activities; Cell Cycle Proteins; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteomics; Ubiquitin-Protein Ligases; Up-Regulation | 2022 |
Carfilzomib 56 mg/m
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides | 2022 |
Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies | 2022 |
SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.
Topics: Cell Line, Tumor; Humans; Lenalidomide; Multiple Myeloma; Sumoylation | 2023 |
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Prognosis; Transplantation, Autologous; Treatment Outcome | 2022 |
Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Prognosis; Retrospective Studies; T-Lymphocytes, Regulatory | 2022 |
Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Canada; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2022 |
Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma.
Topics: Biomarkers; CD56 Antigen; Humans; Lenalidomide; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein | 2022 |
Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome | 2022 |
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Japan; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2022 |
Combination Therapy of an Antibody Specific for Transferrin Receptor 1 (ch128.1/IgG1) With Bortezomib or Lenalidomide Results in Increased Survival in an In Vivo Model of Human Multiple Myeloma: A Brief Communication.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Communication; Dexamethasone; Humans; Immunoglobulin G; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Receptors, Transferrin | 2022 |
Delayed-onset cutaneous eruption associated with lenalidomide in setting of multiple myeloma.
Topics: Exanthema; Humans; Lenalidomide; Multiple Myeloma; Skin; Thalidomide | 2021 |
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Topics: Benzylamines; COVID-19; Cyclams; Cyclophosphamide; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Multiple Myeloma; Pandemics; Retrospective Studies; Transplantation, Autologous | 2022 |
Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing.
Topics: Body Weight; Creatinine; Glomerular Filtration Rate; Humans; Kidney; Lenalidomide; Multiple Myeloma; Renal Insufficiency, Chronic | 2023 |
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Retrospective Studies; Translocation, Genetic; Transplantation, Autologous | 2022 |
Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.
Topics: Amyloidosis; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Multiple Myeloma | 2022 |
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Elotuzumab: no benefit for older patients with newly diagnosed multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Risk Assessment; Transplantation, Autologous | 2022 |
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Plasma Cell; Retrospective Studies; Salvage Therapy | 2022 |
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Thalidomide | 2022 |
Generic Lenalidomide: An opportunity to address the balance of administrative burden and drug safety.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Topics: Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Salvage Therapy | 2022 |
Association of Daratumumab Use With Ocular Events in a Case Series of US Adults.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local | 2022 |
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lactate Dehydrogenases; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Neoplastic Cells, Circulating | 2022 |
Therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma - diagnostic and therapeutic dilemma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2022 |
Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.
Topics: Adult; Cohort Studies; Deductibles and Coinsurance; Female; Health Expenditures; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma | 2022 |
Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Japan; Lenalidomide; Multiple Myeloma; Treatment Outcome | 2022 |
Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies.
Topics: Animals; Cell Membrane Permeability; Female; Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma; Placenta; Pregnancy; Thalidomide | 2022 |
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Mice; Monocytes; Multiple Myeloma | 2023 |
Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2022 |
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
Topics: Drug Resistance; Humans; Immunotherapy; Lenalidomide; Multiple Myeloma; Proteomics; Tumor Microenvironment | 2022 |
Recent Advancements and Future Directions in Frontline Treatment of Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; RNA, Small Interfering; Ubiquitin-Protein Ligases | 2022 |
PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo.
Topics: Adaptor Proteins, Signal Transducing; Animals; Humans; Lenalidomide; Mice; Multiple Myeloma; Peptide Hydrolases; Peroxisome Proliferator-Activated Receptors; Retrospective Studies; Ubiquitin-Protein Ligases | 2022 |
A case of chronic neutrophilic leukemia and multiple myeloma showing the benefits of lenalidomide and cyclophosphamide therapy in treating both conditions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Leukemia, Neutrophilic, Chronic; Multiple Myeloma; Thalidomide | 2022 |
Usability of German hospital administrative claims data for healthcare research: General assessment and use case of multiple myeloma in Munich university hospital in 2015-2017.
Topics: Aged; Bortezomib; Female; Health Services Research; Hospitals; Humans; Lenalidomide; Male; Multiple Myeloma; Retrospective Studies | 2022 |
[A novel cause of acute kidney injury in multiple myeloma: Lenalidomide-induced acute interstitial nephritis].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Nephritis, Interstitial | 2022 |
Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Quality of Life; Transplantation, Autologous | 2022 |
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies | 2022 |
Addition of bortezomib to high-dose cyclophosphamide therapy as a conditioning regimen for autologous peripheral blood stem cell harvest leads to an increased yield of hematopoietic stem cells.
Topics: Antigens, CD34; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cells; Retrospective Studies; Transplantation, Autologous | 2022 |
Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Treatment Outcome; United States | 2022 |
Slow increase of bilirubin concentration during administration of lenalidomide, bortezomib and dexamethasone for multiple myeloma (unmasking previously undiagnosed Gilbert syndrome) and disappearance of necrobiotic xanthogranuloma after complete remission
Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Bortezomib; Dexamethasone; Gilbert Disease; Humans; Hyperbilirubinemia; Lenalidomide; Multiple Myeloma; Necrobiotic Xanthogranuloma; Positron Emission Tomography Computed Tomography | 2022 |
Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2023 |
Lessons for the clinical nephrologist: lenalidomide-induced Fanconi syndrome in a patient with multiple myeloma post stem cell transplantation.
Topics: Bortezomib; Fanconi Syndrome; Humans; Lenalidomide; Multiple Myeloma; Nephrologists; Stem Cell Transplantation | 2022 |
Vascular thrombotic events in the era of modern myeloma therapy.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thrombosis | 2022 |
Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Canada; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Treatment Outcome | 2023 |
Refractory postherpetic neuralgia in a multiple myeloma patient with lenalidomide maintenance therapy: a case report.
Topics: Antiviral Agents; Herpes Zoster; Humans; Lenalidomide; Multiple Myeloma; Neuralgia, Postherpetic | 2022 |
Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.
Topics: Amyloid; Animals; Antineoplastic Agents; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Dexamethasone; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Mice; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Inhibitors; Proteomics; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2022 |
Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dual Oxidases; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma | 2023 |
Dupilumab in Multiple Myeloma: A Case Series.
Topics: Antibodies, Monoclonal, Humanized; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2022 |
Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.
Topics: Bone Marrow; Burkitt Lymphoma; Humans; Immunoglobulin Heavy Chains; In Situ Hybridization, Fluorescence; Lenalidomide; Multiple Myeloma; Mutation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2023 |
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hungary; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Treatment Outcome | 2022 |
[Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Middle Aged; Multiple Myeloma | 2021 |
Carfilzomib's Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Electronic Health Records; Humans; Lenalidomide; Multiple Myeloma | 2022 |
Secondary Hemophagocytic Syndrome in a Patient with Plasma Cell Myeloma and CNS Involvement Treated with Lenalidomide.
Topics: Adult; Diagnosis, Differential; Humans; Immunomodulating Agents; Lenalidomide; Lymphohistiocytosis, Hemophagocytic; Multiple Myeloma; Neoplasms, Second Primary | 2022 |
Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Bortezomib; Cohort Studies; Dexamethasone; Humans; Incidence; Infant; Lenalidomide; Multiple Myeloma; Retrospective Studies; Risk Factors | 2023 |
Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide | 2022 |
Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Republic of Korea; Retrospective Studies | 2023 |
Elotuzumab in multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Chari A, Cho HJ, Dhadwal A, et al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017;1(19):1575-1583.
Topics: Clinical Trials, Phase II as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Panobinostat | 2022 |
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Smoldering Multiple Myeloma; Tumor Microenvironment | 2022 |
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Topics: Biomarkers; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Immunologic Factors; Immunotherapy; Lenalidomide; Multiple Myeloma; Smoldering Multiple Myeloma | 2022 |
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model.
Topics: Animals; Dexamethasone; Heterografts; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma | 2023 |
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
Topics: Antigens, CD19; Humans; Immunotherapy, Adoptive; Lenalidomide; Multiple Myeloma; Receptors, Chimeric Antigen; T-Lymphocytes | 2023 |
Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide-treated myeloma patients.
Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Lenalidomide; Multiple Myeloma; Tryptophan | 2023 |
Habb-e-Asgandh Suppresses Cell Proliferation and Induces Apoptosis through Mitochondria Dysfunction in Multiple Myeloma Cells (RPMI8226).
Topics: Antioxidants; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Lenalidomide; Mitochondria; Multiple Myeloma; Proliferating Cell Nuclear Antigen | 2022 |
Suspected Immune Thrombocytopenic Purpura Induced by Lenalidomide for the Treatment of Myelodysplastic Syndrome with Deletion of Chromosome 5q: A Case Report.
Topics: Aged; Chromosomes; Humans; Lenalidomide; Male; Multiple Myeloma; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2023 |
Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma.
Topics: Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immunomodulating Agents; Lenalidomide; Lymphohistiocytosis, Hemophagocytic; Lymphoproliferative Disorders; Multiple Myeloma | 2023 |
TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.
Topics: Animals; Hematopoietic Stem Cell Transplantation; Immunity; Lenalidomide; Mice; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, IgG; Receptors, Immunologic; Stem Cell Transplantation; Transplantation, Autologous; Tumor Microenvironment | 2023 |
Once Monthly Elotuzumab and Lenalidomide Plus Dexamethasone for Multiple Myeloma: A Multicenter Observation Study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Quality of Life; Retrospective Studies; Treatment Outcome | 2023 |
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma.
Topics: Exanthema; Humans; Hypersensitivity, Delayed; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2023 |
Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual; Prospective Studies | 2023 |
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Multiple Myeloma; Thromboembolism; Thrombosis | 2023 |
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chronic Disease; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous | 2023 |
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Thalidomide; Treatment Outcome | 2023 |
Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe COVID-19?
Topics: Antineoplastic Combined Chemotherapy Protocols; COVID-19; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Carfilzomib, lenalidomide, and dexamethasone maintenance for multiple myeloma: when and for whom?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local | 2023 |
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
Topics: Chromosome Aberrations; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Retrospective Studies; Translocation, Genetic; Transplantation, Autologous | 2023 |
Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Tertiary Care Centers; Thalidomide | 2023 |
[Multiple extramedullary plasmacytomas responding to a reduced dose of carfilzomib following drug-induced thrombotic microangiopathy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Multiple Myeloma; Plasmacytoma; Recurrence; Thrombotic Microangiopathies | 2022 |
[A case-control study of multiple myeloma patients with central nervous system involvement].
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Central Nervous System; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Retrospective Studies | 2022 |
[Analysis of the efficacy and survival of ixazomib-containing regimens in patients with refractory and relapsed multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local | 2022 |
Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Recurrence | 2023 |
Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2023 |
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Lenalidomide; Mice; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2023 |
Larocca A, Bonello F, Gaidano G, et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027-3036.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2023 |
Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Patients; Psoriasis; Thalidomide | 2023 |
Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.
Topics: Aged; Burkitt Lymphoma; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Progression-Free Survival; Retrospective Studies | 2023 |
Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Topics: Adult; Hematologic Neoplasms; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Transplantation, Autologous; United States | 2023 |
Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous | 2023 |
Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Bortezomib; Dexamethasone; Heart Failure; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors | 2023 |
Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy?
Topics: Humans; Immunotherapy, Adoptive; Lenalidomide; Multiple Myeloma; T-Lymphocytes; Thalidomide | 2023 |
S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes.
Topics: Calgranulin A; Calgranulin B; Humans; Lenalidomide; Megakaryocytes; Multiple Myeloma; Proteasome Inhibitors; Tumor Microenvironment | 2023 |
Use of Daratumumab in Patients With Previously Treated Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prospective Studies; Transplantation, Autologous | 2023 |
Lenalidomide maintenance based on a genetic profile.
Topics: Genetic Profile; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Japan; Lenalidomide; Multiple Myeloma | 2023 |
Ixazomib - lenalidomide - dexamethason in heavily pretreated multiple myeloma patients - case reports.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors | 2023 |
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2023 |
Lenalidomide Stabilizes Protein-Protein Complexes by Turning Labile Intermolecular H-Bonds into Robust Interactions.
Topics: Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Proteolysis; Transcription Factors; Ubiquitin-Protein Ligases | 2023 |
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy.
Topics: Bortezomib; Chemokine CXCL10; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2023 |
Different human leukocyte antigen allele related to toxic epidermal necrolysis following lenalidomide treatment for multiple myeloma in a severely allergic family.
Topics: Alleles; HLA Antigens; Humans; Hypersensitivity; Lenalidomide; Multiple Myeloma; Stevens-Johnson Syndrome | 2023 |
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Delivery of Health Care; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies | 2023 |
[Multiple myeloma with laryngeal affectation: an uncommon cause of dysphonia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dysphonia; Humans; Lenalidomide; Male; Multiple Myeloma | 2023 |
Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Retrospective Studies; Turkey | 2023 |
[Access and safety of dexamethasone in multiple myeloma patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Membrane Proteins; Multiple Myeloma; Prognosis; RNA, Long Noncoding | 2023 |
Fever, Pancytopenia, and Tender Erythematous Plaques in a Patient With Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Erythema; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pancytopenia; Thalidomide | 2023 |
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prospective Studies | 2023 |
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous | 2023 |
Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2023 |
A pilot study of adherence to lenalidomide among older patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pilot Projects | 2023 |
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chronic Disease; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome | 2023 |
Acute auto-aggression syndrome following autologous hematopoietic stem cell transplant and lenalidomide for multiple myeloma.
Topics: Aged; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous | 2023 |
Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Registries; Retrospective Studies; Treatment Outcome | 2023 |
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
Topics: Black or African American; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide | 2023 |
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2023 |
Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma.
Topics: Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Lactates; Lenalidomide; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Protein Kinase C-alpha; Tumor Microenvironment | 2023 |
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Europe; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2023 |
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Venous Thromboembolism | 2023 |
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2023 |
c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma.
Topics: Animals; Bone Marrow; Drug Resistance, Neoplasm; Humans; Ikaros Transcription Factor; Lenalidomide; Mice; Multiple Myeloma; Proto-Oncogene Proteins c-fos; Trans-Activators; Transcription Factor AP-1 | 2023 |
Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation.
Topics: Chromosome Aberrations; Female; Hematologic Neoplasms; Humans; Immunomodulating Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Pregnancy; Proteolysis; Proteolysis Targeting Chimera | 2023 |
Vanishing bile duct syndrome in a patient with multiple myeloma treated with bortizomib, lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Cholestasis; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2023 |
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local | 2023 |
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.
Topics: Humans; Immunophenotyping; Lenalidomide; Multiple Myeloma; Patients; Receptors, Antigen, T-Cell, alpha-beta; Tumor Microenvironment | 2023 |
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
Topics: Canada; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous | 2023 |
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Topics: Adult; Aged; Chromosome Aberrations; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous | 2023 |
[Granulocyte-colony stimulating factor-producing multiple myeloma presenting with neutrophilia].
Topics: Aged; Female; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Lenalidomide; Leukocyte Count; Multiple Myeloma | 2023 |
Real-World Pitfalls of Analyzing Real-World Data: A Cautionary Note and Path Forward.
Topics: Bortezomib; Humans; Lenalidomide; Medical Oncology; Multiple Myeloma; Time Factors | 2023 |
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.
Topics: Adult; Animals; Clone Cells; Humans; Lenalidomide; Mice; Multiple Myeloma; Programmed Cell Death 1 Receptor; T-Lymphocytes | 2023 |
Personalized Medicine's Coming of Age: One Drug, One Patient.
Topics: Humans; Lenalidomide; Multiple Myeloma; Precision Medicine | 2023 |
Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Japan; Lenalidomide; Multiple Myeloma; Retrospective Studies; Risk Factors | 2023 |
Multiple myeloma and its treatment contribute to increased platelet reactivity.
Topics: Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Pilot Projects; Thrombosis | 2023 |
[Infection risks and prevention in patients with multiple myeloma].
Topics: Antibodies; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors | 2023 |
Maintain maintenance in multiple myeloma?
Topics: Boron Compounds; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2023 |
Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neutropenia; Retrospective Studies; Thalidomide | 2023 |
Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.
Topics: Anticoagulants; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Venous Thromboembolism | 2023 |
A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach.
Topics: Antineoplastic Agents; Carcinogenesis; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local | 2023 |
Did This Cryptococcosis Patient Have HIV Coinfection?
Topics: Antibodies, Monoclonal; Cryptococcosis; Dexamethasone; HIV Infections; Humans; Lenalidomide; Multiple Myeloma | 2019 |
The Author's Reply to "Did This Cryptococcosis Patient Have HIV Coinfection?"
Topics: Antibodies, Monoclonal; Cryptococcosis; Dexamethasone; HIV Infections; Humans; Lenalidomide; Multiple Myeloma | 2019 |
Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bortezomib; Female; Humans; Hungary; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Salvage Therapy; Treatment Outcome | 2019 |
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Models, Animal; Humans; Lenalidomide; Mice; Multiple Myeloma; Receptors, Chimeric Antigen | 2019 |
Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma.
Topics: Adaptor Proteins, Signal Transducing; Amiodarone; Animals; Cell Line, Tumor; Disease Models, Animal; Humans; Lenalidomide; Mice; Multiple Myeloma; T-Lymphocytes, Cytotoxic; Xenograft Model Antitumor Assays | 2019 |
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
Topics: Animals; Case-Control Studies; Chemokine CXCL12; Chemokines, CXC; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinase 1; Janus Kinase 2; Janus Kinases; Lenalidomide; Macrophages; Male; Mice; Mice, SCID; Monocytes; Mucin-1; Multiple Myeloma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Receptors, CXCR4; Signal Transduction; THP-1 Cells | 2020 |
Successful Retreatment with Elotuzumab for Multiple Myeloma with Extramedullary Relapse while Being Treated with Lenalidomide and Dexamethasone.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Retreatment | 2020 |
TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model.
Topics: Alkaline Phosphatase; Animals; Bone Remodeling; Bortezomib; Cancellous Bone; Collagen; Disease Models, Animal; Female; Fractures, Bone; Green Fluorescent Proteins; Humans; Lenalidomide; Mesenchymal Stem Cells; Mice; Mice, SCID; Multiple Myeloma; Organ Size; Osteoblasts; Osteoclasts; Parathyroid Hormone-Related Protein; Pteridines; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Wound Healing; X-Ray Microtomography | 2019 |
Ixazomib-induced Sweet's syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Sweet Syndrome | 2019 |
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Factor X Deficiency; Humans; Immunologic Factors; Lenalidomide; Male; Melena; Middle Aged; Multiple Myeloma; Stem Cell Transplantation | 2019 |
Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Humans; Immunoglobulin D; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Risk Factors; Survival Analysis; Thalidomide; Treatment Outcome; Young Adult | 2019 |
Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.
Topics: Antibodies, Monoclonal, Humanized; Family; Humans; Lenalidomide; Lymphocyte Activation; Mastocytosis, Systemic; Multiple Myeloma; Signaling Lymphocytic Activation Molecule Family | 2020 |
Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile.
Topics: Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Failure | 2020 |
Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bortezomib; Female; Humans; Lenalidomide; Male; Medicare; Multiple Myeloma; Treatment Outcome; United States | 2019 |
The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues.
Topics: Angiogenesis Inhibitors; Brazil; Cost-Benefit Analysis; Drug and Narcotic Control; Drug Costs; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2019 |
Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs.
Topics: Aged; Antineoplastic Agents; Costs and Cost Analysis; Female; Health Care Costs; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Postoperative Care; Retreatment; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2019 |
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomid
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Thalidomide; Treatment Outcome | 2020 |
[Successful treatment of relapse/refractory multiple myeloma with carfilzomib, lenalidomide, and dexamethasone combination therapy following allogeneic bone marrow transplantation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Transplantation, Autologous | 2019 |
Solitary Plasmacytoma Treated by Lenalidomide-Dexamethasone in Combination with Radiation Therapy: Clinical Outcomes.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Plasmacytoma; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Survival Rate | 2020 |
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Female; Humans; Lenalidomide; Leukocytes, Mononuclear; Mice; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Primary Cell Culture; Protein Kinase Inhibitors; Quinolones; Thiophenes; Xenograft Model Antitumor Assays | 2020 |
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Leukocytes, Mononuclear; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2020 |
In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019.
Topics: Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells.
Topics: Autografts; Cost-Benefit Analysis; Hematopoietic Stem Cells; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous | 2020 |
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Duplication; Chromosomes, Human, Pair 1; Dexamethasone; Disease Progression; DNA Copy Number Variations; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Proportional Hazards Models; Treatment Outcome | 2019 |
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Flow Cytometry; Humans; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Randomized Controlled Trials as Topic | 2020 |
Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome; United Kingdom | 2020 |
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Dosage Calculations; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Progression-Free Survival; Thalidomide | 2019 |
Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Substitution; Febrile Neutropenia; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Piperacillin, Tazobactam Drug Combination; Pyoderma Gangrenosum; Thalidomide | 2020 |
Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2020 |
Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Anthropology, Medical; Female; Humans; Lenalidomide; Male; Multiple Myeloma | 2020 |
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Treatment Outcome | 2020 |
APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.
Topics: Antibodies, Monoclonal, Humanized; Bortezomib; Cell Line, Tumor; Cell Nucleus; CRISPR-Cas Systems; Cytidine Deaminase; DNA Damage; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Lenalidomide; Minor Histocompatibility Antigens; Multiple Myeloma; Mutation; Phosphorylcholine; Polymethacrylic Acids; Radiation; RNA, Small Interfering; Signal Transduction | 2020 |
Combination Lenalidomide/Bortezomib Treatment Synergistically Induces Calpain-Dependent Ikaros Cleavage and Apoptosis in Myeloma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma | 2020 |
Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Eosinophils; Female; Follow-Up Studies; Humans; Lenalidomide; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Retrospective Studies; Time Factors; Time-to-Treatment | 2020 |
Cost-effectiveness of lenalidomide.
Topics: Autografts; Cost-Benefit Analysis; Hematopoietic Stem Cells; Humans; Lenalidomide; Multiple Myeloma | 2020 |
Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antibodies, Monoclonal; B7-H1 Antigen; Dendritic Cells; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Thalidomide | 2020 |
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.
Topics: Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Treatment Outcome | 2020 |
A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colitis, Ischemic; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Transplantation, Autologous | 2020 |
Bortezomib-induced motor neuropathy: A case report.
Topics: Aged, 80 and over; Bortezomib; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Peripheral Nervous System Diseases | 2020 |
Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation.
Topics: Autografts; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Vitiligo | 2020 |
Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; alpha Karyopherins; Biomarkers, Tumor; Cullin Proteins; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Immunomodulation; Lenalidomide; Male; Methylation; Middle Aged; Multiple Myeloma; Mutation; Prognosis; Progression-Free Survival; Ubiquitin-Protein Ligases | 2020 |
Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Treatment Outcome; United Kingdom | 2020 |
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Quality of Life; Transplantation, Autologous; Treatment Outcome | 2020 |
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome | 2020 |
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Italy; Lenalidomide; Multiple Myeloma; Retrospective Studies; Salvage Therapy | 2021 |
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Dexamethasone; Diphosphonates; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Prospective Studies | 2020 |
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boron Compounds; Dexamethasone; Female; Gene Expression; Gene Expression Profiling; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins c-myc; Treatment Outcome | 2020 |
Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.
Topics: Biological Products; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Smoldering Multiple Myeloma | 2020 |
Tuberculosis during lenalidomide maintenance in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide; Transplantation, Autologous; Tuberculosis | 2021 |
[Proteinuria in multiple myeloma: Be careful to iatrogeny].
Topics: Aged; Antineoplastic Agents; Autografts; Biopsy; Bortezomib; Dexamethasone; Female; Glomerulosclerosis, Focal Segmental; Humans; Iatrogenic Disease; Kidney; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteinuria; Thalidomide; Thrombotic Microangiopathies; Withholding Treatment | 2020 |
[Successful treatment with a combination of elotuzumab, lenalidomide and dexamethasone of extramedullary disease in a patient with refractory multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma | 2020 |
Lenalidomide maintenance after second autologous stem cell transplant improves overall survival in multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2020 |
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Survival Rate | 2020 |
Leishmaniasis as an unusual cause of pancytopenia in a patient receiving immunomodulatory therapy for myeloma.
Topics: Aged; Antiprotozoal Agents; Combined Modality Therapy; Drug Substitution; Endemic Diseases; Humans; Immunocompromised Host; Immunomodulation; Leishmania donovani; Leishmaniasis, Visceral; Lenalidomide; Male; Mediterranean Region; Multiple Myeloma; Pancytopenia; Phosphorylcholine; Recurrence; Renal Dialysis; Travel-Related Illness | 2020 |
A case of proliferative glomerulonephritis with immunoglobulin A1-lambda deposits successfully treated by chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow; Dexamethasone; Glomerulonephritis, Membranoproliferative; Humans; Immunoglobulin A; Immunoglobulin lambda-Chains; Immunohistochemistry; Immunologic Factors; Lenalidomide; Male; Microscopy, Electron; Multiple Myeloma; Nephrotic Syndrome; Paraproteinemias; Renal Insufficiency; Treatment Outcome | 2020 |
Intensification and consolidation therapy in multiple myeloma in the current era.
Topics: Bortezomib; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma | 2020 |
An Unusual Cause of a Pathological Vertebral Fracture: Solitary Plasmacytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Decompression, Surgical; Dexamethasone; Disease Progression; Female; Fractures, Compression; Fractures, Spontaneous; Humans; Humeral Fractures; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Laminectomy; Lenalidomide; Multiple Myeloma; Plasmacytoma; Positron-Emission Tomography; Spinal Cord Compression; Spinal Fractures; Spinal Neoplasms; Thoracic Vertebrae; Tomography, X-Ray Computed | 2020 |
Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Contai
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2020 |
Progressive multifocal leukoencephalopathy during treatment with lenalidomide and elotuzumab for multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Leukoencephalopathy, Progressive Multifocal; Multiple Myeloma | 2020 |
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Retrospective Studies; Treatment Outcome | 2020 |
An unusual cause of renal tubular dysfunction in multiple myeloma.
Topics: Fanconi Syndrome; Female; Humans; Immunologic Factors; Kidney Tubules; Lenalidomide; Middle Aged; Multiple Myeloma | 2020 |
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Humans; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; T-Lymphocytes; T-Lymphocytes, Regulatory | 2021 |
Daratumumab: a game changer in myeloma therapy.
Topics: Antibodies, Monoclonal; Humans; Lenalidomide; Multiple Myeloma | 2020 |
An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Renal Insufficiency; Thalidomide; Treatment Outcome | 2020 |
Coincident remission of ankylosing spondylitis after autologous stem cell transplantation for multiple myeloma.
Topics: Aged; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Remission Induction; Spondylitis, Ankylosing; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2021 |
A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzene Derivatives; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2020 |
Pleural plasmacytomas - the role of radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Fatal Outcome; Female; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Pleural Neoplasms; Prednisolone; Thalidomide | 2020 |
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lenalidomide; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Oligopeptides; Proto-Oncogene Proteins c-myc; RNA Interference; RNA, Small Interfering; Therapeutic Index, Drug; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Ubiquitination | 2020 |
[Current Recommendations for the First-Line Therapy of Symptomatic Multiple Myeloma].
Topics: Antineoplastic Agents; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Transplantation, Autologous | 2020 |
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Topics: Cell Line, Tumor; Chemokine CCL5; Coculture Techniques; Humans; Interferon Regulatory Factors; Intramolecular Oxidoreductases; Lenalidomide; Macrophage Migration-Inhibitory Factors; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Neoplasm Proteins; Thalidomide | 2020 |
Morphologic Classification Is an Important Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib or Lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Bortezomib; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies; Treatment Outcome | 2020 |
KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Immunologic Factors; Italy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome | 2020 |
Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide.
Topics: Antineoplastic Agents; Humans; Ikaros Transcription Factor; Immunoassay; Lenalidomide; Multiple Myeloma | 2020 |
A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Europe; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies | 2020 |
The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lenalidomide; Mice; Multiple Myeloma; Proteostasis; Ubiquitin-Protein Ligases | 2020 |
A budget impact analysis of lenalidomide in multiple myeloma Egyptian patients.
Topics: Antineoplastic Agents; Bortezomib; Cost-Benefit Analysis; Cyclophosphamide; Dexamethasone; Egypt; Female; Humans; Lenalidomide; Male; Models, Economic; Multiple Myeloma | 2020 |
Carfilzomib Triplet Fails to Induce Superior PFS in Newly Diagnosed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Oligopeptides; Randomized Controlled Trials as Topic; Survival Rate | 2020 |
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2021 |
Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Medicare; Multiple Myeloma; Neoplasms, Second Primary; United States | 2021 |
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Combined Modality Therapy; Dexamethasone; DNA Mutational Analysis; DNA, Neoplasm; Female; GTP Phosphohydrolases; Humans; INDEL Mutation; Lenalidomide; Male; Membrane Proteins; Middle Aged; Multiple Myeloma; Progression-Free Survival; Stem Cell Transplantation; Survival Rate; Treatment Outcome; Whole Genome Sequencing | 2020 |
Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Dexamethasone; Female; Germany; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Progression-Free Survival; Proteasome Inhibitors; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2020 |
Treatment-triggered onset and diagnosis of Sheehan syndrome in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hypopituitarism; Immunologic Factors; Lenalidomide; Magnetic Resonance Imaging; Multiple Myeloma; Pituitary Gland; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2019 |
Subcutaneous versus intravenous daratumumab in multiple myeloma.
Topics: Administration, Intravenous; Antibodies, Monoclonal; Humans; Lenalidomide; Multiple Myeloma | 2020 |
Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.
Topics: Administration, Intravenous; Antibodies, Monoclonal; Humans; Lenalidomide; Multiple Myeloma | 2020 |
Factors Associated with Dose Modification of Lenalidomide Plus Dexamethasone Therapy in Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma | 2020 |
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Cohort Studies; Coronavirus Infections; COVID-19; Dexamethasone; Disease Progression; Female; Humans; Immunomodulation; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pandemics; Pneumonia, Viral; Prognosis; Remission Induction; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Thalidomide; Treatment Outcome | 2020 |
The gift that keeps on giving: lenalidomide maintenance after second autologous stem cell transplant in multiple myeloma.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Stem Cell Transplantation | 2020 |
[Toll-like receptor CD180 and the bone marrow microenvironment as therapeutic targets in multiple myeloma].
Topics: Antigens, CD; Bone Marrow; Histones; Humans; Lenalidomide; Multiple Myeloma; Toll-Like Receptors; Tumor Microenvironment | 2020 |
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2020 |
Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Progression-Free Survival; Quality of Life | 2020 |
Daratumumab in transplant regimens for myeloma?
Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2020 |
A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Hodgkin Disease; Humans; Lenalidomide; Multiple Myeloma; Pilot Projects; Transplantation, Autologous; Treatment Outcome | 2020 |
Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Registries; Retrospective Studies; Risk Factors; Taiwan; Thalidomide; Treatment Outcome | 2020 |
Successful outcome of anaplastic multiple myeloma with lenalidomide, cyclophosphamide, and dexamethasone therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Multiple Myeloma; Treatment Outcome | 2021 |
Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Topics: Aged; Aged, 80 and over; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Female; Frailty; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Treatment Failure; Treatment Outcome | 2021 |
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
Topics: Animals; Humans; Immunomodulation; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Pharmaceutical Preparations; Thalidomide | 2020 |
Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Survival Rate | 2021 |
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Proliferation; Dexamethasone; Female; Humans; Immunomodulation; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; T-Lymphocytes, Regulatory; Thalidomide | 2020 |
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biosimilar Pharmaceuticals; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Assessment | 2020 |
ARID2 is a pomalidomide-dependent CRL4
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Lenalidomide; Multiple Myeloma; Mutation; Protein Binding; Proteolysis; RNA, Messenger; RNA, Small Interfering; Thalidomide; Time Factors; Transcription Factors; Ubiquitin-Protein Ligases; Ubiquitination | 2020 |
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Canada; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma | 2021 |
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 2021 |
Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Doxorubicin; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm, Residual; Nervous System Diseases; Progression-Free Survival; Proteasome Inhibitors; Thalidomide; Transplantation, Autologous; Vincristine | 2020 |
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Case-Control Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Quality of Life; Registries; Safety; Stem Cell Transplantation | 2021 |
Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report.
Topics: Abdominal Wall; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Examination; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Lenalidomide; Lymphoma, Large-Cell, Anaplastic; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Prednisone; Remission Induction; Skin Neoplasms; Transplantation, Autologous; Vincristine | 2020 |
Standardization of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Fluorodeoxyglucose F18; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stem Cell Transplantation | 2021 |
Self-management of immunomodulatory drug treatment in multiple myeloma patients.
Topics: Humans; Lenalidomide; Multiple Myeloma; Pharmaceutical Preparations; Reproducibility of Results; Self-Management | 2021 |
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Survival Rate | 2021 |
Ixazomib and lenalidomide maintenance therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Female; Glycine; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma | 2021 |
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Patient Dropouts; Prognosis; Retrospective Studies; Survival Rate; Transplantation, Autologous | 2020 |
Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Survival; Female; HEK293 Cells; Humans; Immunologic Factors; Lenalidomide; Mice; Mice, Inbred BALB C; Multiple Myeloma; Point Mutation; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2021 |
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunotherapy; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Standard of Care; Treatment Outcome | 2021 |
Persistent challenges with treating multiple myeloma early.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Cost of Illness; Dexamethasone; Disease Progression; Early Detection of Cancer; Humans; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Protease Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Smoldering Multiple Myeloma; Time-to-Treatment | 2021 |
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hypophosphatemia; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Thalidomide | 2021 |
Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial.
Topics: Cyclin D1; DNA Copy Number Variations; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Nerve Tissue Proteins; Prognosis; Recurrence | 2021 |
B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autografts; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation | 2020 |
Treatments for newly diagnosed multiple myeloma: when endurance is interrupted - Authors' reply.
Topics: Bortezomib; Dexamethasone; Humans; Intention; Lenalidomide; Multiple Myeloma; Oligopeptides | 2020 |
Treatments for newly diagnosed multiple myeloma: when endurance is interrupted.
Topics: Bortezomib; Dexamethasone; Humans; Intention; Lenalidomide; Multiple Myeloma; Oligopeptides | 2020 |
Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma.
Topics: Bortezomib; Dexamethasone; Humans; Ikaros Transcription Factor; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins | 2020 |
[Multiple myeloma with light chain deposition disease showing needle-like crystal inclusions in plasma cells and macrophages in multiple organs].
Topics: Humans; Lenalidomide; Macrophages; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Thalidomide | 2020 |
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Drug Administration Routes; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Young Adult | 2021 |
Original Versus Generic Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Comparison of Efficacy and Adverse Events
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Drugs, Generic; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Odds Ratio; Recurrence; Retreatment; Treatment Outcome | 2021 |
Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Progression-Free Survival | 2022 |
Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; United Kingdom | 2021 |
High-risk myeloma: a challenge to define and to determine the optimal treatment.
Topics: Antibodies, Monoclonal, Humanized; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2021 |
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Proteasome Inhibitors | 2021 |
Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Retrospective Studies; Taiwan; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2021 |
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Drug Resistance, Neoplasm; Genetic Variation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Ubiquitin-Protein Ligases | 2021 |
Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Progression-Free Survival; Republic of Korea | 2021 |
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Czech Republic; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Prospective Studies; Registries | 2021 |
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Retreatment; Retrospective Studies; Treatment Outcome | 2021 |
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Killer Cells, Natural; Lenalidomide; Mesenchymal Stem Cells; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Thalidomide | 2021 |
Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Oncogene Proteins, Fusion; Sulfonamides; Translocation, Genetic; Transplantation, Autologous; Treatment Failure | 2021 |
Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Exanthema; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Risk Factors | 2021 |
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual; Outcome Assessment, Health Care; Progression-Free Survival; Prospective Studies; Randomized Controlled Trials as Topic | 2021 |
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Retrospective Studies; Thalidomide; United States | 2021 |
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Oligopeptides; Progression-Free Survival; Thalidomide | 2021 |
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment.
Topics: Adult; Brugada Syndrome; Humans; Lenalidomide; Male; Multiple Myeloma | 2021 |
The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.
Topics: Canada; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Preoperative Care; Prognosis; Retrospective Studies; Treatment Outcome | 2021 |
Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Latin America; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Progression-Free Survival; Retrospective Studies | 2021 |
Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance.
Topics: Adult; Aged; Antineoplastic Agents; Female; Flow Cytometry; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pilot Projects; T-Lymphocytes, Regulatory | 2021 |
The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Topics: Adult; Aged; Aged, 80 and over; Animals; Bone Marrow; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Gene Knock-In Techniques; Humans; Ikaros Transcription Factor; Interferon Regulatory Factors; Lenalidomide; Male; Mice; Mice, Transgenic; Middle Aged; Multiple Myeloma; Primary Cell Culture; Proteolysis; Signal Transduction; Tumor Escape; Tumor Microenvironment; Tumor-Associated Macrophages; Ubiquitination; Young Adult | 2021 |
Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Depression; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2021 |
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy.
Topics: Aged; Clonal Hematopoiesis; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Venous Thrombosis | 2021 |
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2021 |
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Single-Cell Analysis; Treatment Outcome | 2021 |
A 77-Year-Old Man with Multiple Myeloma and a Lytic Bone Lesion.
Topics: Aged; Angiogenesis Inhibitors; Cryptococcosis; Humans; Lenalidomide; Male; Multiple Myeloma | 2021 |
Spindle cell morphology in myeloma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Shape; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Proteins; Plasma Cells | 2021 |
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Calreticulin; Dexamethasone; Humans; Hydroxyurea; Lenalidomide; Male; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Osteolysis; Primary Myelofibrosis; Remission Induction; Risk Factors; Sequence Deletion; Stomatitis, Aphthous; Thrombocythemia, Essential | 2021 |
Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Topics: Black or African American; Humans; Hyperpigmentation; Immunologic Factors; Incidence; Lenalidomide; Multiple Myeloma; Organ Specificity; Retrospective Studies; Thalidomide | 2021 |
Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2021 |
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy.
Topics: Autografts; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma | 2021 |
[Evaluation of the Clinical Efficacy and Prognosis of Long-Term Maintenance Lenalidomide Therapy in Patients with Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Treatment Outcome | 2021 |
Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.
Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cell Line, Tumor; Humans; Lenalidomide; Multiple Myeloma | 2021 |
Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2021 |
Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis.
Topics: Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Multiple Myeloma; Peripheral Blood Stem Cells; Retrospective Studies | 2021 |
[Progress in the treatment of multiple myeloma with daratumumab].
Topics: Antibodies, Monoclonal; Humans; Lenalidomide; Multiple Myeloma | 2021 |
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Topics: CRISPR-Cas Systems; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pharmaceutical Preparations | 2021 |
Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series.
Topics: Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Patient Acuity | 2021 |
[New European approvals: Carfilzomib with daratumumab and dexamethasone in refractory or relapsed multiple myeloma after a first line of treatment].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Administration Schedule; Drug Approval; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Randomized Controlled Trials as Topic | 2021 |
Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Health Expenditures; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Young Adult | 2021 |
Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy.
Topics: Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual | 2021 |
Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Delivery of Health Care; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies; Treatment Outcome | 2021 |
Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Japan; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pilot Projects; Prognosis; Prospective Studies | 2022 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2021 |
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.
Topics: Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2021 |
[Retrospective Analysis of Bortezomib or Lenalidomide for Very Elderly Patients with Newly Diagnosed Multiple Myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2021 |
A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM).
Topics: Humans; Lenalidomide; Mass Spectrometry; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual | 2021 |
DRESS syndrome after KRd (carfilzomib, lenalidomide, dexamethasone) therapy in a patient with multiple myeloma.
Topics: Dexamethasone; Drug Hypersensitivity Syndrome; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides | 2021 |
Multiple Myeloma with Systemic Amyloidosis: Serum Free Light Chain Dimerization Analysis in the Diagnosis of an Equivocal Case of Plasma Cell Dyscrasia.
Topics: Amyloidosis; Bone Marrow Examination; Cardiomyopathies; Dexamethasone; Humans; Immunoassay; Immunoglobulin Light Chains; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nephelometry and Turbidimetry; Paraproteinemias; Pelvic Bones; Protein Multimerization; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Humans; Hungary; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome | 2021 |
KRd: the new KiD in the French myeloma induction class.
Topics: Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local | 2021 |
Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Bortezomib; COVID-19; Female; Hospitalization; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; SARS-CoV-2; Treatment Outcome | 2021 |
A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Central Nervous System; Combined Modality Therapy; Female; Humans; Immunologic Factors; Injections, Spinal; Japan; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Prognosis; Radiotherapy; Research Design; Retrospective Studies; Surveys and Questionnaires; Survival Analysis | 2021 |
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bortezomib; Dexamethasone; Disease Management; Disease Susceptibility; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Oligopeptides; Retrospective Studies; Venous Thromboembolism | 2022 |
Case of lymphadenopathy with lytic bone lesions.
Topics: Bortezomib; Dexamethasone; Diagnosis, Differential; Humans; Incidental Findings; Lenalidomide; Lymphadenopathy; Male; Middle Aged; Multiple Myeloma; Osteolysis; Thalidomide; Treatment Outcome | 2017 |
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Combined Modality Therapy; Consolidation Chemotherapy; Dexamethasone; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Peripheral Nervous System Diseases; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Germany; Health Surveys; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Transplantation, Autologous | 2017 |
Hepatitis E during lenalidomide treatment for multiple myeloma in complete remission.
Topics: Aged; Female; Hepatitis E; Humans; Immunologic Factors; Lenalidomide; Liver Function Tests; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide; Transaminases | 2017 |
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lenalidomide; Leukemoid Reaction; Multiple Myeloma; Plasma Cells; Thalidomide | 2017 |
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Polymorphism, Single Nucleotide; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Motifs; Animals; Antineoplastic Agents; Gene Deletion; HCT116 Cells; HEK293 Cells; Humans; Lenalidomide; Mass Spectrometry; Mice; Multiple Myeloma; Myelodysplastic Syndromes; Peptide Hydrolases; Proteomics; Substrate Specificity; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination; Zinc Fingers | 2017 |
Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Databases, Factual; Drug Administration Schedule; Drug Costs; Eligibility Determination; Female; Health Expenditures; Health Services Accessibility; Healthcare Disparities; Humans; Immunologic Factors; Insurance Benefits; Lenalidomide; Male; Medicare Part D; Models, Economic; Multiple Myeloma; Process Assessment, Health Care; SEER Program; Thalidomide; Time Factors; Treatment Outcome; United States | 2017 |
Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.
Topics: Adult; Aged; Aged, 80 and over; Australia; Electronic Prescribing; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pharmacy Service, Hospital; Queensland; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bortezomib; Combined Modality Therapy; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pneumonia; Recombinant Fusion Proteins; Recurrence; Salvage Therapy; Syndecan-1; Thalidomide; Transplantation, Autologous | 2017 |
Bortezomib Does Not Prevent the Occurrence of Kaposi's Sarcoma in Patients with Haematological Malignancies: Two Case Reports.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Bortezomib; Female; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Sarcoma, Kaposi; Skin Neoplasms; Thalidomide | 2017 |
Haematological cancer: Where are we now with the treatment of multiple myeloma?
Topics: Bortezomib; Dexamethasone; Hematologic Neoplasms; Humans; Lenalidomide; Multiple Myeloma | 2017 |
Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Intention to Treat Analysis; Lenalidomide; Multiple Myeloma; Quality of Life; Reproducibility of Results; Thalidomide; Time Factors; Treatment Outcome | 2018 |
MUC1-C is a target in lenalidomide resistant multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Computational Biology; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Lenalidomide; Molecular Targeted Therapy; Mucin-1; Multiple Myeloma; Oxidation-Reduction; Peptides; Reactive Oxygen Species; Thalidomide; Tumor Cells, Cultured | 2017 |
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Coculture Techniques; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction; STAT Transcription Factors; Stromal Cells; Thalidomide; Time Factors | 2017 |
Impact of lenalidomide-based induction therapy on the mobilization of CD34
Topics: Aged; Antigens, CD34; Case-Control Studies; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Thalidomide | 2017 |
[A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Dexamethasone; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prospective Studies; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Very-Low-Dose Lenalidomide for Elderly and/or Frail Multiple Myeloma Patients: Lower Might Be Better.
Topics: Aged; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Body Weight; Clinical Trials as Topic; Creatinine; Female; Healthy Volunteers; Humans; Lenalidomide; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Myelodysplastic Syndromes; Young Adult | 2018 |
Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World Experience.
Topics: Aged; Aged, 80 and over; Dexamethasone; Female; Humans; Immunologic Factors; Japan; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2017 |
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Topics: Acetamides; Aged; Aged, 80 and over; Animals; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Disease Models, Animal; Drug Synergism; Female; Gene Expression Profiling; Humans; Ikaros Transcription Factor; Lenalidomide; Male; Mice; Middle Aged; Multiple Myeloma; Proteins; Proto-Oncogene Proteins c-myc; Signal Transduction; Thalidomide; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Circulating MicroRNA; Dexamethasone; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Prognosis; Recurrence; Reproducibility of Results; Retreatment; ROC Curve; Thalidomide; Treatment Outcome | 2017 |
Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Medicare; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Thalidomide; United States | 2017 |
False-positive pregnancy tests in females of reproductive potential receiving lenalidomide in the United States.
Topics: Abnormalities, Drug-Induced; Adult; Ectromelia; False Positive Reactions; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Maternal-Fetal Exchange; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Pregnancy; Pregnancy Tests; United States | 2018 |
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Topics: Adult; Aged; Aged, 80 and over; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Statistical; Multiple Myeloma; Neoplasm Staging; Retrospective Studies; Risk Assessment; ROC Curve; Survival Rate; Thalidomide | 2017 |
Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival-In Most.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2017 |
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Transplantation, Autologous; Treatment Outcome | 2018 |
Maintenance lenalidomide could be most relevant after first-line therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2017 |
A case of multiple myeloma with navicular bone involvement.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Osteolysis; Plasma Cells; Remission Induction; Stem Cell Transplantation; Tarsal Bones; Thalidomide | 2017 |
"Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cyclophosphamide; Cytoplasm; Dexamethasone; Diagnostic Errors; Erythroblasts; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Erythroblastic, Acute; Male; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2017 |
Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; G1 Phase; Heme Oxygenase-1; Histone Deacetylase Inhibitors; Humans; Janus Kinase 2; Lenalidomide; Multiple Myeloma; Resting Phase, Cell Cycle; Signal Transduction; STAT3 Transcription Factor; Thalidomide | 2018 |
Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cytotoxicity, Immunologic; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Immunological Synapses; Immunotherapy, Adoptive; Lenalidomide; Mice; Multiple Myeloma; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Signaling Lymphocytic Activation Molecule Family; T-Cell Antigen Receptor Specificity; T-Lymphocytes; Xenograft Model Antitumor Assays | 2018 |
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian; Black or African American; Bortezomib; Female; Health Services Accessibility; Healthcare Disparities; Hispanic or Latino; Humans; Lenalidomide; Male; Medicare; Multiple Myeloma; Process Assessment, Health Care; Proportional Hazards Models; Risk Factors; SEER Program; Stem Cell Transplantation; Thalidomide; Time Factors; Treatment Outcome; United States; White People | 2017 |
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Chromatin; DNA Methylation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Gene Expression Profiling; Humans; Lenalidomide; Morpholines; Multiple Myeloma; Peptide Hydrolases; Pyridones; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
[Expert consensus for the diagnosis and treatment of patients with renal impairment of multiple myeloma].
Topics: Consensus; Creatinine; Dexamethasone; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Multiple Myeloma; Renal Dialysis; Renal Insufficiency; Renal Insufficiency, Chronic; Thalidomide | 2017 |
Severe Hypoglycemia Caused by Lenalidomide.
Topics: Aged; Antineoplastic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Lenalidomide; Multiple Myeloma; Severity of Illness Index | 2018 |
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2018 |
Lenalidomide plus dexamethasone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2018 |
Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance.
Topics: Adult; Aged; Aged, 80 and over; Humans; Immunologic Factors; Lenalidomide; Lymphocytes; Middle Aged; Multiple Myeloma; Programmed Cell Death 1 Receptor | 2018 |
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Disease Progression; Female; France; Health Expenditures; Health Resources; Hospitalization; Humans; Italy; Lenalidomide; Male; Middle Aged; Models, Econometric; Multiple Myeloma; Retrospective Studies; Thalidomide; United Kingdom | 2018 |
Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Topics: Adult; Aged; Autografts; Disease-Free Survival; Humans; Lenalidomide; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Thalidomide; Time Factors; Transplantation, Autologous | 2018 |
Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report and review of the literature
.
Topics: Aged, 80 and over; Female; Humans; Immunoglobulin lambda-Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Nephrotic Syndrome; Thalidomide | 2018 |
Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Renal Insufficiency; Retrospective Studies | 2018 |
Retinal Pigment Epithelium Tears in a 67-Year-Old Man.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Dexamethasone; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucocorticoids; Humans; Hypertension; Immunoglobulin Light Chains; Kidney Transplantation; Lenalidomide; Male; Multiple Myeloma; Oligopeptides; Paraproteinemias; Retinal Detachment; Retinal Perforations; Retinal Pigment Epithelium; Stem Cell Transplantation; Tomography, Optical Coherence | 2018 |
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation.
Topics: Adult; Aged; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Herpes Zoster Vaccine; Humans; Lenalidomide; Male; Measles; Middle Aged; Multiple Myeloma; Mumps; Rubella; Transplantation Conditioning; Transplantation, Autologous | 2018 |
The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Clarithromycin; Dexamethasone; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2018 |
FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma.
Topics: Adolescent; Adult; Aged; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Transplantation, Autologous; United States; United States Food and Drug Administration; Young Adult | 2018 |
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Thalidomide | 2018 |
A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clarithromycin; Diabetes Mellitus; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2018 |
Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pulmonary Embolism; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2019 |
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Bone Marrow Examination; Drug Resistance; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peptide Hydrolases; Proto-Oncogene Proteins c-myc; Ubiquitin-Protein Ligases; Up-Regulation | 2018 |
[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Counseling; Dexamethasone; Female; Hospitals, University; Humans; Lenalidomide; Male; Medication Adherence; Melphalan; Multiple Myeloma; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Prospective Studies; Thalidomide | 2018 |
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Febrile Neutropenia; Female; Humans; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Thrombosis | 2018 |
Glioblastoma Multiforme in a Patient with Multiple Myeloma: A Case Report and Literature Review.
Topics: Aged; Glioblastoma; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Neoplasms, Second Primary | 2018 |
Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway.
Topics: 25-Hydroxyvitamin D3 1-alpha-Hydroxylase; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Cell Line, Tumor; Cytotoxins; Humans; Lenalidomide; Macrophages; Multiple Myeloma; Vitamin D | 2018 |
Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report.
Topics: Antineoplastic Agents; Female; Graft Rejection; Humans; Kidney Transplantation; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2018 |
Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report.
Topics: Aged; Brain; Dexamethasone; Female; Humans; JC Virus; Lenalidomide; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Myeloma; Neoplasm Invasiveness | 2019 |
Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
Topics: Bortezomib; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Coculture Techniques; Down-Regulation; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Interleukin-6; Lenalidomide; Multiple Myeloma; Neoplasm Invasiveness; Neovascularization, Pathologic; Thalidomide; Vascular Endothelial Growth Factor A | 2018 |
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous | 2018 |
One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
Topics: Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cytotoxicity, Immunologic; Female; Humans; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; Phenotype; Treatment Outcome | 2018 |
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.
Topics: Aged; Antigens, Ly; Antineoplastic Agents; Arginase; Biomarkers, Tumor; Bortezomib; CD11b Antigen; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloid-Derived Suppressor Cells | 2018 |
Widespread intronic polyadenylation diversifies immune cell transcriptomes.
Topics: 3' Untranslated Regions; Angiogenesis Inhibitors; Case-Control Studies; Gene Expression; Gene Library; Gene Ontology; Heavy Chain Disease; Humans; Immunoglobulin mu-Chains; Introns; Lenalidomide; Multiple Myeloma; Plasma Cells; Polyadenylation; Primary Cell Culture; Progression-Free Survival; Transcriptome | 2018 |
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Biomarkers, Tumor; Biopsy; Bone Marrow; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Mutation; Plasma Cells; Signal Transduction; Ubiquitin-Protein Ligases | 2019 |
Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides | 2018 |
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide | 2018 |
Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Hemorrhage; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazoles; Pyridones; Thalidomide; Thromboembolism; Thrombophilia | 2019 |
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Czech Republic; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Progression-Free Survival; Prospective Studies; Registries; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2018 |
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Cause of Death; Female; Geography; Global Burden of Disease; Global Health; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Quality-Adjusted Life Years; Young Adult | 2018 |
Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
Topics: Adaptor Proteins, Signal Transducing; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Structure-Activity Relationship; Thalidomide; Ubiquitin-Protein Ligases | 2018 |
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm, Residual; Progression-Free Survival; Randomized Controlled Trials as Topic; Risk Factors; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 2018 |
The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Observational Studies as Topic; Oligopeptides; Randomized Controlled Trials as Topic; Survival Analysis; Systematic Reviews as Topic | 2018 |
Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chile; Cost-Benefit Analysis; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Markov Chains; Middle Aged; Multiple Myeloma; Quality-Adjusted Life Years; Retrospective Studies | 2018 |
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2018 |
Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Lenalidomide; Markov Chains; Middle Aged; Multiple Myeloma; Quality-Adjusted Life Years; Recurrence; United States | 2018 |
Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.
Topics: Adult; Aged; Disease Progression; Female; Health Resources; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Registries; Transplantation, Autologous; Treatment Outcome; Young Adult | 2018 |
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Patterns, Physicians'; Prospective Studies; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2018 |
Second-generation immunomodulatory drugs in leptomeningeal myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Humans; Immunologic Factors; Lenalidomide; Male; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2019 |
Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4
Topics: Antineoplastic Agents; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases; Ubiquitination | 2018 |
Real‑world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Cross-Sectional Studies; Disease Management; Europe, Eastern; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Treatment Outcome; Young Adult | 2018 |
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Pain; Prognosis; Renal Insufficiency; Serum Albumin; Thalidomide | 2018 |
Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/\
refractory multiple myeloma: a real-life experience
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Pregnancy; Prognosis; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Turkey | 2018 |
GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Creatinine; Drug Dosage Calculations; Female; Glomerular Filtration Rate; Humans; Kidney; Lenalidomide; Male; Middle Aged; Models, Biological; Multiple Myeloma; Prospective Studies; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2019 |
Spindle cell lesion in the bone marrow.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Plasma Cells | 2018 |
Lenalidomide induced reversible parkinsonism, dystonia, and dementia in subclinical Creutzfeldt-Jakob disease.
Topics: Angiogenesis Inhibitors; Brain; Creutzfeldt-Jakob Syndrome; Dementia; Dystonia; Fatal Outcome; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Parkinsonian Disorders | 2018 |
CRISPRing the CRL4
Topics: Adaptor Proteins, Signal Transducing; Cullin Proteins; Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2018 |
Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation.
Topics: Hematopoietic Stem Cell Transplantation; Incidence; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Risk Factors; Survival Analysis; Transplantation, Autologous | 2019 |
Breast plasmacytoma with associated amyloidosis mimicking breast carcinoma.
Topics: Amyloidosis; Aspirin; Breast Diseases; Breast Neoplasms; Female; Humans; Immunoglobulin G; Immunoglobulin M; Lenalidomide; Mammography; Middle Aged; Multiple Myeloma; Plasmacytoma; Ultrasonography, Mammary | 2018 |
Two cases of reversible Fanconi syndrome induced by lenalidomide.
Topics: Aged; Biomarkers; Fanconi Syndrome; Female; Humans; Kidney Tubules, Proximal; Lenalidomide; Middle Aged; Multiple Myeloma | 2019 |
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.
Topics: Benzamides; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Morpholines; Multiple Myeloma; Polycomb Repressive Complex 2; Pyridones; Sequence Analysis, RNA | 2018 |
Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Analysis; Venous Thromboembolism | 2019 |
Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
Topics: Age Factors; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Myeloablative Agonists; Remission Induction; Transplantation Conditioning; Transplantation, Autologous | 2019 |
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Clinical Trials as Topic; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Survival Analysis; Treatment Outcome; White People | 2018 |
Novel combination of tanshinone I and lenalidomide induces chemo-sensitivity in myeloma cells by modulating telomerase activity and expression of shelterin complex and its associated molecules.
Topics: Abietanes; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Lenalidomide; Multiple Myeloma; Shelterin Complex; Telomerase; Telomere; Telomere-Binding Proteins | 2018 |
Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Topics: Adaptor Proteins, Signal Transducing; Animals; Down-Regulation; Humans; Ikaros Transcription Factor; Imidazoles; Lenalidomide; Mice; Mice, Inbred C57BL; Multiple Myeloma; Peptide Hydrolases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Pyridazines; Signal Transduction; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2019 |
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Lenalidomide; Middle Aged; Multiple Myeloma | 2019 |
Carfilzomib weekly 20/56 mg/m
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Recurrence; Salvage Therapy | 2019 |
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Female; Finland; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Progression-Free Survival; Thalidomide; Treatment Outcome | 2018 |
Multiple myeloma presenting as cutaneous leukocytoclastic vasculitis and eosinophilia disclosing a T helper type 1/T helper type 2 imbalance: a case report.
Topics: Aged, 80 and over; Bortezomib; Eosinophilia; Female; Humans; IgA Vasculitis; Immunologic Factors; Lenalidomide; Multiple Myeloma; Paraneoplastic Syndromes; Th1 Cells; Th2 Cells; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2018 |
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Topics: Allografts; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Magnetic Resonance Imaging; Melphalan; Multiple Myeloma; Panobinostat; Prognosis; Protease Inhibitors; Risk; Risk Assessment; Salvage Therapy; Transplantation, Autologous | 2018 |
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2018 |
Successful treatment of central nervous system myeloma manifesting as cauda equina nodules with intrathecal chemotherapy, lenalidomide and dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Cauda Equina; Central Nervous System Neoplasms; Dexamethasone; Humans; Injections, Spinal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome | 2018 |
Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptococcosis; Cryptococcus neoformans; Dexamethasone; Fatal Outcome; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Opportunistic Infections | 2019 |
A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone.
Topics: Aged; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies | 2019 |
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bortezomib; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Immune Reconstitution; Immunologic Factors; Lenalidomide; Leukocyte Count; Lymphocytes; Male; Middle Aged; Monocytes; Multiple Myeloma; Prognosis; Risk Factors; Survival Analysis; Time Factors; Transplantation, Autologous | 2019 |
Lenalidomide as maintenance for every newly diagnosed patient with multiple myeloma.
Topics: Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Thalidomide | 2019 |
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Topics: Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Flow Cytometry; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Real-Time Polymerase Chain Reaction; Risk Factors; Treatment Outcome | 2019 |
[Lenalidomide].
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Multiple Myeloma | 2016 |
Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Postoperative Care; Prognosis; Transplantation, Autologous; Treatment Outcome | 2019 |
Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale.
Topics: Autografts; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Dexamethasone; Drug Screening Assays, Antitumor; Drug Synergism; Janus Kinase 1; Lenalidomide; Male; Mice, SCID; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Oligopeptides; Protein Kinase Inhibitors; Specific Pathogen-Free Organisms; Xenograft Model Antitumor Assays | 2019 |
Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Survival Rate | 2018 |
Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
Topics: Administration, Oral; Adult; Aged; B-Lymphocytes; Biological Availability; Clinical Trials, Phase I as Topic; Creatinine; Datasets as Topic; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Biological; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Renal Elimination; Young Adult | 2019 |
A case of double-refractory multiple myeloma with both the IgH-MMSET fusion protein and the congenital abnormality t(11;22).
Topics: Aged; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 4; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Lenalidomide; Multiple Myeloma; Oncogene Proteins, Fusion | 2019 |
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glycine; Humans; Hungary; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Safety; Salvage Therapy; Survival Rate | 2019 |
lenalidomide (REVLIMID°) in untreated multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Survival Rate; Treatment Outcome | 2016 |
Detection of hemophagocytic extremely multinucleated giant plasma cells after rituximab/low-dose lenalidomide treatment in CD20
Topics: Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Dose-Response Relationship, Drug; Giant Cells; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Rituximab | 2019 |
Remission of light chain proximal tubulopathy in IgG λ-type multiple myeloma by lenalidomide and dexamethasone therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Immunologic Factors; Kidney Diseases; Lenalidomide; Multiple Myeloma; Remission Induction | 2019 |
Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Retrospective Studies; Treatment Outcome | 2019 |
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
Topics: Adaptor Proteins, Signal Transducing; Biomarkers, Tumor; Cell Line, Tumor; Comparative Genomic Hybridization; Cytokines; Drug Resistance, Neoplasm; Gene Expression; Humans; Immunomodulation; Interferon Regulatory Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Protein Binding; Signal Transduction; STAT3 Transcription Factor; Ubiquitin-Protein Ligases | 2019 |
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Core Binding Factor alpha Subunits; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Ubiquitin-Protein Ligases | 2019 |
Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Czech Republic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Registries; Slovakia; Survival Analysis; Treatment Outcome | 2019 |
Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dexamethasone; Drug Evaluation; Female; Ganciclovir; Humans; Immunocompromised Host; Lenalidomide; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Valganciclovir; Virus Activation | 2019 |
Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Topics: Age Factors; Aged; Antineoplastic Agents; Boron Compounds; Bortezomib; Drug Costs; Female; Glycine; Health Care Costs; Health Resources; Hospitalization; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Portugal; Practice Patterns, Physicians'; Progression-Free Survival; Proteasome Inhibitors; Stem Cell Transplantation; Survival Rate; Thalidomide | 2019 |
Response to the Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma".
Topics: Autografts; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2019 |
Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.
Topics: Adult; Aged; Autografts; Benzylamines; Chemotherapy, Adjuvant; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Induction Chemotherapy; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Peripheral Blood Stem Cell Transplantation; Regression Analysis; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2019 |
MAIA under the microscope - bringing trial design into focus.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Progression-Free Survival; Randomized Controlled Trials as Topic; Research Design; Standard of Care; Treatment Outcome | 2019 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Evaluation; Drug Substitution; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Protease Inhibitors; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2019 |
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide.
Topics: Angiogenesis Inhibitors; Disease Progression; Humans; Lenalidomide; Multiple Myeloma | 2019 |
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cytokines; Dexamethasone; Female; Humans; Lenalidomide; Lymphocyte Count; Male; Middle Aged; Multiple Myeloma; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Treatment Outcome | 2019 |
Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.
Topics: Animals; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Leflunomide; Lenalidomide; Mice; Multiple Myeloma; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-pim-1; Tumor Cells, Cultured | 2019 |
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; CRISPR-Cas Systems; Dendritic Cells; Drug Evaluation, Preclinical; HCT116 Cells; Humans; Intracellular Signaling Peptides and Proteins; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; RNA Interference; Ubiquitin | 2019 |
Evaluation of the safety and efficacy of daratumumab outside of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2019 |
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Topics: Antineoplastic Agents; DNA Copy Number Variations; Drug Resistance, Neoplasm; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome, Human; Humans; Ikaros Transcription Factor; Immunoglobulin lambda-Chains; Immunologic Factors; Lenalidomide; Multiple Myeloma; Myeloma Proteins; Plasma Cells; Prognosis; Protein Binding; Proto-Oncogene Proteins c-myc; Recurrence; Survival Analysis; Thalidomide; Translocation, Genetic; Whole Genome Sequencing | 2019 |
Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Disease Susceptibility; Eosinophilia; Exanthema; Female; Humans; Incidence; Lenalidomide; Male; Multiple Myeloma; Propensity Score | 2019 |
Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Premedication; Transplantation, Homologous | 2019 |
Redefining the treatment paradigm for multiple myeloma.
Topics: Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Banding; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Recurrence; Retrospective Studies; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous | 2019 |
Initial Therapy in Older Patients with Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2019 |
Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells.
Topics: Age Factors; Aged; Autografts; Cost-Benefit Analysis; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Spain | 2019 |
Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
Topics: Aged; Aged, 80 and over; Cancer Care Facilities; Desensitization, Immunologic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Exanthema; Female; Humans; Hypersensitivity, Delayed; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Outpatient Clinics, Hospital; Skin; Time Factors; Treatment Outcome | 2019 |
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Proportional Hazards Models; Survival Analysis; Teniposide; Treatment Outcome | 2019 |
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Disease Management; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Registries; Survival Analysis; Treatment Outcome; Young Adult | 2019 |
Clonal evolution in myeloma: a narrow road to remission.
Topics: Cells, Cultured; Clonal Evolution; Humans; Lenalidomide; Multiple Myeloma; Mutation | 2019 |
HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma.
Topics: Apoptosis; Benzene Derivatives; Cell Proliferation; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured | 2019 |
[Efficacy and Safety of Ixazomib-Lenalidomide-Dexamethasone Therapy for Relapsed and Refractory Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Glycine; Humans; Japan; Lenalidomide; Multiple Myeloma; Retrospective Studies | 2019 |
Kinome expression profiling to target new therapeutic avenues in multiple myeloma.
Topics: Cell Cycle Proteins; Humans; Immunologic Factors; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Protein Serine-Threonine Kinases | 2020 |
Facing lenalidomide-refractory myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2019 |
Efficacy and safety of autologous stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome | 2019 |
The future of checkpoint inhibition in multiple myeloma?
Topics: Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma | 2019 |
Relapsed multiple myeloma as TEMPI syndrome with good response to salvage lenalidomide and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Polycythemia; Recurrence; Salvage Therapy; Syndrome; Telangiectasis | 2019 |
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Humans; Lenalidomide; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Signaling Lymphocytic Activation Molecule Family; Thalidomide; Xenograft Model Antitumor Assays | 2020 |
Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Female; Hepatitis B virus; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Virus Activation | 2019 |
Assessing the impact of a matching-adjusted indirect comparison in a Bayesian network meta-analysis.
Topics: Bayes Theorem; Computer Simulation; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Network Meta-Analysis; Placebos; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risk Factors; Thalidomide | 2019 |
Disruption of IRE1α through its kinase domain attenuates multiple myeloma.
Topics: Aged; Animals; Bortezomib; Endoplasmic Reticulum Stress; Endoribonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Mice; Middle Aged; Multiple Myeloma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Signal Transduction; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2019 |
Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost of Illness; Dexamethasone; Disease-Free Survival; Female; Humans; Immunologic Factors; Lenalidomide; Male; Medicare; Middle Aged; Multiple Myeloma; Outcome Assessment, Health Care; United States | 2019 |
Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy.
Topics: Activins; Angiogenesis Inhibitors; Antibodies, Neutralizing; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Humans; Lenalidomide; MAP Kinase Signaling System; Multiple Myeloma; Osteoblasts; Stromal Cells; Thalidomide | 2013 |
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Management; Drug Administration Routes; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Recurrence; Risk; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2013 |
Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Salvage Therapy; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2013 |
Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Drug Administration Schedule; Fatal Outcome; Female; Humans; Iatrogenic Disease; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pneumonia; Thalidomide; Time Factors; Tomography, X-Ray Computed | 2013 |
"IM iD"eally treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient.
Topics: Angiogenesis Inhibitors; Focal Nodular Hyperplasia; Humans; Infarction; Lenalidomide; Liver; Liver Cirrhosis; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2013 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Polyneuropathies; Prospective Studies; Severity of Illness Index; Thalidomide | 2013 |
Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Mice, SCID; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Xenograft Model Antitumor Assays | 2013 |
Multiple myeloma: so much progress, but so many unsolved questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Outcome Assessment, Health Care; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2013 |
Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Cooperative Behavior; Humans; Lenalidomide; Multiple Myeloma; National Cancer Institute (U.S.); Survival Analysis; Thalidomide; United States | 2013 |
Lenalidomide-induced acute lung injury in case of multiple myeloma.
Topics: Acute Lung Injury; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Radiography; Thalidomide; Treatment Outcome | 2013 |
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Bone Marrow; Dexamethasone; Humans; Interferon Regulatory Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Peptide Hydrolases; Plasma Cells; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Thalidomide; Treatment Outcome; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2013 |
Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.
Topics: Apoptosis; Cell Degranulation; Cell Line, Tumor; Cell Proliferation; Cytokines; Dasatinib; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lysosomal-Associated Membrane Protein 1; Lysosomal-Associated Membrane Protein 2; Multiple Myeloma; Protein Kinase Inhibitors; Pyrimidines; Thalidomide; Thiazoles; TNF-Related Apoptosis-Inducing Ligand | 2014 |
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Pyrazines; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Female; Filgrastim; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recombinant Proteins; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2013 |
Cerebrospinal fluid penetrance of lenalidomide in meningeal myeloma.
Topics: Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult | 2013 |
Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
Topics: Humans; Immunologic Factors; Incidence; Lenalidomide; Multiple Myeloma; Prognosis; Thalidomide | 2013 |
Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dexamethasone; Female; Humans; Inflammation; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Th1 Cells; Th2 Cells; Thalidomide; Treatment Outcome | 2013 |
Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide.
Topics: Clarithromycin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2013 |
Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Insulin-Like Growth Factor I; Interleukin-8; Lenalidomide; Multiple Myeloma; Thalidomide; Tumor Necrosis Factor-alpha | 2013 |
Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Multiple Myeloma; Quality of Life; Thalidomide | 2013 |
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Retrospective Studies; Skin; Thalidomide | 2014 |
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Thalidomide | 2013 |
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Lenalidomide; Logistic Models; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Pyrazines; Retrospective Studies; Risk Factors; Survival Analysis; Thalidomide | 2014 |
[The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide].
Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Translocation, Genetic | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine | 2013 |
Disseminated keratotic spicules: a rare manifestation in multiple myeloma and successful response to lenalidomide.
Topics: Diagnosis, Differential; Humans; Immunologic Factors; Keratosis; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2013 |
Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma.
Topics: Aged; Blood Cell Count; Bone Marrow; Humans; Immunohistochemistry; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Thalidomide | 2013 |
Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
Topics: Blood Coagulation; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Phosphatidylserines; Pyrazines; Thalidomide; Thromboplastin | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Very low-dose lenalidomide therapy for elderly multiple myeloma patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
Topics: Acenocoumarol; Age Factors; Antineoplastic Agents; Aspirin; Female; Genetic Predisposition to Disease; Heparin, Low-Molecular-Weight; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; NF-kappa B; Polymorphism, Single Nucleotide; Protein Subunits; Pulmonary Embolism; Thalidomide; Venous Thrombosis | 2013 |
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression; Humans; Hyaluronan Receptors; Hyaluronic Acid; Immunologic Factors; Lenalidomide; Mice; Multiple Myeloma; Protein Binding; Thalidomide; Tretinoin; Xenograft Model Antitumor Assays | 2014 |
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Cohort Studies; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Thalidomide; Time Factors; Transplantation Conditioning; Treatment Outcome | 2013 |
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2013 |
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Republic of Korea; Singapore; Survival Rate; Tertiary Care Centers; Thalidomide | 2013 |
Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Genital Neoplasms, Male; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Orchiectomy; Proteasome Inhibitors; Pyrazines; Secondary Prevention; Spermatic Cord; Stem Cell Transplantation; Testicular Neoplasms; Thalidomide; Vincristine | 2014 |
[Synergistic effect and mechanism of baicalein in combination with lenalidomide-induced apoptosis of myeloma cells].
Topics: Apoptosis; Cell Line, Tumor; Drug Synergism; Flavanones; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2013 |
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Pomalidomide in the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chemokine CXCL12; Chromosome Aberrations; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Receptors, CXCR4; Survival Rate; Thalidomide | 2013 |
5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.
Topics: Abnormal Karyotype; Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2013 |
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Drug Eruptions; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Greece; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thalidomide; Treatment Outcome; Venous Thrombosis | 2014 |
Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Abscess; Female; Host-Pathogen Interactions; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Nocardia; Nocardia Infections; Pyrazines; Thalidomide | 2014 |
[Successful treatment of an HIV-positive multiple myeloma patient with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation and maintenance therapy with lenalidomide].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide | 2013 |
Memory loss during lenalidomide treatment: a report on two cases.
Topics: Adult; Aged; Angiogenesis Inhibitors; Humans; Immunologic Factors; Lenalidomide; Male; Memory Disorders; Multiple Myeloma; Thalidomide; Tomography, Emission-Computed, Single-Photon | 2013 |
[II. Immunomodulation for multiple myeloma].
Topics: Bone Marrow Transplantation; Glucosides; Humans; Immunomodulation; Lenalidomide; Multiple Myeloma; Phenols; Thalidomide | 2013 |
Transplants for the elderly in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2013 |
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Dexamethasone; Female; Greece; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Staging; Osteogenesis; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chromosome Aberrations; Dose-Response Relationship, Drug; Gene Expression; Humans; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
[Myeloma therapy(2) Treatment of transplant-ineligible patients].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Korea; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.
Topics: HMGB1 Protein; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Stevens-Johnson Syndrome; Thalidomide; Thrombomodulin | 2013 |
Initial treatment of nontransplant patients with multiple myeloma.
Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Cytokines; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2014 |
[Acute dyspnea, subfebrile temperatures and chills in a patient with multiple myeloma].
Topics: Acute Disease; Aged; Comorbidity; Dexamethasone; Dyspnea; Hematopoietic Stem Cell Transplantation; Humans; Hypothermia; Lenalidomide; Lung; Male; Multiple Myeloma; Neoplasm Staging; Pulmonary Diffusing Capacity; Radiotherapy, Adjuvant; Remission Induction; Respiratory Function Tests; Shivering; Thalidomide | 2014 |
Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
Topics: B-Lymphocytes; Female; Hodgkin Disease; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2014 |
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2014 |
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gossypol; Humans; Lenalidomide; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia | 2014 |
Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Topics: Adult; Antigens, Surface; Antineoplastic Agents; Case-Control Studies; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Homeostasis; Humans; Immunophenotyping; Lenalidomide; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasm Staging; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thalidomide; Thymus Gland; Transplantation, Autologous; Treatment Outcome | 2014 |
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Topics: Acute Kidney Injury; Anemia; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Drug Substitution; Flank Pain; Humans; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Renal Dialysis; Thalidomide | 2013 |
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Salvage Therapy; Thalidomide; Treatment Outcome; Withholding Treatment | 2014 |
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Cell Line, Tumor; HEK293 Cells; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Proteolysis; Teratogens; Thalidomide; Ubiquitin-Protein Ligases | 2014 |
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; HEK293 Cells; Humans; Ikaros Transcription Factor; Interleukin-2; Lenalidomide; Multiple Myeloma; Proteolysis; T-Lymphocytes; Thalidomide; Ubiquitination | 2014 |
A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide.
Topics: Animals; Cattle; Cloning, Molecular; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immune Sera; Lenalidomide; Multiple Myeloma; Rabbits; Sensitivity and Specificity; Serum Albumin, Bovine; Thalidomide | 2014 |
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endothelial Cells; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Panobinostat; Proteome; Pyrazines; Reactive Oxygen Species; Thalidomide; Transcription, Genetic | 2014 |
Potential new risks of lenalidomide.
Topics: Autoimmune Diseases; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2014 |
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Topics: Adult; Age Distribution; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Registries; Survival Analysis; Sweden; Thalidomide; Treatment Outcome | 2014 |
Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
Topics: Acyclovir; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotic Prophylaxis; Antiviral Agents; Encephalitis, Varicella Zoster; Female; Germany; Herpes Simplex; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunocompromised Host; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Polyradiculopathy; Risk Factors; Simplexvirus; Thalidomide | 2014 |
Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Thalidomide; Transplantation Conditioning | 2013 |
Multiple myeloma and other malignancies: a pilot study from the Houston VA.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Incidence; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pilot Projects; Proportional Hazards Models; Registries; Retrospective Studies; Survivors; Texas; Thalidomide; United States; United States Department of Veterans Affairs | 2014 |
Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Female; Glycosylation; GPI-Linked Proteins; Humans; Immunotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Side-Population Cells; Thalidomide; Up-Regulation | 2013 |
Case of angioedema and urticaria induced by lenalidomide.
Topics: Aged; Angioedema; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide; Urticaria | 2014 |
Lenalidomide and T-cell homeostasis: tolerating immune reconstitution after autologous stem cell transplant.
Topics: Antineoplastic Agents; Homeostasis; Humans; Lenalidomide; Multiple Myeloma; T-Lymphocyte Subsets; Thalidomide | 2014 |
An overview of the progress in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Drug Therapy, Combination; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Stem Cell Transplantation; Thalidomide | 2014 |
Medicine. How thalidomide works against cancer.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Teratogens; Thalidomide; Ubiquitin-Protein Ligases | 2014 |
Bortezomib-induced lung toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Substitution; Female; Humans; Lenalidomide; Lung Diseases; Multiple Myeloma; Pyrazines; Spirometry; Thalidomide | 2014 |
Multiple myeloma and second malignancies.
Topics: Female; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasms, Second Primary; Registries; Thalidomide | 2014 |
Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, Surface; Apoptosis; beta 2-Microglobulin; Cell Proliferation; Complement System Proteins; Humans; Immunologic Factors; Interleukin-6; Lenalidomide; Male; Mesenchymal Stem Cells; Mice; Mice, SCID; Multiple Myeloma; RNA Interference; RNA, Small Interfering; Thalidomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diffusion Magnetic Resonance Imaging; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prospective Studies; Pyrazines; Reproducibility of Results; Thalidomide; Treatment Outcome; Whole Body Imaging | 2014 |
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dendritic Cells; Humans; Lenalidomide; Lymphocyte Activation; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Pyrazines; T-Lymphocytes; Thalidomide; Toll-Like Receptor 9 | 2014 |
Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Necrobiotic Xanthogranuloma; Orbital Neoplasms; Thalidomide | 2013 |
Lenalidomide and second malignancies in myeloma patients.
Topics: Angiogenesis Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide | 2014 |
A limited sampling model to estimate exposure to lenalidomide in multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Area Under Curve; Asian People; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2014 |
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B-Cell Maturation Antigen; B-Lymphocytes; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Humans; Immunologic Factors; Immunotoxins; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Thalidomide | 2014 |
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prognosis; Pyrazines; Retreatment; Salvage Therapy; Thalidomide; Treatment Outcome | 2014 |
The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Flow Cytometry; Hematopoiesis; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide; Time Factors; Treatment Outcome; Young Adult | 2014 |
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drugs, Investigational; Europe; Female; Humans; Japan; Kaplan-Meier Estimate; Lenalidomide; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Consolidation Chemotherapy; Disease Management; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; United Kingdom | 2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2014 |
Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.
Topics: Aged; Female; Humans; Immunologic Factors; Immunologic Memory; Immunomodulation; Immunophenotyping; Lenalidomide; Lymphocyte Activation; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Phenotype; T-Lymphocyte Subsets; Thalidomide | 2014 |
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide | 2014 |
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Thalidomide; Time Factors; Treatment Outcome | 2015 |
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Topics: Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors | 2014 |
Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Clarithromycin; Dexamethasone; Humans; Immune Tolerance; Immunologic Factors; Interleukin-4 Receptor alpha Subunit; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Phosphodiesterase 5 Inhibitors; T-Lymphocytes; Tadalafil; Thalidomide | 2014 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid | 2014 |
Thalidomide and its analogues: comparative clinical efficacy and safety, and cost-effectiveness.
Topics: Angiogenesis Inhibitors; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2014 |
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; alpha Karyopherins; Anti-Inflammatory Agents; Biomarkers, Tumor; Blotting, Western; Carrier Proteins; Clinical Trials, Phase II as Topic; Dexamethasone; Drug Resistance, Neoplasm; Flow Cytometry; Follow-Up Studies; Humans; Ikaros Transcription Factor; Immunologic Factors; Immunoprecipitation; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Prognosis; Prospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Thalidomide; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2014 |
Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dendritic Cells; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2014 |
Allogeneic transplantation in multiple myeloma: a potential renaissance in the era of novel therapies?
Topics: Angiogenesis Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Transplantation Conditioning; Transplantation, Homologous | 2014 |
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Oligopeptides; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous | 2014 |
Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Blood Cell Count; Fatal Outcome; Humans; Knee; Lenalidomide; Male; Multiple Myeloma; Pyoderma Gangrenosum; Skin; Thalidomide | 2015 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib | 2014 |
[Immunomodulatory drugs (IMiDs)].
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms; Thalidomide | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Survival Rate; Tertiary Care Centers; Thalidomide; Treatment Outcome; Young Adult | 2015 |
Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
Topics: Fatal Outcome; Humans; Immunologic Factors; Leg; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Thalidomide | 2014 |
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line, Tumor; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Lenalidomide; Mice; Multiple Myeloma; Neoplasm Transplantation; Nerve Tissue Proteins; Plasmacytoma; Signal Transduction; Thalidomide; Trans-Activators | 2015 |
An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2015 |
Current treatment for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Stem Cell Transplantation; Thalidomide | 2014 |
[Successful treatment with a combination of lenalidomide and dexamethasone for cryoglobulinemia associated with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cryoglobulinemia; Dexamethasone; Female; Humans; Lenalidomide; Multiple Myeloma; Plasmapheresis; Thalidomide | 2014 |
A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Case-Control Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multidetector Computed Tomography; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
[Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Humans; Immunoglobulin A; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies | 2014 |
Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
Topics: Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Agents, Phytogenic; Cell Count; Drug Therapy, Combination; Female; Filgrastim; Gene Expression; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2015 |
Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment.
Topics: Aged; Bile Acids and Salts; Diarrhea; Female; Humans; Lenalidomide; Malabsorption Syndromes; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2014 |
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Female; Humans; Immunohistochemistry; Lenalidomide; Leukemia, Plasma Cell; Leukocyte Common Antigens; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Pyrazines; Remission Induction; Thalidomide; Time Factors; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure | 2015 |
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Time Factors; Treatment Outcome | 2015 |
RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
Topics: Angiogenesis Inhibitors; Apoptosis; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Messenger; RNA, Small Interfering; Thalidomide; Tumor Cells, Cultured | 2015 |
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Animals; Antibody-Dependent Cell Cytotoxicity; Bortezomib; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Immunotherapy; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Male; Mice; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Thalidomide; Xenograft Model Antitumor Assays | 2015 |
Successful re-administration of lenalidomide after lenalidomide-induced pulmonary alveolar hemorrhage in a patient with refractory myeloma.
Topics: Hemorrhage; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pulmonary Alveoli; Thalidomide | 2015 |
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.
Topics: Aged; Antineoplastic Agents; Australia; Boronic Acids; Bortezomib; Cost of Illness; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Respiratory Tract Infections; Risk Factors; Thalidomide | 2015 |
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.
Topics: Benzylamines; Cyclams; Cyclophosphamide; Data Collection; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphoma, Non-Hodgkin; Multiple Myeloma; Practice Patterns, Physicians'; Thalidomide | 2015 |
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Cells, Cultured; Cytotoxicity, Immunologic; Drug Synergism; Flow Cytometry; Humans; Immunoglobulin G; Immunophenotyping; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Receptors, IgG; Receptors, KIR; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thalidomide | 2015 |
Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Dexamethasone; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Myopathies, Nemaline; Neck Muscles; Thalidomide | 2015 |
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2015 |
Multiple myeloma: is a shift toward continuous therapy needed to move forward?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Stem Cell Transplantation; Thalidomide | 2015 |
A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Half-Life; Heterografts; Humans; Lenalidomide; Male; Mice, Inbred ICR; Mice, SCID; Multiple Myeloma; Nuclear Proteins; Nucleophosmin; Osteoclasts; Phthalimides; Thalidomide | 2015 |
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2015 |
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide | 2015 |
MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Drug Synergism; Humans; Immunoglobulin kappa-Chains; Immunophenotyping; Lenalidomide; Leukocytes, Mononuclear; Multiple Myeloma; Phenotype; Plasma Cells; Protein Binding; Thalidomide | 2015 |
[Latest advances on the maintenance therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
Severe hypocalcemia due to lenalidomide.
Topics: Aged; Calcium; Humans; Hypocalcemia; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Severity of Illness Index; Thalidomide | 2015 |
[Thalidomide-associated hypothyroidism in a patient with multiple myeloma].
Topics: Aged; Constipation; Humans; Hypothyroidism; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thyroid Function Tests | 2015 |
Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Cytokines; Female; Flow Cytometry; Follow-Up Studies; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pilot Projects; Prognosis; Prospective Studies; Thalidomide | 2015 |
When less is more: results Herald 'paradigm shift' in treating newly diagnosed multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Congresses as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide | 2014 |
Zeroing in on cereblon.
Topics: Adaptor Proteins, Signal Transducing; Carrier Proteins; Cullin Proteins; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; NF-kappa B; Peptide Hydrolases; Protein Binding; Signal Transduction; Thalidomide; Transcription Factor 3; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A | 2015 |
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Bortezomib; Costs and Cost Analysis; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide | 2015 |
Precipitation of ventricular bigeminy by DMSO during autologous haematopoietic stem cell transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrioventricular Block; Bortezomib; Cryoprotective Agents; Dexamethasone; Dimethyl Sulfoxide; Electrocardiography; Humans; Isotonic Solutions; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Ventricular Premature Complexes | 2015 |
Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Mice; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Thalidomide; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Drug Approval; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
[Carfilzomib in multiple myeloma relapses].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Heart; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2015 |
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
Topics: ADP-ribosyl Cyclase 1; Animals; Bortezomib; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2015 |
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Ital
Topics: Aged; Aging; Antigens, CD34; Biomarkers; Cell Count; Cell Separation; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Failure | 2015 |
A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Computer Simulation; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Netherlands; Quality-Adjusted Life Years; Survival Analysis; Thalidomide | 2016 |
New treatments highlighted for lymphoma and multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dexamethasone; Disease-Free Survival; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Oligopeptides; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2015 |
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma.
Topics: Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Proteolysis; Thalidomide | 2015 |
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Immunomodulation; In Vitro Techniques; Lenalidomide; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Thalidomide; Transfection; Vorinostat | 2015 |
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antigen-Presenting Cells; B7-H1 Antigen; Bone Marrow; Cell Line, Tumor; Cell Proliferation; Humans; Interferon-gamma; Lenalidomide; Multiple Myeloma; Programmed Cell Death 1 Receptor; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Microenvironment | 2015 |
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Neoplasms, Second Primary; Plasmacytoma; Pyrazines; Remission Induction; Risk; Thalidomide; Treatment Outcome | 2015 |
Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Purpura, Thrombotic Thrombocytopenic; Thalidomide | 2015 |
Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Down-Regulation; Female; Humans; Immunologic Factors; Inducible T-Cell Co-Stimulator Ligand; Lenalidomide; Male; Middle Aged; Multiple Myeloma; T-Lymphocytes, Regulatory; Thalidomide | 2015 |
Development of acquired hemophilia A during treatment of multiple myeloma with lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Hemophilia A; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2015 |
[Clinical observations of lenalidomide combination chemotherapy for relapsing or refractory multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Beijing; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2015 |
Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Dexamethasone; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult | 2015 |
Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Glomerular Basement Membrane; Glomerular Filtration Rate; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Kidney Diseases; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proteinuria; Retrospective Studies; Survival Rate; Thalidomide; Waldenstrom Macroglobulinemia | 2015 |
Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Treatment Outcome | 2015 |
Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment.
Topics: Anemia; Antineoplastic Agents; Female; Hemolysis; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2015 |
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Immunologic Factors; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Proportional Hazards Models; Proteasome Inhibitors; Radiography; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide and secondary acute lymphoblastic leukemia: a case series.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Thalidomide; Treatment Outcome; Young Adult | 2017 |
A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; HEK293 Cells; Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination | 2015 |
Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Dexamethasone; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2015 |
[Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma].
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Transplantation, Homologous | 2015 |
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antigens, Differentiation, T-Lymphocyte; Cell Line, Tumor; Female; Histocompatibility Antigens Class I; Humans; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Killer Cells, Natural; Lenalidomide; Ligands; Lymphocyte Activation; Male; Middle Aged; Multiple Myeloma; NK Cell Lectin-Like Receptor Subfamily K; Promoter Regions, Genetic; Receptors, Virus; Thalidomide | 2015 |
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Follow-Up Studies; Health Care Costs; Health Resources; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide | 2016 |
How I treat high-risk myeloma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide | 2015 |
[A Newly Diagnosed Case of Multiple Myeloma in Which Lenalidomide Was Continued after Surgery for a Pancreatic Neuroendocrine Tumor That Developed during Lenalidomide Maintenance Therapy].
Topics: Aged; Female; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Pancreatic Neoplasms; Thalidomide; Tomography, X-Ray Computed | 2015 |
Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Animals; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Female; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Mice, Inbred BALB C; Multiple Myeloma; Spleen; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide | 2015 |
[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Topics: Aged; Factor Xa Inhibitors; Female; Humans; Lenalidomide; Multiple Myeloma; Pyridines; Thalidomide; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism | 2015 |
Ischemic colitis diagnosed by magnetic resonance imaging during lenalidomide treatment in a patient with relapsed multiple myeloma.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Colitis, Ischemic; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Heparin; Humans; Lenalidomide; Magnetic Resonance Imaging; Metronidazole; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2016 |
Visceral leishmaniasis in relapsed and overtreated multiple myeloma in the era of high dose and "novel agent" therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Cyclophosphamide; Dexamethasone; Humans; Leishmaniasis, Visceral; Lenalidomide; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide | 2015 |
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
Topics: Aged; Antineoplastic Agents; Bortezomib; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; United Kingdom | 2015 |
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Expression Profiling; Histone Deacetylase Inhibitors; Humans; Hyaluronan Receptors; Immunoenzyme Techniques; Lenalidomide; Mice; Mice, Nude; Multiple Myeloma; Phenylbutyrates; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Flow Cytometry; Gene Knockdown Techniques; Humans; Ikaros Transcription Factor; Immunoblotting; Immunohistochemistry; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Proto-Oncogene Proteins c-myc; RNA, Small Interfering; Signal Transduction; Thalidomide | 2015 |
CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; CD4-Positive T-Lymphocytes; Immunomodulation; Lenalidomide; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Multiple Myeloma; Thalidomide | 2015 |
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Induction Chemotherapy; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome | 2016 |
Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide | 2016 |
Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Thalidomide; Treatment Outcome | 2015 |
Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Prednisone; Quality-Adjusted Life Years; Thalidomide; Treatment Outcome; United States | 2016 |
Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Cycle; Cyclophosphamide; Dexamethasone; Female; Genotype; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasm Staging; Neutropenia; Peptide Hydrolases; Polymorphism, Single Nucleotide; Thalidomide; Ubiquitin-Protein Ligases; Wnt Signaling Pathway | 2015 |
Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Blotting, Western; Bortezomib; Cell Line, Tumor; Humans; Lenalidomide; Multiple Myeloma; Peptide Hydrolases; Thalidomide; Ubiquitin-Protein Ligases | 2015 |
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease Progression; DNA, Neoplasm; Female; Germ-Line Mutation; Humans; Lenalidomide; Male; Membrane Glycoproteins; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prognosis; Receptors, Interleukin-1; Survival Analysis; Thalidomide; Toll-Like Receptor 4 | 2016 |
New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Topics: Bence Jones Protein; Bendamustine Hydrochloride; Blood Protein Electrophoresis; Bortezomib; Dexamethasone; Humans; Immunoelectrophoresis; Immunoglobulin G; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Thalidomide | 2016 |
Continued role for ASCT in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Multiple Myeloma; Prednisone; Thalidomide | 2015 |
Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Community Pharmacy Services; Fees, Pharmaceutical; Female; Humans; Lenalidomide; Male; Medication Adherence; Multiple Myeloma; Retrospective Studies; Thalidomide | 2016 |
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.
Topics: Animals; Caspase 3; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Ikaros Transcription Factor; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Plasma Cells; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Thalidomide; Trans-Activators | 2016 |
Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; Humans; Interleukin-6; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Phosphorylation; STAT3 Transcription Factor; Syndecan-1; Thalidomide | 2016 |
Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bortezomib; Dexamethasone; Erythrocyte Indices; Erythroid Cells; Erythropoiesis; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Thalidomide; Treatment Outcome | 2016 |
CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bortezomib; Female; Gene Expression; Humans; Immunohistochemistry; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Meta-Analysis as Topic; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Registries; SEER Program; Thalidomide; Young Adult | 2016 |
The Establishment of Indicators of Thrombocytopenia in Patients Receiving Lenalidomide Therapy.
Topics: Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Platelet Count; Retrospective Studies; Risk Factors; Thalidomide; Thrombocytopenia | 2015 |
[Quality of Life Is Associated with Combined Lenalidomide and Dexamethasone Treatment in Japanese Patients with Relapsed or Refractory Multiple Myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Quality of Life; Surveys and Questionnaires; Thalidomide | 2015 |
Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells.
Topics: Angiogenesis Inhibitors; Antibodies; Apoptosis; Base Sequence; Binding Sites; Cell Line, Tumor; Cullin Proteins; Down-Regulation; HEK293 Cells; Humans; Ikaros Transcription Factor; Lenalidomide; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Positive Regulatory Domain I-Binding Factor 1; Promoter Regions, Genetic; Protein Binding; RNA Interference; RNA, Small Interfering; Thalidomide; Ubiquitination | 2016 |
A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.
Topics: Carcinoma; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Second Primary; Thalidomide | 2015 |
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Immunomodulation; Lenalidomide; Mice, SCID; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Thalidomide; Treatment Outcome | 2016 |
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis; Recurrence; Registries; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2016 |
Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Disease Management; Exanthema; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Topics: Bortezomib; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Prognosis; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Hemorrhage; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Remission Induction; Thalidomide; Treatment Outcome; von Willebrand Diseases; von Willebrand Factor | 2016 |
Monoclonal gammopathy-associated pure red cell aplasia.
Topics: Adult; Aged; Bone Marrow; Dexamethasone; Diagnosis, Differential; Female; Humans; Immunoglobulins; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Plasma Cells; Red-Cell Aplasia, Pure; Reticulocyte Count; Reticulocytes; Thalidomide; Young Adult | 2016 |
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Consensus; Cytogenetics; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Risk Factors; Thalidomide; Transplantation, Autologous | 2016 |
Differential effects of lenalidomide during plasma cell differentiation.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Plasma Cells; Thalidomide | 2016 |
Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
Topics: Aged; Aged, 80 and over; Cohort Studies; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Renal Insufficiency; Retrospective Studies; Severity of Illness Index; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide - the new melphalan?
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Thalidomide | 2016 |
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Health Care Costs; Humans; Lenalidomide; Life Expectancy; Male; Middle Aged; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Sweden; Thalidomide; Treatment Outcome | 2016 |
Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; C-Reactive Protein; Chromosome Aberrations; Chromosomes, Human, Pair 1; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Exosomes; Female; Gene Amplification; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Microarray Analysis; MicroRNAs; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Risk Factors; Thalidomide; Tumor Microenvironment | 2016 |
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Argonaute Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; MicroRNAs; Multiple Myeloma; Peptide Hydrolases; Protein Binding; Thalidomide; Ubiquitin-Protein Ligases | 2016 |
Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.
Topics: Aged; Bile Duct Neoplasms; Bortezomib; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Cholangiocarcinoma; Humans; Lenalidomide; Male; Multiple Myeloma; Thalidomide; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
[Clinical Analysis of Multiple Myeloma Patients Aged over 80 Years].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2016 |
[Curative Efficacy of Lenalidomide plus Low Dose Dexamethasone for Multiple Myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Ifosfamide; Lenalidomide; Multiple Myeloma; Remission Induction; Thalidomide | 2016 |
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Internationality; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Prospective Studies; Salvage Therapy; Thalidomide | 2016 |
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice?
Topics: Aged; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Male; Multiple Myeloma; Risk Factors; Thalidomide; Thrombosis; Vitamin K | 2016 |
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Oligopeptides; Quality of Life; Quality-Adjusted Life Years; Recurrence; Thalidomide; United States | 2016 |
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bortezomib; Female; Humans; L-Selectin; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Recurrence; Survival Analysis; Thalidomide; Vascular Cell Adhesion Molecule-1 | 2016 |
Achievement of hemodialysis discontinuation with lenalidomide and dexamethasone therapy in a refractory BJP-type multiple myeloma patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Dialysis; Renal Insufficiency; Thalidomide; Treatment Outcome | 2016 |
Acute Renal Failure Associated with Lenalidomide Treatment in Multiple Myeloma: A Rare Occurrence?
Topics: Acute Kidney Injury; Aged; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
Topics: Adaptor Proteins, Signal Transducing; Basigin; Cell Cycle Proteins; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Oncogene Proteins; Peptide Hydrolases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Teratogenesis; Thalidomide; Ubiquitin-Protein Ligases | 2016 |
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.
Topics: Animals; Cell Line, Tumor; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Thalidomide; Virus Activation; Virus Latency | 2016 |
LC-MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Chromatography, Liquid; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Monitoring; Humans; Immunosuppressive Agents; Lenalidomide; Limit of Detection; Multiple Myeloma; Tandem Mass Spectrometry; Thalidomide | 2016 |
Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
Topics: Antineoplastic Agents; Bortezomib; Canada; Combined Modality Therapy; Costs and Cost Analysis; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2016 |
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Phenotype; Thalidomide | 2016 |
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide | 2016 |
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Odds Ratio; Population Surveillance; Retrospective Studies; Risk Factors; Thalidomide | 2017 |
Risk factors for neutropenia with lenalidomide plus dexamethasone therapy for multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Hemoglobins; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Risk Factors; Thalidomide | 2016 |
Pleural effusion as a manifestation of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diagnosis, Differential; Humans; Kidney Failure, Chronic; Lenalidomide; Lung Neoplasms; Male; Multiple Myeloma; Pleural Effusion; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Multiple Medium Amoebic Liver Abscesses Successfully Treated with Medication and Comprehensive Percutaneous Catheter Drainage.
Topics: Catheterization; Drainage; Female; Humans; Immunologic Factors; Lenalidomide; Liver Abscess, Amebic; Metronidazole; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Prospective Studies; Recurrence; Sensory Receptor Cells; Severity of Illness Index; Thalidomide; Time Factors | 2016 |
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Topics: Antineoplastic Agents; Bortezomib; Drug Therapy, Combination; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Panobinostat; Proportional Hazards Models; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dexamethasone; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Staging; Proportional Hazards Models; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2016 |
Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis.
Topics: Aged; Angiogenesis Inhibitors; Drug Monitoring; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Dialysis; Thalidomide; Treatment Outcome | 2016 |
Maintenance lenalidomide after transplantation: How much is enough?
Topics: Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2016 |
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2016 |
Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression; Gene Knockdown Techniques; Humans; Isoenzymes; Lenalidomide; MAP Kinase Signaling System; Multiple Myeloma; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; ras Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Thalidomide; TOR Serine-Threonine Kinases | 2017 |
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Enzyme Activation; Female; Humans; Immunoglobulin Isotypes; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasm, Residual; Oligopeptides; Proteasome Endopeptidase Complex; Thalidomide; Treatment Outcome | 2017 |
Expansion of Th
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Multiple Myeloma; T-Lymphocytes; Th1 Cells; Thalidomide; Zoledronic Acid | 2017 |
The possible role of burden of therapy on the risk of myeloma extramedullary spread.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Sarcoma, Myeloid; Survival Rate; Thalidomide | 2017 |
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Treatment Outcome; Vorinostat | 2016 |
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Consolidation Chemotherapy; Disease Progression; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Prospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cardiotoxicity; Heart Diseases; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Propensity Score; Proportional Hazards Models; Risk; Thalidomide | 2017 |
Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone and Bones; Bone Marrow; Bortezomib; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteolysis; Radiation Dosage; Retrospective Studies; Sensitivity and Specificity; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2016 |
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Thalidomide; Treatment Outcome | 2017 |
Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cohort Studies; Dexamethasone; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Survival Rate; Thalidomide; United States; Young Adult | 2017 |
Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs.
Topics: Aged; Antigens, CD34; Blood Cells; Bone Marrow Cells; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Thalidomide | 2017 |
High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Ikaros Transcription Factor; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2016 |
Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma.
Topics: Biomarkers; Cell Survival; Cytokines; Dendritic Cells; Humans; Immunologic Factors; Immunomodulation; Immunophenotyping; Lenalidomide; Multiple Myeloma; Phenotype; T-Lymphocyte Subsets; Thalidomide | 2017 |
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide | 2017 |
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Disease Progression; Gene Expression; Humans; Immunoglobulin Light Chains; Immunoglobulin M; Immunoglobulins; Lenalidomide; Multiple Myeloma; Prognosis; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2017 |
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Outpatient Clinics, Hospital; Retrospective Studies; Survival Rate; Thalidomide | 2017 |
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Lung Toxicity after Lenalidomide Treatment in a Patient with Multiple Myeloma.
Topics: Dexamethasone; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstitial; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2017 |
Polyvalent immunoglobulins, platelet lysate and lenalidomide: cocktail for polyfunctional NK cells expansion for multiple myeloma.
Topics: Blood Platelets; Cell Proliferation; Culture Media; Female; Humans; Immunoglobulins; Killer Cells, Natural; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2017 |
Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.
Topics: Aged; Angiogenesis Inhibitors; Female; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Renal Dialysis; Thalidomide | 2017 |
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.
Topics: Administration, Oral; Adult; Aged; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2017 |
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Registries; Thalidomide; Time Factors | 2017 |
Multiple myeloma cells' capacity to decompose H
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum Stress; Humans; Hydrogen Peroxide; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxidative Stress; Peptide Hydrolases; Peroxidase; Proteolysis; Thalidomide; Ubiquitin-Protein Ligases | 2017 |
Population pharmacokinetics of lenalidomide in multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Body Surface Area; Creatinine; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Thalidomide | 2017 |
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Topics: Biomarkers, Tumor; Bone Marrow Cells; Dexamethasone; Gene Expression; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Multiple Myeloma; Survival Rate; Thalidomide; Treatment Outcome | 2017 |
Treatment of newly diagnosed myeloma: Bortezomib-based triplet.
Topics: Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Thalidomide | 2016 |
Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status.
Topics: Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Risk Factors; Thalidomide | 2016 |
Recommend maintenance therapy with lenalidomide in multiple myeloma.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Transplantation, Autologous | 2016 |
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bortezomib; Humans; Lenalidomide; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Multiple Myeloma; Neoplasms, Multiple Primary; Positron Emission Tomography Computed Tomography; Thalidomide; Thoracic Vertebrae; Treatment Outcome | 2017 |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Evaluation, Preclinical; Humans; Immunoconjugates; Lenalidomide; Maytansine; Mice; Multiple Myeloma; Syndecan-1; Thalidomide | 2017 |
Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Survival; Dexamethasone; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Panobinostat; Protein Binding; Proteolysis; Proto-Oncogene Proteins c-abl; Thalidomide; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination | 2017 |
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Bortezomib; Casein Kinase I; Cell Line; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thalidomide; Tumor Suppressor Protein p53 | 2017 |
[Cold agglutinin disease of IgA class as early manifestation of multiple myeloma and resolution after treatment with new anti-myeloma drugs].
Topics: Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin A; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide | 2016 |
Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antilymphocyte Serum; Deprescriptions; Female; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Kidney; Kidney Transplantation; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Mycophenolic Acid; Polycystic Kidney, Autosomal Dominant; Tacrolimus; Thalidomide | 2017 |
Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy.
Topics: Aged; Factor Xa Inhibitors; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazoles; Pyridones; Thalidomide; Treatment Outcome; Venous Thromboembolism | 2017 |
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Approval; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Randomized Controlled Trials as Topic; Recurrence; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide-associated progressive multifocal leukoencephalopathy.
Topics: Humans; Lenalidomide; Leukoencephalopathy, Progressive Multifocal; Middle Aged; Multiple Myeloma; Prognosis | 2017 |
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbidity; Drug Resistance, Neoplasm; Europe; Female; Humans; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Quality of Life; Recurrence; Retreatment; Thalidomide; Treatment Outcome | 2017 |
[Treatment of myeloma in the elderly].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide | 2008 |
The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Endpoint Determination; Evidence-Based Medicine; Humans; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Research Design; Thalidomide; Treatment Outcome; United States | 2008 |
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Topics: Alkaline Phosphatase; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Thalidomide; Transforming Growth Factor beta | 2008 |
New treatments in multiple myeloma: beyond optimal treatment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2008 |
Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Lenalidomide; Mevalonic Acid; Multiple Myeloma; Protein Prenylation; Simvastatin; STAT3 Transcription Factor; Thalidomide | 2009 |
Lenalidomide therapy in systemic mastocytosis.
Topics: Aged; Female; Humans; Lenalidomide; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2009 |
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Glucocorticoids; Heparin, Low-Molecular-Weight; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Risk Factors; Thalidomide; Thromboembolism | 2009 |
Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Thalidomide | 2009 |
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.
Topics: Antineoplastic Agents; Cytoskeleton; Dexamethasone; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Models, Statistical; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Thalidomide; Time Factors; Treatment Outcome | 2008 |
Aspirin as thromboprophylaxis in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Chemoprevention; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Thrombosis | 2008 |
Myeloma patient wins fight for drug not yet approved by NICE.
Topics: Antineoplastic Agents; Drug Approval; England; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Terminally Ill; Thalidomide | 2008 |
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Placebos; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Clarithromycin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoglobulins; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Thalidomide | 2008 |
The current landscape of multiple myeloma treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Patient Selection; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous | 2008 |
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
Topics: Antigens, CD1; Cell Line; Cytotoxicity, Immunologic; Humans; Immunotherapy; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Thalidomide | 2008 |
A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
Topics: Anemia, Aplastic; Antineoplastic Agents; Biopsy; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2009 |
Novel agents in myeloma: an exciting saga.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Thrombosis | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2008 |
Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangitis; Hepatic Artery; Humans; Immunoglobulin Light Chains; Ischemia; Lenalidomide; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Thalidomide | 2009 |
Lenalidomide in renal insufficiency--balancing the risks and benefits.
Topics: Antineoplastic Agents; Area Under Curve; Humans; Lenalidomide; Multiple Myeloma; Renal Insufficiency; Risk; Thalidomide; Treatment Outcome | 2009 |
Health department sets up cost sharing deal for multiple myeloma drug.
Topics: Antineoplastic Agents; Cost Sharing; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2009 |
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
Topics: Age Factors; Aged; Analysis of Variance; Boronic Acids; Bortezomib; Drug Evaluation; Female; Greece; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
[Lenalidomid (Revlimid) in the treatment of multiple myeloma--first experience in the Czech Republic].
Topics: Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2008 |
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
Topics: Adult; Aged; Chromosome Aberrations; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Remission Induction; Retrospective Studies; Risk Assessment; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Lenalidomide; Multiple Myeloma; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Thalidomide; Time Factors; Treatment Outcome | 2009 |
Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Topics: Antineoplastic Agents; Dexamethasone; Drug Approval; Drug Therapy, Combination; France; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide | 2008 |
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow; Combined Modality Therapy; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Ifosfamide; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Failure; Vincristine | 2009 |
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Multiple Myeloma; Pyrazines; Research Design; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2009 |
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2009 |
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Consensus Development Conferences as Topic; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Medical Oncology; Multiple Myeloma; Pyrazines; Thalidomide | 2009 |
Neutrophilic dermatosis complicating lenalidomide therapy.
Topics: Antineoplastic Agents; Biopsy; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Skin; Sweet Syndrome; Thalidomide | 2009 |
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
Topics: Hematopoietic Stem Cell Transplantation; HLA-DR Antigens; Humans; Killer Cells, Natural; Lenalidomide; Leukopenia; Multiple Myeloma; Recurrence; Salvage Therapy; T-Lymphocytes; Thalidomide; Thrombocytopenia; Treatment Outcome | 2010 |
Lenalidomide for the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Health Care Rationing; Humans; Lenalidomide; Multiple Myeloma; Quality-Adjusted Life Years; Recurrence; Technology Assessment, Biomedical; Thalidomide; United Kingdom | 2009 |
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Thalidomide | 2009 |
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
Topics: Antineoplastic Agents; Bone Morphogenetic Protein 2; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Humans; Lenalidomide; Multiple Myeloma; Osteoblasts; Pyrazines; RNA, Messenger; Sp7 Transcription Factor; Thalidomide; Transcription Factors; Tumor Cells, Cultured | 2010 |
[Lenalidomide in the treatment of multiple myeloma].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2009 |
Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lenalidomide; Male; Multiple Myeloma; Plasma Cells; Remission Induction; Thalidomide | 2009 |
Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Histone Demethylases; Histones; Humans; Lenalidomide; Lymphoma; Multiple Myeloma; Oxidoreductases, N-Demethylating; Thalidomide; Transcription Factors | 2009 |
Myeloma-associated polyneuropathy responding to lenalidomide.
Topics: Adult; Female; Humans; Lenalidomide; Multiple Myeloma; Paraneoplastic Polyneuropathy; Thalidomide | 2009 |
Relapse/Refractory myeloma patient: potential treatment guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Towards a new standard of care for patients with myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Quality of Health Care; Risk Assessment; Thalidomide; Time Factors; Treatment Outcome | 2010 |
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Venous Thromboembolism | 2010 |
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
Topics: Acneiform Eruptions; Aged; Boronic Acids; Bortezomib; Candida albicans; Candidiasis; Desonide; Dexamethasone; Doxycycline; ErbB Receptors; Fluconazole; Folliculitis; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
Researchers debate best use of stem cell transplants in patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chronic Disease; Clinical Trials as Topic; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2009 |
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dexamethasone; Disease Models, Animal; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Panobinostat; Pyrazines; Random Allocation; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Down-Regulation; Granulocyte Colony-Stimulating Factor; Granulocyte Precursor Cells; Granulocytes; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Myeloid Progenitor Cells; Neutropenia; Neutrophils; Platelet Aggregation; Proto-Oncogene Proteins; Risk Factors; Thalidomide; Trans-Activators; Venous Thromboembolism | 2010 |
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; In Vitro Techniques; Lactones; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrroles; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide; Young Adult | 2010 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Pyrazines; Thalidomide; Transplantation, Autologous; Vincristine | 2010 |
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous | 2010 |
Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Thalidomide | 2010 |
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
Topics: Adenosine Triphosphate; Apoptosis; Biomarkers, Tumor; Blotting, Western; Caspase Inhibitors; Caspases; Cell Proliferation; Dexamethasone; Drug Synergism; Gene Expression Profiling; Humans; Immunomodulation; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Retinoblastoma Protein; T-Lymphocytes; Thalidomide; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2010 |
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma.
Topics: Adult; Antineoplastic Agents; Cryoglobulinemia; HLA-B27 Antigen; Humans; Lenalidomide; Lumbar Vertebrae; Male; Multiple Myeloma; Sacroiliac Joint; Spondylarthropathies; Thalidomide | 2010 |
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Clone Cells; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Karyotyping; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Polyploidy; Protease Inhibitors; Pyrazines; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2010 |
Lenalidomide-induced interstitial lung disease.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Diagnosis, Differential; Dinoprostone; Female; Humans; Lenalidomide; Lung; Lung Diseases, Interstitial; Multiple Myeloma; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Creatinine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Kidney; Lenalidomide; Male; Methotrexate; Middle Aged; Multiple Myeloma; Renal Insufficiency; Thalidomide | 2010 |
Multiple myeloma patients experience high response rate with new three-drug combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Humans; Lenalidomide; Leukocytes; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2009 |
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide; Time Factors; Treatment Outcome; X-Rays | 2010 |
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide | 2010 |
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Panobinostat; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2010 |
Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
Topics: Antigens, CD34; Antineoplastic Agents; Blood Component Removal; Cyclophosphamide; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Medical Records; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2011 |
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous | 2010 |
Treatment of newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2008 |
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
Topics: Antibodies, Monoclonal; Antigen-Antibody Complex; Antigens, CD; Antineoplastic Agents; Apoptosis Regulatory Proteins; B7-H1 Antigen; Cell Line, Tumor; Chemokine CXCL12; Cytotoxicity, Immunologic; Down-Regulation; Humans; In Vitro Techniques; Interferon-gamma; K562 Cells; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Programmed Cell Death 1 Receptor; Receptors, CXCR4; Signal Transduction; Thalidomide | 2010 |
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Salvage Therapy; Thalidomide; Treatment Outcome | 2010 |
Clinical management of myeloma--state of the art.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.
Topics: Antigens, CD34; Antineoplastic Agents; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide | 2011 |
Lenalidomide-induced hypersensitivity pneumonitis.
Topics: Adrenal Cortex Hormones; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential; Drug Hypersensitivity; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2010 |
A case of lenalidomide-induced hypersensitivity pneumonitis.
Topics: Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Diagnosis, Differential; Drug Hypersensitivity; Humans; Lenalidomide; Lung; Male; Multiple Myeloma; Thalidomide; Tomography, X-Ray Computed | 2010 |
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2010 |
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytogenetic Analysis; Female; Humans; Immunomodulation; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide | 2010 |
Frontline regimens for multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results.
Topics: Aged; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Spin Labels; Thalidomide; Treatment Outcome | 2010 |
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cytokines; Epigenesis, Genetic; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Signal Transduction; Stromal Cells; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; T-Lymphocytes; Thalidomide | 2010 |
Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Dialysis; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide-induced acute interstitial nephritis.
Topics: Acute Disease; Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Nephritis, Interstitial; Thalidomide | 2010 |
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide for bortezomib-resistant multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Health Status Indicators; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Failure | 2010 |
Lenalidomide efficacy in bortezomib-resistant myeloma.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Gene Deletion; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Risk Factors; Thalidomide; Treatment Failure | 2010 |
Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Retrospective Studies; Thalidomide; Treatment Outcome | 2011 |
Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 1; Cohort Studies; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.
Topics: Aged; Anti-Inflammatory Agents; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Blotting, Western; Case-Control Studies; Cell Proliferation; Clinical Trials, Phase II as Topic; Cytotoxicity, Immunologic; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Flow Cytometry; Humans; Immunization; Interleukin-2; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Multiple Myeloma; Natural Cytotoxicity Triggering Receptor 1; NK Cell Lectin-Like Receptor Subfamily K; Prospective Studies; T-Lymphocytes; Thalidomide | 2011 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Complement System Proteins; Cytotoxicity, Immunologic; Humans; Immunophenotyping; Immunotherapy; Lenalidomide; Multiple Myeloma; Thalidomide; Tumor Cells, Cultured | 2011 |
In vivo efficacy of griseofulvin against multiple myeloma.
Topics: Animals; Antifungal Agents; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Ciclopirox; Griseofulvin; Humans; Immunosuppressive Agents; Lenalidomide; Lymphoma; Mice; Mice, Inbred BALB C; Multiple Myeloma; Pyridones; Signal Transduction; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Survival Rate; Thalidomide | 2010 |
Lenalidomide: an update on evidence from clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2010 |
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Discovery; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Survival Rate; Thalidomide; Transplantation, Autologous; Young Adult | 2011 |
A new standard of care in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Standard of Care; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2011 |
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.
Topics: Antineoplastic Agents; beta Catenin; Casein Kinase Ialpha; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Proto-Oncogene Proteins c-myc; Signal Transduction; Thalidomide; Transcription, Genetic; Wnt Proteins; Wnt3 Protein; Wnt3A Protein | 2011 |
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Costs; Drug Resistance, Neoplasm; Drug Utilization; Female; France; Health Care Costs; Hospitals, University; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Pyrazines; Recurrence; Retrospective Studies; Thalidomide | 2011 |
Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Inflammation Mediators; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2011 |
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Thalidomide | 2011 |
Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Apoptosis Regulatory Proteins; Bone Marrow Cells; Cell Movement; Chemokine CCL2; Chemokine CXCL12; Chickens; Chorioallantoic Membrane; Culture Media, Conditioned; Endothelial Cells; Female; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lenalidomide; Male; Membrane Proteins; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Proteome; Proto-Oncogene Proteins; Selenoprotein W; Signal Transduction; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Coma; Fatal Outcome; Female; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Stroke; Thalidomide; Thromboembolism; Tomography, X-Ray Computed | 2011 |
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; ATP-Binding Cassette Transporters; Bone Marrow Cells; Cell Division; Cell Fractionation; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Signal Transduction; Stromal Cells; Syndecan-1; Thalidomide | 2011 |
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Interactions; Drug Resistance, Neoplasm; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Retrospective Studies; Thalidomide; Treatment Outcome | 2011 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
Topics: Apoptosis; Blotting, Western; CCAAT-Enhancer-Binding Protein-beta; Cell Separation; Down-Regulation; Eukaryotic Initiation Factor-4E; Flow Cytometry; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Immunohistochemistry; Immunologic Factors; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Transfection | 2011 |
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzimidazoles; Cell Line, Tumor; Drug Synergism; Humans; Lenalidomide; Male; Mice; Mice, SCID; Models, Biological; Multiple Myeloma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; STAT3 Transcription Factor; Thalidomide; Treatment Outcome; Urea; Xenograft Model Antitumor Assays | 2011 |
Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.
Topics: Adrenal Insufficiency; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bence Jones Protein; Calcium; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Monitoring, Physiologic; Multiple Myeloma; Patient Selection; Radiography; Thalidomide; Time; Treatment Outcome; Venous Thromboembolism | 2011 |
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Control Studies; Cytokine Receptor gp130; Female; GATA2 Transcription Factor; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Receptors, CXCR4; T-Lymphocyte Subsets; Thalidomide; Transplantation, Autologous | 2011 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2011 |
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Dexamethasone; Disease-Free Survival; Drug Evaluation; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Mitotic Index; Multiple Myeloma; Plasma Cells; Proportional Hazards Models; Retrospective Studies; Thalidomide; Treatment Outcome | 2011 |
Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Stevens-Johnson Syndrome; Thalidomide; Transplantation, Homologous | 2012 |
Spontaneous huge hematoma in the abdominal wall after lenalidomide.
Topics: Abdomen, Acute; Abdominal Wall; Antineoplastic Agents; Female; Hematoma; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide; Tomography, X-Ray Computed | 2011 |
Thalidomide: the tragedy of birth defects and the effective treatment of disease.
Topics: Abnormalities, Drug-Induced; Angiogenesis Inhibitors; Animals; Dose-Response Relationship, Drug; Ectromelia; Female; Humans; Lenalidomide; Leprosy; Multiple Myeloma; Nausea; Oxidative Stress; Pregnancy; Teratogens; Thalidomide; Treatment Outcome; United States | 2011 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane | 2011 |
Allogeneic transplantation in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Mice; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2011 |
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Thalidomide; Translocation, Genetic | 2011 |
Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy.
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Health Services Accessibility; Humans; Lenalidomide; Multiple Myeloma; Placebos; Quality of Life; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytogenetics; Dexamethasone; Humans; Immunoglobulin Isotypes; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Time Factors; Transplantation, Homologous; Treatment Outcome | 2011 |
Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematologic Neoplasms; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Thyroid Diseases; Thyroid Function Tests | 2011 |
Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Diffuse alveolar hemorrhage associated with lenalidomide.
Topics: Aged; Antineoplastic Agents; Hemorrhage; Humans; Lenalidomide; Male; Multiple Myeloma; Pulmonary Alveoli; Radiography; Thalidomide | 2011 |
Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Lenalidomide; Male; Multiple Myeloma; Plasmacytoma; Sarcoma, Myeloid; Thalidomide | 2012 |
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retreatment; Thalidomide | 2011 |
Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Cells, Cultured; Cytokines; Down-Regulation; Epitopes, T-Lymphocyte; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukocyte Common Antigens; Lymphocyte Activation; Middle Aged; Multiple Myeloma; Paraproteinemias; T-Lymphocyte Subsets; Thalidomide; Up-Regulation | 2011 |
Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swed
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Sweden; Thalidomide | 2011 |
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genes, myc; Humans; Interferon Regulatory Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Prognosis; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Treatment Outcome; Tumor Cells, Cultured | 2011 |
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, Western; Boron Compounds; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thalidomide; Xenograft Model Antitumor Assays | 2011 |
Reversible pulmonary toxicity due to lenalidomide.
Topics: Antineoplastic Agents; Cough; Dyspnea; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2012 |
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Agents; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Regression Analysis; Survival Analysis; Thalidomide | 2011 |
Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Plasmacytoma; Recurrence; Thalidomide | 2011 |
Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin A; Lenalidomide; Middle Aged; Multiple Myeloma; Pemphigus; Pyrazines; Remission Induction; Thalidomide | 2011 |
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosome Aberrations; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Peptide Hydrolases; Pyrazines; RNA, Small Interfering; Thalidomide; Ubiquitin-Protein Ligases | 2011 |
Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Economic; Multiple Myeloma; Norway; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Thalidomide | 2011 |
Sudden significant total protein concentration change: not an analytical problem.
Topics: Aged; Antineoplastic Agents; Blood Proteins; Boronic Acids; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Serum Albumin; Serum Globulins; Thalidomide | 2011 |
A third-generation IMiD for MM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Multiple Myeloma; Stevens-Johnson Syndrome; Thalidomide | 2011 |
Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Monitoring; Drugs, Investigational; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin M; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2012 |
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigen-Antibody Complex; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cytotoxicity, Immunologic; Drug Evaluation, Preclinical; Humans; Immunomodulation; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Ligands; Mice; Mice, Inbred C57BL; Multiple Myeloma; Receptors, KIR; Thalidomide; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2012 |
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Depression; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Exanthema; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Prognosis; Recurrence; Risk Factors; Thalidomide; Treatment Outcome; Tremor | 2012 |
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
Topics: Aged; Antineoplastic Agents; Cytokines; Female; Fever; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2011 |
Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholestasis, Intrahepatic; Humans; Jaundice; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2012 |
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Myeloma and second primary cancers.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Leukemia, Myeloid; Melphalan; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Probability; Risk Assessment; Thalidomide | 2011 |
Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Dexamethasone; Drug Eruptions; Female; HLA-A Antigens; HLA-B Antigens; HLA-C Antigens; HLA-DQ beta-Chains; HLA-DRB1 Chains; Humans; Italy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prednisolone; Severity of Illness Index; Thalidomide; White People | 2012 |
What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
Cerebral venous thrombosis in an individual with multiple myeloma treated with lenalidomide.
Topics: Aged, 80 and over; Antineoplastic Agents; Female; Humans; Intracranial Thrombosis; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thrombosis | 2011 |
Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.
Topics: Antineoplastic Agents; Humans; Immunomodulation; Immunosuppressive Agents; Lenalidomide; Lung Diseases, Interstitial; Male; Middle Aged; Multiple Myeloma; Radiography; Thalidomide | 2012 |
Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Drug Administration Schedule; Humans; Lenalidomide; Lymphocyte Count; Middle Aged; Multiple Myeloma; T-Lymphocytes; T-Lymphocytes, Regulatory; Thalidomide; Treatment Outcome | 2012 |
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
Drug interaction between lenalidomide and itraconazole.
Topics: Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Female; Humans; Intestinal Absorption; Itraconazole; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Prednisone; Thalidomide | 2012 |
Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cells, Cultured; Dexamethasone; Humans; Immunoglobulin G; Immunoglobulin M; Interleukin-2; Interleukin-6; Lenalidomide; Leukocytes, Mononuclear; Multiple Myeloma; Pokeweed Mitogens; Thalidomide | 2012 |
Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, CD; Antineoplastic Agents; Cell Degranulation; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Synergism; Female; GPI-Linked Proteins; Humans; Immunoglobulin Fc Fragments; Killer Cells, Natural; Lenalidomide; Lymphocyte Activation; Lymphocyte Depletion; Macaca fascicularis; Mice; Mice, SCID; Multiple Myeloma; Phagocytosis; Plasma Cells; Thalidomide; Xenograft Model Antitumor Assays | 2012 |
Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Topics: Adult; Aged; Antigens, CD34; Blood Platelets; Cyclophosphamide; Drug Administration Schedule; Drug Dosage Calculations; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutrophils; Remission Induction; Thalidomide; Transplantation, Autologous; Treatment Failure | 2012 |
p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Cell Nucleus; Chromosomes, Human, Pair 17; Dexamethasone; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Gene Deletion; Hemizygote; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Survival Rate; Thalidomide; Tumor Suppressor Protein p53 | 2012 |
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2012 |
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Growth Differentiation Factor 15; Humans; Lenalidomide; Male; Melphalan; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Signal Transduction; Thalidomide | 2012 |
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Renal Insufficiency; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Topics: Animals; beta Catenin; Cell Line, Tumor; Disease Models, Animal; Diuretics; Drug Therapy, Combination; Ethacrynic Acid; Humans; Lenalidomide; Mice; Mice, Inbred BALB C; Multiple Myeloma; Thalidomide; Wnt Signaling Pathway | 2012 |
Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy.
Topics: Aged; Castleman Disease; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Meninges; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Osteolysis; POEMS Syndrome; Prospective Studies; Thalidomide; Vascular Endothelial Growth Factor A | 2012 |
Multiple myeloma and immunomodulation: regulating the regulatory cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclic AMP; Dexamethasone; Glucocorticoids; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Male; Models, Immunological; Multiple Myeloma; Signal Transduction; T-Lymphocytes; T-Lymphocytes, Regulatory; Thalidomide | 2012 |
[Case report: Reversible posterior leukoencephalopathy associated with the treatment of multiple myeloma: a case report].
Topics: Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Renal Insufficiency; Thalidomide | 2012 |
Thalidomide and lenalidomide: overview of the French pharmacovigilance database.
Topics: Databases, Factual; France; Hematologic Diseases; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Neurotoxicity Syndromes; Off-Label Use; Pharmacovigilance; Thalidomide; Vascular Diseases | 2012 |
Hair repigmentation associated with the use of lenalidomide: graying may not be an irreversible process!
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Cell Differentiation; Cell Movement; Cytokines; Hair Color; Hair Follicle; Humans; Lenalidomide; Male; Melanocytes; Multiple Myeloma; Thalidomide | 2013 |
Therapy with lenalidomide plus dexamethasone-induced bone formation in a patient with refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Dexamethasone; Female; Humans; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteogenesis; Radiography; Thalidomide | 2012 |
Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
Topics: Aged; Algorithms; Antigens, CD34; Benzylamines; Cyclams; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Thalidomide | 2012 |
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Humans; Humerus; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; POEMS Syndrome; Prednisolone; Recurrence; Salvage Therapy; Thalidomide; Transplantation, Autologous | 2012 |
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
Topics: Activins; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Case-Control Studies; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Survival Rate; Thalidomide | 2012 |
Multiple myeloma: treatment evolution.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Young Adult | 2012 |
Frontline treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide | 2012 |
Stem cell transplantation for multiple myeloma: current and future status.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Developing Countries; History, 20th Century; History, 21st Century; Humans; Lenalidomide; Multiple Myeloma; Patient Care; Pyrazines; Stem Cell Transplantation; Thalidomide | 2012 |
Targeted therapy of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Secondary Prevention; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2012 |
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
Topics: Antigens, CD; Antineoplastic Agents; Bone Marrow Cells; Female; Humans; Immunophenotyping; Lenalidomide; Male; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2012 |
Lenalidomide in myeloma--a high-maintenance friend.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Stem Cell Transplantation; Thalidomide | 2012 |
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Lenalidomide; Male; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; State Medicine; Survival Analysis; Thalidomide; United Kingdom | 2013 |
Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Heme Oxygenase-1; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Tumor Cells, Cultured | 2012 |
Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations.
Topics: Cohort Studies; Humans; Infections; Lenalidomide; Multiple Myeloma; Thalidomide | 2012 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Lenalidomide enhances anti-myeloma cellular immunity.
Topics: Antineoplastic Agents; Cancer Vaccines; Cell Proliferation; Dendritic Cells; Humans; Immunity, Cellular; Immunoblotting; Lenalidomide; Lymphocyte Activation; Multiple Myeloma; T-Lymphocyte Subsets; T-Lymphocytes; Thalidomide | 2013 |
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Risk Factors; Thalidomide; Treatment Outcome | 2012 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine | 2013 |
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; PAX5 Transcription Factor; Phenotype; Positive Regulatory Domain I-Binding Factor 1; Prognosis; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Regulatory Factor X Transcription Factors; Repressor Proteins; Syndecan-1; Thalidomide; Transcription Factors; X-Box Binding Protein 1 | 2012 |
[It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide | 2012 |
Lenalidomide: second cancers.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Pharmacovigilance; Thalidomide | 2012 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Thalidomide; Threonine; Xenograft Model Antitumor Assays | 2012 |
Second to none.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoplasms, Second Primary; Thalidomide | 2012 |
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Lenalidomide; Mice; Mice, SCID; Molecular Sequence Data; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Random Allocation; Thalidomide; Thiophenes; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2013 |
How to select among available options for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Second primary malignancies and myeloma therapy: fad or fact?
Topics: Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Stem Cell Transplantation; Thalidomide | 2012 |
Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cancer Care Facilities; Enoxaparin; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Specialization; Thalidomide; Thrombosis; Warfarin | 2013 |
Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2013 |
Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.
Topics: Aged; Female; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Stevens-Johnson Syndrome; Thalidomide | 2013 |
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug Costs; Health Care Costs; Hospitalization; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Multivariate Analysis; Netherlands; Prognosis; Pyrazines; Recurrence; Regression Analysis; Retrospective Studies; Thalidomide; Young Adult | 2013 |
Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Multiple Myeloma; Secondary Prevention; Thalidomide | 2012 |
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.
Topics: Adult; Antineoplastic Agents; Female; France; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2013 |
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Thalidomide; Treatment Outcome | 2013 |
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
Topics: Antineoplastic Agents; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chemokine CCL3; Coculture Techniques; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Integrin alpha4; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoprotegerin; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modality Therapy; Dacarbazine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine | 2013 |
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatine Kinase, MM Form; Cyclohexanecarboxylic Acids; Dexamethasone; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunologic Factors; Kidney Diseases; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Pravastatin; Pyrazines; Rhabdomyolysis; Thalidomide | 2012 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.
Topics: Aged; Biopsy; Bone Marrow; Cytogenetic Analysis; Female; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide | 2013 |
Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Cluster Analysis; Dexamethasone; Endothelial Cells; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Stress, Physiological; Thalidomide; Venous Thromboembolism | 2013 |
High frequencies of response after limited primary therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Total cost comparison in relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fees, Pharmaceutical; Health Expenditures; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Clinical Trials, Phase II as Topic; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoadjuvant Therapy; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2013 |
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Health Care Costs; Health Resources; Hospitalization; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide | 2013 |
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States | 2013 |
Initial success, frequent recurrence: tomorrow's multiple myeloma treatments and the value of subtype analysis. Interview with David Siegel.
Topics: Antineoplastic Agents; Cancer Vaccines; Humans; Lenalidomide; Managed Care Programs; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Secondary Prevention; Sequence Analysis, DNA; Thalidomide | 2012 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Cells, Cultured; Class I Phosphatidylinositol 3-Kinases; Dexamethasone; Female; Humans; Indazoles; Inhibitory Concentration 50; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sulfonamides; Thalidomide; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD11b Antigen; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cytokines; Flow Cytometry; HLA-DR Antigens; Humans; Immunologic Factors; Lenalidomide; Lewis X Antigen; Lipopolysaccharides; Multiple Myeloma; Myeloid Cells; Pyrazines; Reactive Oxygen Species; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes; Thalidomide; Tumor Burden; Tumor Microenvironment | 2013 |
Can NKT cells extinguish smoldering myeloma?
Topics: Dendritic Cells; Female; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidomide; Male; Multiple Myeloma; Thalidomide | 2013 |
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center.
Topics: Adult; Age Factors; Aged; Cyclophosphamide; Data Collection; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Practice Guidelines as Topic; Retrospective Studies; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Moving disease biology from the lab to the clinic.
Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Division; Drug Delivery Systems; Heterocyclic Compounds, 3-Ring; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Protease Inhibitors; Pyrazines; Pyridines; Thalidomide | 2003 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.
Topics: Clinical Trials as Topic; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Thalidomide | 2004 |
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Division; Cell Line, Tumor; Drug Synergism; Humans; Lenalidomide; Multiple Myeloma; Protein Kinases; Sirolimus; Stromal Cells; Thalidomide; TOR Serine-Threonine Kinases | 2004 |
Novel immunomodulatory therapies in the treatment of multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Humans; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Multiple Myeloma; Thalidomide | 2004 |
Circulating endothelial progenitor cells in multiple myeloma: implications and significance.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Cells, Cultured; Endothelium, Vascular; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Stem Cells; Thalidomide; Umbilical Veins | 2005 |
[Multiple myeloma -- therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2005 |
New therapies for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Platelet Aggregation Inhibitors; Polydeoxyribonucleotides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
New agents and approaches in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2003 |
Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Signal Transduction; Thalidomide | 2005 |
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Topics: Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Apoptosis; CD40 Antigens; CD40 Ligand; CD56 Antigen; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Humans; Immunization, Passive; Interleukin-6; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Thalidomide | 2005 |
Combo drug therapy beneficial for new cases of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2006 |
Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Biopsy; Diagnosis, Differential; Drug Eruptions; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Skin; Thalidomide; Tumor Necrosis Factor-alpha | 2006 |
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.
Topics: Antigen Presentation; Cells, Cultured; Galactosylceramides; Humans; Killer Cells, Natural; Lenalidomide; Ligands; Lymphocyte Activation; Multiple Myeloma; Thalidomide | 2006 |
Lenalidomide and venous thrombosis in multiple myeloma.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Multiple Myeloma; Multivariate Analysis; Thalidomide; Venous Thrombosis | 2006 |
Lenalidomide and venous thrombosis in multiple myeloma.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Venous Thrombosis | 2006 |
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspirin; Dexamethasone; Fibrinolytic Agents; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Thromboembolism; Thrombosis; Treatment Outcome | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxaparin; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Recurrence; Risk; Thalidomide; Thromboembolism; Time Factors | 2006 |
[A cure for multiple myeloma?].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Topics: Amyloidosis; Anti-Inflammatory Agents; Clinical Trials as Topic; Dexamethasone; Drug Eruptions; Drug Therapy, Combination; Humans; Lenalidomide; Medical Records; Minnesota; Multiple Myeloma; Prevalence; Retrospective Studies; Severity of Illness Index; Thalidomide | 2006 |
New drugs for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Design; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
Anticoagulation regimens for thalidomide and lenalidomide.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Risk Factors; Thalidomide; Treatment Outcome; Venous Thrombosis | 2006 |
Novel agents for multiple myeloma treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Design; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.
Topics: Antineoplastic Agents; Cells, Cultured; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Lenalidomide; Models, Biological; Multiple Myeloma; Osteoclasts; Oxidative Stress; Plasma Cells; Proto-Oncogene Proteins c-jun; Signal Transduction; Thalidomide; Tumor Suppressor Protein p53 | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
Topics: Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Dyspnea; Female; Fever; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Syndrome; Thalidomide | 2007 |
Bortezomib and lenalidomide effective in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Successful desensitization in a patient with lenalidomide hypersensitivity.
Topics: Adult; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2007 |
Advances in the treatment of MDS, multiple myeloma, and CLL.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Prognosis; Pyrazines; Risk Assessment; Thalidomide | 2007 |
Managing patients with multiple myeloma and mantle cell lymphoma: where are we now?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Nurse's Role; Nursing Assessment; Oncology Nursing; Pyrazines; Thalidomide | 2007 |
Multiple myeloma patient care: treatment options and nursing considerations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Pyrazines; Thalidomide | 2007 |
Lenalidomide, a thalidomide derivative, shows promise in various applications.
Topics: Antineoplastic Agents; Drug Monitoring; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Terminology as Topic; Thalidomide | 2007 |
Spinal epidural lipomatosis in myeloma.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Dexamethasone; Disease Progression; Humans; Lenalidomide; Lipomatosis; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Spinal Cord; Spinal Diseases; Thalidomide; Treatment Outcome | 2007 |
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Stem Cell Transplantation; Survival Rate; Thalidomide | 2007 |
Lenalidomide in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2007 |
Lenalidomide-induced severe hepatotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Drug Resistance, Neoplasm; Humans; Lenalidomide; Liver; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2007 |
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Thalidomide | 2007 |
Lenalidomide--the phoenix rises.
Topics: Antineoplastic Agents; Drug Design; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Thalidomide | 2007 |
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2008 |
How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
Topics: Antineoplastic Agents; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Venous Thrombosis | 2007 |
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Thalidomide; Thrombosis | 2007 |
Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neutropenia; Recombinant Proteins; Thalidomide; Treatment Outcome | 2008 |
Concurrent radiation therapy and lenalidomide in myeloma patient.
Topics: Antineoplastic Agents; Combined Modality Therapy; Dexamethasone; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cells; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Mice; Mice, Inbred Strains; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Syndecan-1; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7; Tumor Stem Cell Assay | 2008 |
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Topics: Aged; Angiogenic Proteins; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Capillaries; Cytokines; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Prognosis; Pyrazines; Thalidomide | 2008 |
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lenalidomide; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Remission Induction; Retrospective Studies; Thalidomide; Treatment Outcome | 2008 |
Thromboembolic events with lenalidomide-based therapy for multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Incidence; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prednisone; Risk Factors; Survival Rate; Thalidomide; Venous Thrombosis | 2008 |
Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Remission Induction; Retrospective Studies; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Vincristine | 2008 |
Azotemia associated with use of lenalidomide in plasma cell dyscrasias.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azotemia; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Paraproteins; Renal Dialysis; Thalidomide | 2008 |